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ABSTRACT 
Introduction 
Despite being available for more than 50 years, there is still much to learn about 
paracetamol. Postoperative analgesic regimens that maintain good pain control while 
minimising exposure to opiates are beneficial and paracetamol has had a resurgence in 
this role since an IV formulation came to market. However there is evidence to suggest 
currently licensed doses are sub-therapeutic, especially when administered orally or 
rectally. Higher, unlicensed doses are now being advocated but, prior to this study, there 
was little evidence of their safety in surgical patients. When assessing drug safety in 
surgical patients a number of surgery and patient related factors influence results, and 
these must be considered. 
Methods 
Major and intermediate surgical patients were recruited from two hospitals in Ireland. 
They were administered IV paracetamol at either 9g or 4g daily doses. In addition they 
received daily sub therapeutic doses of four other medicines to indicate the activity of 
their CYP450 enzymes that are involved in paracetamol metabolism. Urine and blood 
samples were collected to determine paracetamol pharmacokinetics, CYP450 activity, 
inflammatory cytokine concentration and for evidence of hepatotoxicity.  
Results 
There were 33 patients that participated in the study. There was no evidence of clinically 
significant hepatotoxicity occurring in any patient during the study period, but there could 
have been changes following this time. Paracetamol disposition was shown to change, 
however half-life remained relatively constant. There were a number of changes to the 
way paracetamol was metabolised following surgery that maintained this rate of 
elimination. 
Conclusion 
Doses of up to 9g per day given to major surgical patients for up to five days 
postoperatively produced no evidence of hepatotoxicity. Further research is warranted to 
determine the clinical utility of these higher doses 
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AIMS AND OBJECTIVES 
Aims 
The overall aim was to examine the safety of unlicensed doses of paracetamol in major 
surgical patients.  
 
Objectives 
The objectives of the research were to: 
1. Measure markers of hepatotoxicity in surgical patients for evidence of change 
arising from paracetamol administration; 
2. Establish IV paracetamol pharmacokinetics and metabolite concentrations from 
plasma and urine samples to assess changes to disposition; and 
3. Measure activity of CYP450 enzymes and inflammatory cytokines to examine for 
an association with paracetamol disposition 
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THESIS STRUCTURE 
This Thesis examines the safety of high doses of paracetamol in major surgical patients. In 
doing so, it presents information concerning the changes in drug metabolism that occur 
around the time of surgery that could be applied to a wide array of drugs. Previous work 
by Kennedy et al (1996) has demonstrated changes to paracetamol’s metabolism as a 
result of surgery. Although the overall clearance of paracetamol, hepatic blood flow and 
the volume of distribution were all unaltered, there was an important change to the way 
paracetamol was metabolised postoperatively, with an increase in the toxic metabolites 
(Kennedy 1996). These toxic metabolites are produced by CYP450 enzymes, which are 
well known as the source of many drug-drug interactions and inter-subject variability. 
Current literature evidences a renewed interest in the role of paracetamol in 
postoperative analgesia, with some groups advocating higher, unlicensed doses. When 
reported alteration to metabolism is considered in light of increased paracetamol doses 
being used in major surgical patients, there is a clear need for further investigation in this 
area. What cannot be determined from the earlier work, and what is lacking in the 
literature, is an understanding of why these changes occur. This is a major focus of this 
project.  
The novel component of this project is to simultaneously assess the effect surgery has on 
paracetamol metabolism and cytochrome P450 activity in order to understand these 
changes better. Increasing the understanding of the role the cytochrome P450 enzymes 
play in the changes to paracetamol metabolism is not only vital to this study, it will also 
provide information relevant to approximately 80% of clinically utilised medicines that 
share one of the cytochromeP450 enzymes involved in paracetamol’s metabolism.  
The context of this project is explained by first defining pain and pain mechanisms and 
the significance of postoperative pain, methods to treat it and paracetamol’s place within 
that treatment (Chapter 1.1). Chapter 1.2 focuses specifically on paracetamol itself, with 
particular emphasis on its metabolic pathway. Surgery is a time of great physiological 
changes which would intuitively be expected to impact on drug metabolism, since the 
liver is a major player in these changes. Chapter 1.3 discusses these changes to drug 
disposition in the surgical patient during this crucial time. Many other patient factors can 
also impact on paracetamol metabolism and these are discussed in Chapter 1.4. The final 
two sections concern the Phase I enzyme system which is responsible for the production 
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of paracetamol’s toxic metabolite. Chapter 1.5 reviews the enzymes of Phase I 
metabolism and Chapter 1.6 covers the means of assessing it. 
The research is then presented and the paracetamol study is then explained. 
Pivotal to the interpretation of the changes to metabolism occurring to patients, was the 
ability to measure the drugs which were being used either therapeutically or as markers 
of enzyme activity. As such, this project involved considerable assay development for 
both paracetamol and its metabolites in plasma and urine and the various parent drugs 
and their metabolites in plasma and urine. Whilst several separate assays could have 
been developed, substantial work resulted in the development of one assay with all 
probes and their metabolites being able to be recovered in one run. Techniques used 
were HPLC and LCMS. 
Physiological responses to surgery were monitored as per usual with the clinical situation, 
but changes in cytokines were measured using ELISA assays and correlated with 
alterations in the metabolite patterns.  
Clinical pharmacists are seen by many as the “Scientist in the High Street”. Pharmacists 
are trained to pull together all the elements of chemistry, pharmaceutics, pharmacology, 
biology and physiology to provide individualised patient care. This Thesis represents the 
development and application of those skills and knowledge to solve a clinical question. It 
involved the development of a novel assay as an instrument to answer part of this 
question which spanned the spectrum of chemistry to the patient. 
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1 INTRODUCTION 
1.1 BACKGROUND 
1.1.1 DEFINING PAIN 
The International Association for the Study of Pain (IASP) defines pain as the “unpleasant 
sensory and emotional experience associated with actual or potential tissue damage or 
described in terms of such damage”. Pain is therefore not a stimulus, but an individual 
and subjective perceptual experience (Basbaum et al. 2008). This experience is the final 
product of a complex information-processing network. There are a multitude of genetic, 
psychological, behavioural and social factors that may increase or decrease an individual’s 
response to, and description of, pain (Schaible et al. 2004; Webster 2008). Such factors 
include: previous pain experiences, cultural background, social supports, the meaning and 
consequence of the pain (e.g. if the pain-causing surgery is curative or palliative), the 
degree of control felt over the pain and disease, as well as fear, anxiety or depression 
(Loeser et al. 1999). These will all interact to produce what an individual describes as 
pain. Pain is thus different from nociception, which merely refers to perception of painful 
stimuli by the brain.  
Pain is the most common reason for consultation with a General Practitioner (GP) and is 
the most frequent symptom in hospitals (Loeser et al. 1999). In the acute setting, pain 
normally has a protective function to encourage healing and prevent on-going tissue 
damage. It serves as a rapid warning system to the motor neurons to act to minimise 
detected physical harm and preserve tissue integrity. Those with congenital or acquired 
insensitivity to pain can suffer many various health problems as a result of impairment to 
this warning system (Isselbacher 1994). Regardless of its aetiology, health professionals 
have a duty to help those in pain, not only treating the underlying cause but also using 
effective strategies to rapidly relieve suffering (Aronoff et al. 2005). The IASP and World 
Health Organisation (WHO) state that “the relief of pain should be a human right” (Schug 
et al. 2005). 
Pain can be broadly classified into two main types; acute nociceptive or chronic 
neuropathic. Each has different clinical features. 
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1.1.1.1 NOCICEPTIVE PAIN 
Nociceptive pain is the most common type of pain observed in acute clinical settings. It 
usually has a definable cause (Greene et al. 1993) and is considered the normal response 
to a noxious chemical, thermal or mechanical stimuli that arise from surgery, trauma or 
acute illness (Carr et al. 1999; McCaffery et al. 1999). Nociceptive pain results from the 
stimulation of specialised primary sensory nerve fibres (nociceptors) in the skin, 
periosteum, dental pulp, subcutaneous tissue and joint, visceral and somatic structures. 
This occurs most often from tissue damage and/or inflammation (Isselbacher 1994; 
Australian and New Zealand College of Anaesthetists and Faculty of Pain Management 
2005).  
The stimulation of these nociceptors results in impulses that travel along the peripheral 
nerve, past the sensory cell bodies in the dorsal root ganglion, along the dorsal roots and 
into the spinal cord or brain stem (Figure 1.1-1). Within the spinal cord or brain stem, the 
impulses activate second or third order neurons in the thalamic, limbic and cortical 
structures in the central nervous system (CNS) which is interpreted as pain by a conscious 
brain (Basbaum et al. 2008).  
Nociceptor is 
stimulated-
Impulse generated
Painful event
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Signal received 
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Figure 1.1-1 Pain transmission pathway (Basbaum et al. 2008) 
Nociceptors require a high level of stimulation to create an impulse, so that they only 
transmit stimuli of noxious intensity (Rang et al. 2000). Mechanical or thermal receptors 
transmit much lower intensity stimuli, reflecting the necessity for subtlety in the type of 
information these receptors convey. Sufficient noxious stimulation causes the membrane 
of the nociceptor to become permeable to sodium ions, causing depolarisation. As other 
ions, such as potassium, efflux from the cell, the cell repolarises as it becomes negative 
again. If sufficient depolarisation and repolarisation occurs, an action potential is created 
and the stimulus is converted into an impulse, which is transmitted along the nociceptive 
fibres that extend from the cell body (Bruton et al. 2006).  
In the absence of any inflammation, acute pain will resolve quickly once the noxious 
stimulus has been removed. However, in the presence of inflammation, nociceptive 
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activity changes. Increased levels of prostaglandins (PG) and other inflammatory 
components, monoamines, cytokines, peptides and other eicosanoids, known collectively 
as the ‘inflammatory soup’, bathe the nociceptor (Kasper et al. 2008). These 
inflammatory mediators can promote intense and on-going stimulation of peripheral 
nociceptors, sustaining the initial response well after the noxious stimulus has been 
removed. This affects existing nociceptors and also activates dormant ones (Carr et al. 
1999). Such prolonged stimulation results in the sensitisation of nociceptors. Peripheral 
and central sensitisation causes the amplification of subsequent pain stimuli (both 
intensity and area of pain) and a lowered pain threshold. The outcome is that a low level 
stimulus, such as movement, touch or heat, becomes sufficient to activate nociceptors 
and result in pain. This is a protective strategy to avoid or minimise further injury and 
promote healing in the area of the injury (Charlton et al. 1999).  
Once generated in the periphery, the impulse is transmitted to the dorsal horn of the 
spinal cord along C or A-δ (delta) fibres. The fibre used for transmission further divides 
nociceptive pain into two groups, somatic or visceral, each with their own distinguishing 
features. Visceral pain involves C fibres, which are unmyelinated, small in diameter and 
slow-conducting, transmit poorly localised, dull, cramping or aching pain, whereas A-δ 
fibres are partially myelinated, large in diameter and fast-conducting and transmit well-
localised, sharp, hot or stinging pain, termed somatic pain (Basbaum et al. 2008). C fibres 
are sensitive to mechanical, thermal and chemical stimuli, whereas A-δ fibres are 
primarily sensitive to mechanical and thermal stimuli. Visceral pain may also have 
associated symptoms such as nausea and sweating. Both somatic and visceral pain may 
be accompanied by other signs of autonomic hyperactivity such as hypertension, 
tachycardia and pallor (Kasper et al. 2008).  
At the end of the C or A-δ nociceptive fibre, the impulse travels across the synaptic cleft 
at the interface (also known as synapse) of the visceral or somatic nociceptors and the 
dorsal horn, at which site all incoming signals from the periphery are integrated into the 
CNS (Carr et al. 1999). Neurotransmitters, such as substance P, adenosine triphosphate 
(ATP) and glutamate are released from the presynaptic nerve and diffuse across the 
synapse, interacting with receptors on the post-synaptic nerve. Similar to impulse 
generation in the periphery, if enough ion exchange occurs, the impulse is recreated in 
the post-synaptic nerve. At this stage endogenous opioids act on the opiate receptors on 
the presynaptic nerve, blocking the release of these neurotransmitters, particularly 
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substance P, and preventing further transmission of the painful signal (Basbaum et al. 
2008), thereby dampening the transmission of incoming signals (Carr et al. 1999).  
Ascending pathways then convey the nociceptive information rostrally to thalamic, limbic 
and cortical structures responsible for affective and sensory discriminative responses 
(Carr et al. 1999). These cephalad structures are involved in the experience and memory 
of pain and suffering. 
The final process of nociception is the changing or inhibiting of pain impulses known as 
modulation. Because this involves neurons originating in the brain stem that descend to 
the dorsal horn of the spinal cord, the pathways of modulation are also known as the 
descending pain system. By releasing substances such as endogenous opioids (encephalin 
and endorphins), serotonin (5HT), noradrenalin, -aminobutyric acid (GABA) and 
neurotensin, these descending fibres can inhibit the transmission of noxious stimuli and 
produce analgesia. This pain modulation is thought to contribute to the wide variation in 
pain experienced amongst a group of individuals given the same noxious stimuli (Loeser 
et al. 2001). 
1.1.1.2 NEUROPATHIC PAIN 
Neuropathic pain is associated with injury or disease of the peripheral or central nervous 
system and can be considered a disease rather than a symptom (Charlton et al. 1999). 
Following such an insult to the nervous system, a number of changes occur, including the 
development of central sensitisation, the reorganisation of synaptic connections in the 
spinal cord, and hyper-excitability of damaged peripheral nerves. This can result in 
normally non-painful stimuli being interpreted as painful, or pain occurring spontaneously 
without any stimulus. Historically, any type of pain was termed chronic pain if it has 
lasted longer than six months although the line has become a lot less clear in recent years 
with increased understanding of pain pathology. As this Thesis is only concerned with 
acute pain, neuropathic pain will not be discussed further. 
1.1.2 BURDEN OF PAIN 
It is difficult to determine if pain is a problem for the general population. While accurate 
statistics from national and international epidemiologic studies are not available, data 
from a variety of sources suggest that annually 15-20% of the population have acute pain 
in the United States and many other industrialized nations, and 25-30% have chronic pain. 
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The appropriate management of pain remains one of the most important pressing issues 
of society in general, and the scientific community and the health professions in 
particular. Millions upon millions of people are afflicted with acute and chronic pain each 
year, and in many patients it is inadequately relieved (Loeser et al. 1999). As a result, pain 
is the most frequent cause of suffering and disability that seriously impairs the quality of 
life for millions of people throughout the world (Loeser et al. 2001).  
1.1.3 POSTOPERATIVE PAIN 
Acute nociceptive pain is a predictable outcome of surgery due to the tissue damage that 
is caused (Millen et al. 2003). Surgical trauma causes the release of bradykinin, 
leukotrienes, histamine, substance P and PGs. These inflammatory cytokines lead to 
sensitisation of nociceptors, transduction from the periphery and the experience of pain 
(see Section 1.1.1.1).  
Maximal postoperative pain occurs for approximately three days following surgery. This 
time period varies widely, with the site and extent of the surgery being among the best 
predictors. Pain then decreases as wound healing and overall patient recovery takes 
place. Epidemiological studies have shown young females are at a higher risk of 
experiencing severe pain postoperatively than other surgical groups, with other factors, 
such as level of pre-existing pain, whether the surgery is curative or palliative and 
previous experiences of postoperative pain, also important contributors, as described in 
Section 1.1.1.1 (Shipton 2005; Macintyre et al. 2007). 
The experience of pain itself is a potent stimulus for the autonomic nervous system. 
Injury causes afferent neural stimuli and activation of the autonomic nervous system, and 
adds to the stress response of endocrine, metabolic and inflammatory activation 
contributing to organ dysfunction (Loeser et al. 1999; Kehlet et al. 2001a). These 
homeostatic responses occur at the injury site (e.g. cytokine release), in the adrenal 
cortex (release of corticosteroids), in the immune system and in widely distributed areas 
of the brain (Loeser et al. 1999). The stress response is detailed further in Section 1.3. 
It is a popular misconception amongst Irish surgical patients that pain after a surgical 
procedure is indicative of healing (Murphy et al. 2007). However, pain is not associated 
with or required for the healing of surgical wounds. There is evidence that poorly 
controlled postoperative pain actually impairs wound healing (McGuire et al. 2006), with 
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many of the immune and neuroendocrine functions critical to wound healing being 
dysregulated by pain. 
1.1.3.1 THE IMPORTANCE OF PAIN CONTROL AFTER SURGERY  
The need for reduction in pain postoperatively is not only a humanitarian necessity but, 
as described in the previous section, leads to better outcomes at both system and patient 
levels.  
At the system level, pain can precipitate or increase the duration of hospital stay (Chung 
1995), increase the cost of healthcare and reduce patient satisfaction (Sharrock et al. 
1995; Strassels et al. 2002; Shang et al. 2003). Prolonged recovery time can also result in 
delays in return to work (both inside and outside of the home) and the subsequent 
economic implications that follow these delays (Joshi et al. 2005). 
At the patient level, inadequate control of postoperative pain causes further preventable 
morbidity, leading to prolonged recovery time and increased risk of complications 
(Beauregard et al. 1998; Iohom et al. 2006). The importance of pain control to surgical 
patients was shown in a survey of 250 surgical patients across the United States, which 
found that patients are more concerned about pain after surgery than whether the 
surgery would actually improve their condition (Apfelbaum et al. 2003). 
Complications that are thought to increase from inadequately controlled pain include: 
decreased vital capacity, chest infection, hypoxia, respiratory failure (Ballantyne et al. 
1998), tachycardia, hypertension, myocardial ischaemia, myocardial infarction, delayed 
gastric emptying, nausea, vomiting (Anderson et al. 1996), neuroendocrine disturbances, 
metabolic disturbances, thrombus formation, insomnia, anxiety and depression 
(Apfelbaum et al. 2003).  
An increasingly prominent postoperative complication, chronic postsurgical pain, can also 
arise from even brief intervals of acute pain. The experience of pain early on in recovery is 
thought to shape the way pain evolves at later stage. Changes in gene expression of 
neurons, the basis of sensitisation, occur within 20 minutes of injury (Crombie et al. 1998; 
Carr et al. 1999; Crombie et al. 1999; Perkins et al. 2000). This can induce long-term 
neuronal remodelling and sensitisation, leading to chronic postsurgical pain (Australian 
and New Zealand College of Anaesthetists and Faculty of Pain Management 2005). Some 
researchers believe acute pain should be viewed as the initiation phase of an extensive, 
 7 
 
persistent nociceptive and behavioural cascade triggered by tissue injury, and that 
adequate analgesia can prevent this cascade (Carr et al. 1999). 
With the trend toward ambulatory surgery and shorter hospital stays, adequate analgesia 
and avoidance of the complications listed above are especially important. Patient 
monitoring that might otherwise identify pain related complications is reduced with 
shorter inpatient stays (Schug et al. 1998).  
Since the identification of these long-term negative sequelae arising from poorly 
controlled postoperative pain, there have been several changes in surgical analgesia. 
Many of these changes have questioned traditional practices and most of them have 
involved changes to the use of medicines. There is now an increased focus on the 
prevention of pain, rather than its treatment because meticulous, perioperative analgesia 
can lower analgesic requirement and improve functional status months after surgery 
(Gottschalk et al. 1998).  
Historically, bolus doses of morphine had been the mainstay of postoperative analgesia. 
This new philosophy of prevention rather treatment saw the dawn of “multimodal 
analgesia” in the 1990’s (Kehlet et al. 1993). This was accompanied by a substantial 
increase in the prominence of postoperative pain in the research literature (U.S. National 
Library of Medicine et al. 2011)(Figure 1.1-2). 
 
Figure 1.1-2 Per cent of Pubmed titles containing “postoperative pain” (U.S. National Library of Medicine et al. 2011) 
Despite the evidence for fastidious pain management and analgesic administration, pain 
following surgery is still reported in the literature as occurring at “an unacceptable 
frequency and severity” (Rocchi et al. 2002; Apfelbaum et al. 2003). The designation of 
pain as the ”fifth vital sign” was originally used to increase the visibility of pain 
assessment in the clinical arena in the early 1990s (American Pain Society Quality of Care 
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Committee 1995), and while the attention given to pain has increased in recent years, 
practice patterns are much slower to change (Carr 2002; Dihle et al. 2006; Breivik et al. 
2008; Ene et al. 2008).  
Patients often report high levels of satisfaction with the effectiveness of their pain 
medication despite reporting poor satisfaction with overall pain control, indicating 
patients’ low expectations from analgesia or inadequate administration of effective 
analgesia (Bostrom et al. 1997; Rocchi et al. 2002).  
1.1.3.2 OPTIMISING POSTOPERATIVE PAIN CONTROL 
Optimal pain control reduces the intensity of movement-evoked pain and the surgical- 
stress response, improves postoperative recovery and reduces duration of hospital stay 
(Hriesik et al. 2008).  
Research on pain control to discover optimal methods of analgesia is difficult for a 
number of reasons. Pain research in the clinical setting is complicated by issues of 
consent, ethics and the subjective nature of pain. Moreover, clinical pain cannot be 
equated with experimentally induced pain, nor can it be objectively measured. In the 
clinical setting pain has to be accepted at the level it is reported. Other factors such as 
anxiety, sleep disruption and illness burden cannot be duplicated in the experimental 
setting, and conversely results arising from tightly controlled experimental studies may 
not be achievable or even applicable in a busy ward setting (Carr et al. 1999).  
Current best practice of postoperative pain management advocates a multimodal 
approach, targeting different pain pathways with combinations of medication, often in a 
stepwise approach. The well-known WHO pain ladder (Figure 1.1-3) was designed for 
management of non-acute pain. The ladder shows recommended progression of 
analgesics used for treating increasingly severe pain but it can be applied in reverse, in a 
step-down manner, in the postoperative setting (Shang et al. 2003).  
The use of multiple analgesics as part of multimodal analgesia acknowledges that there is 
not one perfect drug for treating all types of postoperative pain and approaches the 
treatment and prevention of acute pain from several different angles to uncouple tissue 
injury from the nociceptive and behavioural cascade that normally ensues (Carr et al. 
1999).  
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Figure 1.1-3 World Health Organisation analgesic ladder (Crews 2002).  
There is good evidence that multimodal approaches not only achieve better analgesia but 
potentially reduce side effects and analgesic requirements (Park et al. 1994; Breivik 
2002). By spreading analgesic demand across several different classes, the requirement of 
more side-effect-prone drugs, such as opiates, can be significantly reduced. Indeed, the 
avoidance of opiate use has become a key focus of modern analgesia (Cohen 1980; Smith 
1989). Analgesics are commonly evaluated in terms of their ‘morphine-sparing effect’. 
This is a measure of the average consumption of morphine of patients who also receive 
an additional drug under evaluation compared with a similar group of patients receiving 
morphine alone (Cobby et al. 1999). Studies that examine the effect of paracetamol and 
NSAIDs administration on morphine usage report morphine sparing of  30% (Cobby et al. 
1999; Fayaz et al. 2004; Pettersson et al. 2005). This represents a paradigm shift from 
historic use of one opiate as sole source of postoperative analgesia.  
By reducing the quantity of opiate used in exchange for other analgesics, there can be a 
reduction in nausea, vomiting, respiratory rate depression, constipation, ileus and other 
side effects associated with opiate use, without any compromise of analgesia.  
Improved analgesia can also result from the frequent dosing of different analgesics from 
standardised prescriptions and protocol (Harmer et al. 1998). In multimodal approaches, 
there is always at least one analgesic in sufficient concentration for therapeutic effect, in 
contrast to past opiate based practices of waiting for a previous dose to become sub-
therapeutic before a subsequent dose could be given, resulting in uncontrolled or 
“breakthrough” pain. 
There are several analgesics used for the treatment of acute pain. Most involve 
minimising the effects of substances involved in inflammation or transmission of pain 
signals. For example, a patient who undergoes a laparoscopic bowel resection may 
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receive paracetamol and parecoxib intravenously, fentanyl and bupivicaine epidurally, 
fentanyl transdermally and a lidocaine patch applied to the port sites. As the patient 
improves, oxycodone may be given orally (Harney 2009).  
Analgesics currently used in the acute pain setting can be considered in four classes: 
paracetamol, anti-inflammatories, local anaesthetics and opiates. Each class will be 
discussed briefly, covering its method of action and role within current pain management 
strategies. Because of paracetamol’s importance to the Thesis, it is mentioned here but 
covered in greater detail in later sections.  
1.1.3.2.1 PARACETAMOL 
The WHO has recommended that paracetamol be used as the starting point for all 
analgesic regimens and it is a major ingredient in numerous prescription analgesics and 
over-the-counter medications (World Health Organisation 2009). Paracetamol is the most 
commonly used analgesic in the world with 24 billion doses being sold annually in the US 
alone (Amar et al. 2007).  
Compared with other analgesics, paracetamol is favoured as a first-line agent because it is 
cheap, safe and relatively free from side effects. It is not mood altering and does not 
cause tolerance, addiction, dependence or withdrawal. Its efficacy has been 
demonstrated in a wide variety of acute and chronic painful syndromes (Bannwarth et al. 
2003; Remy et al. 2005; Schug et al. 2005). It can be used safely during pregnancy and 
lactation (Prescott 1996).  
Due to this safety, paracetamol plays a particularly important role in the treatment of 
surgical patients on discharge because of its wide commercial availability and lack of legal 
restrictions associated with potent opiate analgesics (Apfelbaum et al. 2003). Fear of 
addiction to opiates and avoidance of their adverse effects also leads to more patients in 
this setting using paracetamol.  
Paracetamol is also suitable for combining with other analgesics and has been shown to 
improve the quality of analgesia and reduce a patient’s demand for stronger pain relief 
(Cobby et al. 1999). In part due to its wide availability and perceived safety, deliberate or 
accidental overdose are not uncommon. In overdose, paracetamol can cause potentially 
fatal damage to the liver. The mechanism of action of paracetamol is discussed in Section 
1.2 
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Paracetamol’s role postoperatively has changed dramatically in the last decade. The rise 
of multimodal analgesia and fall of cyclo-oxygenase-2 selective inhibitors (COX-2 
inhibitors) have caused re-examination of the other non-opiates available. Use of non-
selective Nonsteroidal anti-inflammatory drugs (NSAIDs) had decreased postoperatively 
because of their gastrointestinal toxicity and increased bleeding risk, risks COX-2s were 
specifically designed to avoid (Guindon et al. 2007). So with few remaining alternatives, 
attention refocused on paracetamol. There were several key events around the time of 
the COX-2 withdrawal in 2004 that gave paracetamol new life in postoperative analgesia: 
 Paracetamol in combination NSAIDs was shown to improve postoperative 
analgesia above NSAID administration alone (Hyllested et al. 2002); 
 Paracetamol was shown to be “morphine sparing” (Delbos et al. 1995; Cobby et al. 
1999; Korpela et al. 1999; Hernandez-Palazon et al. 2001; Fayaz et al. 2004); 
 Licensed rectal doses of paracetamol were shown to be inadequate (Kvalsvik et al. 
2003); 
 Studies exceeding licensed doses were published in the literature, both in loading 
doses (Juhl et al. 2006; Gregoire et al. 2007) and repeated postoperative doses 
(Schug et al. 1998); 
  A well tolerated IV formulation of paracetamol was bought to the European 
market and licensed in Ireland in 2003 (Bristol-Myers Squibb 2009).  
The last event was the most significant in changing the role of paracetamol 
postoperatively. This formulation overcame the two most significant barriers to wide 
spread use of paracetamol postoperative: paracetamol’s poor oral absorption 
postoperatively; and patient distaste for rectal administration (Sinatra et al. 2005). 
So the situation evolved of the more widespread use of a potentially toxic drug, that 
previously was poorly absorbed now being given by a route that guaranteed complete 
absorption. It was these concerns about toxicity that led to the research contained in this 
thesis being conducted. 
1.1.3.2.2 ANTI-INFLAMMATORIES (NSAIDS/COX-2 INHIBITORS/STEROIDS) 
NSAIDs and COX-2s are generally considered second-line analgesics in the treatment of 
acute pain. While corticosteroids share their analgesic activity, corticosteroids are 
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accompanied by multiple systemic adverse effects that outweigh their usefulness as 
analgesics. 
When considering the mechanism of action of NSAIDs, and that of paracetamol later, it is 
useful to briefly review the inflammatory response (Figure 1.1-4). Trauma to cells, either 
by injury or infection, activates phagocytic cells already present in the tissue. These 
phagocytes digest foreign or injured cells and release inflammatory mediators that 
augment the inflammatory response (Diaz-Perez et al. 1976; Goetzl 1976; McClatchey et 
al. 1976).  
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Figure 1.1-4 Eicosanoid synthesis and place of anti-inflammatory drug activity 
A major component of cell membrane, phospholipid, is released as foreign or injured cells 
are digested by phagocytes, or as a direct result or cellular injury. Phospholipids are then 
broken down by the enzyme phospholipase into arachidonic acid (AA). AA is then 
enzymatically processed into a group of signalling molecules, collectively called 
eicosanoids. Eicosanoids are classified into four families, leukotrienes or one of the three 
families of prostanoids: prostaglandins (PG), prostacyclins and thromboxanes (Soberman 
et al. 2003). 
The availability of free AA, which must be liberated from esterified stores in complex 
lipids, limits the synthesis of eicosanoid, and their subsequent activity (van Dorp et al. 
1964; Goetzl 1976; McClatchey et al. 1976).  
PGs are the most relevant eicosanoid to anti-inflammatory activity. AA is converted to 
PGG2 by cyclooxygenase (COX). PGG2 is then subject to further enzymatic activity to form 
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the other prostanoids, one of which being PGE2. PGE2 is most relevant to pain and 
inflammation as it is responsible for peripheral sensitisation. Although PGs themselves 
have no intrinsic pain-evoking properties, they act to sensitise nociceptors to bradykinin, 
serotonin, histamine, adenosine and other components of the ‘inflammatory soup’, as 
discussed above, perpetuating the effect of the initial noxious stimulus (Armstrong et al. 
2008). By inhibiting PG production, NSAIDs prevent a crucial step in the inflammatory 
response and amplification of pain stimulus (Figure 1.1-5).  
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Figure 1.1-5 Site of action of Anti-inflammatories (Extension of fig. 1.1-1) 
Corticosteroids target phospholipases, which are required for AA synthesis, whereas 
NSAIDs and COX-2 inhibitors inhibit COX producing PG. The net result of all three drugs is 
reduced PG production. Because PGs are also involved in the homeostatic mechanisms of 
maintaining the gastric mucosa, gastrointestinal erosion is a significant side effect of both 
corticosteroids and NSAIDs (Macintyre et al. 2007). The antiplatelet effect of NSAIDs, 
derived from the inhibition of thromboxane synthesis, is also well documented. While 
useful as antithrombotics in cardiovascular medicine, NSAIDs used as antiplatelets may 
have negative consequences for postoperative bleeding and haemostasis (Niemi et al. 
1997).  
Anti-inflammatory drugs are synergistic with paracetamol, improving analgesia when 
given in combination (Hyllested et al. 2002; Schug et al. 2005) and having a significant 
morphine- sparing effect of up to 30% (Cobby et al. 1999; Romsing et al. 2002). NSAIDs 
are available in formulations for oral, rectal and intramuscular use, although the latter 
route is used infrequently. 
1.1.3.2.3 LOCAL ANAESTHETICS 
Local anaesthetics have been used since the native South Americans discovered the 
numbing effects of the coca plant. Its derivative, cocaine, was first used medicinally in the 
19th century but has since been replaced with synthetic analogues with more favourable 
side effect profiles (Yentis et al. 1999). Local anaesthetics act by blocking sodium channels 
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in a nerve cell membrane, preventing it from depolarising, thereby inhibiting generation 
of an action potential and blocking transmission of the painful stimulus in the spinal cord 
(Shang et al. 2003; Macintyre et al. 2007). 
Local anaesthetics are utilised increasingly in advanced techniques or ‘regional 
anaesthesia’. These include paravertebral block, used prior to breast surgery, or 
infiltration of port sites following laparoscopic surgery, in order to minimise postoperative 
pain (Australian and New Zealand College of Anaesthetists and Faculty of Pain 
Management 2005). They are more traditionally used topically, prior to cannulation, for 
anaesthesia during short procedures, such as dental extraction, or in combination with 
opiates for epidural anaesthesia.  
Local anaesthetics are rapidly metabolised and have negligible oral bioavailability. If a 
prolonged effect is desired, they must be given by infusion or injection into tissue with 
poor blood flow.  
For procedural pain, local anaesthetics may be used as a sole agent (e.g. suture 
insertion/removal, dental procedures), providing analgesia only while the procedure is 
taking place. For procedures where pain is expected to be more prolonged, an 
intraoperative dose will provide relief immediately postoperatively, when pain is most 
severe, or an infusion is used to provide continuing treatment. Transdermal patches of 
local anaesthetic are currently en vogue for continued delivery of anaesthetic to a painful 
area, such as laparoscopic port sites or new stomas and have the significant advantage of 
minimising systemic drug administration.  
Local anaesthetics are not specifically analgesics and can block all nerve conduction, both 
motor and sensory. The smaller diameter, unmyelinated C fibres are most responsive to 
local anaesthetics, and large, myelinated A fibres the least responsive. This allows some 
specificity with respect to which nerves are blocked. C fibres, which convey 
pain/temperature and postganglionic autonomic (sympathetic) signals are the first to be 
affected, followed by B fibres (sympathetic), Aδ (pain, touch, temperature), Aγ (muscle 
spindle tone), Aβ (touch, pressure) and, finally, Aα (motor, proprioception) (Macintyre et 
al. 2007). Sympathetic blockade is reported first, followed by pain and temperature 
blockade.  
Because local anaesthetics block sympathetic innervation and pain transmission, they are 
able to prevent ‘evoked’ pain, the hyperalgesia and allodynia arising from central 
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sensitisation that can follow surgical trauma. Subsequently, there is increasing evidence 
of reduction in recovery time and post-surgical chronic pain syndromes with the use of 
local anaesthetics (Boezaart 2006). The use of these drugs in regional anaesthesia has also 
been shown to reduce the incidence of nausea and vomiting as well as thromboembolic, 
pulmonary, cardiovascular and gastrointestinal complications (Guindon et al. 2007). 
When used by skilled operators, side effects of local anaesthetics are very rare. Common 
minor-moderate adverse effects from epidural administration are associated with 
blockade of touch or motor function which can impede the return to mobility and hinder 
recovery. More serious adverse effects can occur when local anaesthetics are injected or 
absorbed into the blood stream. The resultant adverse effects also arise from the 
blockade of sodium channels, leading to interference with the generation of action 
potentials and conduction in the heart, causing arrhythmias, and in the CNS, causing 
convulsions (Macintyre et al. 2007). Single enantiomer formulations have improved 
selectivity for sensory over motor blockade and decreased potential for cardiotoxicity 
(Macintyre et al. 2007). 
1.1.3.2.4 OPIATES 
The term “opiate” refers to a broad range of narcotic drugs that were originally derived 
from opium. Now synthetically manufactured, opiates share many structural similarities 
chemically but their analgesic activity varies widely (Shang et al. 2003). They are potent 
analgesics, used mainly for moderate to severe pain. Opiates reduce the distressing, 
affective component of pain more so than dull the sensation of pain itself (Drolet et al. 
2001). Unlike paracetamol and anti-inflammatory drugs, the dose/response of opiates 
varies greatly between individuals, and even within the individual, depending on their 
state of health. Dose adjustment based on age is more appropriate than doses based on 
weight (Camu et al. 2002). Individualisation of dose is essential because of the wide 
variation in response; opiates are fatal in overdose and have many common adverse 
effects. The most common adverse effects due to opiates include nausea and vomiting, 
sedation, respiratory depression, euphoria and dysphoria, among many, many others 
(Shang et al. 2003). 
Exogenous opiates act by mimicking the body’s own endogenous opiates involved in the 
descending pathways of pain regulation (Schaible et al. 2004). Exogenous opioids exert 
their analgesic activity in the same way, binding to opiate receptors on the presynaptic 
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nerve, blocking the release of neurotransmitters and impeding nociceptive transmission. 
They also act supraspinally to activate inhibitory pathways that descend to the spinal 
segment (Camu et al. 2002).  
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Figure 1.1-6 Site of action of opiates (continuation of Figure 1.1-1) 
Opiates are extremely effective analgesics and are the basis of pharmacological 
management of postoperative pain (Carr et al. 1999). The diffuse, visceral pain carried by 
C fibres is especially sensitive to opiates, whereas the Aδ fibres are less sensitive (Guindon 
et al. 2007). Opiates used most often postoperatively include morphine, fentanyl, 
oxycodone and tramadol.  
From a practical standpoint, most opiates used for the control of acute pain are 
controlled drugs in Ireland which must be stored securely and face restrictions on their 
prescribing, dispensing and administration. In a hospital setting these restrictions can 
hinder or delay their administration. On discharge and at home they may not be 
prescribed because of these restrictions, or prescribed in insufficient quantity. 
Paracetamol and anti-inflammatory drugs are not subject to these restrictions, an 
important advantage to their use.  
Morphine is the most commonly used opiate in the acute pain setting, both intra-
operatively and postoperatively. It is cheap and widely available in both oral and 
parenteral formulations. It is considered the gold standard with which other analgesics 
are compared and has been used as an analgesic for centuries.  
Morphine’s metabolism is via Phase II glucuronidation (a pathway shared by paracetamol, 
described in Section 1.2) to two products; predominantly morphine-3-glucuronide (M3G) 
and morphine-6-glucuronide (M6G) in lesser amounts. M6G has increased analgesic 
potency and fewer side effects compared with morphine. Conversely, M3G has no 
analgesic properties but is associated with producing several of the adverse effects 
associated with morphine, including sedation, respiratory rate depression and clinical 
tolerance. M3G may also antagonise morphine (Wittwer et al. 2006). Both metabolites 
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rely on active renal excretion. Accordingly, morphine should be avoided in patients with 
end-stage renal disease and its dose reduced in renal impairment, as substantial amounts 
of M3G can accumulate, causing all the adverse effects with inadequate pain control.  
Fentanyl is used both intraoperatively and postoperatively; however, it is not available in 
an oral formulation due to high first-pass losses. It has a shorter half-life- an advantage 
given the fluctuating demands for analgesia in the surgical patient- and requires no 
adjustment for renal impairment. Both fentanyl and morphine are used in combination 
with local anaesthetics in spinal anaesthesia (Macintyre et al. 2007).  
Tramadol is a mixed agonist, affecting serotonergic receptors in addition to opiate 
receptors. It is less potent than morphine but is associated with many of the same 
adverse effects, particularly changes in consciousness, with the elderly being the most 
susceptible. Access to the drug is simpler as it is not a controlled drug, although there are 
reports of change to this status (Macintyre et al. 2007). Tramadol’s mixed agonism and 
effect on multiple receptor types is thought to lead to its high percentage of CNS adverse 
effects. Oxycodone is a more recent addition to the acute pain formulary. It is increasingly 
used in place of oral morphine, having twice the analgesic potency, but is subject to less 
frequent adverse effects, particularly nausea, vomiting and changes to consciousness. It is 
preferred by many patients, but at greater than ten times the cost of an equivalent dose 
of oral morphine, its cost-utility is debated by pharmacoeconomists (Macintyre et al. 
2007). 
In addition to standard routes of administration, opiates can be used with specialised 
techniques postoperatively. Intravenous (IV) patient-controlled analgesia with morphine 
is available in most Irish hospitals and is considered the optimal treatment for 
postoperative pain in patients who are unable to take oral medication (McCaffery et al. 
1999). Some specialised centres will also offer patient-controlled epidural analgesia. 
When compared with intermittent bolus dosing of opiates, patient-controlled analgesia 
results in better pain control and greater patient satisfaction, without increasing the 
incidence of opioid-related adverse effects (Macintyre et al. 2007). The intensity of pain is 
rarely constant, but with patient-controlled analgesia, small and frequent IV bolus doses 
of opioid can be given whenever the patient becomes uncomfortable, enabling rapid 
titration to the degree of pain the patient is experiencing. This flexibility helps to 
overcome the wide patient variability (8-10 fold) in opiate requirement and avoids dose-
related adverse effects. It can also save medical/nursing time involved in the assessment 
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and administration of intermittent analgesia (Macintyre et al. 2007). One study in 
patients undergoing abdominal surgery showed significantly improved pain control, but 
with greater than twice the morphine consumption, in patients with patient-controlled 
analgesia compared to nurse administered intramuscular prn morphine (Everett et al. 
2005). Despite the greatly increased consumption of morphine, the patient-controlled 
analgesia group did not have a greater incidence of adverse effects. Nurse administration 
of prn opiates varies greatly between nurses (Gordon et al. 2008a), reinforcing the role of 
the patient as the best person to control their own analgesia. All of these findings: better 
pain control, increased opiate consumption, no increase in significant adverse effects, are 
emphasised in a Cochrane Review (Hudcova et al. 2006). 
Intrathecal and epidural routes of administration opiates are also used. They reduce the 
drug load to the patient and, potentially, the adverse effects. Adverse effects from 
opiates are often mediated by peripheral receptors, which are avoided by direct 
administration in the CNS. This route can also provide sustained analgesia for 12-24 hours 
after administration due to the sparsity of opiate metabolising enzymes in the CNS. 
However, the utility of opiates is often limited by their adverse effects. Respiratory 
depression is potentially life-threatening, constipation is almost guaranteed, and nausea 
and vomiting is a common cause of cessation of treatment. Pruritus from opiate induced 
histamine release is also a significant cause of morbidity. Some of the many other 
significant adverse effects include urinary retention, hallucinations, drowsiness and 
confusion, to which the elderly are more prone and more sensitive (Cobby et al. 1999). 
The adverse effects are so considerable that, as described above, the “morphine-sparing 
effect” is a commonly used indicator of the benefit of other analgesia.  
Managing the adverse effects from opiate use adds considerably to the cost of these 
otherwise cheap drugs. A double-blind randomised controlled trial comparing IV 
morphine with IV ketorolac for treating pain after limb injury, showed that while the 
acquisition costs of ketorolac were three times those of morphine, when administration 
costs, adverse events and admission for adverse events were taken into account, 
ketorolac was much cheaper (Rainer et al. 2000).  
Concern over the safety and addiction potential of opiates often results in under-
prescribing and inadequate dosing in the hospital setting, even in the presence of severe 
pain and minimal or no side effects (Gordon et al. 2008b). This often leads to inadequate 
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analgesia (Schug et al. 2007). Interpatient variability can alter response to opiates and 
lead to wide- ranging effects from a similar dose (Schug et al. 2007). Factors that affect 
response include patient and drug characteristics such as prior drug exposure, prior 
responses to analgesics, age, organ function, pain severity, anticipated pain duration, co-
morbid conditions and concomitant drug use (Macintyre et al. 2007; Gordon et al. 
2008b). Due to these factors, titration of opiates to the optimal dose is difficult to 
achieve, and rarely happens (Bannwarth et al. 2003). While opiates are more effective as 
analgesics, the fear of adverse effects limits their application. Similarly, fear over the 
renal, haematological and gastrointestinal adverse effects of NSAIDs also limits their 
usage. Avoidance of these adverse effects is especially important perioperatively. 
Paracetamol, which has a wide therapeutic index and an enviable safety profile, has many 
advantages in this way that are reflected in its wide use postoperatively. 
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1.2 PARACETAMOL 
Paracetamol is a white, odourless, crystalline powder with a melting point of 169-171°C 
and a molecular weight of 151.2 g/mol. The octanol/water partition co-efficient is 0.5 
(Moffat et al. 2011). The empirical formula is C8H9NO2 and structural formula is shown in 
Figure 1.2-1. 
 
Figure 1.2-1 Paracetamol 
Paracetamol is a weak organic acid with a pKa of 9.5. It is moderately soluble in hot 
water, alkaline aqueous solutions and more polar organic solvents such as methanol and 
acetone (Prescott et al. 1971).  
1.2.1 DISCOVERY 
Paracetamol was first synthesised in 1878 (Morse 1878). It was developed as an 
antipyretic agent along with its prodrug, phenacetin, in the second half of the 19th 
century after its parent drug, acetanilide, was found to cause cyanosis and 
methaemoglobinemia (Bertolini et al. 2006). Phenacetin went to market ahead of 
paracetamol because it was believed to be less toxic, although the details of this reported 
toxicity were unclear (Prescott 1996). It was not until 1948 that Brodie and Axelrod 
showed that paracetamol was the major metabolite of phenacetin and that it was 
paracetamol that conferred phenacetin’s pharmacological activity, thereby ‘rediscovering’ 
paracetamol (Brodie et al. 1948).  
1.2.2 PHARMACEUTICAL DOSAGE FORMS 
Paracetamol is unusual in that it is available in a wide variety of formulations. Hampered 
by poor aqueous solubility (1 in 70) it had been available in tablets, capsules, 
suppositories and suspensions for many decades (Van Aken et al. 2004). Advances in 
formulation provided an effervescent soluble tablet and more recently IV infusions, 
initially as a prodrug, proparacetamol (Depre et al. 1992), and more recently as 
paracetamol itself (Van Aken et al. 2004). Proparacetamol is no longer in use and is not 
licensed in Ireland (Irish Pharmaceutical Healthcare Association 2010). While increasing 
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access to the drug, the variety of formulations and combinations of paracetamol with 
other medications has been implicated as a cause of unintentional overdose (Albertson et 
al. 2010). 
Following single doses in healthy adults, the route of administration does not have a 
significant effect on metabolism (Clements et al. 1984) with identical elimination half-
lives following a 1g IV or oral dose (Depre et al. 1992), however the pattern of 
metabolism may be different. 
1.2.3 CLINICAL PARTICULARS 
1.2.3.1 THERAPEUTIC INDICATIONS 
Oral and rectal formulations of paracetamol are licensed in Ireland for the short-term 
management of headaches, musculoskeletal disorders, menstrual pains, toothache and 
for symptoms of common colds and flu. It may also be used for the relief of mild to 
moderate pain associated with osteoarthritis (Glaxo Smith Kline 2008). IV formulations 
are indicated in the short-term treatment of moderate pain following surgery and short 
term treatment of fever (Bristol-Myers Squibb 2009). 
1.2.3.2 POSOLOGY AND METHOD OF ADMINISTRATION 
Licensed doses of paracetamol for adults are 1g repeated if necessary 3-4 times a day, at 
a minimum four hour interval to a maximum of 4g in any 24 hour period. For children the 
does is 10-15mg/kg/dose at the same interval (Glaxo Smith Kline 2008; Bristol-Myers 
Squibb 2009). IV formulations of paracetamol are administered to deliver the same 
licensed dosage as detailed above by IV infusion over 15 minutes (Bristol-Myers Squibb 
2009). 
1.2.3.3 DRUG INTERACTIONS 
Paracetamol has few clinically significant drug interactions. The most notable are: 
1. Prolonged use of paracetamol may enhance the anticoagulant effect of coumarins 
and may inhibit the metabolism of busulphan; 
2. The absorption of paracetamol may be enhanced by metoclopramide and reduced 
by colestyramine; and 
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3. Probenecid can almost half paracetamol clearance by inhibiting conjugation with 
glucuronic acid (Lacy et al. 2005; Klasco 2009). 
There is also evidence of oral contraceptive hormones increasing the glucuronidation of 
paracetamol, although the clinical relevance is uncertain (Bock et al. 1994). 
1.2.3.4 WARNINGS, CONTRAINIDCATIONS AND PRECAUTIONS FOR USE 
Doses above those currently licensed are associated with liver damage. Because of the 
variety of products available that contain paracetamol, it is important that only one 
source of paracetamol is administered at any one time.  
Paracetamol is contraindicated in those hypersensitive to paracetamol, or any of the 
excipients (Glaxo Smith Kline 2008; Bristol-Myers Squibb 2009). It should be used with 
caution in those with hepatocellular insufficiency, severe renal insufficiency, chronic 
alcoholism, chronic malnutrition or dehydration (Bristol-Myers Squibb 2009). 
1.2.3.5 PREGNANCY AND LACTATION 
Although no comprehensive studies have been conducted, paracetamol is not thought to 
cause undesirable effects during pregnancy or for the new born infant. One study has 
shown minor alterations to disposition (Miners et al. 1986). Experience with IV 
formulations is especially limited (Bristol-Myers Squibb 2009).  
Following oral administration, paracetamol is excreted in small amounts into the breast 
milk, however no undesirable effects have been reported and paracetamol may be used 
in breast-feeding women (Bannwarth et al. 2003; Graham et al. 2005b). 
1.2.3.6 UNDESIRABLE EFFECTS 
Considering the quantity of paracetamol consumed annually, it is remarkably safe drug. 
Undesirable effects are either classified as rare (>1/10000, <1/1000) or very rare 
(<1/10000) (Bristol-Myers Squibb 2009). Studies have shown paracetamol adverse effects 
to be comparable with placebo (Moore et al. 1997). Most of the reported adverse 
reactions involve hepatotoxicity. Other rarer adverse effects are those common to most 
medicines; nausea, vomiting, rash, blood disorders and allergy (Fischereder et al. 1984).  
Initial IV formulations of proparacetamol were associated with higher rates of allergy, 
however these have improved since paracetamol replaced proparacetamol. 
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Proparacetamol is a diethylglycidyl ester of paracetamol and after being cleaved by 
esterases present in the body, the remaining diethylglycine was a known allergen 
(Graham et al. 2005b). Proparacetamol was also associated with pain at the injection site 
on infusion, however paracetamol infusions have less than half the incidence, in one 
study reducing from 33% to 14.7% (p<0.005) (Murat et al. 2005).  
More recently, IV paracetamol has been related to hypothermia and hypotension. These 
appear to be related to the rate of administration, occurring only in susceptible 
individuals, such as those hypovolaemic after surgery. Because paracetamol is poorly 
soluble, mannitol and disodium phosphate are used to increase its solubility. Both of 
these excipients are known to cause hypotension, and in those affected, reducing the 
infusion rate minimises this adverse response (Klasco 2009).  
1.2.3.6.1 LIVER TOXICITY 
The metabolism of paracetamol produces a hepatotoxic metabolite, N-acetyl-p-
benzoquinoneimine (NAPQI). Theoretically, alterations that produce significantly more 
NAPQI or reduce its conjugation could lead to toxicity, but this does not occur at 
therapeutic doses.  
Prospective studies show that repeated use of a true therapeutic paracetamol dosage 
may slightly increase the level of serum aminotransferase activity, but hepatic injury, 
failure or death, have also been reported, although extremely rarely (Kurtovic et al. 2003; 
Moling et al. 2006). Some retrospective reports show a higher rate of increased serum 
aminotransferase levels, and several reported associated liver injury and death in 
paracetamol users. However, inaccuracies in recording of paracetamol dose in some case-
reports suggest that these cases may be inadvertent overdoses, rather than true 
therapeutic dosages (Dart et al. 2007). These reports may also be confounded by 
aminotransferase increases from other causes. Additionally, a retrospective review of 
pooled aminotransferase data measured during placebo treatments of nearly 500 
patients from 13 Phase I studies showed that 20% of the subjects had at least one 
aminotransferase value above the upper limit of the reference range (ULRR) and 7.5% had 
at least one value twice the ULRR (Rosenzweig et al. 1999).  
Aside from intentional overdoses, toxicity is very rare and confined to case reports mostly 
in alcoholic adults and children who have been accidentally overdosed by their care-
givers (Whitcomb et al. 1994).  
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1.2.3.7 OVERDOSE  
Paracetamol overdose is potentially life threatening and can result from single doses of 
12g, or 150mg/kg of paracetamol (Brok et al. 2006). Paracetamol overdose presents as 
pallor, nausea, vomiting, anorexia and abdominal pain. Those with paracetamol overdose 
may exhibit liver damage, manifested by liver transaminases elevation eight hours after 
ingestion of the overdose. Paracetamol overdose presents as pallor, nausea, vomiting, 
anorexia and abdominal pain. Alterations to glucose metabolism and metabolic acidosis 
may also occur (James et al. 2003). Severe poisoning may progress to hepatic failure, 
encephalopathy, coma and death (Bartlett 2004). 
IV n-acetylcysteine is an effective antidote to paracetamol overdose when administered 
within eight hours of the paracetamol dose. Although its benefit declines after this time, 
it still may be beneficial up to and beyond 24 hours. Activated charcoal and methionine 
may also be of benefit in those who have ingested >12g (Clark 2001; Bartlett 2004; Brok 
et al. 2006).  
Paracetamol is regarded as a very safe drug in normal doses although in overdose 
fatalities can occur (Bailey 1980; Shayiq et al. 1999; Schmidt et al. 2002; Acello 2003; Lee 
2004; Holubek et al. 2006). Its perception as being such a safe drug has led to toxicity and 
overdose in those who were taking it with therapeutic intent (Graham et al. 2005b). 
Unfortunately, because of paracetamol’s wide availability, it is also frequently used for 
self-harm. This can result in a prolonged painful death from liver failure. In a study of all 
11,092 presentations to Irish hospitals due to deliberate self-harm during 2004, 7,933 
related to drug overdose of which 31% involved paracetamol (Ní Mhaoláin et al. 2009). 
The incorporation of n-acetylcysteine into paracetamol formulations was attempted to 
minimise harm, however the additional expense of these products prevented their wide-
spread use (Clark 2001). When considering the maximum dose of paracetamol it is 
important to evaluate both the frequency as well individual dose. There are numerous 
reports of intentional overdose linked to paracetamol, but these are taken as a single 
dose (Prescott 2000b; Sheen et al. 2002b). Similar amounts may be safe if taken in divided 
doses throughout the day, and this is one of the hypotheses of this Thesis. 
Early observations of toxicity from acute overdoses have shown paracetamol’s disposition 
to be non-linear (Prescott 1996), which has been confirmed in single dose studies of 
doses ranging from 0.325g to 3g (Slattery et al. 1987; Borin et al. 1989). This is thought to 
 25 
 
due to saturation of the enzymes involved in sulphonation and the depletion of its co-
factors (section 0). This finding led to the fear that repeated doses at or slightly above the 
licensed dose would lead to accumulation of paracetamol and a disproportionate rise in 
NAPQI, with subsequent toxicity (Gelotte et al. 2007). However, a more recent study by 
Gelotte et al. examined the safety and disposition of paracetamol after repeated doses of 
up to 8g/day for three days. They found paracetamol had linear kinetics after the first 
dose, which did not change after reaching steady state (Gelotte et al. 2007). They also 
showed that data modelled from initial doses did not predict those of steady state, with 
the actual concentrations being much lower than those predicted. As discussed above, 
the authors of this study suggest there is an increase in clearance of paracetamol over 
time accompanying increased formation clearance of paracetamol glucuronide. 
Rats given substantially higher doses of paracetamol IV, up to 600mg/kg, had a prolonged 
half-life and decreases in clearance. As the dose of paracetamol increased, more of the 
dose was excreted into the bile with biliary excretion as a proportion of dose increasing 
from 20 to 49% over the dose range of 37.5 to 600mg/kg. Similarly, over the same dose 
range the biliary excretion of the glucuronide metabolite increased from 10.5% to 40.2% 
of the total recovered dose, but the urinary recovery of the glucuronide metabolite 
remained relatively constant around 20% of the recovered dose. At 600mg/kg the 
glucuronide conjugate represented over 70% of the recovered dose, however at doses at 
or above 600mg/kg a significant decline in the rate constant for glucuronide formation 
was noted. Comparable results were seen for the rate for glutathione (GSH) conjugation 
at 300 mg/kg, whereas the formation of the sulphate conjugate was decreased at lower 
dosages (75 mg/kg). The authors concluded that glucuronidation was a high-capacity, 
high-dose saturable pathway of paracetamol metabolism which preferentially excretes 
the product in bile after high dosages (Hjelle et al. 1984). 
1.2.4 PHARMACOLOGICAL PROPERTIES 
1.2.4.1 PHARMACODYNAMIC PROPERTIES 
There are two systemic effects of paracetamol that are of clinical significance: antipyresis 
and analgesia (Bruton et al. 2006).  
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1.2.4.1.1 ANTIPYRESIS 
Pyresis, the elevation of body temperature, is part of the body’s response to eradicate 
infection. In response to the presence of foreign cell components arising from 
phagocytosis, cells derive PGs from AA and release them into the circulation. In the CNS, 
it is thought endothelial cells are responsible for PG synthesis (Cao et al. 1996). PGs, 
especially PGEs, act on the hypothalamus to increase the set point of body temperature. 
Subsequently body temperature rises through heat generation and conservation 
measures (Feldberg et al. 1972; Kasper et al. 2008).  
Paracetamol has no effect on pyresis that is not mediated by prostaglandins (Dey et al. 
1974). It was later discovered that paracetamol prevents PGE2 synthesis by inhibiting 
prostaglandin H2 synthase (PGHS) in the brain (Flower et al. 1972), and that endothelial 
cells are especially sensitive to these actions of paracetamol (Kis et al. 2005). Despite 
considerable research and clinical use for more than a century, the exact mechanism of 
the other actions and therapeutic concentration required for those actions of 
paracetamol is still unclear (Graham et al. 2005a; Bertolini et al. 2006).  
1.2.4.1.2 ANALGESIA 
The mechanisms of pain and pain transmission are discussed in the previous section, 
1.1.1, while the inflammatory process and mechanism of action of NSAIDs is discussed in 
1.1.3.2.2. Two pieces of information from these previous sections are important to the 
discussion of paracetamol’s mechanism of analgesia: 
1. Nociceptors exposed to PGs are sensitised and require a lower intensity of 
stimulation to cause pain; and 
2. Inhibition of PG synthesis reduces this sensitisation and result in analgesia. 
1.2.4.1.2.1 PLACE OF ACTION- PERIPERHAL OR CENTRAL? 
Since paracetamol and NSAIDs have similar antipyretic and analgesic effects clinically, 
much investigation has sought to prove paracetamol inhibits PGHS in a similar way to 
NSAIDs. While there is little doubt NSAIDs act through the peripheral inhibition of the 
COX site on PGHS (Vane 1971; Brooks et al. 1991), the evidence for where paracetamol 
works is conflicting and both central and peripheral pathways may be involved. Although 
paracetamol may have some effect on PGHS, this effect is different from that seen with 
NSAIDs (Anderson 2008). Paracetamol’s lack of any significant anti-inflammatory or 
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antiplatelet activity in vivo are the sentinel differences from NSAIDs, and are consistent 
with a lack of peripheral inhibition of PG synthesis (Clissold 1986; Bruton et al. 2006). 
Despite this finding, peripheral activity is supported by several experimental studies: 
 Lim et al. showed in 1964 that greater analgesia could be achieved when 
paracetamol is administered intra-arterially, proximal to a painful stimulus, rather 
than IV (Lim et al. 1964); 
 Paracetamol was shown to block peripheral autonomic response to pain induced 
by bradykinin injection into the spleen of dogs (Guzman et al. 1964); 
 In perfused livers, action potentials, either spontaneous or from toxic stimuli, 
were inhibited in hepatic nerves by paracetamol (Andrews et al. 1973); 
 Paracetamol was shown to suppress the production of some components of the 
inflammatory soup such as bradykinin, adenosine triphosphate, slow reacting 
substance C and AA in the same way as NSAIDs (Vargaftig et al. 1973); and 
 Paracetamol was also been shown to reduce pain and oedema, widely accepted as 
a typical inflammatory response, mediated, in part, by PGs’ peripheral actions 
(Vinegar et al. 1976).  
While these studies indicate a peripheral activity, there is also considerable evidence in 
favour of a central mechanism of action: 
 Paracetamol concentrations in the CSF match the response to fever (Anderson et 
al. 1998) and pain (Anderson et al. 2001) more closely than concentrations in the 
plasma; 
 Paracetamol reduces pain following administration directly into the CNS (Pelissier 
et al. 1996); and 
 Paracetamol inhibits PG release in the CNS following peripheral noxious stimuli 
(Muth-Selbach et al. 1999).  
While these strongly support activity in the CNS, it is the lack of significant anti-
inflammatory or antiplatelet activity in vivo that are the strongest findings in favour of a 
central mechanism of action.  
1.2.4.1.2.2 NATURE OF ANALGESIC ACTIVITY  
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As it is central to the understanding of the dose/response relationship, and why 
paracetamol has no clinically relevant peripheral activity in vivo, it is worth reviewing the 
most popular proposed mechanisms of action of paracetamol. 
Prescott believes debate on paracetamol’s activity has arisen because of the nature of 
paracetamol’s PG inhibition (Prescott 1996). In humans, paracetamol is generally 
considered to be a weak inhibitor of PG synthesis, exhibiting a highly variable capacity in 
different cell and tissue types (Aronoff et al. 2006).  
The majority of NSAIDs and COX-2 inhibitors inhibit PG synthesis by non-covalently 
binding to the COX active site, physically obstructing the entry of AA, thereby preventing 
this oxygenation process from occurring. However, the current wisdom is that this 
mechanism is not shared by paracetamol which does not work within the COX active site 
but rather the second site involved in the oxygenation, the peroxidase active site (POX). 
Here paracetamol prevents the formation of a tyrosine radical by POX, which is essential 
for COX activity (Figure 1.2-2). 
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Figure 1.2-2 Inflammatory cascade and location of paracetamol’s activity 
Paracetamol inhibits the formation of the tyrosine385 radical (Tyr385*) by peroxidase (POX). Tyr385*is required by 
cyclooxygenase (COX) to metabolise arachidonic acid to PGG2 
PG synthesis begins when PGHS enzymes oxygenate AA to give PGH2. PGH2 synthesis from 
AA occurs in two stages: 
1 AA is metabolised to PGG2 by COX; 
2 PGG2 is metabolised to PGH2 by POX. 
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As mentioned previously, both COX and POX are different active sites on the same 
enzyme PGHS. A more detailed synopsis of the steps is presented in Figure 1.2-3. 
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Figure 1.2-3 Schematic of prostaglandin H2 synthase (PGHS) metabolism of arachidonic acid to PGH2. 
Reduction of the ferryl protoporphyrin IX cation (Fe[IV]=OPP*+) at the peroxidase site is necessary for the formation of 
the tyrosine-385 radical (Tyr385*) at the cyclooxygenase site. Paracetamol partially reduces Fe(IV)=OPP*+ decreasing 
the amount available for regeneration of Tyr385*, impairing COX activity. In cells with high peroxide concentration 
greater amounts of Fe(IV)=OPP*+ are produced, overwhelming the actions of paracetamol (adapted from Aronoff et al. 
1996 and Anderson 2008). 
Stage 1, the metabolism of AA to PGG2, occurs in two steps. In the first step a hydrogen 
atom is taken from AA by a tyrosine 385 free radical (Tyr385*) present in the COX active 
site. The second step is this arachidonyl radical using oxygen to produces a PGG2* radical.  
In stage 2, PGG2 is reduced to the equivalent alcohol, PGH2 and Tyr385* is reformed. This 
reduction of PGG2 to PGH2, in the haem containing POX active site, yields an oxidised 
haem radical cation, ferryl protoporphyrin IX (Fe[IV]=OPP*+). Fe(IV)=OPP*+ is then used to 
generate Tyr385* from Tyr385 in the COX active site by intramolecular ion transfer. The 
Tyr385* is then reused by COX. The newly formed partially reduced haem [Fe(IV)] is 
further reduced to the resting state [Fe(III)] (Aronoff et al. 2006). 
POX then reduces hydroperoxides to re-oxidise the haem from the resting Fe(III) state to 
the catalytic Fe[IV]=OPP*+. A variety of hydroperoxides can be used, not just PGG2, each 
with varying efficiency (Markey et al. 1987). Hydroperoxides of fatty acids, such as AA, are 
preferred substrates, as is the case with PGG2, while hydrogen peroxide is a weak 
substrate (Ohki et al. 1979).  
Summarised, COX is dependent on POX to produce the Tyr385* radical for its activity, 
whereas POX does not rely on COX.  
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At this molecular level, most NSAIDs and COX-2 inhibitors work by competitively 
inhibiting the entry of AA and subsequent production of PGG2, with the exception of 
aspirin which, uniquely, covalently modifies the COX site, permanently inactivating it. 
Paracetamol, however, is a reducing co-substrate for the POX active site, like PGG2, 
reducing POX haem from the higher oxidative Fe(IV) state back to its resting Fe(III) state. 
Unlike PGG2, when paracetamol is the co-substrate, Tyr385 is not reproduced, thus 
starving COX of its co-substrate Tyr385* (Boyd et al. 1981; Moldeus et al. 1982; Harvison 
et al. 1986; Markey et al. 1987; Potter et al. 1987; Harvison et al. 1988a). Because the 
electron is being transferred to paracetamol rather than Tyr385 it would be expected that 
paracetamol radicals would be produced, and this has indeed been shown (Boyd et al. 
1981; Moldeus et al. 1982). 
Peroxides, such as PGG2, which arises from COX, oxidise the POX haem back to its 
catalytically active Fe(IV) state, opposing the actions of paracetamol. Experimentally, 
lowering the concentration of peroxides enhances paracetamol’s inhibition of PGHS 
(Ouellet et al. 2001) and conversely, increasing the peroxide concentration reduces it 
(Boutaud et al. 2002). Therefore it can be seen increasing the amount of AA increases the 
amount of PGG2 which in turn overwhelms any inhibitory action of paracetamol (Ouellet 
et al. 2001).  
Initially paracetamol was thought to have similar activity to NSAIDs action on COX. 
However, further evidence for paracetamol’s activity on POX, as oppose to COX, arises 
from paracetamol’s lack of antagonism of NSAIDs on the COX active site (Catella-Lawson 
et al. 2001; Ouellet et al. 2001) and antagonism of paracetamol’s activity following 
addition of exogenous PGG2, which does not occur with NSAIDs (Boutaud et al. 2002). In 
studies where PGHS concentrations have been increased but AA concentrations have 
remained constant, paracetamol activity has decreased, in contrast to the activity of 
NSAIDs.  
1.2.4.1.2.3 PARACETAMOL’S LACK OF ANTI-PLATELET AND ANTI-INFLAMMATORY 
ACTIVITY 
The most clinically relevant point of difference between NSAIDs and paracetamol is 
paracetamol’s lack of anti-platelet and anti-inflammatory activity. With respect to anti-
platelet activity, there are two factors which make platelets resistant to the actions of 
paracetamol, which also add to the understanding of paracetamol’s mechanism of action 
in other cells.  
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Firstly, in inflammation, there is an explosive activation of phospholipase A2 in platelets 
by receptor dependent stimuli. This results in an equivalently dramatic increase in PGG2, 
which in turn causes resistance to inhibition of PGHS by paracetamol.  
Secondly, on activation, a substantial amount of the lipid hydroperoxide 12-
hyroperoxyicosatetraenoic acid (12-HpETE) is formed by the platelet 12-lipoxygenase, 
further increasing the cells peroxide tone (Johnson et al. 1998). 12-HpETE acts as a 
peroxide co-substrate for POX, which is preferred by POX over paracetamol, preventing 
paracetamol returning POX to its resting state (Calzada et al. 1997; Boutaud et al. 2002). 
This action by platelets, the rapid increase in PGG2 and production of a preferred co-
substrate, also adds to the picture of how different cells respond to paracetamol. When 
stimulated by the same concentration of exogenous AA, platelets are completely resistant 
to the actions of paracetamol at concentrations that completely block PGHS activity in 
human umbilical vein endothelial cells. As discussed in Section 1.2.4.1.1, endothelial cells 
are particularly sensitive to the PGHS inhibitory actions of paracetamol (Kis et al. 2005).  
Understanding the importance on the peroxide tone of a cell during activation also 
explains paracetamol’s lack of anti-inflammatory activity. Similar peroxide-producing 
enzymes, such as platelet 12-lipoxygenase, are highly expressed in inflammatory 
leukocytes. Their products together with peroxynitrite and hydrogen peroxide generated 
by activated macrophages, vastly increase the peroxide tone of these cells. This greatly 
reduces the activity of paracetamol in these cells in inflammatory settings, explaining 
paracetamol’s lack of an anti-inflammatory effect. Certain types of monocyte-
marcophage cell lines require over 200 times the concentration of paracetamol to achieve 
the same block in PGHS activity given the same AA stimulation because of their 
considerably greater peroxide tone (Fels et al. 1982; Martin et al. 1984; Sun et al. 1996). 
Indeed, there is evidence that concentrations of paracetamol that completely inhibit PG 
synthesis in endothelial cells actually stimulated PG synthesis in some types of 
inflammatory cells (Aronoff et al. 2006). 
1.2.4.1.2.4 OTHER POSTULATED MECHANISM OF ACTION 
COX-3, a splice variant of the constitutive PGHS (COX)-1, has been suggested to be the 
site of action of paracetamol (Chandrasekharan et al. 2002), but genomic and kinetic 
analysis indicates that this selective interaction is unlikely to be clinically relevant 
(Bertolini et al. 2006).  
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There are many other theories surrounding the pharmacology of paracetamol including a 
central serotonergic mechanism through agonism of 5HT-3, supported by the antagonism 
of paracetamol’s analgesia by tropisetron and granisetron, (Alloui et al. 2002; Pickering et 
al. 2006; Pickering et al. 2007) and activation of cannabinoid receptors (Bertolini et al. 
2006). Despite initial theories of similar mechanism to salicylates (Woodbury 1965) and in 
vivo effects similar to a COX-2 inhibitor, clinically today, paracetamol is almost 
unanimously considered to have no peripheral anti-inflammatory activity. 
Research into this area is complicated by many factors: major differences in both in vitro 
and in vivo effects of paracetamol on PG biosynthesis (Danon et al. 1983); variability in 
PGHS activity depending on source of PGHS; problems controlling co-factor 
concentrations (Aronoff et al. 2006); and in vivo effects also being procedure dependent 
(Gray et al. 2005). In a comment still relevant today, Prescott wrote in his 1996 
bibliographic review of all studies researching into the mechanism of action of 
paracetamol, that: 
“Paracetamol may either inhibit, stimulate or have no effect on prostaglandin 
synthesis depending on the tissue selectivity, the source of the enzyme, the drug 
concentration, the presence or absence of cofactors and experimental conditions. 
The role of prostaglandins in the peripheral analgesic actions of paracetamol 
remain a subject for debate” (Prescott 1996). 
1.2.4.2 PHARMACOKINETIC PROPERTIES 
At concentrations achieved following licensed doses the pharmacokinetics of paracetamol 
are linear, independent of dose and constant with repeated administration (Bannwarth et 
al. 2003). Each of the four factors that influence drug pharmacokinetics, absorption, 
distribution, metabolism and elimination are now discussed.  
1.2.4.2.1 ABSORBTION OF PARACETAMOL  
An advantage of paracetamol is that it is available for oral, IV or rectal administration.  
1.2.4.2.1.1 ORAL 
Paracetamol is rapidly absorbed following oral administration by passive transport 
according to first-order kinetics (Heading et al. 1973). In humans, the majority of 
paracetamol is absorbed from the jejunum (Ueno et al. 1995). The increased rate of 
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absorption from the small intestine is thought due to the greater surface area and hence 
absorptive capacity, compared with the stomach or colon (Prescott 1996). Accordingly, 
gastric emptying is the rate limiting step of absorption. Delays to gastric emptying have 
substantial impact on paracetamol absorption (Kennedy 1996). Peak plasma 
concentrations are obtained 0.5-1.5hrs after intake of standard tablets or capsules. With 
effervescent tablets, drug absorption and onset of action are more rapid than with 
conventional tablets. Oral paracetamol has an absorption half-life of 4.5 minutes with no 
lag time. There are approximately 25% first pass losses which vary with the dose and 
number of doses and accordingly bioavailability varies from 60 to 98% (Clissold 1986). 
Food does not affect the extent of absorption, but does reduce the rate by up to 49% in 
one study of healthy volunteers. The maximum plasma concentrations from 1g of 
paracetamol reduced from 12.6μg/mL to 6.38μg/mL between the fasted and fed states 
(Stillings et al. 2000).  
1.2.4.2.1.2 RECTAL 
Paracetamol absorption from the rectum is incomplete and slow when compared with 
oral absorption. There is wide variation in absorption between individuals and may be 
greater in children than adults (Hahn et al. 2000; Bannwarth et al. 2003; Pettersson et al. 
2006). There is an absorption half-life of 35 minutes, with a 40 minute lag time and a 
reduced area-under the concentration time curve (Anderson et al. 1996). Because of this 
delay, peak concentrations are reduced and occur up to two hours after administration, 
resulting in unsatisfactory analgesia (Prescott 1996). The relative bioavailability of a 
suppository compared with a suspension has been shown to be as low as 30% but is 
generally considered to range from 60 to 90% (Dange et al. 1987). Rectal temperature can 
also effect the rate and extent of absorption, with a significant effect being shown in 
infants (van Lingen et al. 1999). 
1.2.4.2.2 DISTRIBUTION OF PARACETAMOL 
Paracetamol is rapidly distributed following IV administration with a half-time of less than 
20 minutes (Clements et al. 1984) and has been modelled both a non-compartmental and 
two compartment model (Rawlins et al. 1977; Rowland et al. 1995; Allegaert et al. 2004; 
Liukas et al. 2011). It has a volume of distribution (Vd) 9L/kg (Flouvat et al. 2004) in adults 
and is similar in young and elderly subjects of either sex (Prescott 1996). At therapeutic 
concentrations, generally considered to be less than 30mg/L, paracetamol’s protein 
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binding is negligible (Clissold 1986) but can increase up to 50% in overdose (Milligan et al. 
1994; Klasco 2009). In obesity, the weight corrected Vd is reduced (Prescott 1980; Depre 
et al. 1992; Ward et al. 1999). 
Paracetamol distributes relatively evenly between tissue and plasma with concentrations 
lowest in the fat and cerebrospinal fluid and highest in the liver and kidney. It is 
distributed into the brain and cerebrospinal fluid in small and variable amounts by passive 
diffusion. Here paracetamol has a delayed and sustained peak concentration that occurs 
two to three hours after administration (Bannwarth et al. 1992; Klasco 2009). 
Paracetamol is also distributed in the saliva where its concentration is similar to that in 
plasma. Saliva can be seen as an ultra-filtrate of plasma and for some compounds the 
saliva: plasma ratio is constant (Fuhr et al. 1993; Fuhr et al. 1994). Secretion into saliva is 
suggested to be by passive diffusion, which will vary depending on the solubility of the 
drug in the saliva and salivary glands. Factors which determine this solubility include: the 
pH of saliva and lipid solubility, molecular mass, spatial configuration, pKa and extent of 
plasma protein binding of the drug (Häckel et al. 1996; Skopp et al. 1999). Small 
hydrophilic drugs show the best correlations, as the equilibration and equal partitioning 
between plasma and saliva is rapid enough to be clinically useful for monitoring. 
Saliva sampling has been used for determining paracetamol pharmacokinetics, however 
there are some issues with this technique: 
 Only unbound drug can partition into saliva, so alterations to plasma protein 
binding or plasma protein concentration can invalidate results; 
 Saliva more accurately reflects arterial concentrations, rather than venous (Posti 
1982), raising questions over the accuracy especially during the absorptive phase 
of oral formulations (Smith et al. 1991); 
 Bias towards increased saliva concentrations are seen when compared with 
plasma values (Borin et al. 1989); 
 The concentration of paracetamol’s metabolites do not correlate, making it 
unreliable if metabolite patterns are needed (Al-Obaidy et al. 1995; Prescott 
1996). 
Saliva concentration still may have a clinical role in diagnosis and treatment of overdose; 
one study showed no false negatives, although false positives were seen (Wade et al. 
2008). While there are obvious advantages over the more invasive plasma sampling 
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methods, more than one in five patients still reported difficulty with saliva sampling 
(Wade et al. 2008).  
1.2.4.2.3 METABOLISM OF PARACETAMOL  
Paracetamol’s metabolism is complex, involving all of the body’s major pathways of drug 
metabolism. It has a mixed, competitive and sequential biotransformation pattern shown 
in Figure 1.2-4, Figure 1.2-5 and Figure 1.2-6 that results from Phase I oxidation 
competing with Phase II conjugation (Clissold 1986; Zamek-Gliszczynski et al. 2006). While 
metabolism is commonly shown as Figure 1.2-5, which accounts for the majority of 
metabolites, there are also several short-lived metabolites that are shown in Figure 1.2-6. 
The liver has the greatest mass of drug metabolising enzymes and is the primary site of 
paracetamol metabolism, although drug metabolising enzymes are present in many other 
places in the body (e.g. the blood, gut, liver, kidney, lungs). Typical products of 
metabolism are inactive, detoxified and more likely to be excreted in the urine or faeces 
(via bile) (Kennedy et al. 1998). The same metabolic pathways of paracetamol are used 
for and regulated by transformation of other substrates that naturally occur in the body 
i.e. cortisol and ketones. The role of Phase I and Phase II pathways in the metabolism of 
paracetamol is now considered. 
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Figure 1.2-4 Metabolism of Paracetamol (Prescott 1996) 
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Figure 1.2-5 Paracetamol metabolism shown as structural formulas 
1.2.4.2.3.1 PHASE I METABOLISM- THE ROLE OF CYP450 ENZYMES 
The Phase I pathway is a minor but important contributor to paracetamol metabolism. 
Although involving only about 5-10% of a licensed dose, this pathway is important for two 
reasons: 
 The toxicity of its product, NAPQI; 
 The inconsistent activity and variable expression of the cytochrome P450 (CYP450) 
mixed function oxidase enzymes involved.  
The production of NAPQI is the only toxic element of paracetamol’s metabolism and it is 
the only dose-limiting factor (Zaher et al. 1998). NAPQI is a potent electrophile and is so 
toxic to the liver that it is often used as a model toxin to understand the mechanisms of 
hepatic cell injury and death (Davies et al. 1991; Elferink et al. 2008). It binds covalently to 
critical cellular proteins in hepatocytes resulting in covalent modification and inhibition of 
enzyme activity. Mitochondrial proteins are especially sensitive to these changes and 
ultimately this leads to a loss of mitochondrial energy production. Once intracellular 
antioxidants are depleted, NAPQI also causes genomic injury and cell death through both 
necrosis and apoptosis (James et al. 2003).  
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Figure 1.2-6 All elements of paracetamol metabolism showing all short-lived metabolites with major metabolites 
underlined in bold 
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Loss of energy production in the cell also compromises Phase II conjugation processes, 
processes that would otherwise detoxify NAPQI or prevent its formation (Dills et al. 
1986)(section to 0). At worst, these processes culminate in fulminant liver failure and 
death (Hinson et al. 2004; Grypioti et al. 2006). The CYP450 enzymes which produce 
NAPQI are subject to genetic and environmental influence. These cause induction, 
inhibition and polymorphisms of these enzymes. Subsequently, CYP450 enzymes are a 
major source of inter and intra-patient variability in drug response and toxicity of 
paracetamol and many other drugs. Because of their frequent involvement in drug 
metabolism, the understanding of these changes is an area of intense research (Zamek-
Gliszczynski et al. 2006). While the normal role of the CYP450 enzymes to paracetamol 
metabolism is discussed here, further details of the CYP450 enzymes are given in Section 
1.5, while details of CYP450 changes relevant paracetamol metabolism in the surgical 
patient are given in section 1.3 and 1.4. 
The main function of Phase I reactions is to add or reveal sites for Phase II reactions, and 
usually does not result in large changes to molecular weight or water solubility of the 
substrate/drug. Other enzyme families do contribute to Phase I metabolism of other 
drugs, but, as is the case with paracetamol, CYP450 enzymes account for the vast majority 
of Phase I metabolism. 
The CYP450 family is comprised of many isoforms, all of which have differing affinity for 
substrates. Many isoforms of CYP450 have been shown to oxidise paracetamol to NAPQI 
in vitro and in vivo. While there can be considerable variation between individuals, these 
enzymes exhibit even greater inter-species preferential differences (Hong et al. 1987; 
Johansson et al. 1990; Schenker et al. 2001; Walubo et al. 2004). This is relevant to the 
study of paracetamol because, as a known toxin, much of the research pertinent to 
paracetamol use in stressed patients has been done in animal models. In humans, CYP2E1 
has been shown consistently to account for over 90% of the Phase I metabolism of 
paracetamol at licensed doses (Anundi et al. 1993; Manyike et al. 2000). This has been 
confirmed by various inhibition and induction studies that have shown paracetamol’s 
preference for CYP2E1. Post-mortem histological studies of patients who have died from 
paracetamol overdose have also shown that the zonation of hepatocyte death to be 
consistent with CYP2E1 distribution (Anundi et al. 1993; Manyike et al. 2000). 
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CYP2E1 metabolises very few other drugs. Furthermore, no other drugs in common 
clinical use are known to cause clinically significant induction or inhibition of CYP2E1, 
resulting in few drug interactions, further contributing to paracetamol’s safety 
(Bannwarth et al. 2003). 
At doses of paracetamol exceeding 1g in humans other CYP450 enzymes may be involved. 
CYP2E1 is a low capacity, high affinity enzyme and at higher concentrations of 
paracetamol it may be overwhelmed leading to the involvement of CYP450 enzymes 
CYP1A2, 2D6 and particularly 3A4 (Harvison et al. 1988b; Anundi et al. 1993; Prescott 
1996; Frye et al. 1997; Chen et al. 1998; Tonge et al. 1998; Dong et al. 2000; Manyike et 
al. 2000; Zhu et al. 2001; Tanaka et al. 2003; Sharma et al. 2004; Zhou et al. 2004; 
Jaeschke et al. 2006; Laine et al. 2009). The low-capacity nature of CYP2E1 may explain 
some of the interspecies differences in paracetamol metabolism shown in studies. Doses 
used in animal studies typically greatly exceed those used in humans and such doses 
would increase the involvement of other CYP450 enzymes (Prescott 1996). Similarly, the 
use of supra-therapeutic doses in experimental animals may have also contributed to 
fears that some CYP450 inducers (e.g. rifampicin (Prescott et al. 1981), caffeine (Tsutsumi 
et al. 1989)) or inhibitors (e.g. cimetidine (Miners et al. 1984a)) could increase risk of 
paracetamol toxicity, all of which have not been shown in humans (Rumack 2004). 
The product of the Phase I metabolism of paracetamol, NAPQI, is then subjected to 
further metabolism by Phase II pathways, along with 80-90% of the remaining, 
unmetabolised paracetamol.  
1.2.4.2.3.2 PHASE II METABOLISM 
Unusually, three Phase II reactions contribute to the metabolism of paracetamol: GSH 
conjugation, sulphonation and glucuronidation. Phase II reactions increase the water 
solubility and molecular weight of a compound and add a negative charge. Substrates of 
Phase II metabolism, such as paracetamol are normally lipophilic and diffuse into the 
intracellular space of the hepatocyte. Conversely, the products of Phase II conjugation are 
typically too hydrophilic to diffuse across the hepatocyte membrane and require active 
transport either across the canalicular membrane into bile or basolateral membrane into 
sinusoidal blood for later excretion into the urine (Zamek-Gliszczynski et al. 2006). Phase 
II metabolism can occur either: 
 40 
 
 Directly on a parent drug containing an appropriate metabolic handle; or as more 
often is the case 
  On functional groups added or exposed by Phase I oxidation reactions. 
The first case is seen in the esterification of paracetamol’s phenolic hydroxyl group with 
either glucuronic acid or sulphate, while GSH conjugation of the Phase I product NAPQI 
exemplifies the second case (Zamek-Gliszczynski et al. 2006). The relative contributions of 
these reactions are detailed in Figure 1.2-4 (Gregus et al. 1988). Sulphonation and 
glucuronidation reactions often compete for the same substrate (Mulder 1986). 
Glucuronidation involves the transfer of glucuronic acid from its carrier uridine 
diphosphate-glucuronic acid (UDP-GA) to hydroxyl, amino, carboxyl and sulfhydryl groups 
resulting in a more acidic, water soluble compound (Kaushik et al. 2006). This transfer is 
undertaken by UDP-glucuronosyltransferase (UGT) enzymes which transfer the glucuronic 
acid. UDP-GA is synthesised in the cytoplasm and requires glucose-1-phosphate (G1P) 
conjugation to uridine diphosphate which is finally oxidised to UDP-GA. The preferential 
source of the G1P, whether endogenous or exogenous, is not known, however impaired 
glucuronidation in calorie malnutrition and hypoxia have been reported. Although oxygen 
is not required for this pathway, hypoxia is known to induce glycolysis, which in turn 
reduces the availability of glucose for UDP-GA formation. In vitro this can be overcome by 
endogenous glucose administration indicating that exogenous and endogenous sources of 
glucose have a role (Aw et al. 1984; Aw et al. 1991) (Figure 1.2-7). 
 
Figure 1.2-7 Glucuronidation pathway in Homo sapiens (Pico et al. 2008) 
As with CYP450 enzymes, UGT enzymes are also sub-classified, with the isoform UGT1A6 
largely responsible for paracetamol glucuronidation. UGT are relatively constitutive and 
undergo sparse modulation. Induction of UGT enzymes results in only a two to three fold 
increase in total protein, substantially less than seen with CYP450 enzymes (Zamek-
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Gliszczynski et al. 2006). Glucuronidated compounds are generally pharmacologically 
inactive because their lipid solubility is reduced, making crossing cell membranes unlikely, 
and their structure is altered, which modifies their interaction with receptors (Kaushik et 
al. 2006).  
Paracetamol is also a substrate of two sulphotransferases (SULT), 1A1 and 1A3. These 
enzymes specialise in catalysing sulphonation of hydroxyl groups and monoamine groups 
on phenolic-type molecules. Sulphonation is governed by availability of inorganic sulphate 
and the rate of SULT activity; the depletion of the former and the saturation of the latter 
leads to the sulphonation being overwhelmed (Zamek-Gliszczynski et al. 2006). The 
inorganic sulphur is essential for the synthesis of the co-factor 3’-phosphoadenosine-5’ 
phosphosulphate (PAPS) (Figure 1.2-8) and is absorbed from the diet or produced from 
oxidation of sulphur containing amino acids. The high affinity, low capacity nature of SULT 
enzymes and low concentration of co-factor mean that, while sulphonation predominates 
over other processes at low substrate concentrations, they are saturated readily. Once 
overwhelmed, glucuronide conjugation predominates as substrate concentrations 
increase (Zamek-Gliszczynski et al. 2006). 
 
Figure 1.2-8 Sulphonation pathway in Homo sapiens (Pico et al. 2008) 
Sulphonation often works in tandem with glucuronidation on overlapping substances. In 
paracetamol metabolism sulphonation plays a smaller role (30-35%) than glucuronidation 
(50-60%) at licensed doses (Gregus et al. 1988). In addition to differing enzyme affinity, 
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the predominance of glucuronidation over sulphonation may be explained by the 
concentrations of their respective co-factors. Hepatic PAPS has a concentration in 
humans of ≈23 nmol/g liver compared with ≈300 nmol/g liver of UDP-GA. The hepatic 
PAPS concentration is low enough to be depleted rapidly and is at concentrations lower 
than those required for maximum SULT velocity (Zamek-Gliszczynski et al. 2006). PAPS 
can be synthesised quickly and it is the supply and hepatocellular concentrations of 
inorganic sulphate, not the hepatic biosynthesis of this co-factor that is thought to be the 
rate limiting step of sulphonation in vivo (Hjelle et al. 1985; Zamek-Gliszczynski et al. 
2006). Inorganic sulphate too is much lower than its glucuronidation counterpart G1P. 
Whereas G1P is essential for cellular respiration and in high concentrations, the inorganic 
sulphate is supplied from catabolic processes that supply and breakdown cysteine. 
Accordingly as inorganic sulphate concentration dwindles, PAPS is depleted rapidly and 
sulphonation is reduced (Mulder et al. 1978; Hjelle et al. 1985; Kim et al. 1992). While this 
exhaustion of sulphonation co-factor occurs readily in man, saturation of glucuronidation 
co-factor is virtually unachievable, requiring plasma paracetamol concentrations 100 fold 
greater than those needed for sulphonation exhaustion (Reith et al. 2009), equating to 
massive paracetamol doses of several 100mg/kg (Hjelle et al. 1985; Zamek-Gliszczynski et 
al. 2006; Lee et al. 2007). Despite consistent reductions in sulphonation with increasing 
doses of paracetamol, the result is that the combined rate of sulphonation and 
glucuronidation reactions is linear and the hepatic extraction ratio of paracetamol 
remains relatively constant (Clements et al. 1984).  
Whereas sulphonation activity is highest in the periportal region of the liver, where 
xenobiotics are first presented, glucuronidation mostly occurs in the perivenous region, 
where Phase I oxidation greatest, on whose products Phase II reactions generally depend 
(Anundi et al. 1993; Zamek-Gliszczynski et al. 2006). As paracetamol doses are increased 
or repeated, sulphonation processes are unable to cope and paracetamol continues 
towards the centre of the lobule and into areas of increased glucuronidation (Clements et 
al. 1984). While this reduction could be due to co-factor exhaustion, it could also occur as 
a result of enzyme saturation. Complicating this differentiation is the critical differences in 
sulphonation activity between mice and rats, in which the majority of these studies are 
based. Whereas sulphonation in rats is limited by depletion of PAPS, in mice it is limited 
by SULT activity (Dalhoff et al. 1993; Kim et al. 1995a; Liu et al. 1996). 
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From this discussion it may seem that glucuronidation makes sulphonation redundant, 
however sulphonation’s role in paracetamol metabolism is still an important one in 
preventing toxicity. This importance of sulphonation is demonstrated in two groups of 
individuals. Firstly, children have greater expression of SULT enzymes compared with 
adults and this is thought to confer their tolerance for much greater mg/kg doses of 
paracetamol (van Lingen et al. 1999; van der Marel et al. 2003; Allegaert et al. 2004). 
Secondly are those with defective transport of inorganic sulphate into the cell. These 
individuals have reduced sulphonation capacity and are more susceptible paracetamol-
induced hepatotoxicity (Lee et al. 2006). Indeed, genetic variations that impair almost 
every aspect of sulphonation have been identified and linked to increased sensitivity to 
paracetamol hepatotoxicity (Nowell et al. 2006; Dawson et al. 2007). 
Both glucuronide and sulphate conjugates have much smaller Vd than paracetamol and 
their rates of formation are much greater than their excretion, both of which lead to their 
accumulation in plasma (Sahajwalla et al. 1991; Miners et al. 1992; Haderslev et al. 1998). 
Another Phase II reaction, GSH conjugation, takes place on the product of the 5-10% of 
the paracetamol dose metabolised by the Phase I pathway, NAPQI. As a potent 
electrophile and Phase I metabolite, NAPQI is a typical substrate for GSH conjugation. 
GSH conjugation results in the detoxification of NAPQI which could otherwise bind 
covalently to intracellular macromolecules (Corcoran et al. 1980; Nelson 1990; 
Tirmenstein et al. 1990). Similarly to its substrate NAPQI, GSH conjugation accounts for 
only a small percentage of the overall phase II metabolism but without it paracetamol 
would be universally toxic at licensed doses (Tirmenstein et al. 1990). 
GSH is a substrate naturally occurring in the body, but the body’s ability to synthesise GSH 
is limited. GSH is synthesised by the formation of a peptide bond between glutamic acid 
and cysteine, followed by the addition of glycine. GSH is in high concentrations in the liver 
and conjugation may occur spontaneously, although it is much more efficient when 
catalysed by glutathione S-transferase (GST). Hepatic concentrations of GSH are by far the 
highest of the co-factors utilised in the three Phase II reactions discussed. Consequently 
intracellular GSH is difficult to deplete, although it can be accomplished with extremely 
high amounts of substrate. Hepatic supplies of reduced GSH begin to be depleted over a 
range of 0.5 to 3gm of paracetamol (Lane et al. 2002). A toxic dose of paracetamol can 
deplete GSH levels by as much as 90% (James et al. 2003; Buzaleh et al. 2005). 
Anaesthetics place an additional demand on GSH in the surgical patient, reducing stores 
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by as much as 30%. With GSH depleted, severe hepatotoxicity can occur. This is the 
situation following overdose of paracetamol. Here the large amount of NAPQI 
overwhelms available stores of GSH. If not bound by GSH, NAPQI is free to bind to 
hepatocellular proteins as discussed above. Accordingly, it is the body’s limited ability to 
synthesise GSH that determines the safe dose of paracetamol and why single high doses 
are more toxic that the equivalent divided dose. Any increase in the ratio of NAPQI to 
GSH generally results in toxicity. This can occur when too much paracetamol is given or 
when changes to metabolism produce more NAPQI, or less GSH. Potential causes of 
increased apparent production of NAPQI are discussed further below and in Sections 1.3 
and 1.4.  
GSH production can be increased with the administration of additional N-acetyl-cysteine, 
which is used clinically as the antidote to paracetamol toxicity. GSH conjugates are 
commonly hydrolysed sequentially to form a cysteine metabolite followed by N-
acetylation to form a mercapturate metabolite, as is the case with paracetamol (Prescott 
1996; Zamek-Gliszczynski et al. 2006). 
In the Phase II metabolism of paracetamol, the per cent of paracetamol metabolised by 
sulphonation decreases with increasing doses (Clements et al. 1984). This in itself is not of 
concern as glucuronidation is more than capable of maintaining paracetamol’s Phase II 
metabolism. What is of concern is the complex interaction between sulphonation, GSH 
conjugation and their respective co-factors (Figure 1.2-9) and if this exhaustion of 
sulphonation could reflect and even cause deficiency of GSH and reduce conjugation of 
NAPQI (Mannery et al. 2010). This is because cysteine can be used as a precursor for both 
sulphonation and GSH conjugation. 
Cysteine
Diet
Body protein 
breakdown 
Methionine via 
transsulfuration
Paracetamol- 
sulphate
Glutathione
Inorganic 
Sulphate
Paracetamol
Paracetamol-
cysteine
NAPQI
 
Figure 1.2-9 Sources and fate of cysteine in paracetamol metabolism. GSH is both a source and consumer of cysteine. 
Inhibition of sulphonation does not increase GSH synthesis (adapted from (Lu 1999)) 
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The complexity of the interaction is demonstrated following administration of the 
antidote to paracetamol poisoning, n-acetyl cysteine which, as mentioned above, is 
merely a source of cysteine. This alters the pattern of urine excretion of paracetamol, 
increasing the GSH conjugates by 10%, but also resulted in a substantial 27% increase in 
the excretion of the sulphate conjugate (Lauterburg et al. 1983; Slattery et al. 1987). 
The demands for sulphonation in vivo are quantitatively greater than that of GSH 
conjugation, not only for paracetamol metabolism, but for homeostasis in general. When 
there are demands on both sulphonation and GSH, cysteine is diverted from GSH 
biosynthesis to synthesis of PAPS in an attempt to preserve sulphonation capacity 
(Dalhoff et al. 1993).  
In addition to these limitations on synthesis, dietary sources in fasting, malnourished or 
elderly patients are normally not sufficient in cysteine for paracetamol metabolism 
anyway (Reicks et al. 1988; Gregus et al. 1994a; Gregus et al. 1994b; Raguso et al. 2000; 
Joint FAO/WHO/UNU Expert Consultation on Protein and Amino Acid Requirements in 
Human Nutrition 2007; Nimni et al. 2007; Mannery et al. 2010). When demands exceed 
dietary intake, cysteine is produced endogenously by catabolism of one of three sources 
(in descending order of prominence):  
 Methionine and serine (via the transsulphuration pathway);  
 GSH stores; and 
 Body protein (Di Buono et al. 2003; Pujos-Guillot et al. 2011). 
In those with diets insufficient in cysteine, supplies of methionine are also likely to be 
lacking as they are generally present in a 1:1 ratio (Nimni et al. 2007). If dietary supplies 
of cysteine or methionine are limited, further cysteine can be supplied from catabolism of 
GSH. This is limited by the supply of GSH and occurs at the expense of GSH conjugation 
(Moriarty-Craige et al. 2004). This source of cysteine is especially relevant to paracetamol 
metabolism as it is GSH that detoxifies NAPQI, and the breakdown of GSH for cysteine 
may harm this process and increase the risk of paracetamol toxicity (Blackledge et al. 
1991; Wu et al. 2004). The depletion of GSH stores for cysteine was shown initially in 
experimental animals given diets deficient in cysteine and methionine which led to a GSH 
reduction of up to 60% (Rozman et al. 1992) More recent evidence in humans support 
this observation with anorexic individuals deficient in sulphur amino acid intake shown to 
have 30% less GSH than controls (Zenger et al. 2004). The extent of paracetamol’s 
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demands on this system were shown when therapeutic doses were shown to significantly 
decrease plasma GSH concentrations above that consumed in GSH conjugation, showing 
its role as a pool of cysteine (Moriarty-Craige et al. 2004; Mannery et al. 2010). 
The final source, body protein, is catabolised at the expense of muscle growth and repair 
(McLean et al. 1989) and it is this protein catabolism for inorganic sulphate that is 
thought to determine the rate of obligatory nitrogen loss (Millward 1998). Fasting 
patients receiving 4g of paracetamol a day are estimated to mobilise up to 50g of skeletal 
muscle per day to supply the cysteine required for paracetamol’s metabolism and 
homeostasis (Pujos-Guillot et al. 2011). The implications of this skeletal muscle 
catabolism were demonstrated in rats fed a diet of 1% paracetamol devoid of sulphur 
containing amino acids. These rats failed to grow until cysteine and methionine were 
replaced in their diet, a phenomena not seen with this dietary restriction alone (McLean 
et al. 1989). A similar study in rats given methionine-deficient diets showed prolonged 
paracetamol administration caused significant weight loss through protein catabolism 
(Reicks et al. 1988). In humans, colon carcinoma cells have shown similar results with 
cysteine deficiency inhibiting cell division and decreasing intracellular GSH concentration 
(Miller et al. 2002). 
Final hurdles may arise to the sulphonation of paracetamol, even in the presence of 
adequate plasma concentrations. Inorganic sulphate, once sourced from the catabolic 
processes detailed above, must be then transported into the cell (Hendrix-Treacy et al. 
1986). Like many of the transporter molecules in the body the activity of these 
transporters are affected by stress. Even if the rate of formation was unaffected 
membrane bound transport molecules must transport the newly sulphonated compound 
back out of the cell (Buist et al. 2003; Chu et al. 2004). These transporters are also 
suspected to be downregulated in times of stress (Chu et al. 2004). 
Despite the evidence for sulphate depletion, there is also support for saturation of 
sulphotransferase activity as the major factor restricting the rate of paracetamol 
sulphonation, not the depletion of inorganic sulphate (Blackledge et al. 1991). This would 
be a preferable situation for the safety of paracetamol as GSH conjugation of NAPQI 
would be unaffected. In chronic dosing studies, recovery of paracetamol, particularly as 
the sulphate conjugate, drops along with total urinary sulphate output (Pujos-Guillot et 
al. 2011), but in all cases there was still some inorganic sulphur in the urine (Blackledge et 
al. 1991), and plasma concentrations of GSH, plasma sulphates and amino acids were 
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largely unaffected (Mannery et al. 2010; Pujos-Guillot et al. 2011). When overdoses of 
paracetamol have been taken over prolonged periods paracetamol sulphate is produced 
and inorganic sulphate is still quantifiable in plasma. One alternative explanation for this 
is that shifts towards glucuronidation occur well before free sulphate stores are depleted 
(Blackledge et al. 1991) and this suggests that plasma levels of inorganic sulphate must be 
sufficiently high for sulphonation to work effectively. This may be caused by limitations of 
the transport of cofactors. Cofactors of sulphonation are synthesised intra-cellularly and 
rely on active transport to maintain intracellular concentrations of their precursors, 
mainly inorganic sulphate (Lee et al. 2006). Demand may exceed the capacity of these 
sulphate transporters. Alternatively homeostatic inhibition of these transporters may 
occur given the essential roles sulphonation has. Several critical metabolically active 
hormones are deactivated by inorganic sulphate including the catecholamines, 
norepinephrine and dopamine amongst many other (Roth et al. 1982; Kauffman 2004), 
which are increased following surgery (Yoshizumi et al. 1998).  
While plasma concentrations of these sulphur compounds have been shown to remain 
steady, what is missing from this story is what is happening to the hepatocellular 
concentration of these compounds. 
There is a substantial difference in plasma concentration of inorganic sulphate during the 
day, with concentrations exhibiting a circadian rhythm, lowest at 1100 and highest 1900 
hours with a 25.8% average difference between the high and low concentrations. In one 
study repeated administration of 650mg paracetamol four times a day for four day 
reduced inorganic sulphate by 30.1%. Circadian rhythm still occurred, with the difference 
between the high and low increasing to 31.3% (Hoffman et al. 1990). This study also 
showed reduced renal excretion and renal clearance of inorganic sulphate by 51 and 33% 
respectively (Hoffman et al. 1990) 
Additionally, the increase in catecholamines that arise from the stress response may 
compete with paracetamol for metabolism by SULTs but also are known to suppress the 
activity of transporter molecules (Morgan et al. 2008). The findings of Slattery et al, that 
administration of n-acetylcysteine dramatically increases the formation clearance of 
sulphate and GSH conjugates, support this proposition. This also illuminates the different 
mechanisms behind the toxicity of acute and chronic paracetamol overdose. While acute 
overdose brings about the immediate exhaustion of GSH stores, chronic usage causes the 
gradual subjugation of GSH synthesis to NAPQI production (Slattery et al. 1987). 
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Dietary deficiencies of sulphate and cysteine alone has no major effect on paracetamol 
conjugation but their combined deficiency caused a significant decrease in excretion of 
the sulphate conjugate (Krijgsheld et al. 1981)Serum inorganic sulphate levels were 
elevated in patients who take paracetamol regularly (Hendrix-Treacy et al. 1986), and 
there is evidence the endogenous synthesis of cysteine is increased. 
Finally, this interaction between sulphonation and GSH conjugation raises questions over 
the reliability of previous assessments of Phase I metabolism of paracetamol which is 
generally obtained through measures of paracetamol cysteine and its metabolite 
paracetamol mercapturate in urine. If GSH supply was limited, this may also restrict 
conjugation of NAPQI and produce less paracetamol cysteine. It would follow that 
recovery of paracetamol would reduce with chronic and elevated doses and this has 
indeed been shown in these situations (Pujos-Guillot et al. 2011). After 14 days of 
receiving 3g/day of paracetamol, a group of 10 elderly men and women had overall 
reductions urinary excretion of paracetamol to only 77% of the daily dose at day fourteen 
(Pujos-Guillot et al. 2011). This value is substantially lower than the 85-95% recovery 
reported in healthy adults (Forrest et al. 1982). Excretion of paracetamol sulphate was 
particularly effected, reducing to less than 20% of the total paracetamol excreted in the 
urine, compared to the 30-35% reported in healthy adults (Clements et al. 1984). Over 
the 14 day course substantial amounts of sulphur were excreted in the urine but despite 
this there was no significant effect on plasma sulphate concentrations or amounts of 
sulphur containing amino acids. This indicated activity of homeostatic mechanisms to 
maintain sulphate concentrations and indeed evidence of increased activity of the 
transulphonation pathway was shown. Curiously these patients spontaneously increased 
their dietary protein intake (Pujos-Guillot et al. 2011).  
1.2.4.2.3.3 SATURATION OF PARACETAMOL METABOLISM 
As discussed above, sulphonation has a limited capacity in man. A study comparing 
paracetamol doses of 20mg/kg with 5mg/kg, showed dose-dependent sulphate 
conjugation of paracetamol after both IV and oral administration (Clements et al. 1984). 
The reduction of the sulphate conjugation at higher doses is matched by increases in 
glucuronidation. This study also showed much lower renal clearance of paracetamol 
sulphate at the higher dose, indicating saturation of both the formation and the renal 
clearance of the sulphate conjugate. It also observed that higher doses of paracetamol 
lead to a reduction in paracetamol’s plasma clearance. 
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A more recently published study by Gelotte et al. (2007) examined the disposition of 
paracetamol in healthy young adults at doses of 4, 6 and 8g/day for three days. Gelotte et 
al. suggests there is evidence that with increasing doses, paracetamol induces its own 
glucuronidation, and that the increase exceeds the reduction of sulphonation with a net 
increase in paracetamol clearance overall (Gelotte et al. 2007). The same authors also 
showed that with increasing dose there were statistically significant increases in recovery 
of paracetamol and paracetamol glucuronide but reduction in sulphate in the urine. There 
was no change in the percentage excreted as thiols either in the urine or plasma. The 
authors considered the increase in glucuronidation explained the less than dose-
proportional increase in plasma paracetamol concentration and the absence of a more 
than dose proportional increase in excretion through NAPQI and GSH conjugation, which 
would be expected given the saturation of sulphonation. As part of this, these authors 
postulate paracetamol to be an inducer of UGT1A6.  
The reduction in sulphate excretion has also been shown in other studies to occur on the 
fourth day when patients received lower doses of 650mg every six hours (Hendrix-Treacy 
et al. 1986; Hindmarsh et al. 1991). These studies observed a reduction in serum sulphate 
levels and reduced renal clearance of inorganic sulphate after four days of 650mg 
paracetamol every six hours (Hoffman et al. 1990). However, the study by Hendrix-Treacy 
et al. examining kinetics and disposition of the same dose, 650mg every six hours, after 
chronic dosing, found an increase in plasma sulphate level, suggesting it is the 
sulphotransferases activity rather than sulphate depletion that leads to decreased 
sulphonation in most cases (Hendrix-Treacy et al. 1986).  
1.2.4.2.4 EXCRETION OF PARACETAMOL 
All metabolites of paracetamol are excreted in the urine. Biliary excretion is not an 
important pathway in man at licensed doses (Jayasinghe et al. 1986). Only 2.6% of any 
oral dose is excreted in bile, mostly as the cysteine conjugate. Renal excretion amounted 
to 91.3% of the total dose (Siegers et al. 1984).  
Paracetamol has a clearance of 13.5L/h and a elimination half-life of two-four hours, 
which is prolonged in children and infants (Prescott 1996). 
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1.2.4.3 MAXIMUM DOSE OF PARACETAMOL 
1.2.4.3.1 DOSE AND CONCENTRATIONS 
The current licensed dose of 4g per day in Europe is not well founded on experimental 
evidence and is based on avoidance of toxicity rather than affecting efficacy(Bristol-Myers 
Squibb 2009). This may be due, in part, to paracetamol’s wide therapeutic index. There 
are very few drugs in common use with such a wide mg/kg dose where a 45kg adult 
female would receive the same dose as a 120kg male (22 vs. 8mg/kg), nor are there many 
where the daily dose is considered in grams and not milligrams or micrograms. With 
regard to dose, paracetamol is a fairly blunt instrument. 
There is no clear indication in the literature of an optimal analgesic dose or maximum safe 
dose of paracetamol, nor is there a clearly defined analgesic concentration for 
paracetamol. Ward et al. alerted the pain management community to this dearth of 
information in a prominent journal in 1999, but the question of an analgesic 
concentration still remains unanswered. Prescott refers to a concentration range for 
achieving antipyresis as “probably about 5-20mg/L” (Prescott 1996) but he and more 
recent authors continue to point out that there are few studies in which drug 
concentrations and effects have been measured simultaneously in man (Gibb et al. 2008). 
It is generally accepted the concentration for analgesia is higher than that for antipyresis, 
as suggested by Beck et al. (Beck et al. 2000) and in vitro paracetamol has been shown to 
produce dose-dependent depression of nociceptive activity in rat and human models 
(Carlsson et al. 1987). Replicating these in vitro findings in a clinical setting has proven 
elusive. 
While the majority of drugs exhibit concentration-efficacy relationships, some researchers 
believe that there is no direct correlation between serum concentrations of paracetamol 
and its analgesic or antipyretic effect. They cite the poor correlation between time of 
peak plasma concentration and peak analgesia (Prescott 1996; Bannwarth et al. 2003). 
Other groups have shown a good correlation between plasma concentration and 
effectiveness, once a delayed-response was included (where the maximum effectiveness 
follows Cmax) (Seymour et al. 1981; Nielsen et al. 1992). Gibb and Anderson explain this 
discrepancy as the result of the response not being directly related to the concentration 
in the plasma, but rather an effect compartment, whose concentrations are proportional 
to those found in the cerebro-spinal-fluid (CSF) (Gibb et al. 2008). These authors support 
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this theory by suggesting the delay between the peak concentration in the plasma and 
the peak clinical effect is a result of the partitioning between these compartments. They 
also point out the concentration/time curve following oral dosing of paracetamol 
approaches bell shape with the absorption phase resembling the elimination phase. They 
suggest the symmetry of this curve may confound determining an exact therapeutic 
concentration as, for example, 10mg/L would occur on both sides of the curve’s Cmax 
making it impossible to determine which one conferred the drug’s effectiveness unless 
plasma concentrations are constantly monitored (Figure 1.2-10). These authors suggest 
that a significant difference in pain threshold does occur by one hour post-dose in 
association with a plasma concentration of 12mg/L (Gibb et al. 2008). Other authors still 
relate paracetamol’s peak concentration to the central analgesic effect of paracetamol, 
but without reference to time, finding that intravenous paracetamol is at least as 
effective as oral formulations (Luthy et al. 1993). Although IV and oral formulations have 
equivalent areas of concentration/time curve, there are reports of greater and prolonged 
analgesic activity following IV administration (p<0.01) (Jarde et al. 1997). 
 
Figure 1.2-10 Time and concentration profile following a theoretical oral paracetamol dose  
A concentration of 10mg/L is achieved before (absorption phase) and after (elimination phase) maximum concentration 
(Cmax). The delay between maximum concentration and peak effect is approximately one hour (adapted from (Gibb et 
al. 2008)). 
Because of the lack of a clear therapeutic concentration and the subjective nature of pain, 
some research has used antipyresis as a surrogate marker of adequate concentration 
because it is easier to objectively measure and can be reproduced reliably with the 
administration of endotoxins (Kis et al. 2005). This method is also not without its 
criticisms: 
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 Body temperature is subject to circadian variation which may mask or exaggerate 
temperature reduction;  
 The aetiology of the fever may affect the rate of fever reduction; and 
 The initial temperature may influence the magnitude of drug response (Gibb et al. 
2008). 
One clinical trial examining the paracetamol concentrations of major surgical patients 
receiving rectal paracetamol 1g six hourly, concluded the dose to be too low, citing that 
the concentrations had failed to reach those required for antipyretic effect (10-20mg/L; 
≈66-133μmol/L) (Kvalsvik et al. 2003). Similar results were shown in another study 
examining rectal doses of 20 or 40mg/kg in surgical patients. They also concluded that 
analgesic concentrations may not have been reached, even at the 40mg/kg dose (Beck et 
al. 2000).  
Other research has shown no improvement in pain relief with increasing dose from 1g to 
2g in a dental pain model (Skoglund et al. 1991). Conversely, a systematic review has 
shown the number of patients who need to receive the drug to achieve a 50% relief of 
pain (number needed to treat, NNT) reduced from 5 for a 600 or 650mg paracetamol 
dose to 3.6 for a 1g dose (Moore et al. 1997). This review included data from over 1000 
patients involved in 29 studies of post-dental, postpartum and postoperative pain.  
In paediatric patients, paracetamol is thought to produce dose related analgesia with 15-
20mg/kg, reducing pain scores (Bolton et al. 2002; Tay et al. 2002) compared with 
10mg/kg, which has not been shown to be superior to placebo and was associated with 
high requirements for supplemental analgesia (Watcha et al. 1992).  
This uncertainty over the maximum dose, withdrawal of alternatives and repeated 
evidence of benefit, has contributed to an increasingly widespread trend of doses greater 
than the licensed adult dose (4g/24hr) being used in the perioperative environment. 
Loading doses of 2g intraoperatively have been shown to be superior to 1g in terms of 
magnitude and duration of analgesic effect, improving pain control and reducing 
morphine demand with no additional adverse effect (Juhl et al. 2006; Remy et al. 2006; 
Gregoire et al. 2007). 
Higher doses of up to 6g/24hrs have shown similar results when compared with morphine 
patient-controlled analgesia usage alone (Schug et al. 1998). The usual dose of 1g every 
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six hours has a less than 10mg sparing effect on 24hr morphine consumption and does 
not significantly reduce morphine side effects (Sinatra et al. 2005). 
There is some theoretical rationale for using doses above 4g/24hr. The theory of the 
“effect compartment” proposed by Gibb and Anderson, required paracetamol to 
distribute into and accumulate in theoretical third compartment for therapeutic effect. 
Accordingly, the simplest method to reduce paracetamol’s time to effect is to increase 
the dose, in a similar way to the loading doses used for other drugs.  
This has been shown experimentally. A dose of 1g every six hours has been shown to be 
insufficient even to produce antipyresis, however rectal doses of 40mg/kg did produce 
concentrations in this antipyretic range, although they were not shown to be clinically 
superior to 20mg/kg doses (Beck et al. 2000). The study by Korpela et al. demonstrated a 
linear relationship between increasing rectal paracetamol dose and analgesia and showed 
significant differences between 40 and 60mg/kg doses when compared with placebo. 
Another group measured the anti-nociceptive effect of 0.5, 1 and 2g of IV paracetamol in 
11 healthy volunteers and found dose dependent reductions in nociceptive activity of 23, 
28 and 40% respectively (Piguet et al. 1998). Researchers who showed paracetamol 
activity related to cannabinoid receptors also found that paracetamol inhibits COX in the 
brain, but at concentrations not attainable at current analgesic doses (Bertolini et al. 
2006). A study by Temple et al. which gave healthy adults up to 2g every six hours for 3 
days, found no clinically important elevations in aminotransferase levels during or for 
three days after the study (Temple et al. 2007) 
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1.3 CHANGES TO DRUG ABSORPTION, DISTRIBUTION, METABOLISM OR EXCRETION 
DUE TO SURGERY AND ANAESTHESIA 
Surgery is a time when the body faces an extraordinary amount stress over a short 
period. Systemically, anxiety, pain, hemodynamic changes and cardiovascular instability 
(Barker et al. 1987; Kennedy et al. 1998) combine with local proliferation of pro-
inflammatory cytokines, complement factors, acute phase proteins and pituitary 
hormones (Bone 1996). Their combined metabolic effect, referred to as the ‘stress 
response’, produces a catabolic, immunosuppressed state and activates the sympathetic 
nervous system (Bessey et al. 1993). The effect can persist for several days after surgery 
(Kehlet 1996) and is even greater in patients who have pre-existing pathology, a genetic 
predisposition to surgical stress or are of the male gender (Guillou 1993; Pape et al. 2000; 
Ono et al. 2005; Giannoudis et al. 2006). This stressed, catabolic state has many 
implications for drug therapy.  
While the influence of the stress response can be substantial, surgery exposes the body to 
a vast array of other factors that can also alter drug disposition, especially when 
compared with a population of young healthy males, in whom most drug disposition 
studies are based.  
On admission, surgical patients are likely to be of advancing age, have pre-existing 
pathologies, malnutrition and many will be taking multiple medicines. As a result of 
surgery they may also be kept from mobilising and may be kept nil per oral, fasted for 
many days before and after surgery. They will be exposed to a wide range of new drugs 
(patients undergoing major surgery receiving an average of 12 different medications) in 
addition to having their usual medication with-held (Kennedy et al. 2000). Withholding a 
patient’s usual medication can lead to acute abstinence syndromes, such as the 
tachycardia and hypertension that follows abrupt withdrawal of beta-blockers (Nimmo et 
al. 1988). This, in addition to surgical trauma, places an extraordinary amount of stress on 
the body and changes the way it deals with medicines. It has been shown the longer 
patients are without their normal medication, the more non-surgical complications they 
suffer (Kennedy et al. 2000).  
This section discusses the stress response experienced by the surgical patient. It is 
complicated, multifaceted and interlinked (Figure 1.3-1). The impact of the stress 
response on the various aspects of drug disposition; absorption, distribution, metabolism 
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and elimination are detailed below. Where available, the effect on paracetamol 
disposition is given, and where not, examples of drugs that share processes with 
paracetamol are used.  
 
Figure 1.3-1 Stress response schematic showing its complexity of interlinking.  
Solid lines indicate direction of stimulus, broken lines represent suppression. Red boxes show physical symptoms of stress 
response. Abbreviations used: AAG- α1-acid-glycoprotein; ACTH- adrenocorticotropic hormone; AVP- arginine 
vasopressin; CNS- central nervous system; CRH- corticotrophin releasing hormone; HPA- hypothalamic-pituitary adrenal 
axis; PVN- paraventricular nucleus;  
1.3.1 STRESS RESPONSE 
Evolution did not anticipate modern surgery with aseptic techniques and so the body’s 
response to surgical trauma is as if the emergency was infection (Nathan 2002). The stress 
response is mounted in reply to this perceived microbial threat and, to a much lesser 
degree, the insult to cardiovascular homeostasis that also arises from surgery. The extent 
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of inflammatory stress is a key determinant of susceptibility to hepatotoxicity from 
paracetamol (Roth et al. 2010). 
The stress response is an integrated hormonal and metabolic response, rather than a 
series of isolated reflexes. It occurs after injury or trauma and involves both hormonal and 
metabolic systems (Selye 1976). Creating a catabolic state, it is thought to be an 
evolutionary adaptation to allow injured animals to utilise their own fuel stores to survive 
convalescence, sparing glucose for use by neurones (Desborough 2000; Kopp Lugli et al. 
2010). Other systemic changes include; sharpened attention, increased glucose utilisation 
and blood flow to the brain and muscle, modulation of the immune response, inhibition 
of reproductive physiology, decreased feeding and appetite, and water retention 
(Sapolsky 2000). Although virtually all of the body’s systems are eventually affected by 
surgical trauma, the neuroendocrine, cardiovascular, gastrointestinal and immune 
systems are the first to show functional change and subsequent changes to drug 
disposition (Carrasco et al. 2003). The initiation of the stress response varies, depending 
on whether the stressor is an immediate or delayed risk to homeostasis. Stressors that 
are an immediate risk must be transmitted quickly and are processed via the limbic 
insensitive pathway. Delayed risks require sensory processing before becoming stressful 
(limbic stress pathway). An example of this is described in Figure 1.3-2.  
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Figure 1.3-2 Initiation of Stress Response 
Figure shows two pathways of initiation: limbic stress pathway (left) that is slower and occurs in response to less 
imminent danger, and limbic insensitive pathway (right) which is rapid and occurs when there is a perceived threat to 
survival(Drolet et al. 2001). 
A slip of a dentist’s drill is an immediate danger and requires an immediate response, 
whereas the sound of a dentist’s drill is only stressful when compared with memory of 
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the drill slipping in the past. For an individual with previous dental trauma the sound of a 
dentist’s drill evokes a stress response; palms sweat, senses are heightened etc., but the 
response is not as quick as if a new incident had occurred (Herman et al. 1997).  
Historically, the response to injury was thought to consist of three stages: 
 Hypodynamic ebb phase (shock). In the first moments after injury blood flow is 
redirected to maintain perfusion of vital organs and minimise blood loss;  
 Hyperdynamic flow phase. Blood flow is increased to remove waste and provide 
nutrients to the injured area to encourage repair in the first days after injury; and 
 Recuperation phase. Lasting several months, this phase restores the body to pre-
injury conditions (Smith et al. 1998). 
While a useful overview, current opinion is that the response to injury is much more 
complicated than initially described (Giannoudis et al. 2006). 
In modern surgical practice, the stress response, whose main function is the eradication 
of infection, is seen as unnecessary and indeed deleterious to recovery (Giannoudis et al. 
2006). This is due to the widespread use of aseptic techniques and antibiotics, which have 
all but eliminated the dangers once posed by microbial invasion (Nathan 2002). Now the 
need for the surgical stress response has been reduced, progress in surgical care has 
arisen due to the developments in understanding of this response and, most importantly, 
techniques to modify or block it (Desborough 2000). 
The changes to the endocrine and immune systems that arise during the stress response 
are complex and highly interactive. The normal physiological function of each of these 
systems will be briefly described, followed by their role in the stress response. 
1.3.1.1 ENDOCRINE RESPONSE 
The endocrine system is involved in homeostasis through the secretion of various 
hormones from endocrine glands throughout the body into the blood stream. The 
hormones travel in the blood to their target site where they interact with a receptor. The 
hormone-receptor binding is very specific. This triggers the target site to perform a 
specific action and can lead to: 
 Change in function (ranging from that of a single cell through to a whole organ) 
 Alteration of energy usage;  
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 The triggering of growth and development; or 
 In the case of trophic hormones, triggering other endocrine glands to release 
other hormones.  
This enables the endocrine system to regulate many of the other systems throughout the 
body in response to demands of homeostasis (Kohl et al. 2006).  
1.3.1.1.1 INITIATION OF THE STRESS RESPONSE 
From the time of incision, the activity of the endocrine system changes. Somatic and 
visceral afferent neuronal signals travel from the point of injury along sensory nerve roots 
through the dorsal root ganglion, up the spinal cord to the medulla. From there they pass 
through the amygdala and on to the hypothalamic paraventricular nucleus (PVN), 
bypassing the limbic system (Figure 1.3-2). These signals are thought to travel along the 
same fast conducting A-delta fibres as nociceptive signals (Kehlet 1989; Van de Kar et al. 
1999; Desborough 2000).  
Once at the PVN, the signal triggers the hypothalamic-pituitary-adrenal axis (HPA) and 
increases the production of releasing hormones(Egdahl 1959). 
With respect to the stress response, there are two important releasing hormones 
secreted from the PVN: corticotrophin-releasing hormone (CRH) and arginine vasopressin 
(AVP) (Whitnall 1993). These releasing hormones act on the posterior and anterior 
pituitary (Miner 2008). Following secretion, CRH goes into the pituitary portal circulation 
whereas AVP is secreted into posterior pituitary for storage and later release into the 
systemic circulation. 
With the involvement of the locus coeruleus, the sympathetic nervous system is also 
activated by CRH, by increasing release of norepinephrine from presynaptic nerve 
terminals and increasing secretion of epinephrine from the adrenal medulla (de Kloet et 
al. 2008; Guest 2008).  
The majority of these initial processes in the PVN are subject to modulation by 
endogenous opioids, most commonly enkephalin. Endogenous opiate production may be 
stimulated by leukocytes or inflammatory cytokines (Glattard et al. 2010). Opioids 
diminish stress-induced changes in the endocrine system and levels of enkephalin mRNA  
are increased in the PVN after acute stress(Lightman et al. 1987). The mechanism by 
which endogenous opiates act in modulation of the stress response is still uncertain, 
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although opioids have been shown to reduce peripheral nociceptive impulses, which may 
reduce stimulation of the hypothalamus (Drolet et al. 2001; Miner 2008; Glattard et al. 
2010; Madbouly et al. 2010a). 
1.3.1.1.2 EFFECT OF INCREASES IN SYMPATHETIC ACTIVITY 
The increase in plasma concentration of norepinephrine and epinephrine is one of the 
first detectable changes of the stress response, occurring within minutes of incision. The 
increase in concentration is proportional to the extent of injury, although it is short-lived, 
returning to baseline concentrations within hours of the initial trauma (Douglas et al. 
1989).  
This increase in sympathetic tone contributes to the characteristic symptoms associated 
with stress, such as tachycardia, hypertension and peripheral vasoconstriction. The 
efferent sympathetic stimulation and circulating catecholamines also alter the function of 
visceral organs including the kidney, pancreas and liver.  
In the kidney, increased circulatory concentrations of norepinephrine increase production 
of renin. Renin promotes the conversion of angiotensin I to angiotensin II. Angiotensin II is 
a potent vasoconstrictor and also promotes the secretion of aldosterone from the adrenal 
cortex (Ganong 2001). Aldosterone promotes sodium resorption from the distal 
convoluted tubule of the kidney, resulting in reduced urine production (Nicholson 2005).  
In the pancreas, α-adrenergic inhibition by circulating catecholamines prevents β cells 
from secreting insulin, whilst glucagon secretion is transiently increased. Insulin is an 
anabolic hormone normally released from the pancreas after eating, in response to 
increasing concentrations of glucose and amino acids in the blood. Its function is 
threefold:  
 Promoting glucose uptake and utilisation by cells; 
 Promoting glucose storage in the liver as glycogen; and 
 Inhibiting gluconeogenesis, the process of de novo glucose production by protein 
catabolism and lipolysis (Desborough 2000).  
In the absence of insulin, hyperglycaemia develops.  
The effects of inhibiting insulin secretion are further augmented by catecholamine-
induced resistance of cells to the remaining insulin in circulation, and the increase in 
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glucagon release (Thorell et al. 1994; Guest 2008). Glucagon is a catabolic hormone that 
opposes the actions of insulin. It increases hepatic glycogenolysis and gluconeogenesis, 
although its role in postoperative hyperglycaemia is minor compared with the decreased 
insulin secretion and sensitivity (Ni Choileain et al. 2006). Failure of homeostatic 
mechanisms to maintain euglycaemia ensues. 
Stressed individuals are therefore in a catabolic state, hyperglycaemic, oxidising skeletal 
muscle protein and fat stores for gluconeogenesis. This resultant hyperglycaemia after 
surgery may encourage wound infection, further impair wound healing and is a predictor 
of poor outcome in the critically ill (Bochicchio et al. 2005). The weight loss and muscle 
wasting as a result of the gluconeogenesis and lipolysis causes significant amounts of 
nitrogen to be excreted into the urine (Wilmore 1991). Urinary nitrogen concentration 
can be used as a marker of the extent of the stress response as can plasma glucose 
concentrations and insulin/glucagon ratios (Campbell et al. 1984; Anand et al. 1987; 
Bessey et al. 1993; Glaser et al. 1995).  
1.3.1.1.3 EFFECT OF INCREASES IN PITUITARY HORMONE SECRETION 
The pituitary is a major endocrine gland of homeostasis. While the pituitary releases the 
majority of the trophic hormones involved in the stress response, it remains under 
control of the hypothalamus. The pituitary is divided into two lobes, anterior (AP) and 
posterior (PP).  
In response to the increased level of the trophic hormone CRH and the increased AVP 
synthesis in the PVN, the AP releases adrenocorticotropic hormone (ACTH). Stress also 
causes the release of growth hormone from the AP. The PP releases the AVP synthesised 
in the PVN in response to activation of the HPA. AVP has its own stimulatory paracrine 
effect on ACTH release, synergistically with CRH, creating a positive feedback loop. 
However, AVP’s main function is as an anti-diuretic. AVP acts on cells that line the distal 
nephron, causing the translocation of aquaporin water channels from endosomes to the 
luminal membrane, promoting reabsorption of water. Additionally, constriction of 
vascular smooth muscle cells occurs (Guest 2008; Costello-Boerrigter et al. 2009). 
Increasing amounts of ACTH enter the systemic circulation from the AP and travel to the 
adrenal cortex, stimulating the release of glucocorticoids. Norepinephrine released from 
the brain stem nuclei is also involved in glucocorticoid secretion but the pathways 
involved in this control are not clear (Ferreira-Silva et al. 2009). Surgery is one of the most 
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potent stimulators of ACTH, and cortisol release is measurable minutes after the 
commencement of surgery (Thoren 1974; Nicholson et al. 1998; Desborough 2000). 
Cortisol levels peak four to six hours after surgery, when they can be greater than four 
times normal. The extent of the increase depends on the severity of surgical trauma and 
anaesthetic intervention (Traynor et al. 1981; Chernow et al. 1987; Nicholson et al. 1998). 
This increase in glucocorticoid has a strong catabolic effect. This adds to the 
catecholamine stimulated changes in the pancreas, further reducing glucose utilisation 
and promoting catabolism through protein breakdown, lipolysis and gluconeogenesis 
(Kopp Lugli et al. 2010). 
Glucocorticoids also have anti-inflammatory activity, inhibiting macrophage and 
neutrophil accumulation into areas of inflammation and interfering with inflammatory 
mediator synthesis, particularly PGs. This also has a suppressive effect on cytokine 
production, and as cytokines promote ACTH release, this forms a negative feedback loop. 
The cortisol response to surgery is sufficient to depress interleukin-6 (IL-6). IL-6 
concentrations and have a suppressive effect on the immune system (Desborough 2000). 
Cortisol also inhibits the synthesis of CRH and ACTH (Guest 2008). Cortisol is so effective 
that synthetic analogs of cortisol are used clinically as anti-inflammatories e.g. 
hydrocortisone (Han et al. 2002). 
The Growth Hormone, also released from the AP, further contributes to catabolism by 
stimulating the release of somatomedins, also known as insulin-like growth factors, which 
are mainly synthesised in the liver. Somatomedins normally promote cell growth and 
division, but also further stimulate glycogenolysis, lipolysis and reduce glucose uptake in 
the tissue (Guest 2008). 
Thyroid function is also affected with reductions to thyroid stimulating hormone and tri-
iodothyronine (T3) secretion after surgery (Edwards 1997). This can lead to changes in 
both metabolic activity and oxygen consumption of most of the metabolically active 
tissues in the body, although this is offset by the close functional association with 
catecholamines, whose concentrations uniformly increase in the stress response (Thoren 
1974; Desborough 2000). There are also increases in oxytocin and prolactin synthesis in 
the PVN, although the importance of these hormones to the stress response is uncertain 
(Guest 2008). 
As a result of the endocrine elements of the stress response the surgical patient is: 
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 Sympathetically activated (tachycardic, hypertensive, sweating and pale); 
 Catabolic; 
 Hyperglycaemic; 
 Oliguric; 
 Peripherally vasoconstricted; and 
 Immunosuppressed. 
1.3.1.2 IMMUNE RESPONSE 
The immune system is typically involved in the eradication of injured or foreign cells by 
producing an immune response. It is a complex combination of organs, tissues, cells and 
cell products such as antibodies and cytokines.  
Tissue injury following surgical incision causes macrophages to migrate to the damaged 
area. This increases vascular permeability and generates high circulating concentrations 
of IL-1β, IL-6 along and tumour necrosis factor-α (TNF-α) at the site of injury (McMahon et 
al. 1993).  
Although the major initiation of the stress response is from afferent neural stimuli, a 
variety of humoral factors are also involved, most of which arise from the immune 
response (Holte et al. 2002). Cytokine production at the site of injury, especially IL-6 and 
TNF-α, trigger release of subsequent components (Kehlet 1989). TNF-α is released first 
from activated macrophages and it stimulates the release of more cytokines, especially IL-
6, the main cytokine for inducing the systemic changes of the stress response. IL-6 levels 
peak about 24 hours after surgery and remain elevated for 48-72 hours postoperatively 
(Sheeran et al. 1997). High levels of inflammatory cytokines are also associated with 
increased mortality and morbidity after surgery (Roumen et al. 1993a). The cytokines act 
locally mediating and maintaining the inflammatory response to tissue injury and initiate 
some of the systematic changes that occur. 
Systemic changes from IL-6 release include the production of acute phase proteins in the 
liver, such as C-reactive protein (CRP), fibrinogen and other anti-proteinases. These acute 
phase proteins go on to modulate metabolic pathways and hormonal responses 
(Giannoudis et al. 2006). IL-6 also causes alterations in the synthesis of binding proteins, 
decreasing albumin and transferrin and, in most cases, increasing α1-acid-glycoprotein 
(AAG)(Bourguignat et al. 1997). AAG’s physiological role is in the regulation of the stress 
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response as a major steroid and catecholamine binder (Ganguly et al. 1967; Sager et al. 
1987). However, AAG is also adept at binding basic and neutral lipophilic drugs, 
particularly bupivacaine and anti-retrovirals (Holley et al. 1984; Fournier et al. 2000; Israili 
et al. 2001). During the acute phase response, IL-6 also acts directly on the pituitary to 
stimulate ACTH and AVP secretion. This contributes to the initiation of the endocrine 
response and ultimately increases cortisol concentrations (Roumen et al. 1993a). Cortisol 
in turn has a suppressive effect on cytokine production, impairing the immune response, 
completing a negative feedback loop (Desborough 2000; Ni Choileain et al. 2006). 
Studies examining cytokine patterns following surgery report early, transient rises in IL-1β 
and TNF-α followed by later and more sustained elevations in plasma IL-6 and cortisol 
concentrations. Peak IL-6 concentrations have been related to the duration of surgery 
(Cruickshank et al. 1990; Baigrie et al. 1992; Haas et al. 2003). One study examined 
metabolic responses of 158 patients receiving either hip or knee arthroplasty. They 
showed cortisol levels peaked within 12 hours of surgery, ahead of IL-6, which peaks on 
the second postoperative day (Hall et al. 2000). Laparoscopic and open bowel resections 
follow similar patterns, with most reports showing reduced cytokine levels following 
laparoscopic surgery (Leung et al. 2000; Schwenk et al. 2000; Veenhof et al. 2011). 
Due to the immune response elements of the stress response the surgical patient has: 
 Large accumulations of inflammatory cells and pro-inflammatory mediators at the 
site of injury; 
 Increased vascular permeability at the site of injury; 
 Perpetuation of the endocrine response; and 
 Altered plasma protein binding. 
1.3.1.3 INFLUENCE OF SURGERY 
When performing a surgical procedure, surgeons must have a clear view of the operative 
field in order to perform their task. Historically, this involved a long and deep incision, the 
use of clamps to prevent bleeding and retractors to expose the site. As camera and 
monitor technologies advanced in the latter half of the 20th century their use to give a 
magnified view of the operative field to the surgeon on a monitor screen provided an 
alternative to traditional open surgery. The camera and other surgical instruments could 
be inserted through small incisions, or port sites, and manipulated by the surgeon from 
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the outside. This laparoscopic, minimally invasive approach is now routine for many 
diagnostic and surgical procedures. For a cholecystectomy, laparoscopic surgery typically 
involves three 0.5-1cm incisions for the insertion of instruments, compared with 
laparotomy, involving a 20-25cm incision through skin, subcutaneous tissue, three layers 
of muscle and then peritoneum. It is to be expected then that laparoscopic procedures 
cause less physical trauma to the patient, with less stimulation of the stress response and 
subsequent alteration to drug disposition. 
A recent systematic review in 2009 by Vlug et al. compared laparoscopic techniques with 
open surgery. Identified in this review were a number of studies which had found 
favourable outcomes for laparoscopic surgery such as shorter hospital stays, and 
reductions in readmission, mortality and morbidity, but they were of poor design (Vlug et 
al. 2009). Because of the lack of good quality studies the review concluded there was as 
yet insufficient robust evidence of significant superiority of laparoscopic techniques over 
open surgery. However, there is little doubt that laparoscopic surgery is accompanied by 
less extensive tissue damage, painful stimuli, fluid shifts and necessity for opioid analgesia 
(Mythen 2005). Additionally surgery that minimises tissue dissection and retraction is 
likely to minimise the stress response (Giannoudis et al. 2006; Madbouly et al. 2010a). 
Indeed, a number of studies have shown reductions in some inflammatory markers 
accompanying laparoscopic techniques (Glaser et al. 1995; Kehlet 1999; Desborough 
2000; Jess et al. 2000; Le Blanc-Louvry et al. 2000; Gupta et al. 2001). 
Despite the predicted reductions in stress response this has not lead to a wholesale 
reduction in all inflammatory markers, and perioperatively markers of stress are often 
similar in the two surgical techniques (Le Blanc-Louvry et al. 2000). One study showing 
this compared the inflammatory response following open and laparoscopic inguinal 
hernia repairs (Jess et al. 2000). In terms of the stress response, TNF-α and IL-2 
concentrations were not significantly different, although IL-6 concentrations rose 
significantly rose more sharply following open surgery (p<0.00). Additionally there were 
significantly shorter recovery times in the laparoscopic group (median recovery days for 
laparoscopic and open surgery 2 vs. 13 respectively). Other studies have reported similar 
trends (Mansour et al. 1992; Bruce et al. 1999; Chaudhary et al. 1999; Kristiansson et al. 
1999; Grande et al. 2002). Another study found similar inflammatory and metabolic 
responses between laparoscopic and a “mini-laparotomy” procedures (McMahon et al. 
1993). 
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Open surgery is also accompanied by greater increases in endogenous morphine release 
following surgery, another marker of the stress response (Madbouly et al. 2010b). Less 
invasive surgery does have other benefits for pulmonary function and reduction in 
hypoxemia than with open surgery (Mimica et al. 2000), and is manifested clinically in 
reductions of pain, morbidity and duration of hospital stay (Kehlet 1999; Le Blanc-Louvry 
et al. 2000). Laparoscopic approaches also lead to reductions in gastrointestinal paralysis 
and subsequent earlier return to oral nutrition, which has itself been shown to lead to 
reductions in catabolism and risk of septic complications (Kehlet 1997; Andersen Henning 
et al. 2006).  
1.3.1.4 INFLUENCE OF ANAESTHESIA AND ANALGESIA 
The method of ventilation, type of pain relief, extent of resuscitation, use of rapid onset, 
short acting anaesthetic agents, use of muscle relaxants and choice of tubes, drains and 
catheters, may all have a role in minimisation of the surgical stress through a variety of 
mechanisms (Kehlet 1989; Wilmore 2002). 
The type of anaesthesia itself has not been shown to be a major influence on the stress 
response to surgery, except for the use of high doses of opioid anaesthesia. This is 
consistent with the body’s own endogenous opiate system having a role in the 
modulation, mediation and regulation of the stress response and observations of 
exogenous opiates reducing the emotional and affective response to pain (Drolet et al. 
2001). High doses of opiates can reduce intra-operative but not postoperative changes to 
hypothalamic and pituitary hormone secretion (Kehlet 1996). Morphine and fentanyl 
have been shown to suppress the release of ACTH and thereby cortisol, with a dose of 
15ug/kg of fentanyl sufficient to suppress the cortisol and glucose responses in lower 
abdominal surgery (Lacoumenta et al. 1987). However, to achieve meaningful 
suppression in upper abdominal surgery, doses that result in unacceptable respiratory 
depression are required. Conventional doses of opiates result in modest reductions in 
stress response when administered via patient-controlled analgesia, with slightly greater 
reductions when administered epidurally. While there is evidence of opiates reducing the 
stress-induced neuroendocrine and autonomic responses, paradoxically opiates stimulate 
these systems in the non-stressed state, leading to the development of hyperalgesia 
(Drolet et al. 2001). 
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NSAIDs have been shown to attenuate the endocrine metabolic response to endotoxin in 
vitro, but in studies of surgical patients the effect is less pronounced (Chambrier et al. 
1996).  
Conversely, incisional and regional anaesthesia can reduce both pain and the pituitary 
stress response by blocking afferent nerve fibres and their contribution to hypothalamic 
and sympathetic activation (Kehlet 1996). In current practice, regional anaesthesia is 
commonly used in addition to general anaesthesia because of this effect on the stress 
response and the subsequent benefits for organ function and postoperative outcome 
(Rodgers et al. 2000; Wilmore 2002). Neural block with local anaesthetics can 
substantially change the majority of hormonal and metabolic changes, reducing 
endocrine responses and postoperative catabolism (Vedrinne et al. 1989; Holte et al. 
2002; Schricker et al. 2002). Pain relief is achieved, pulmonary is function improved and 
incidence of ileus is reduced. This provides for earlier oral nutrition and mobility (Kehlet 
1996). The same agents administered intravenously, intraperitonealy or intrapleuraly do 
not significantly alter the stress response (Kehlet 1996). 
The approach to postoperative pain control also has clinically significant outcomes. If a 
“prn” (as required) approach is utilised for controlling postoperative pain, higher 
concentrations of stress hormones, more intense pain, more substantial catabolism and 
greater immune impairment than with regional anaesthetic blockade can result (Kehlet 
1997). Pre-emptive analgesia, that is analgesia administered before the onset of injury, 
can also minimise the stress response (Miner 2008). 
1.3.1.5 OTHER ATTEMPTS TO MODIFY STRESS RESPONSE 
Much attention has been devoted to reducing the impact of the stress response in the 
surgical patient. Being catabolic, the surgical patient is utilising skeletal muscle to produce 
energy. In attempts to reduce this gluconeogenesis patients have been administered 
supplemental glucose, which resulted in undesirable hyperglycaemia (Schricker et al. 
2002). Amino acid infusions have had better outcomes, resulting in positive protein 
balance and reduction in endogenous glucose production (Donatelli et al. 2006). 
1.3.1.6 IMPLICATIONS OF THE STRESS RESPONSE  
The net result of the stress response is a postsurgical state characterised by fat and 
muscle breakdown, hyperglycaemia and impaired immune function. There is an increase 
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in catabolism to provide energy from fuel stores within the body (Desborough 2000). 
Retention of salt and water to maintain fluid volume and cardiovascular homeostasis can 
result in fluid overload, tissue oedema and congestive heart failure if fluids are not 
carefully managed. With tachycardia and hypertension arising from catecholamine 
stimulation, there is an increased risk of myocardial ischaemia and reduced blood flow to 
the periphery (Guest 2008). Stimulation of the liver to produce acute phase proteins 
causes reductions in the synthesis of albumin and increases in AAG. High levels of 
inflammatory cytokines have also been shown to alter CYP450 activity (Frye et al. 2002; 
Morgan et al. 2008), while even mild inflammation has been shown to increase the 
demand for sulphur containing amino acids, causing increased diversion of cysteine away 
from GSH production (Mercier et al. 2006). 
These factors can have significant implications for drug disposition and are discussed in 
more detail under the headings absorption, distribution, metabolism and elimination 
below. 
1.3.2 ABSORPTION 
In the non-surgical patient, drugs taken orally must pass down the oesophagus into the 
stomach, dissolve from the dosage form and enter the small intestine. Food and 
medicines taken orally normally pass from the stomach to the small intestine within half 
an hour (Adelhoj et al. 1985). The small intestine is the main site of absorption for any 
ingested compound, whether it be food, drug or toxin (Chan et al. 2004). The bulk of 
absorption occurs in the upper jejunum. Along with the majority of the small bowel, the 
jejunum is a highly vascularised tissue, covered in a mucous membrane with internal 
projections called villi. A villus is coated in an epithelial brush boarder membrane (Figure 
1.3-3).  
These characteristics give it a high surface area ideal for the efficient absorption of gut 
contents. Absorption is so efficient that the rate substances leave the stomach into the 
small intestine is normally the rate limiting step of absorption (Marcos et al. 1996). These 
qualities are clear when considering that the average adult consumes approximately 800-
1000g of food and 1200-1500mL of water per day, of which only 50g and 100mL is 
excreted unabsorbed (Mythen 2005). In addition to absorption, the intestinal epithelium 
must act as barrier, protecting the body from the outside world, repelling harmful 
substances and expelling waste for excretion.  
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Figure 1.3-3 Routes of Intestinal Absorption (Hayashi et al. 1997) 
Substances for absorption are chemically diverse, with substantial variance in size and 
lipophilicity and this diversity also applies to orally administered drugs. Accordingly, a 
drugs absorption from the lumen of the intestine into the blood can be quite difficult, and 
varies with a compound’s affinity for specialised membrane transport systems and 
intracellular metabolising enzymes (Chan et al. 2004).  
Most compounds cross the intestinal epithelia by one of two routes; paracellular or 
transcellular. Which route a compound uses is determined by its size and ionic charge 
(Levine 1970). Small, hydrophilic, ionised drugs can be absorbed by the paracellular 
pathway, through the tight junctions between epithelial cells. It relies on active transport, 
utilising specialised transport proteins. Accordingly, absorption by the paracellular 
pathway is small (Hayashi et al. 1997).  
The transcellular pathway across the epithelia is almost exclusively accomplished by the 
partition and passive diffusion of non-ionised, lipophilic drugs. Most oral medicines are 
lipophilic and rely on this route for absorption (Hunter et al. 1997). In most cases it is 
passive, not requiring any active transport, but some hydrophilic or charged molecules 
also utilise transcellular transport, exploiting specialised transport mechanisms such as 
pinocytosis for entry into epithelial cells (Gubbins et al. 1991; Chan et al. 2004). 
Entry into the enterocyte does not assure a compound’s passage across the basolateral 
membrane and into the blood stream. Efflux proteins at the apical membrane transport 
many compounds back out into the intestinal lumen, and often determine the extent of a 
compound’s absorption. Compounds may also be modified by metabolising enzymes 
found within the enterocyte. This intracellular metabolism may inactivate a drug or make 
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it an efflux protein substrate (Chan et al. 2004). Once a drug has crossed the basolateral 
membrane it is transported in the hepatic portal vein to the liver where it will again be 
exposed to a variety of metabolising enzymes.  
In reference to drugs, the fraction of the administered dose that reaches the systemic 
blood is referred to as a drug’s bioavailability. It is determined by two factors: 
1. The amount not absorbed; and 
2. The amount lost to metabolism either in the intestine or liver as it is absorbed 
(referred to as first pass metabolism or loss) (Bruton et al. 2006; Backes et al. 
2008). 
Of the changes in the stomach and small intestine, the most significant factors that affect 
absorption are: 
 The rate of emptying from the stomach to the small intestine (gastric emptying) 
(Section 1.3.2.1); 
 The ability of the small intestine to absorb the drug (small bowel absorption) 
(Section 1.3.2.2); and 
 The first pass metabolism of the drug (Section 1.3.2.3) 
Changes to these factors that arise from surgery mean that oral absorption is, at best, 
unreliable in postoperative patients (Noble et al. 2000). As the first step of drug 
disposition, changes to drug absorption can severely alter the effectiveness of orally 
administered medicine.  
1.3.2.1 GASTRIC EMPTYING 
Gastric emptying can be delayed substantially in the postoperative patient for a variety of 
reasons. Two of the most significant factors are the: 
1. Nature and duration of surgery; and 
2. Use of drugs, especially opiates. 
As this step is often absorption-rate limiting, understanding changes to gastric emptying is 
the first and perhaps most crucial step to understanding changes to drug disposition in 
postoperative patients. Delays to absorption will typically reduce maximum plasma 
concentration (cmax), and extend the time taken to achieve it (tmax). This can delay 
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therapeutic effect, e.g. analgesics, or even failure of the therapy if it relies on rapid 
absorption for effectiveness e.g. antibiotics and antiarrhythmics (Nimmo et al. 1988).  
Changes to the motility pattern of the gastro-intestinal tract as a result of surgery have 
been known since the early 20th century (Livingston et al. 1990), however the implications 
of this alteration to drug therapy were elucidated in the 1970s (Heading et al. 1973). 
More recently, retropulsive disposition of fluid from the small intestine back into the 
stomach was observed following surgery, further impacting on the rate of absorption 
(Kennedy et al. 2006). 
1.3.2.1.1 INFLUENCE OF SURGERY 
Gastric emptying is diminished or absent following any major procedure and ileus, the 
total paralysis of the gut, may occur, especially when the peritoneum is entered, the small 
bowel is manipulated or the procedure is long (Graber et al. 1982; Livingston et al. 1990; 
Kalff et al. 1998; Le Blanc-Louvry et al. 2000). In many case series ileus is reported at rates 
of >90% following intra-abdominal surgery (Kehlet et al. 2001b; Mythen 2005). This 
reduction in motility was initially thought to occur from sympathetic hyperstimulation as 
a result of surgical stress (Mythen et al. 1994). However, as discussed above, metabolic 
derangement, peritoneal irritation, electrolyte imbalance, hypovolaemic and 
perioperative medicines are now understood to have a greater contribution (Graber et al. 
1982; Wallden et al. 2006). 
1.3.2.1.2 THE ROLE OF OPIATES AND OTHER AGENTS 
Perioperative medications most typically associated with delaying gastric emptying are 
opiate, adrenergic and anticholinergic drugs (Clark et al. 1980; Todd et al. 1983). These 
are commonly used as analgesics, anaesthetics, psychotropics, cardiovascular and 
autonomic drugs around the time of surgery (Kennedy et al. 1998).  
All other factors are insignificant in the face of opiates (Kehlet et al. 2002). They have 
been shown to diminish propulsive contraction of the gut and delay gastric emptying 
(Crighton et al. 1998). Delayed emptying associated with opiate use has been shown to 
persist for at least five hours after dosing (Ingram et al. 1981) and the time to empty 50% 
of an ingested solution from the stomach is increased 8 to 10 fold after pethidine or 
diamorphine administration (Nimmo et al. 1975). There is partial reversal of the delay by 
opiate antagonists naloxone and methylnaltrexone (Frame et al. 1984). The efficacy of 
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methylnaltrexone, which does not cross the blood brain barrier, indicates the delay is 
peripherally rather than centrally mediated (Murphy et al. 1997).  
The exact mechanism of opiate delays is unclear, but is thought to arise from agonism of 
peripheral μ opiate receptors. Opiate receptors are found throughout the gut, but are 
present in especially high numbers in the gastric antrum and proximal duodenum. 
Activation of the opioid receptors in the presynaptic nerve terminals of the mesenteric 
plexus causes increased resting tone and decreased propulsive peristaltic waves of the 
gut (Fiocchi et al. 1982; Manara et al. 1985; Manara et al. 1986). Agonists of these opiate 
receptors all cause delays to gastric emptying (Polak et al. 1979).  
When studies have investigated multiple contributing factors in the cause of delays to 
gastric emptying, opiate use predominates. A group of 20 patients undergoing elective 
cholecystectomy were examined for their ability to empty 100ml of water from the 
stomach before and on the first day after their procedure (Ingram et al. 1981). Emptying 
was grossly retarded following an injection of opiate. No correlation was found between 
age, sex, duration of procedure or anaesthetics and the authors concluded opiate use was 
the most significant factor in a patient’s inability to tolerate oral fluids and that 
alternative analgesia should be sought or opiate administration reduced.  
The method of administration of the opiate is also influential, with pulse doses of opiates 
appearing to delay gastric emptying further than continuous infusions of an equivalent 
dose (Nimmo et al. 1988). Long anaesthesia with inhaled anaesthetics may also delay 
gastric emptying but the changes are relatively small compared with that seen after 
administration of opiates (Adelhoj et al. 1984).  
One study attempting to show the influence of these factors used opiate free anaesthesia 
with sevoflurane in 25 patients undergoing laparoscopic cholecystectomy, but did not 
show significant improvements to delayed gastric emptying over propofol and 
remifentanyl based anaesthesia in the same number of patients (Wallden et al. 2006). 
However, two aspects of the method may have reduced the study’s sensitivity to 
changes; the paracetamol they used to measure gastric emptying was ‘dissolved’ in a 
large volume of water before administration down a nasogastric tube, which is a poor 
marker of delay (Kennedy et al. 2003), and the study period was only two hours, 
prohibiting analysis of area under the concentration/time curve (AUC). 
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Minor delays to gastric emptying have also been shown to occur from alterations to 
posture. A study of 20 patients prior to cardiac catheterisation examined the difference in 
oesophageal transit time whilst standing or supine. Also using paracetamol absorption to 
determine gastric emptying, they found supine patients to have significantly reduced Cmax 
from 8.76 ± 1.17 to 5.92 ± 0.95μg/mL (p<0.04), with tmax 70 minutes longer. Both are 
strong indicators of delay to gastric emptying (Channer et al. 1985).  
Other commonly used medications in surgery, benzodiazepines, have no independent 
effect on gastric emptying (Adelhoj et al. 1985), nor does pain or anxiety alone, unless 
they cause delayed mobilisation or eating or invoke the stress response (Marsh et al. 
1984; Le Blanc-Louvry et al. 2000).  
1.3.2.1.3 DURATION OF DELAYED GASTRIC EMPTYING 
The duration of the delay to gastric emptying following surgery is highly variable. In most 
cases, delays to gastric emptying and postoperative ileus resolve spontaneously after 
two-three days (Livingston et al. 1990), but in severe cases, delayed gastric emptying can 
persist for weeks or even months in those with multiple risk factors (Marcos et al. 1996). 
Emptying can be reduced even in the presence of bowel sounds or the passing of flatus 
(Kennedy et al. 1998), and even if the stomach was not directly involved in the procedure 
(Condon et al. 1986). 
1.3.2.1.4 IMPACT OF DELAYED GASTRIC EMPTYING 
Delays to gastric emptying are characteristically shown in changes to paracetamol 
absorption. Paracetamol absorption is frequently used because it is poorly absorbed from 
the stomach, relying on gastric emptying for absorption (Heading et al. 1973; Todd et al. 
1983; Marsh et al. 1984; Nimmo et al. 1988). Changes to absorption in the surgical 
patient are substantial. Kennedy et al. used paracetamol syrup to demonstrate reductions 
of almost 50% in cmax (30.2 vs. 16.3mg/L) and greater than doubling in tmax (35 vs. 119min) 
comparing values from before and two days after major abdominal surgery (Kennedy et 
al. 2006).  
For drugs that are acid labile, such as penicillin, the extent of absorption can also be 
reduced if gastric emptying is delayed, as these drugs are degraded by prolonged 
exposure to the harsh environment in the stomach (Nimmo et al. 1988).  
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In addition to impacting on absorption of medication, the risk of intolerance, 
regurgitation and aspiration of oral food and fluids may also be a result of delayed gastric 
emptying. There is also a contribution to constipation and ileus (Mythen 2005). In 
addition to patient discomfort, ileus is a significant burden on the health system at a 
minimum through delays to discharge (Livingston et al. 1990). 
With increasing attention on enhanced recovery programmes to reduce inpatient stays 
many strategies to minimise changes to gastric emptying have been investigated. Sparing 
opiates has a major role in this, alongside minimally invasive surgical techniques, regional 
anaesthesia, early mobilisation and early return to enteral feeding (Kehlet et al. 2001b). 
1.3.2.2 SMALL BOWEL ABSORPTION 
Once the drug is released from the stomach, absorption from the small bowel is itself 
dependent on three factors relating to the small bowel mucosa: 
 The blood supply; 
 The motility; and 
 The integrity of the mucosa.  
Changes to these factors in the perioperative period can cause reductions in absorption 
and bioavailability, particularly of drugs that are already poorly absorbed (Uhing et al. 
1995). But for the majority of drugs, changes to the factors listed are insignificant 
compared with the impact of delayed gastric emptying. Such is the case with 
paracetamol. As a weak acid, with a pKa of 9.5, it is largely unionised over the 
physiological pH range (Prescott et al. 1971). This, together with its favourable water and 
lipid solubility, means that it is rapidly and completely absorbed from the small bowel by 
passive diffusion (Bagnall et al. 1979). Therefore, any changes to paracetamol absorption 
from the small bowel are utterly dwarfed by reductions in gastric emptying.  
1.3.2.2.1 BLOOD SUPPLY 
The gut normally receives 15 to 20% of the total cardiac output, which can double two-
three hours following food ingestion (Lantz et al. 1981). Such supply is well in excess of 
the nutritional demands of the enterocytes alone (Lundgren 1967). A rapid blood flow is 
required to remove absorbed substances, which maintains the concentration gradient 
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required for passive diffusion and the health and barrier function of enterocytes (Gubbins 
et al. 1991). 
In the very early postoperative period, when haemostasis is most in danger, blood flow is 
rapidly redistributed away from the gut to maintain circulatory volumes to the more vital 
organs (Kennedy et al. 1998). In addition, spinal and epidural analgesics block autonomic 
vasoconstrictors, which results in vasodilation of large vessels, further reducing afterload, 
cardiac output and ultimately blood flow to the bowel (Winne 1979).  
Theoretically this reduction in blood flow to the gut could impair absorption of drugs that 
rely on passive diffusion (Levine 1970). But to significantly influence drug absorption 
changes to blood flow must be substantial and sustained (Winne 1979). Ischaemia of five 
minutes or less does not impair absorption; more prolonged periods may, but only during 
the time of ischaemia (Robinson et al. 1965; Bailie et al. 1987). Paradoxically, passive 
absorption may be increased once ischaemia ends, potentially allowing pyrogens to 
translocate across the gut wall (Crissinger et al. 1990). 
Active transport of substances is impaired during and after prolonged periods of 
ischaemia, indicating oxygen deficiency damages active transport mechanisms (Varro et 
al. 1965; Ochsenfahrt et al. 1973). However these changes do not have a significant effect 
on paracetamol absorption due to its passive diffusion.  
In the uncomplicated surgical patient, the large blood supply to the gut makes it unlikely 
that any significant reduction in passive absorption occurs (Lundgren 1967). In vivo 
substantial reductions in splanchnic flow (35% of normal in dog models) must occur 
before the efficiency of passive diffusion is affected (Crouthamel et al. 1975). Only the 
most critically-ill who have prolonged reduction to cardiac output and splanchnic flow 
may have some reductions to drug absorption (Kennedy et al. 1998). 
Paradoxically oedematous patients may also have impaired absorption (Berkowitz et al. 
1963). While occasionally shown in surgical patients, this is more commonly seen in 
severely oedematous congestive cardiac failure patients who show resistance to oral 
furosemide (Berkowitz et al. 1963). 
1.3.2.2.1.1 ASSESSMENT OF BLOOD FLOW TO THE GUT 
It is worth considering how blood flow to the gut and liver is assessed because the 
assumption that surgery causes no significant alteration to blood flow to the gut, and 
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subsequently the liver, is important to this Thesis. If blood flow was reduced this could 
cause alterations to drug metabolism by reducing cofactor and substrate delivery that is 
not being assessed. 
The gut provides 75% of the blood supply to the liver, therefore measurement of the 
latter provides a good approximation of the former (Desforges et al. 1953; Horner 
Andrews 1957). Two methods are commonly used to approximate hepatic blood flow: 
 Measurement of the disappearance of a hepatically excreted compound; or 
 Measurement of the appearance of a hepatically produced metabolite. 
Either compound or metabolite must possess a number of other favourable 
characteristics. One such compound, indocyanine green dye, is an example of the first 
method of approximation and has been used extensively to approximate blood flow to 
the gut (Caesar et al. 1961; Gibaldi 1991; Kanaya et al. 1995; Jacob et al. 2007). 
Because the liver is so efficient at extracting indocyanine green from the plasma and 
because 75% of the blood supply to the liver is from the portal vein (Desforges et al. 
1953; Horner Andrews 1957), the plasma disappearance of this compound approaches 
that of the splanchnic blood flow. Accordingly, it can also be used to assess blood flow to 
the mesenteric, splenic and hepatic vessels.  
Work by Kennedy et al. which preceded this research (Kennedy et al. 2006) administered 
indocyanine green and measured the plasma disappearance to approximate blood flow to 
the gut of 12 major abdominal surgery patients before and after surgery. No statistically 
significant difference in mean disappearance of indocyanine green was found. 
Another study examined indocyanine green clearance in patients before and after 
undergoing elective surgery with various types of inhaled anaesthetics. Although one 
inhaled anaesthetic, halothane, did reduce indocyanine clearance, it is not commonly 
used in current practice. Isoflurane and sevoflurane, two other assessed gases in current 
use, did not cause any significant change in indocyanine clearance (Kanaya et al. 1995). 
These results have been shown by other authors (Frink et al. 1992; Nakaigawa et al. 
1995), in other surgical groups (Murray et al. 1992a; Murray et al. 1992b) and confirmed 
by other, more invasive methods (Gatecel et al. 2003). In addition, pigs infected with 
Actinobacillus pleuropneumoniae also did not show any alteration to indocyanine green 
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clearance, indicating that bacterial sepsis alone also does not alter hepatic blood flow 
(Monshouwer et al. 1995).  
1.3.2.2.2 MOTILITY 
Small bowel motility is necessary for the mixing of substances in the bowel, moving them 
into close contact with the brush border membrane, where absorption occurs (Spiller 
1994). In surgical patients, co-ordination of small bowel motility is reduced, reducing the 
efficiency of absorption (Kennedy et al. 2006). 
As for gastric emptying, opiates are implicated in the reduction of small bowel motility, as 
are prolonged procedures involving small bowel manipulation, but unlike gastric 
emptying, small bowel motility returns approximately six hours after surgery in almost all 
patients (Fiocchi et al. 1982). Because small bowel motility is restored quickly in most 
cases, assuming the absence of ileus, it may be assumed that drug mixing is not 
significantly altered postoperatively (Kennedy et al. 1998).  
1.3.2.2.3 INTEGRITY OF THE MUCOSA  
The integrity of the mucosa can also influence drug absorption. Changes seen from 
surgical stress include alteration to cell morphology and loss of normal villus shape. This 
can result in reductions in absorptive area and potentially reduction in absorption by the 
transcellular route. These changes even occur in cardiac or orthopaedic surgery when the 
surgical injury is quite remote from the gut (Mythen 2005).  
Changes to pore size in the gut wall can also occur, allowing even large molecules to pass 
through the mucosa (Crissinger et al. 1990) and increased intestinal permeability has 
been shown after major abdominal surgery (Roumen et al. 1993b; Kennedy 1996). 
Inflammation and infection can also impair the activity of transporter and metabolising 
enzymes present in the gut wall (Aitken et al. 2006).  
1.3.2.3 FIRST PASS METABOLISM 
First pass metabolism broadly involves enzymes present in the brush border cells and the 
liver. As drugs pass from the intestinal lumen into the mesenteric capillaries they are 
exposed to many of the same drug metabolising enzymes that are found in the liver, 
predominately the Phase II conjugation enzymes glucuronosyltransferases and 
sulphotransferases (Pacifici et al. 1986; Rogers et al. 1987; Peters et al. 1991), although 
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Phase I CYP450 enzymes, particularly CYP3A4, are also present (Thummel et al. 1997). 
These enzymes of intestinal metabolism are localised primarily in the mucosal 
enterocytes. 
Similar metabolism can occur again in the parenchymal cells of the liver as absorbed 
drugs flow through the hepatic portal vein to the liver for the first time on their way to 
the inferior vena cava and systemic circulation (Thummel 2007). 
There are some reports of anaesthesia inhibiting intestinal CYP450 enzymes which may 
increase the extent of absorption of orally administered drugs that are normally 
extensively metabolised in the first pass. However, difficulties arising from delays to 
gastric emptying that occur from most anaesthesia and decoupling the contributions of 
the intestine from the liver to first pass metabolism complicates this research (Doherty et 
al. 2002; Thelen et al. 2009).  
Generally changes to first pass metabolism in the surgical patient are of minor 
importance in comparison to the other factors discussed above, and generally first pass 
metabolism is not an important contributor to paracetamol metabolism (Clements et al. 
1984). 
1.3.2.4 ABSORPTION FROM OTHER SITES 
Intramuscular drug absorption can also be affected by surgery and result in erratic plasma 
levels and unpredictable clinical effects (Ueno et al. 1995). Among other factors, the rate 
of drug absorption following intramuscular injection depends on blood flow at the site of 
administration. Anaesthesia and surgery produces a fall in muscle blood flow and this can 
delay drug absorption. This effect can be minimised by administration into the deltoid 
rather than the gluteus (Nimmo et al. 1988). Absorption following subcutaneous 
administration is similarly dependent on blood flow and can show comparable 
fluctuations (Kennedy et al. 1998). Absorption from the rectal route is already erratic and 
highly variable and in the absence of pyrexia, this situation is not improved in the surgical 
patient (Reddy et al. 2002). 
1.3.3 DISTRIBUTION 
Once a drug has reached the systemic circulation it is distributed throughout the body, 
firstly in the blood and then the tissues to varying degrees. In this way the body can be 
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considered to be made up of a number of compartments. The first, or central, 
compartment represents the blood volume. The second, or peripheral, compartment 
represents the tissues of the body. Depending on the nature of the drug it may be 
distributed into other compartments, such as the CNS. The amount of drug found in each 
compartment represents its distribution, and is the result of several drug and patient 
related factors. In general terms, drugs that are hydrophilic prefer the predominantly 
aqueous environment of the plasma in the central compartment while those that are 
lipophilic distribute more rapidly into the periphery, preferring the more hydrophobic 
adipose and muscle tissue. The binding of drugs to plasma proteins within the central 
compartment also influences to the distribution of lipophilic drugs, as bound drugs are 
retained in the central compartment (Bruton et al. 2006). 
Patient related factors may prevent drugs from distributing to their full extent. In the 
surgical patient prolonged operations frequently result in hypovolaemia, vasoconstriction 
and acidosis. These can alter drug distribution. Many of these factors can be considered 
as changes to either blood flow, drug binding or extracellular fluid. 
The distribution of fentanyl, for example, can be altered in surgical patients. Because of 
its lipophilicity, it has a high binding capacity to adipose tissue and muscle. As fentanyl is a 
weak acid, acidosis increases this binding capacity, prolonging fentanyl storage in the 
periphery. As the acidosis is corrected postoperatively by re-warming, volume 
replacement and buffers, fentanyl is released from its binding sites. This can result in a 
second peak, with potential for toxicity (Caspi et al. 1988; Klausner et al. 1988).  
There have been reports of changes to the distribution of paracetamol in surgical 
patients. The Vd of intravenous paracetamol was found to increase from 69.2L in healthy 
volunteers (Flouvat et al. 2004) to 85.0L in patients undergoing hip arthroplasty (Viscusi 
et al. 2008). Another study examined the intravenous paracetamol kinetics in medium 
(equivalent to a High Dependency Unit setting) and Intensive Care Unit patients. They 
found the distribution of paracetamol in Intensive Care Unit patients significantly higher 
(71.09L) than the medium care unit patients (50.88L p=0.033)(de Maat et al. 2010). 
Along with these changes, there are also reports about the inhibition and down 
regulation of a variety of drug transporter proteins, such as P-glycoprotein (PGP), a widely 
expressed efflux pump. Inhibition is linked with levels of inflammation (Morgan et al. 
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2008). PGP is involved in several areas of drug distribution, including the transport of 
compounds from the: 
 Intestinal epithelia, back out into the lumen, reducing bioavailability; 
 Cells back out into the extracellular fluid, conferring multidrug resistance to many 
drugs, including several chemotherapeutic agents; 
 Hepatocytes, into the bile for elimination; and 
 CNS, back across the blood brain barrier into the periphery, reducing exposure of 
the CNS to the drug. 
Any reduction in the activity of PGP that occurs during inflammation or infection can 
therefore be seen to have a wide range of effects on the distribution of drugs that are 
transporter substrates, such as: 
 Increased intestinal absorption and bioavailability; 
 Increased sensitivity of cells to drugs; 
 Reduced clearance of drugs; and 
 Reduction of transport of drugs across the blood-brain barrier. Drugs that are 
normally transported out of the CNS by PGP can enter, accumulate and potentially 
cause CNS toxicity.  
These changes can have important clinical ramifications. Decreases of 50-70% in hepatic 
PGP activity have been reported (Piquette-Miller et al. 1998). These reductions can 
reduce drug clearance, prolonging drug exposure and potentially lead to drug 
accumulation, if multiple doses are given (Goralski et al. 2003).  
Important changes also occur in the CNS. Here, patients with severe CNS trauma, such as 
through infection or surgery, can develop an inflammatory response in the brain. When 
morphine is used in these patients it has been observed that, while it is mostly well 
tolerated for a few days, some patients go on to become agitated, in a similar manner to 
those in renal failure who accumulate the CNS irritant metabolite M3G. This metabolite is 
normally excluded from the CNS by PGP in the blood brain barrier (Letrent et al. 1999a; 
Letrent et al. 1999b). Consequently, inhibition of PGP has been shown to lead to 
morphine metabolite accumulation in the CNS (Morgan et al. 2008). This may affect a 
wide variety of drugs that are PGP substrates (e.g. cyclosporine, digoxin and HIV protease 
inhibitors), which functioning PGPs normally exclude from the CNS (Morgan et al. 2008). 
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Other work has shown that systemic inflammation, not just inflammation in the CNS, can 
cause changes to PGP activity at the blood-brain barrier (Wang et al. 2005). 
1.3.3.1 BLOOD FLOW 
Anaesthesia usually results in a brief reduction in cardiac output and blood flow to several 
different areas of the body, particularly the kidneys, liver and muscle (Hickey et al. 1980). 
When this is coupled with a reduction in blood volume for reasons discussed in 1.3.2.2.1, 
the size of the central compartment into which drugs are delivered can be reduced, 
especially in the early postoperative period (Kennedy et al. 1998). When reductions to 
cardiac output are large and a drug’s target organ is in the central compartment, 
unexpected toxicity following intravenous drug administration can occur. This effect is 
more pronounced in the elderly, who have age related reductions in central compartment 
volume (Moffat et al. 1983). 
The increase in circulating catecholamines arising from the stress response can also alter 
blood flow. By causing vasoconstriction, catecholamines cause changes to perfusion 
pressure and regional blood flow. This can further impact on the rate and extent of drug 
distribution (Udelsman et al. 1994). 
1.3.3.2 DRUG BINDING 
While paracetamol is not known to be highly protein bound at licensed doses, binding has 
been shown following overdose. Thus understanding changes to drug binding following 
surgery is important. Lipophilic drugs may reversibly bind to plasma proteins, increasing 
their concentration in the central compartment. However, only the unbound drug has 
pharmacological activity and is available for metabolism. Any alteration to plasma protein 
binding therefore has important implications to drug therapy. Reductions to drug binding 
could result in unexpected toxicity and conversely therapeutic failure may arise as a result 
of increase drug binding (Streat et al. 1985).  
Serum albumin is the most important plasma protein for drug disposition. Serum albumin 
turnover increases after surgery and the concentration of albumin falls significantly for a 
number of days as a result of the stress response, particularly in sepsis (John et al. 1969). 
Surgical patients malnourished or catabolic as a result of their pathology may be 
hypoalbuminaemic preoperatively (Mann et al. 1987). For drugs that are highly bound to 
albumin a reduction in albumin concentration can increase the volume of distribution 
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(van Dalen et al. 1990). This can have implications for the intensity and duration of the 
action of the drug as it is only the unbound fraction of the drug which is active. 
Reductions to fraction of bound drug may result in increased activity of the drug, or even 
toxicity, as is the case with lidocaine, pethidine and propranolol (Kennedy et al. 1998; 
Kratochwil et al. 2002). 
The second most important plasma binding protein, AAG, has similar affinity for lipophilic 
drugs. It is an acute phase protein and may rise as a consequence of stress and surgery 
(Israili et al. 2001). Its synthesis in the liver is stimulated as part of the acute phase 
response to increasing concentrations of catecholamines and inflammatory cytokines 
(Fournier et al. 2000). Elevated levels of AAG can continue at least 5 days postoperatively 
and may result in increased binding of highly bound basic and neutral drugs, resulting in 
reduced unbound fraction and effective drug concentration, and apparent reduction to 
the volume of distribution (Davies et al. 1988). Drugs reported to show this effect include 
bupivicaine (Wulf et al. 1989), lidocaine, propranolol (Sager et al. 1989; Davies et al. 1991; 
Hunter et al. 1997; Doherty et al. 2002), pethidine (Julius et al. 1989) and prazosin(Sager 
et al. 1989). For highly bound drugs, if increased plasma binding proteins result in even a 
small reduction in unbound fraction of the drug, therapeutic failure can result, as only the 
unbound drug is pharmacologically active (Julius et al. 1989). 
Theoretically, iso-osmotic fluids administered during surgery can cause haemodilution of 
plasma proteins, increasing the free fraction of a highly protein bound drug. Conversely, 
colloidal fluids can result in increased amounts of bound drug, although the clinical 
relevance of this is uncertain (Svensen et al. 1997). 
1.3.3.3 EXTRACELLULAR FLUID 
Postoperative patients have an increased volume of extracellular fluid (Beckhouse et al. 
1988). Aldosterone and AVP are secreted as part of the endocrine response to surgery to 
maintain the circulating blood volume. These substances cause the retention of salt and 
water, and consequently the enlargement of the extracellular fluid volume.  
The distribution of this extracellular fluid can also change in the postoperative patient. 
Extracellular fluid can leak out of the plasma into a theoretical ‘third space’. The 
inflammatory cytokines, PGs, kinins and leukotrienes increase capillary permeability 
causing an accumulation of fluids in the interstitial space, resulting in ‘third spacing’. This 
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causes a net loss of extracellular fluid from plasma. Fluid sequestered in this way is 
unavailable to the plasma, which may alter drug distribution, particularly of those drugs 
with small distribution volumes (Fleck et al. 1985). The authors of the study cited above in 
Section 1.3.3 involving medium and intensive care unit patients (de Maat et al. 2010) 
postulated such a mechanism was responsible for the increase in Vd of paracetamol in 
the more severely ill intensive care patients. 
Postoperative patients with significant third spacing can have substantial changes in 
observed plasma concentrations of hydrophilic drugs such as aminoglycosides and higher 
doses may be required to maintain concentrations in the therapeutic range (Dasta et al. 
1988). As such, aminoglycosides have been frequently used to assess changes to the 
volume of extracellular fluid. As aminoglycoside antibiotics do not bind to plasma proteins 
and are very hydrophilic, their distribution volume closely parallels that of the 
extracellular fluid. There are several studies using gentamicin that show dramatic 
increases to the volume of extracellular fluid following surgery (Zaske et al. 1980; 
Beckhouse et al. 1988; Dasta et al. 1988; Reed et al. 1989). 
One such study by Dasta and Armstrong of 181 critically ill surgical patients found the Vd 
of the aminoglycoside gentamicin was increased to 0.36 ± 0.1L/kg, nearly 50% above the 
reference value of 0.25L/kg (Dasta et al. 1988). These patients also gained on average 
8.4kg in weight and 11.6L of fluid, further indicating changes to volume of distribution, 
although no direct correlation with Vd and fluid balance could be made.  
It is possible that surgery may also alter Vd through changes to total body water, but no 
clinically significant instances have been reported (Nimmo et al. 1988). 
1.3.4 METABOLISM  
As discussed in Section 1.2, the body’s aim for drug metabolism is to a produce a 
compound excretable in the urine or bile. There are two phases of drug metabolism: 
Phase I prepares a compound for Phase II metabolism, which involves conjugating the 
compound to a more aqueous soluble moiety, easing its excretion into the bile and urine. 
As stated previously compounds do not necessarily proceed through Phase I prior to 
Phase II, with some using only the Phase II pathway. 
While changes to absorption are perhaps the most dramatic change in drug disposition in 
the surgical patient, these can be surmounted by parenteral administration. Changes to 
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metabolism are not so easily avoided and represent one of the most clinically relevant 
alterations to drug disposition for the majority of surgical patients.  
Most of the metabolic reactions are catalysed by enzymes and their activity may be 
altered in surgical patients by one of two ways: 
 Alteration of enzyme activity; and 
 Lack of enzyme cofactors or substrates. 
Enzyme activity can be affected by the acute phase response when the expression of 
most enzymes is inhibited, although some are induced. This is discussed in greater detail 
below. 
Changes arising from the endocrine aspects of the stress response and alterations to 
nutrition can affect the availability of co-factors, such as glucose. Glucose is used as a fuel 
to supply adenosine-5’-triphosphate which is essential for enzyme activity including those 
involved in drug metabolism (Aw et al. 1984).  
Changes to respiration and blood flow can also reduce supply of oxygen. All CYP450 
enzymes use oxygen as a direct substrate whereas only some Phase II enzymes require 
oxygen for the generation of essential co-factors. Relatively minor reductions in oxygen 
supply, such as may arise from surgery and anaesthesia, have been shown in vitro to 
impair these metabolic processes. CYP450 enzymes are especially sensitive to these 
changes although in situations of poor nutrition or fasting, Phase II processes may also be 
affected (Aw et al. 1984; Angus et al. 1990). 
Most of the drugs used in anaesthesia are able to reduce drug metabolism whether it 
occurs by oxidation, reduction or conjugation. Halothane, an inhaled anaesthetic no 
longer in use, was known to inhibit a vast array of drugs including propranolol, fentanyl, 
ketamine, pethidine, antipyrine, diazepam and phenytoin. This inhibition of drug 
metabolism occurred during anaesthesia and persisted well into the postoperative period 
(Reilly et al. 1985; Nimmo et al. 1988). Mice anaesthetised with halothane, isoflurane and 
sevoflurane had reductions to UDP-glucuronic acid, a co-factor required for 
glucuronidation, of 40-52% as compared with that in unanesthetised control mice 
(Watkins et al. 1990). 
Apart from these reports, there is a surprising lack of literature examining these changes 
to metabolism in the surgical patient. This is perhaps in part due to some of the same 
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issues mentioned in Section 1.1 concerning consent, ethics and randomisation. The study 
of these changes may also falsely be seen as lacking clinical relevance for several reasons:  
 Changes may have been explained as arising from other sources, such as inter-
subject variability normally experienced with many medications, such as 
morphine; 
 Changes may not have been detected because many of the affected patients are 
seriously ill, making drug toxicity difficult to identify; 
 Changes may not be have been detected because most drugs have a wide safety 
margin and many pathways are not capacity limited; 
 The increased monitoring provided while in the surgical unit can adjust the dose 
to a patient’s response, rather than administering a fixed dose, avoiding toxicity; 
 Changes to metabolism have been unnoticed due to the lack of pre-operative 
requirement of the medication or postoperative observation; and 
 A lack of interest within the surgical specialties.  
However, shorter inpatient stays accompany modern surgical practices and very few 
surgical patients are cared for in intensive care or high dependency units. Accordingly, 
surgical patients are receiving less monitoring and are discharged earlier. Given that 
changes to drug metabolism may persist for several days, even weeks, after surgery, 
greater understanding is needed to protect the surgical patient.  
A number of drugs given to surgical patients have no set dose and must be titrated to the 
patients’ response. This implies a patient must experience periods of inefficacy and 
toxicity, so that a midpoint can be obtained. Having a greater understanding of changes 
to drug metabolism that occur perioperatively may also enable a midpoint dose to be 
predicted more accurately, providing effective doses sooner. While many of the changes 
to metabolism due to surgery may occur at a subclinical level, they can have serious 
consequences when they do become apparent; not only when toxicity occurs but also the 
other potential outcome, lack of efficacy. The area is clearly worthy of study if these 
outcomes are to be minimised.  
1.3.4.1 REPORTS OF CHANGES TO PARACETAMOL’S METABOLISM 
Because paracetamol is widely used in surgical patients there have been some studies 
that have examined changes to its metabolism. Other information regarding changes to 
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paracetamol metabolism can be gained from studies that were primarily assessing other 
aspects of drug disposition of surgical patients, such as absorption.  
The results of these studies are conflicting. One study examined the pharmacokinetics of 
paracetamol in seven children/adolescents (median age 13.7 years) during major surgery, 
four weeks after chemotherapy. Neither major surgery for tumour resection or 
chemotherapy had a major impact on paracetamol metabolism in this study (Wurthwein 
et al. 2005). 
Conversely, Lewis et al.(Lewis et al. 1991) compared excretion of a single oral dose of 1.5g 
of paracetamol in a group of volunteers and in general surgical patients on day one 
postoperatively. They found statistically significant decreases in the unchanged 
paracetamol and paracetamol sulphate and increased amounts of mercapturic acid 
recovered in the urine, but found no changes to AUC or t½ of paracetamol.  
While there are some reports of inhibition of drug metabolism immediately following 
surgery which persists into the early postoperative period, paradoxically there is also 
evidence that a period of enzyme induction follows, which may have given rise to the 
conflicting reports above. Enzyme induction may occur four to eight days following 
surgery by approximately 30-50%, returning to normal by four weeks (Nimmo et al. 
1981). This induction can have dangerous ramifications for drugs such as paracetamol 
which has a toxic metabolite and veritably increased metabolism of paracetamol after 
surgery has been reported (Ray et al. 1985). There are also similar reports of halothane 
anaesthesia alone inducing paracetamol’s metabolism (Ray et al. 1986; Lewis et al. 1991).  
One of the major shortcomings of these studies is the use of saliva paracetamol 
concentrations. While discussed in greater detail in Section 1.4, of relevance here is the 
lack of any information on the relative concentration of paracetamol metabolites gained 
from these samples. Without this information no conclusions can be made about 
contributions of Phase I or II to the increase of paracetamol’s metabolism. Kennedy et 
al.(Kennedy 1996) did examine this in urine samples with HPLC. Using a single oral 1.5g 
dose of paracetamol, they found significant differences in the pre- and postoperative 
levels of glucuronide conjugate (p < 0.01) and cysteine conjugate (p < 0.05) but no 
significant differences in the pre- and postoperative levels of mercapturate conjugate (p < 
0.01) and sulphate conjugate (p < 0.05) excreted in urine over five hours. The finding was 
reconfirmed in longer studies lasting for five days postoperatively(Kennedy 2009a)  
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1.3.4.2 PHASE I 
The stress response is considered a major contributor to alteration of Phase I metabolism 
(Section 1.3.1). Inflammation caused by infection or underlying inflammatory conditions 
are known to down regulate most drug metabolising enzymes and transporters, both in 
acute scenarios, such as following surgery, or chronic conditions such as extra-hepatic 
cancer, inflammatory bowel disease or congestive heart failure(Frye et al. 2002; Carcillo 
et al. 2003; Haas et al. 2003; Aitken et al. 2006; Morgan et al. 2008).  
1.3.4.2.1 CLINICAL CONSEQUENCE OF CYP450 INHIBITION 
This reduction in Phase I activity can lead to a decrease in drug clearance, increasing 
plasma drug concentrations and potentially may cause drug toxicity or increases in the 
incidence of adverse effects (Schmith et al. 2008). One of the first reports of this arose 
from an outbreak of influenza-b in the early 1980’s when 11 young children receiving 
theophylline prophylatically for asthma were hospitalised with severe theophylline 
toxicity. They presented with symptoms as severe as cardiac abnormalities and 
convulsions. One child’s theophylline half-life had increased fivefold, from four to 20 
hours, and suffered severe, permanent brain damage as a result of the theophylline-
induced convulsions (Kraemer et al. 1982). It was suspected inflammation arising from 
the viral infection inhibited CYP1A2, causing theophylline accumulation and toxicity 
(Morgan et al. 2008). One review stated that infection or inflammation can decrease 
metabolic clearance of CYP450 substrates by 20-70% (Aitken et al. 2006). The impact of 
this clinically is much greater than is generally reported (Morgan et al. 2008) and may be 
overlooked for reasons discussed in Section 1.3.4.  
1.3.4.2.2 MECHANISM OF CYP450 INHIBITION 
One of the first experiments to show the effect of inflammation on CYP450 activity in man 
examined the effect of lipopolysaccharide (LPS) on antipyrine clearance. An artificial 
stimulant of the immune system, LPS, has shown to reduce clearance of antipyrine, a non-
specific marker for CYP450 enzyme activity, in healthy men (Shedlofsky et al. 1994). It had 
been earlier shown in mice that it was the inflammatory cytokines produced in response 
to the administration of LPS, rather than the LPS itself, which caused this down regulation 
of CYP450 enzymes (Shedlofsky et al. 1987). Further evidence of the involvement of 
cytokines arises from the finding that inflammation in the CNS, such as that arising from 
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meningitis, affects drug disposition in the brain and peripheral systems (Garcia Del Busto 
Cano et al. 2003). It is even thought the inflammation-induced inhibition of CYP450 
enzymes are involved in the pathogenesis of some types of Parkinson’s disease (Goralski 
et al. 2004).  
Cytokines IL-1, IL-6, IFN-γ and TNF-α have all been implicated in CYP450 down-regulation. 
Interestingly, each is thought to have different effects on different CYP450 enzymes and 
there may also be some overlap between them, with the effects not being additive 
(Morgan 1997; Renton 2000; Morgan 2001; Renton 2001; Renton 2004; Morgan et al. 
2008). Given that the concentration, time course and mix of cytokines vary depending on 
the source of infection and inflammation it is therefore possible that the effect on CYP450 
regulation will also vary (Aitken et al. 2006; Richardson et al. 2006). IL-6 is thought to be 
key, and is by far the most potent down-regulator of CYP450 with strong correlations 
between IL-6 concentrations and reductions to CYP450 activity (Gurley et al. 1997; 
Siewert et al. 2000; Morgan et al. 2008). 
In further proof of the involvement of the immune system, pharmacological doses of 
hydrocortisone, a immunosuppressant, produced an immediate increase in the clearance 
of antipyrine in human studies (Breckenridge et al. 1973). Corticosteroids have also been 
shown to induce CYP3A4 (Pichard et al. 1992; Shimamoto et al. 1999). 
Research indicates CYP450 enzymes are down regulated during generation of host 
defences at the level of gene transcription, with a subsequent drop in the corresponding 
mRNA, protein and enzyme activity (Renton 2004). There may also be post-translational 
steps on some CYP450s which include enzyme modification and increased degradation 
(Aitken et al. 2006). LPS brings about swift and substantial down-regulation of several 
hepatic CYP450 mRNAs. Transcriptional suppression is thought to be an important factor 
in CYP450 mRNA down-regulation and suppression of some CYP450 genes occurs within 
one hour of LPS injection in rats (Cheng et al. 2003).  
Despite the speed of this change to transcription, which makes the pace of enzyme 
induction appear glacial, it cannot explain the rapidity at which mRNA is down-regulated. 
It is thought that changes to mRNA stability must also occur. Even so, the mRNA 
suppression is not fast enough to explain the changes in CYP450 protein expression and 
activity (Morgan et al. 2008). Interestingly, nitric oxide, which can arise from neutrophil 
activation, has been found to have a role in CYP450 enzyme inhibition and protein 
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degradation (Ferrari et al. 2001; Vuppugalla et al. 2005), which may provide the final 
piece in the puzzle.  
Oxidative stress may also have a role in CYP450 down-regulation. Antioxidants and 
inhibitors of xanthine oxidase and nicotinamide adenine dinucleotide phosphate (NADPH) 
oxidase have been shown to inhibit LPS-induced CYP3A11 down-regulation, although the 
mechanism is uncertain (Xu et al. 2004; Xu et al. 2005).  
It is probable that constitutive expression of CYP450 is not significantly affected. Some 
CYP450 isoforms are induced following exposure to certain drugs, such as occurs with 
CYP3A4 during treatment with rifampicin or diazepam (Heubel 1969; Pessayre et al. 
1978). This induction is triggered by Pregane X receptor (PXR) (Lehmann et al. 1998; 
Kliewer et al. 2002). It has been found that PXR is also downregulated in hepatocytes 
during inflammation. However, as downregulation of CYP3A has been shown in the 
absence of alteration to PXR expression (Sachdeva et al. 2003), this is unlikely to be a 
significant contributor to changes in Phase I activity unless substantial CYP450 induction 
had previously taken place (Goralski et al. 2005).  
Roles for the constitutive androstane receptor (CAR) have also been proposed. CAR has a 
similar role to PXR and inhibition of CAR has been shown to reduce CYP450 response to 
inducing stimulus such as phenobarbital exposure. CAR itself is positively regulated by 
glucocorticoids, which, as previously discussed, also inhibit cytokine release, further 
implicating the stress response in enzyme regulation (Sachdeva et al. 2003).  
In summary there is still a lot of uncertainty in this area. CYP450 inhibition is thought to 
occur rapidly following inflammation and it is likely that LPS has a role. This inhibition 
seems to apply more to enzymes that are induced, rather than those that are 
constitutively expressed, so that while inflammation may reduce a CYP450 enzyme’s 
activity, it will not eliminate it.  
1.3.4.2.3 PATIENT BASED FACTORS AND EFFECTS ON CYP450 ISOENZYMES 
Given the relevance of CYP450 to paracetamol metabolism and this Thesis, it is important 
to consider the impact on the different isoenzymes.  
Recent reviews have summarised animal studies investigating the effects of cytokines and 
inflammation on CYP450 regulation (Morgan 1997; Renton 2001; Aitken et al. 2006). 
Importantly, hepatocyte expression of human and rodent CYP450 enzymes is regulated in 
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a similar manner (Morgan 2001). In rats, enzymes down-regulated by inflammation 
include CYPs 1A1, 2A1, 2C6, 2C7, 2C11, 2C33, 2E1, 3A2 and 4F4 and in mice 1A2, 2A5, 
2C29, 2E1, 3A11, 4A10, 4A14, 4F15 and 4F16. There is much less research of this type in 
humans.  
In vitro, inflammatory cytokines associated with the stress response, IL-1β, IL-6 and TNF-
α, have been shown to reduce the expression of CYP1A2, 2E1 and 3A mRNA by at least 
40% in human hepatocyte cultures (Abdel-Razzak et al. 1993). Conversely, IL-4, a cytokine 
involved in T-helper-cell activation, can induce 2E1 up to 5 fold (Abdel-Razzak et al. 1993), 
and is strongly implicated in the pathogenesis of drug-induced liver injury, however IL-4 is 
not significantly elevated as part of the stress response (Njoku 2010). 
One study examined antipyrine metabolism in 57 children with multiple organ failure, 
critical illness or bacterial sepsis. The half-life of antipyrine was increased up to five fold 
and clearance was reduced up to threefold, indicating suppression of several CYP450 
enzymes. Consistent with findings discussed above, clearance was reduced the most in 
those with higher levels of IL-6 (Carcillo et al. 2003). 
As a model of chronic inflammation, Frye et al. gave a cocktail of drugs to estimate the 
activity of CYP1A2, 2C19, 2D6 and 2E1 to patients with congestive heart failure. They 
showed inflammatory cytokines IL-6 and TNF-α suppressed CYP1A2 and 2C19 activity, but 
did not appear to affect 2E1 or 2D6 (Frye et al. 2002). Similar results were shown in in 
vitro testing of hepatocyte cultures by Muntané-Relat et al. (Muntane-Relat et al. 1995). 
These authors examined the effect of known enzyme inducers on the activity of CYP 1A1, 
1A2 and 3A4 with and without the presence of inflammatory cytokines IL-1α, IL-6 and 
TNF-α. By measuring mRNA levels they showed the cytokines substantially reduced the 
impact of enzyme inducers on protein synthesis, with reductions in both CYP1A1/1A2 and 
CYP3A4, consistent with the findings of Frye. 
Another study examined CYP3A4 in 16 patients following abdominal aortic aneurysm, 
complete or partial colectomy or peripheral vascular surgery with graft (Haas et al. 2003). 
They found reductions in CYP3A4 activity of between 20-60% with greatest reductions at 
least 72 hours after surgery. Interestingly, peak IL-6 levels occurring 24-36 hours after 
surgery. The authors drew attention to the scale of this inhibition by drawing 
comparisons with the inhibition following administration of ketoconazole, clarithromycin, 
delavirdine and amprenavir, drugs well known to inhibit CYP3A4 (Lacy et al. 2005). 
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1.3.4.2.3.1 CANCER 
Chronic inflammation is a common feature in patients with solid tumours. Cancer patients 
have been shown to have down regulated CYP3A (Rivory et al. 2002; Robertson et al. 
2008), with functionally relevant alteration to pharmacodynamics/pharmacokinetics of 
substrates of CYP3A (Charles et al. 2006), correlating with plasma concentrations of IL-6 
(Rivory et al. 2002). Much of the interpatient variation in response to cytotoxic 
chemotherapy is attributed to differences in CYP3A4 activity as CYP3A4 is responsible for 
the clearance of several cytotoxic agents: taxanes, vinca alkaloids, cyclophosphamide, 
tamoxifen, camptothecines, etoposide, imatinib and gefitinib (Morgan et al. 2008). Given 
these observations, the authors of this review recommended that CYP3A4 phenotyping 
would be a superior means of dose estimation to current crude estimates based on body 
surface area (Morgan et al. 2008).  
It has been shown that variation in CYP3A4 genotype alone is unlikely to significantly alter 
clearance of cytotoxics (Lepper et al. 2005), but rather cancer-induced inflammation is 
thought to be responsible. Inflammation is present in more than 60% of patients with 
advanced cancer and they have significantly reduced CYP3A4 activity; again there are 
links with IL-6 concentrations (Charles et al. 2006) as well as CRP (Slaviero et al. 2003). Of 
specific relevance to this Thesis is the finding that colorectal cancers, in particular, have 
shown IL-6 protein actually within the malignant cells of tumours, indicating cytokine-
stimulated release from Kupffer cells is not the only source of IL-6 in cancer patients 
(Brozek et al. 2005). Slaviero et al. also showed a link between reduced CYP3A4 mediated 
clearance and greater toxicity of vinorelbine and docetaxel (Slaviero et al. 2003). 
1.3.4.2.3.2 DEHYDRATION AND STARVATION 
Over 25% of hospital inpatients may be malnourished, either occurring before their 
admission to hospital or subsequently (Thompson 1995). Factors contributing to 
malnutrition in the surgical patient include increased nutritional requirements associated 
with their illness, increased losses e.g. from malabsorption, stricturing processes limiting 
nutritional intake, aggressive bowel preparations or stoma output and prolonged periods 
nil by mouth. All patients are routinely starved before surgery, often commencing the 
prior evening. Many surgical patients who have undergone major surgery or experienced 
complications are still not fed on day three postoperatively (Kennedy 1996). Prolonged 
starvation can contribute to the stress response and insulin resistance. Metabolic 
pathways more specific to paracetamol, in particular CYP2E1 activity (Nygren 2006), are 
 91 
 
well known to be up-regulated in starvation alone (Pessayre et al. 1980; Burk et al. 1990; 
Prasad et al. 1990; Manyike et al. 2000).  
Figure 1.3-4 shows the source of energy for CYP450 activity is NADPH. NADPH is derived 
from glucose-6-phosphate (G6P), which is itself derived from gluconeogenesis or dietary 
glucose. During gluconeogenesis NADPH production consumes G6P before glucose is 
produced. Accordingly, during periods of intense CYP450 activity, glucose arising from 
gluconeogenesis is reduced. Gluconeogenic substances enhance CYP450 activity by 
increasing NADPH production. In this way oxidation is closely linked to gluconeogenesis 
(Bánhegyi et al. 1988). As CYP450 systems derive energy straight from a source 
stimulated by starvation (i.e. gluconeogenesis), starvation does not cause the reductions 
in activity seen in other enzyme systems, in fact as described above, activity of CYP2E1 
has been shown to be increased by starvation.  
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Figure 1.3-4 Intracellular glucose regulation and CYP450 
The relationship between to CYP450 activity and intracellular glucose regulation is shown (top right). Abbreviations: 
G6P- Glucose-6-Phosphate, NADPH- Nicotinamide Adenine Dinucleotide Phosphate. Remainder of diagram is shown in 
Figure 1.3-5 
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Protein-containing infusions alone have been shown to prevent elements of the stress 
response (Kopp Lugli et al. 2010) by preserving the activity of drug metabolising enzymes 
(Pessayre et al. 1978). Preoperative glucose infusions have been shown to reduce 
postoperative insulin resistance, further implying the importance of preoperative 
nutrition to preventing CYP450 downregulation (Ljungqvist et al. 1994).  
Dehydration, a common factor in the early postoperative period, is not thought to 
influence Phase I activity greatly, although there are some dissenters (Lee et al. 2008). 
Zafar et al. found that after 96 hours of dehydration the clearance of paracetamol in rats 
was unaffected, although they did show an increase in the glucuronide conjugate and 
reductions in the unchanged paracetamol excreted (Zafar et al. 1987). The significance of 
this is uncertain, given metabolism in the rat does not accurately reflect paracetamol 
metabolism in humans. This may also be a function of changes to excretion, rather than 
metabolism per-se. 
Changes in CYP450 activity in dehydrated rats were reported by Kim et al. in 2001 who 
showed CYP2E1 protein levels increased three fold, without effect on CYP1A2, 2B1, 2C11 
or 3A4 (Kim et al. 2001). However, in their discussion, the authors noted that water 
deprivation was associated with reduced food intake and they suspected the effect on 
CYP2E1 arose from the reduction in food intake rather that dehydration as such. 
Following this work Kim et al. went on to again deprive rats of water but give glucose 
supplementation. They found glucose supplementation ameliorated the changes to 
CYP2E1 activity, confirming that the effects of starvation were of greater consequence to 
CYP2E1 activity than water deprivation (Kim et al. 2006). These findings were echoed in a 
study of surgical patients by Jorquera et al. By providing an exogenous source of glucose 
and protein through administration of parenteral nutrition following surgery, Jorquera et 
al. was able to diminish reductions of antipyrine clearance seen in control patients who 
did not receive the infusion (Jorquera et al. 1994).  
When considering the complexities of the stress response and other changes experienced 
by the surgical patient, the involvement of insulin, glucose, corticosteroids and cytokines 
all probably have a role in the regulation of drug metabolising enzymes. 
1.3.4.2.4 PHYSIOLOGICAL ROLE OF CYP450 INHIBITION 
The question of why CYP450 enzymes are downregulated during inflammation remains a 
subject of debate. Some theories include: 
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 The dependency of the acute phase response on haem. Downregulation of CYP450 
would increase the availability of haem and augment the acute phase response; 
 The protection of the liver against additional oxidative stress. The inflammatory 
response causes oxidative stress which contributes to infection-induced hepatic 
injury. CYP450 enzymes produce reactive oxygen species therefore 
downregulation of CYP450 could prevent further contributions to this stress; and 
 The execution of the inflammatory response. Some CYP450 enzymes generate 
products with anti-inflammatory and vasodilatory activity. Downregulation of 
these enzymes would prevent inhibition of the immune response as well as the 
contribution to hypotension, a significant predictor of morbidity in septic shock 
(Fleming 2001; Aitken et al. 2006). 
While it is clear CYP450 is regulated by inflammation, it is a curious finding that the 
reverse is true. CYP450 inhibitors exacerbate and CYP450 inducers attenuate fever caused 
by inflammatory stimuli (Aitken et al. 2006). The immune response following 
administration of endotoxin to individuals receiving rifampicin, an enzyme inducer, would 
be enhanced, whereas the response of an individual receiving the enzyme inhibitor 
clarithromycin is diminished in comparison. 
1.3.4.3 PHASE II 
Whilst there is some literature on Phase I metabolism perioperatively, research into 
alterations in Phase II enzyme activity perioperatively has been almost absent. Compared 
with the CYP450 system, very little is known about changes to Phase II processes arising 
from surgery, inflammation or infection (Xin 2002; Aitken et al. 2006). This may be due to 
the perception that there is little variation in this pathway in comparison with Phase I 
enzyme activity.  
1.3.4.3.1 ALTERATION TO ENZYME ACTIVITY 
There are two reports relating to changes in Phase II activity postoperatively; both 
showing reductions in the proportion of Phase II products excreted in the urine. Results 
were calculated as ratios between the total of Phase II metabolites (paracetamol 
glucuronide and paracetamol sulphate), to Phase I metabolites (paracetamol cysteine and 
paracetamol mercapturate). In the first study, where patients acted as their own controls, 
patients were given a single dose of paracetamol at least one day preoperatively and 
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again on day two postoperatively. There was a significant reduction in the ratio of Phase 
II:I metabolites of paracetamol postoperatively (Kennedy 1996). In the second study, 
patients again acted as their own controls and received a single daily dose, but the 
duration of administration was extended to five days post-surgery. Twenty seven patients 
undergoing elective major abdominal surgery completed the study. The ratio of Phase II:I 
metabolites dropped from 28 preoperatively, to 5 postoperatively, indicating a 
substantial shift towards the production of the hepatotoxic metabolite (Kennedy 2009a). 
This confirmed earlier incidental findings showing significant reductions in paracetamol 
glucuronide excretion and increased in paracetamol cysteine excretion (Kennedy 1996).  
Glucuronidation and sulphation often occur on overlapping substrates, and to date, 
specific probes for these pathways have not been validated. This may explain the 
difficulty in ascribing alterations to one specific pathway and lack of clinical reports of 
toxicity arising from changes to Phase II metabolism.  
1.3.4.3.1.1 SULPHATION 
Sulphation is a high affinity, low capacity reaction, predominating at low substrate 
concentrations (Section 1.2). Once again there are few studies specifically dealing with 
sulphate conjugation perioperatively. Reith et al. showed that with increasing doses of 
paracetamol, the proportion of the dose excreted as paracetamol sulphate decreased 
(Reith et al. 2009). This effect may also be seen in single doses as paracetamol sulphate 
excretion was markedly reduced, approaching significance, in the first study by Kennedy 
et al. in 1996.  
Depletion of the inorganic sulphate and saturation of SULT enzymes occur following 
paracetamol administration (Hjelle et al. 1985). SULT enzyme 2A1 and the enzyme that 
synthesises SULT enzymes’ cofactors, PAPS synthase 2, have both been shown to be 
downregulated by LPS induced inflammation. Similar results have been shown for 
SULT1A1 and 1C1 with up to 76% suppression of sulphating activity being reported 
(Shimada et al. 1999; Kim et al. 2003; Kim et al. 2004). As observed for CYP450 enzymes, 
PXR and CAR are implicated in the down-regulation of SULT enzymes (Kim et al. 2003). 
1.3.4.3.1.2 GLUCURONIDATION 
Glucuronide conjugation predominates at high substrate concentrations, once sulphation 
has been saturated (Zamek-Gliszczynski et al. 2006). The enzymes involved in 
glucuronidation, UGT, are known to be regulated by factors affected by inflammation 
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(Aitken et al. 2006). Compared with changes in CYP450 enzymes, decreases in hepatic 
UGT activity are minor, species and stimuli-dependent (Aitken et al. 2006). Only one study 
in human liver biopsies has correlated decreases in mRNA of UGT1A4, 2B4 and 2B7 with 
inflammation (Congiu et al. 2002). 
1.3.4.3.1.2.1 GLUCOSE REGULATION AND GLUCURONIDATION 
Because glucuronidation contributes substantially more to the metabolism of 
paracetamol than any other pathway, and is also capable of conjugating greater amounts 
of parent drug, lack of substrate, G1P, for conjugation could be a reason for this reduction 
observed postoperatively. 
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Figure 1.3-5 Intracellular glucose regulation and Glucuronidation 
The relationship between to glucuronidation and intracellular glucose regulation is shown. Abbreviations: G6P- Glucose-
6-Phosphate; G1P- Glucose-1-Phosphate; UTP- Uridine triphosphate; UDP- Uridine diphosphate; UGT- Uridine 5'-
diphospho-glucuronosyltransferase. 
Figure 1.3-5 shows G1P is required for glucuronidation and it is thought that the G1P used 
arises exclusively from glycogenolysis, not from dietary sources per se. Inhibition of 
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glycogenolysis also inhibits glucuronidation and glucose does not reduce glucose 
production arising from gluconeogeneic substances. Glucuronidation activity is 
proportional to carbohydrate reserves with maximum rates seen in livers with the largest 
glycogen reserves. Conversely, depletion of glycogen by starvation inhibits 
glucuronidation. As a result things that inhibit glycogenolysis may impair glucuronidation 
(Bánhegyi et al. 1988).  
Applying these findings to the surgical patient is difficult. Patients are catabolic following 
surgery; tissues are resistant to insulin and with reduced uptake and utilisation of glucose, 
are frequently hyperglycaemic. Insulin resistance and perioperative starvation would 
normally promote glycogenolysis and therefore glucuronidation, but the high ambient 
glucose levels inhibit glycogenolysis. The net result on glycogenolysis and therefore 
glucuronidation is uncertain (Schenker et al. 2001). There are some in vivo studies. One 
study showed short periods of starvation not to affect glucuronidation in 
patients(Rumack 2004). Kennedy et al., also did not find an appreciable change in the 
paracetamol Phase II:I metabolite ratio when patients resuming light diets following 
major abdominal surgery (Kennedy 2009b).  
1.3.4.3.1.3 GSH CONJUGATION 
In starved patients, hepatic concentrations of GSH are diminished through lack of dietary 
cysteine intake. In these patients there is an increased risk of hepatotoxicity from reactive 
oxygen species such as NAPQI (Figure 1.3-6). Whitcomb found starvation reduced GSH 
concentration up to 50% in the liver tissue of adult rodents (Whitcomb et al. 1994). This is 
thought to be due to the utilisation of the hepatic and intestinal GSH stores as reservoirs 
to supply cysteine during cysteine reservoirs during food deprivation (Strubelt 1980; Cho 
et al. 1981; Di Simplicio et al. 1997). 
No changes to constitutive expression of GST have been found to arise from LPS-induced 
inflammation; however induction of GST may be prevented by inflammation (Maheo et 
al. 1998). Downregulation of induced expression is thought to be by accelerated 
degradation of mRNA, in a similar manner to CYP450 downregulation (Maheo et al. 1997). 
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Figure 1.3-6 Role of glucuronidation in paracetamol detoxification and sources of cysteine (Lu 1999) 
While no changes to GST activity have been found, GST requires GSH, and the synthesis of 
this cofactor can be rate limiting. One of the major determinants of GSH synthesis is the 
availability of cysteine. As already described, exogenous cysteine is generally obtained 
from the diet and protein breakdown while endogenous cysteine can be synthesised de 
novo in the liver from methionine by the transsulphuration pathway (Takada et al. 1984; 
Colell et al. 1997; Fernandez-Checa et al. 1997). Cysteine is unusual amongst amino acids 
as it exists in two forms. Inside the cell it is found in its' reduced, sulph-hydryl form, 
cysteine. Outside the cell, in the extracellular fluid, it autooxidises to its disulphide form, 
cystine. Aside from diet, the main factors that determine hepatocellular availability of 
cysteine are firstly the activity of the membrane transport of cystine, cysteine and 
methionine and secondly, the activity of the transsulphuration pathway (Fernandez-
Checa et al. 1997). In normal conditions rat hepatocytes uptake cysteine at a rate about 
three fold higher than methionine and 13 fold higher than that of cystine. Explaining this, 
cysteine transport occurs under normal physiological conditions; however, cystine uptake 
by hepatocytes is poor, but can be stimulated after prolonged exposure to insulin and 
dexamethasone (Takada et al. 1984). This could indicate regulation as part of the stress 
response. Additionally, the enzyme responsible for GSH synthesis, γ-glutamylcysteine 
synthetase, (GCS), is modified by factors involved in inflammation and the stress 
response, being induced by cytokines TNF-α and IL-1β, insulin and glucocorticoids, but 
inhibited by high glucose concentrations (Urata et al. 1996; Lu 1999).  
1.3.5 EXCRETION 
Through the process of metabolism a drug is more readily excretable, most commonly 
through the kidneys into the urine, or into the bile from the liver. Once a drug is 
metabolised there are some factors due to surgery and anaesthesia which may influence 
its excretion: 
GlutathioneCysteine Glutamylcysteine
Paracetamol-
cysteine
G
lu
ta
m
yl
cy
st
ei
n
e 
sy
n
th
et
as
e
G
lu
ta
th
io
n
e
sy
n
th
et
as
e
Diet
Protein 
breakdown 
Methionine via 
transsulfuration
NAPQI
G
lu
ta
th
io
n
e-
S-
Tr
an
sf
er
as
e
 98 
 
 Altering the rate of delivery to the organ of excretion; and 
 Changing the activity of enzymes or other active or passive process of excretion 
(Nimmo et al. 1988).  
These are discussed below. 
1.3.5.1 ALTERING THE RATE OF DELIVERY TO THE ORGAN OF EXCRETION 
The excretion of some drugs is so efficient that it is limited by the rate at which they are 
delivered to their organ of excretion. Such drugs are known to have a high extraction ratio 
as in the case of volatile anaesthetics, which are excreted by the lungs. They rely on 
pulmonary blood flow to determine their rate of elimination. Because pulmonary blood 
flow is determined by cardiac output and, as discussed above, cardiac output can be 
reduced around the time of surgery, surgery can reduce their clearance (Nimmo et al. 
1988). These effects are most pronounced immediately after surgery (Haas et al. 2003). 
Similarly, drugs such as opiates and β-blockers, that have a high hepatic extraction ratio 
depend on blood flow to the liver to determine rate of elimination (Nies et al. 1976). 
However as paracetamol has only an intermediate hepatic extraction ratio this is not 
particularly relevant to its disposition (Mather et al. 1986; Nimmo et al. 1988). (Mather et 
al. 1986; Nimmo et al. 1988). 
Blood to the kidney can also be reduced and this has been shown to impair renal 
elimination of gentamicin (Nimmo et al. 1988; Kim et al. 2001; Kim et al. 2006; Lee et al. 
2008). It may also have implications for other drugs and metabolites which rely on renal 
excretion. These drugs could accumulate and, if they have pharmacological activity, such 
as morphine metabolites, potentially cause toxicity (Nimmo et al. 1988). In the case of 
paracetamol, renal failure may cause the glucuronide and sulphate metabolites to 
accumulate however, because they are pharmacologically inert, they are 
pharmacologically inert, it does not necessitate dose adjustment. 
1.3.5.2 CHANGES TO THE ACTIVITY OF ENZYMES OR OTHER ACTIVE OR PASSIVE 
PROCESS OF EXCRETION 
Other changes due to surgery can lead to alteration of physiological pH and by affecting 
ionisation states of compounds, this may affect excretion processes. Paracetamol is a 
weak organic acid with a pKa of 9.5. It is therefore largely unionised in urine over the 
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physiological pH range and accordingly its excretion is much slower than glomerular 
filtration rates. Because of its pKa, its clearance is not influenced by changes in urine pH, 
but is affected by changes in urine flow although the effect is modest. In one study, 
increases in urine flow rate from 1.6 to 13.7mL/min resulted in less than a doubling of 
paracetamol clearance(Prescott et al. 1973). Reductions to urine flow are frequently seen 
in surgical patients, especially in the early postoperative period, followed by a period of 
diuresis, and these changes may alter the excretion of paracetamol. However, 
paracetamol glucuronide and paracetamol sulphate are extensively ionised in biological 
fluids, irrespective of pH, and their clearance is therefore unaffected by changes in 
urinary pH or urine flow (Prescott et al. 1973; Prescott 1980). Both paracetamol and its 
metabolites share similar mechanisms of active renal tubular secretion, and along with 
other enzymes discussed above, this may be down-regulated during periods of 
inflammation or infection (Duggin et al. 1975).  
Although changes to hepatic enzymes involved in excretion of drug metabolites into the 
bile may occur as a result of surgery, these are not well documented. Reductions in bile 
flow and bile salt excretion has been reported following surgery, which may arise from 
impairment of transporter molecules in the canaliculi as discussed above (Herman et al. 
1971; Prandi 1975), but the implications for drug therapy and paracetamol use is 
uncertain.  
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1.4 OTHER INFLUENCES OF PARACETAMOL DISPOSITION 
Because of the uncertainty around therapeutic concentrations, literature surrounding 
changes to paracetamol disposition is primarily concerned with toxicity and its prediction.  
Paracetamol is considered an extremely safe drug, especially when it is taken into account 
that the annual United Kingdom (UK) consumption could be measured in the hundreds of 
tonnes (Sheen et al. 2002a). While safe in almost all individuals, there is evidence of 
toxicity at licensed doses, although these are generally limited to case reports. Reviewing 
these case reports reveals a number of common factors for paracetamol toxicity. As 
discussed in Section 1.2 these can summarised into two types of risk:  
 Those that increase NAPQI production (usually through CYP2E1 induction); or  
 Those that impair GSH conjugation of NAPQI (usually through depletion or 
impaired supply of GSH’s co-factors). 
In the majority of case reports of toxicity where licensed doses have been used, both 
types of risk factor can be identified and it is unlikely that either one factor alone is 
sufficient to cause toxicity. The main causes of these risk factors are discussed below. 
1.4.1 ALCOHOL 
Table 1.4-1 Summary of alterations to paracetamol disposition with alcohol intake 
 NAPQI Production GSH 
Acute alcohol  - 
Chronic alcohol   
Alterations to paracetamol disposition in alcoholism are centred on ethanol-induced 
changes to CYP2E1 activity, the enzyme primarily responsible for the production of 
paracetamol’s hepatotoxic metabolite, NAPQI. This is compounded by reductions to the 
supply of GSH (Table 1.4-1).  
The understanding of the interaction between CYP2E1, ethanol and paracetamol 
disposition is complicated by the fact that acute and chronic ethanol intake have opposite 
effects (Prescott 1996). When administered concurrently, ethanol is preferentially 
metabolised by CYP2E1 over paracetamol. Thus individuals with suicidal intent who 
consume a bottle of whisky along with a bottle of paracetamol are provided a large 
degree of protection from paracetamol toxicity by the ethanol in the whisky (Prescott et 
al. 1983). Providing blood-ethanol concentrations remain sufficiently high, paracetamol 
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metabolism proceeds along non-toxic Phase II pathways as CYP2E1 remains occupied with 
ethanol metabolism (Prescott 2000a; Thummel et al. 2000; Waring et al. 2008).  
The detrimental effects of ethanol arise from chronic administration (Liangpunsakul et al. 
2005). However, the risk arising from ethanol-related induction of CYP2E1 alone may be 
overstated and requires a substantial and continuous level of ethanol consumption which 
is reversed quickly by short periods of abstinence.  
A significant level of induction is difficult to achieve because, like many CYP450 enzymes, 
CYP2E1 is a leaky enzyme that, in the absence of substrate, it generates reactive oxygen 
species that increase its own degradation (Liangpunsakul et al. 2005). Because ethanol is 
a substrate of CYP2E1, this stabilises the CYP2E1 enzyme, reducing the rate of 
degradation and effectively increasing their amount. CYP2E1 is normally biphasic with 
half-lives of 7 and 37 hours (Rumack 2002). Ethanol dramatically extends the fast 
component of degradation so that the half-life appears as a single 37 hour duration 
without any transcriptional change to mRNA for CYP2E1 (Eliasson et al. 1992). A modest 
(about four-fold) increase in CYP2E1 activity is observed in those individuals who 
consume substantial amounts of ethanol on a daily basis to maintain blood ethanol 
concentrations around 250mg/dL. However, this requires the consumption of sufficient 
ethanol to continuously maintain blood alcohol concentrations at least five times the 
legal driving limit in UK (Girre et al. 1994; Dilger et al. 1997; Dupont et al. 1998). As 
consumption increases beyond this there appears to be increased synthesis of CYP2E1 as 
well in addition to the stabilisation described above (Waring et al. 2008). To give further 
context, Thummel et al. projected a doubling of NAPQI formation would require an 
individual to consume greater than 50 bottles of wine over eight days (Thummel et al. 
2000). Even once achieved, this induction of CYP2E1 is short-lived, with 50% being lost 
after 36-48 hours of abstinence, returning to within normal ranges after 8 days (Perrot et 
al. 1989; Girre et al. 1994; Lucas et al. 1995). 
While consuming alcohol, the increased risk presented by this CYP2E1 induction is 
balanced by the protection afforded by the ethanol present in the blood. Therefore, in 
those individuals with ethanol-induced CYP2E1 induction, the period of greatest risk from 
paracetamol toxicity is upon acute withdrawal, such as may occur upon admission to 
hospital (Perrot et al. 1989; Schiodt et al. 2002; Graham et al. 2005b). At this most 
susceptible time there can be an increase of 22% in the mean formation of NAPQI 
(Thummel et al. 2000), reducing the average single dose required for toxicity from 15.9g 
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to 13g according to current treatment guidelines (Sivilotti et al. 2005), however, 
indications of the increased sensitivity to licensed doses cannot be found. 
While the role of CYP2E1 induction may be less important, chronic consumption of 
alcohol does independently increase the mortality of paracetamol overdose, both as 
single doses (Schiodt et al. 2002) and repeated supra-therapeutic doses (Alhelail et al. 
2011) indicating the effect of other risk factors.  
When licensed doses are considered, the role of GSH conjugation may be more important 
in chronic consumers of alcohol. Following chronic consumption of alcohol, GSH synthesis 
and transport into mitochondria is reduced (Lu 1999; Lee et al. 2004b). This could 
decrease an alcoholic’s capacity to detoxify NAPQI, which as described above may be in 
increased amounts due to CYP2E1 induction (Fernandez-Checa et al. 1987; Lauterburg et 
al. 1988; Sinclair et al. 2000a; Sinclair et al. 2000b). Additionally, higher energy 
requirement and subsequent malnutrition seen in chronic alcoholics (often despite 
adequate nutritional intake) may impair regeneration of GSH, further impeding the 
detoxification of NAPQI (Lieber 1991; Gloria et al. 1997; Bergheim et al. 2003). The impact 
of malnutrition is discussed further below in Section 1.4.5.  
Despite an increased sensitivity to paracetamol toxicity and several case reports of 
alcoholics with severe and even fatal liver damage after therapeutic doses of paracetamol 
(Whitcomb et al. 1994; Moling et al. 2006; Krahenbuhl et al. 2007; Claridge et al. 2010), 
hepatotoxicity has not been shown in prospective studies. Benson gave 4g 
paracetamol/day to patients with chronic liver disease including alcoholic cirrhosis for up 
to 14 days and showed no adverse effects (Benson 1983). A larger placebo controlled 
study of 385 alcoholics published in 2005 found similar safety of therapeutic doses in this 
population (Dart et al. 2000; Kuffner et al. 2005). Critics of the relationship between 
alcoholism and enhanced toxicity of licensed doses question the validity of the recorded 
dose in these case reports. Ingestion of paracetamol with therapeutic intent does not 
always mean therapeutic doses are taken (Whitcomb et al. 1994) and extrapolation of 
measured serum concentrations was indicative of overdose in most cases (Prescott 
2000a). Additionally, delayed presentation to care centres and poor recollection of dose 
taken may also have a role in enhancing cell sensitivity in alcoholics (Whitcomb et al. 
1994). Delayed presentation or incorrect reporting of time of overdose of one or two 
hours can make a large difference to the way a patient is treated and their likelihood of 
developing hepatotoxicity (Rumack 2004). Despite links between alcoholism and 
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paracetamol toxicity, this has only been shown with paracetamol overdose and there is 
little evidence that licensed doses carry any additional risk (Rumack 2004; Benson et al. 
2005; Kuffner et al. 2005; Dart et al. 2010). Even so the FDA require all paracetamol sold 
in the United States to be labelled with the warning: 
“If you consume 3 or more alcoholic drinks every day, you should ask your doctor 
whether you should take acetaminophen (paracetamol) or other pain 
relievers/fever reducers. Acetaminophen may cause liver failure” (Graham et al. 
2005b).  
1.4.2 SMOKING 
Table 1.4-2 Summary of alterations to paracetamol disposition with smoking 
 NAPQI Production GSH Glucuronidation 
Smoking  -  
Cigarette smoking’s effect on paracetamol disposition is small when compared with 
alcohol (Mishin et al. 1998). Its main effect is to induce CYP1A2, a minor contributor to 
Phase I metabolism at licensed doses, although some changes to CYP2E1 have also been 
identified. There may also be induction of glucuronidation of paracetamol, which could 
potentially oppose these changes, reducing paracetamol’s toxicity (Table 1.4-2). 
Polycyclic aromatic hydrocarbons (PAHs), the products of incomplete combustion, are 
some of the major lung carcinogens found in tobacco smoke and are also inducers of 
UGT1A6, CYP450 1A1, 1A2 and possibly CYP2E1 (Schmidt et al. 2003; Kroon 2007). The 
metabolism of many drug substrates can be induced in smokers resulting in a clinically 
significant decrease in pharmacological effects. These changes have also been reported in 
individuals exposed to second hand smoke (Mayo 2001). Effects have been shown to 
continue for several days after withdrawal of tobacco smoke exposure, with no effect of 
withdrawal seen in the first 24-36 hours (Kroon 2007), although values normalise to pre-
exposure levels within one week of cessation (Eldon et al. 1987; Faber et al. 2005). Other 
compounds in tobacco smoke such as acetone, pyridine, heavy metals, benzene, carbon 
monoxide and nicotine may also interact with hepatic enzymes but their effects appear to 
be less significant. 
The effect of tobacco smoke on CYP1A2 appears to be most pronounced. The induction of 
CYP1A2 by tobacco smoke and other aromatic hydrocarbons is well established. It is 
linked to transcriptional events and is probably tissue specific (Zevin et al. 1999). The two-
fold higher CYP1A2 activity commonly seen in smokers may increase clearance and 
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necessitate higher doses of drugs that are CYP1A2 substrates (Fuhr et al. 1993; de Leon et 
al. 2003; Kroon 2007; Backman et al. 2008). Clearance of theophylline is increased by 58-
100% (Zevin et al. 1999) while caffeine concentrations of smokers can be one half to one 
third of non-smokers (Benowitz et al. 2003). 
Increases in CYP2E1 activity and expression due to smoking have been shown in mouse 
lung, kidney and liver, although most studies in humans have failed to demonstrate 
significant induction of CYP2E1 in smokers (Miller 1989; Girre et al. 1994; Howard et al. 
2001). Induction may be due to repeated exposure to some of the substrates of CYP2E1 
found in tobacco smoke (i.e. NMDA, pyridine, benzene, acetone, styrene and vinyl 
chloride)(Zevin et al. 1999), however their effect is small compared with the inducing 
effects of ethanol, as described in the previous section (Mishin et al. 1998). One study of 
CYP2E1 activity in humans smokers showed intra-individual changes  of smokers before 
and then a week after cessation, although the effect was not seen in all subjects 
(Benowitz et al. 2003). These authors suggested the large inter-individual variation in 
CYP2E1 activity masks the moderate effects of smoking in studies that use a between 
subject design, such as the one by Girre et al. (Benowitz et al. 2003). This wide variation in 
response may be related to the presence of CYP2E1 gene alleles that are associated with 
higher or lower susceptibility to induction by cigarette smoking (Hu et al. 1999).  
Some glucuronide conjugation can also be induced by PAH. Cigarette smoke exerts 
differential effects on UDP-glucuronosyltransferases; and for many drug substrates 
clearance is increased. (Ochs et al. 1981; Grech-Belanger et al. 1985; Fleischmann et al. 
1986; Walle et al. 1987; Bock et al. 1994; Zevin et al. 1999; Kroon 2007). Paracetamol 
glucuronidation was found to be increased in some smokers and those exposed to PAH, 
through induction of UGT1A6. Interestingly the authors noted a correlation with caffeine 
oxidation (a marker of CYP1A2 activity) in the study group, suggesting an element of co-
regulation (Bock et al. 1994).  
The impact of these changes on paracetamol at licensed doses is minor. At these doses 
there is no evidence of a significant change in paracetamol’s half-life, Vd or clearance due 
to cigarette smoking (Pantuck et al. 1974; Mucklow et al. 1980; Miners et al. 1984b; Bock 
et al. 1987; Scavone et al. 1990; Bock et al. 1994; Dong et al. 1998). Although increased 
Phase I metabolism in smokers has been shown, the resultant increase in NAPQI at 
licensed doses is quantitatively unimportant. Following overdose, however, cigarette 
smoking has been shown to be an independent risk factor for severe hepatotoxicity and 
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mortality (Schmidt et al. 2003). In overdose situations the role of CYP1A2 may be more 
important as limited capacity of CYP2E1 is overwhelmed, leading to increased 
involvement of other CYP450 enzymes. If pre-existing induction of CYP1A2 from smoking 
was present, the subsequent increase in NAPQI production could explain the poorer 
outcome of smokers following overdose (Benowitz et al. 2003).  
It is important to note that these interactions are caused by the PAHs in tobacco smoke 
with only sparse evidence of a contribution of nicotine per se. Therefore nicotine 
replacement therapy does not cause the same pharmacokinetic drug interactions as 
tobacco smoke. However, pharmacodynamic drug interactions do result from nicotine, 
the majority arising from the activation of the sympathetic nervous system which can 
affect the pharmacological activity of certain drugs, but this is not important for the 
activity of paracetamol (Kroon 2007).  
1.4.3 AGEING 
Table 1.4-3 Summary of alterations to paracetamol disposition with aging 
 NAPQI Production GSH 
Aging - - 
Frailty -  
Both pharmacodynamic and pharmacokinetic factors are responsible for age related 
changes to paracetamol disposition, although the cumulative effect is much smaller than 
alcohol or smoking (Ochs et al. 1981).  
Regardless of the small scale of changes, the incidence of all serious adverse drug 
reactions increase with increasing age, even after controlling for increased medication 
use (Moore et al. 2007). Even though the majority of paracetamol poisoning cases are 
adolescents and young adults, most paracetamol associated deaths occur in an older 
population (Schmidt 2005). Additional risk factors that contribute to this poor outcome in 
the elderly include an increased time to presentation, poly-pharmacy, poor recollection of 
consumed dose and a greater prevalence of alcohol abuse (Schmidt 2005). Starvation and 
malnourishment is also more prevalent in the elderly which carry their own risk (see 
Section 1.4.5 below)(Schwartz 2007) and insufficient dietary intake of sulphur containing 
amino acids are observed in the elderly (Maher 2005; Mercier et al. 2006). However, 
many studies show no change to disposition of paracetamol at licensed doses in the 
elderly (Triggs et al. 1975; Miners et al. 1988) and there is no evidence age should be 
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considered when deciding the dose of paracetamol in adults (Divoll et al. 1982b; Miners 
et al. 1988; Klasco 2009). 
As people age they become more sensitive to adverse effects of drugs (Demeure et al. 
2006), however it may be the frailty that accompanies aging that is more related to 
changes in drug disposition (Wynne et al. 1990). It is frailty that is associated with a loss 
of reserves and increased state of vulnerability to paracetamol toxicity, not aging per se 
(Mitchell et al. 2011b) and frailty has been shown as a better predictor of deranged liver 
function than age in hospitalised patients receiving regular paracetamol (Mitchell et al. 
2011a)(Table 1.4-3). 
There are some reports of changes to drug absorption in the elderly. These changes are 
minor and not shown consistently, with most studies showing no change to absorption 
kinetics at all (Gainsborough et al. 1993; Schwartz 2007). Small but statistically significant 
reductions in the bioavailability of paracetamol in elderly subjects have been shown, but 
these were lost when co-administered with food (Divoll et al. 1982b). 
There may also be small reductions to Vd. Physiologically, with increasing age comes 
increasing body fat, reduction of body size, intravascular volume, organ volume and 
muscle volume, especially in females (Schwartz 2007). This may lead to reductions in Vd 
which have been shown in studies, especially in females (Schwartz 2007). been shown in 
studies using paracetamol (Divoll et al. 1982a; Liukas et al. 2011). 
Typically there are also declines in renal and hepatic function (Klotz 2009), especially in 
women (Schwartz 2007). Generally, however, half-life of paracetamol is unchanged by 
aging (Divoll et al. 1982a; Galinsky et al. 1986; Miners et al. 1988; Wynne et al. 1990; 
Liukas et al. 2011). Two more recent studies do exhibit some changes: serum paracetamol 
concentrations increased in elderly after five days of therapy (Mitchell et al. 2011a) and in 
a second, clearance was reduced in the elderly with marked increases in exposure to 
paracetamol following a 1g dose (Liukas et al. 2011). 
There are few studies that explain the changes to disposition seen in these last two 
studies. Generally there is very little age-related change to hepatic clearance, but when 
occurring, Phase I reactions are more impaired than Phase II in the elderly (Klotz 2009) 
which only account for a small amount of paracetamol’s clearance.  
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Typically, the role of age in the interindividual variation in Phase I’s CYP450 activity is 
relatively minor (Bebia et al. 2004; Liu et al. 2005) and has been shown to both increase 
and decrease (Galinsky et al. 1986). Determining CYP450 in the elderly is complicated by 
the presence of a number of confounders, which increase with age (Johansson et al. 
1990). Such age-related changes include reductions in creatinine clearance. Once these 
changes are accounted for, observed age-related differences often disappear (Bebia et al. 
2004). Specifically there is no evidence of change in the activity of CYP1A2 or CYP2D6 
(Simon et al. 2001; Bebia et al. 2004). There may be a small degree of induction of CYP2E1 
(Bebia et al. 2004), but this was not seen in an earlier study (Kim et al. 1995b). Clearance 
of CYP3A substrates have been shown to both increase (Bebia et al. 2004) and decrease 
with age (Schwartz 2006) but this is not due to alteration in the activity of the enzyme 
(Schwartz 2006). Aging-related alteration in the clearance of CYP450 substrates is thought 
more likely to be secondary to changes in liver blood flow, size, or drug binding and 
distribution with aging (Hunt et al. 1992a; Hunt et al. 1992b; Klotz 2009). Again, frailty is 
more associated with decline in CYP450 function (Wynne et al. 1990; Wynne 2005). In the 
disposition of paracetamol itself, shifts towards Phase I metabolism seen upon chronic 
dosing to inpatients are more prominent in the elderly, with age related increases to 
urinary recovery of paracetamol cysteine (Pickering et al. 2011).  
Changes to Phase II pathways are also minor. Glucuronidation of paracetamol has been 
shown to reduce in frailty (Wynne et al. 1990) and chronic dosing in the elderly (Pickering 
et al. 2011). Reports of increases (Galinsky et al. 1986) and no effect due to aging also 
exist (Miners et al. 1988). A small reduction in sulphonation has been reported (Galinsky 
et al. 1986; Miners et al. 1988; Pickering et al. 2011) although sulphonation was 
preserved in frailty (Wynne et al. 1990). GSH content of the liver has been shown to 
reduce with age (Liu et al. 2004; Maher 2005; Mercier et al. 2006) and age related 
increases in the demand for cysteine may reduce availability of cofactors for GSH 
formation (Mercier et al. 2006). This effect is compounded by the finding that diets 
containing insufficient inorganic sulphur and sulphur containing amino acids are more 
common in the elderly (Nimni et al. 2007). Despite this, the effect on paracetamol 
disposition has not been shown in all studies (Galinsky et al. 1986; Miners et al. 1988). 
At the other end of the spectrum, neonates do exhibit changes. The half-life of 
paracetamol in neonates is prolonged to 3.5 hours, however, this dissimilarity to adult 
rates reduces by the age of six months (van Lingen et al. 1999). This may be in part due to 
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a lack of glucuronidating enzymes, which have been shown to be deficient in neonates. 
One study found the expression of some UGT transcripts significantly lower in paediatric 
liver, leading to substantially reduced glucuronidation activity of up to 24 fold compared 
to adult controls for one of their study drugs, ibuprofen (Strassburg et al. 2002).  
1.4.4 OBESITY 
Table 1.4-4 Summary of alterations to paracetamol disposition with obesity 
 NAPQI Production GSH activity GSH reserves 
Obesity    
There are several changes to drug disposition that relate to obesity, but, in the absence of 
other accompanying risk factors, namely steatohepatitis and subsequent hepatic 
impairment, these changes do not confer additional risk of paracetamol toxicity (Table 
1.4-4). 
A drugs Vd may be increased in obese individuals (Blouin et al. 1999). In lipophilic drugs 
with a Vd greatly beyond that of intravascular volume, there is a risk that such an increase 
can lead to drug accumulation, escalating the risk of a drug’s toxicity (Abernethy et al. 
1982b). Because paracetamol is only of intermediate lipid solubility and its Vd is only 
slightly greater than the intravascular volume, obese individuals are not thought to be at 
a greater risk of paracetamol toxicity due to this factor (Abernethy et al. 1982a; Varela et 
al. 2008).  
Metabolism of paracetamol has been reported to be increased in obese individuals and 
those with steatohepatitis (Abernethy et al. 1982a). The degree of increased activity of 
some CYP450 enzymes in obese man is more closely linked to the degree of adiposity of 
the liver, rather than the degree of obesity itself (Raucy et al. 1991; de la Maza et al. 
2000; Emery et al. 2003). This illustrates similarities between the changes in CYP450 
activity due to alcoholism and obesity. Similarly, changes to CYP450 activity in obese 
individuals have been shown to normalise following weight loss (Emery et al. 2003).  
Of primary importance to paracetamol metabolism, CYP2E1 activity is increased in obese 
man (O'Shea et al. 1994). Kotylar et al. reviewed the literature on CYP450 changes as a 
result of obesity and concluded that CYP2E1 was induced, CYP3A4 was inhibited and the 
effect on CYP1A2 and CYP2D6 was unclear (Hunt et al. 1992b; Kotlyar et al. 1999). In 
addition to increased CYP450 activity, there is also evidence that obesity reduces the 
activity of GSH peroxidase, the enzyme which detoxifies the CYP450 product NAPQI, 
adding further to the risk of paracetamol toxicity (Karaouzene et al. 2011).  
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While there is evidence of changes that increase risk from the Phase I system, obesity is 
not listed as a risk factor for paracetamol toxicity (Bristol-Myers Squibb 2009). Two 
factors found in obese individuals offer protection against NAPQI toxicity. Generally, 
obese individuals are well-nourished and are likely to have additional stores of co-factors 
required for GSH conjugation, which are necessary for NAPQI detoxification, and are 
subsequently able to detoxify a greater drug load. These additional stores of cofactor may 
explain why the reduced number of GSH peroxidase shown by Karaouzene et al (ibid) did 
not equate to a reduced level of activity. Furthermore, evidence of increased rates of 
glucuronidation in obese individuals would suggest further protection from paracetamol 
toxicity as this would draw paracetamol away from the toxic Phase I pathway (Xu et al. 
2012). 
1.4.5 NUTRITION 
Table 1.4-5 Summary of alterations to paracetamol disposition with malnutrition 
 NAPQI Production GSH activity GSH reserves 
Malnutrition    
TPN    
Of all the factors discussed in this section, malnourishment is the most relevant to 
paracetamol toxicity at licensed dose in the surgical patient, with evidence for both 
increased NAPQI production and reduced GSH conjugation (Table 1.4-5).  
Malnourishment, the intake of a diet insufficient to supply nutritional needs, occurs in 
over 25% of hospital inpatients, particularly the elderly (Thompson 1995). Nearly a 
quarter of elderly patients presenting for surgery are malnourished, often a consequence 
of semistarvation (Schenker et al. 2001). Additionally, overnight starvation/fasting is 
experienced preoperatively by all surgical patients receiving general anaesthesia and is 
aggravated by the use of aggressive bowel preparations, which usually result in 
dehydration (Holte et al. 2004). Following surgery, many patients are subjected to 
restricted diets and fasting may be prolonged for several days in those whose surgery 
requires the bowel to be rested. When allowed to eat, prolonged periods of insufficient 
energy intake are common, due to nausea, pain or lack of appetite (Nygren 2006) 
Poor nutrition or periods of starvation are also common themes in reports of fatalities 
following “normal doses” of paracetamol (Eriksson et al. 1992; Whitcomb et al. 1994; 
Kurtovic et al. 2003; Vitols 2003; Moling et al. 2006). Hepatotoxicity only arose in patients 
taking chronic supra-therapeutic doses of paracetamol following impaired nutrition or 
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fasting (Whitcomb et al. 1994). However analysis of the effect of nutrition on paracetamol 
disposition is complicated by two factors: difficulties in obtaining accurate dietary 
histories and the differences in the effects of chronic malnutrition, starvation and 
dehydration (which often accompanies starvation). There is evidence for the role of Phase 
I and Phase II pathways. 
In man, malnourishment has been shown to increase (Krishnawamy et al. 1977), decrease 
(Narang et al. 1977; Homeida et al. 1979) and not to change CYP450 activity (Sanchez et 
al. 1982). Total fasting has been shown to induce CYP450 (Hong et al. 1987) and CYP2E1 
activity specifically (Johansson et al. 1990; Liu et al. 1993). In malnutrition, there seems to 
be a differentiation between the effect on CYP450 between protein and carbohydrate 
deprivation, with the relative contribution of these to total calorie content being the most 
important predictor, not the calorie content itself. As previously discussed, any induction 
of CYP450 enzymes, particularly CYP2E1 can increase NAPQI production and predispose 
to toxicity (Schenker et al. 2001). 
Following on from this, the development of ketosis seems to be an important cause of 
CYP2E1 induction (Johansson et al. 1990) and it is a common factor that links fasting, high 
fat diets, diabetes and starvation to CYP2E1 induction (Yun et al. 1992). In the absence of 
carbohydrates and insulin, ketones are produced as a by-product from gluconeogenesis 
and the breakdown of fatty acids. These ketones appear to inhibit the breakdown of 
CYP2E1 enzymes, effectively causing induction (Eliasson et al. 1992). Further evidence is 
supplied by the reduction of CYP2E1 activity following the administration of glucose (Kim 
et al. 2006), insulin (Truong et al. 2005), or diets rich in carbohydrate/poor in protein 
(Mgbodile et al. 1972; Hayes et al. 1974; Campbell et al. 1976; Campbell 1977; Tranvouez 
et al. 1985; Jorquera et al. 1996), which would all reverse ketosis. Carbohydrate rich 
parenteral nutrition has been shown to reduce CYP450 activity, regardless of the amount 
of calories provided (Anderson et al. 1979; Knodell et al. 1984; Knodell et al. 1989; 
Jorquera et al. 1996). Specific changes from protein calorie malnutrition have been shown 
in a 60% suppression of CYP1A2 and 40-50% of CYP2E1 (Lee et al. 2004a). This is 
consistent with findings of the concentrations of theophylline (a CYP1A2 substrate) in 
asthmatic children being 62% higher in those with high carbohydrate diets indicating 
reduced activity of CYP1A2 (Feldman et al. 1980). Conversely, protein rich diets cause a 
marked increase to CYP450 activity (Alvares et al. 1976; Campbell et al. 1976; Jorquera et 
al. 1994; Jorquera et al. 1996). Protein rich, hypo-calorific parenteral nutrition given to 
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surgical patients for five days postoperatively significantly enhanced CYP450 activity, 
nearly halving antipyrine half-life (Jorquera et al. 1994). Conventional amino acid 
solutions have an identical effect (Pantuck et al. 1984). An elegant study demonstrated 
this by showing a reduction of similar magnitude upon switching from a regular to protein 
rich diet, which was reversed to original values upon initiation of a carbohydrate rich diet 
(Kappas et al. 1976).  
These changes have not borne out alteration to paracetamol disposition or toxicity in 
humans (Schenker et al. 2001), and even inhibition of CYP2E1 metabolism has been 
shown following a maximum 36 hour fast (O'Shea et al. 1994). However, crucially, ketosis 
did not always develop in this study (Schenker et al. 2001). It seems likely that in the 
presence of prolonged periods of fasting with accompanying development of ketosis 
some degree of induction of CYP2E1 may also occur in humans, however this is unlikely to 
increase the risk of adverse effects associated with CYP2E1 (O'Shea et al. 1994).  
There also seems to be an important role of Phase II metabolism. Malnourished patients 
presenting with paracetamol toxicity excrete twice the amount of Phase I products as 
healthy individuals, indicating changes to all three pathways of paracetamol’s Phase II 
metabolism (Davis et al. 1976). 
For paracetamol disposition, the most important changes to Phase II metabolism in 
malnutrition and perhaps metabolism in general, are to GSH. As discussed in Section 1.2, 
GSH conjugation and sulphonation both depend on a supply of cysteine and methionine 
from the diet: cysteine is used in the synthesis of GSH and supplies inorganic sulphur for 
the synthesis of the sulphonation cofactor PAPS. Diets require at least 0.9g of 
cysteine/methionine per day to eliminate 4g/day dose of paracetamol and this equates to 
on average an additional 50g of protein (Glazenburg et al. 1983; Gregus et al. 1994a). In 
the opinion of Nimni et al. the diets of lacto-ovo-vegetarians, vegans, those on a "health 
conscious diet” and those over 75 years were insufficient to metabolise paracetamol 
without harming homeostatsis (Nimni et al. 2007). In those with deficient diets, 
paracetamol elimination is slower and a greater amount of paracetamol is eliminated via 
NAPQI (Gregus et al. 1994a). In addition to harming sulphonation, these reductions to 
GSH will impair NAPQI detoxification. Tissue GSH levels are depleted by fasting (Liu et al. 
1993) and anorexic subjects have been shown to have 30% less GSH than controls (Zenger 
et al. 2004). The effect of starvation may be even greater in surgical patients who are 
exposed to other drugs, such as propofol, that also deplete GSH during their own 
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conjugation processes (James et al. 2003; Buzaleh et al. 2005). Diets restricted in sulphur 
containing amino acid slow GSH synthesis (Lyons et al. 2000) having a marked effect on 
the redox status of cells (Miller et al. 2002). Rats show reduced GSH conjugation of NAPQI 
following fasting, with reductions to GSH concentration of up to 50% (Whitcomb et al. 
1994). This is thought to arise from reduced cysteine intake following food deprivation 
(Cho et al. 1981). Supplementation of parenteral nutrition with glutamine, a precursor of 
GSH, has been shown to maintain GSH concentrations postoperatively and has even been 
linked to shortened hospital stays (Fan et al. 2009). 
Lack of glucose or sulphate may also reduce glucuronidation and sulphonation and result 
in greater amounts being metabolised by the Phase I pathway to NAPQI (Price et al. 1987; 
Price et al. 1988). Both the rate and amount of paracetamol glucuronidation depend on 
hepatic carbohydrate reserves (Price et al. 1988). Postoperatively, patients are catabolic, 
being forced to supply glucose from amino acids through gluconeogenesis contributing to 
up to a 10-fold difference of glucuronidation activity between fed and fasting states(Price 
et al. 1988). However, short periods of starvation have not been shown to affect 
glucuronidation in patients (Schenker et al. 2001; Rumack 2004). Similarly, sulphonation 
also relies on inorganic sulphate being retrieved from the diet. With greater demands on 
sulphur containing amino acids from potentially increased NAPQI production, poor 
dietary supply can also impair sulphonation. 
Dehydration, a common factor in the early post-operative period, is not thought to 
influence paracetamol metabolism greatly (Zafar et al. 1987; Kim et al. 2001; Kim et al. 
2006) but there are no studies on dehydration-related changes to disposition in man.  
Adequate nutrition can minimise these risks. Glucose and protein infusions prevent 
elements of the stress response (Kopp Lugli et al. 2010), which in turn have their own 
impact on drug metabolism (see Section 1.3), and may preserve the activity of drug 
metabolising enzymes (Jorquera et al. 1994). Prolonged use of licensed doses of 
paracetamol necessitates intake of increased amounts of sulphur containing amino acids 
(Reicks et al. 1988) and curiously these have been shown to spontaneously occur (Pujos-
Guillot et al. 2011). Without an increase the restricted availability of cysteine and 
methionine may impair protein synthesis methylation reactions, and drug detoxification 
(Reicks et al. 1988).  
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1.4.6 DIABETES 
Table 1.4-6 Summary of alterations to paracetamol disposition with diabetes 
 NAPQI Production GSH activity 
Diabetes   
The situation regarding paracetamol metabolism in diabetics is unclear. Work in 
laboratory animals shows induction of all of the main CYP450 enzymes of paracetamol 
metabolism and inhibition of GSH conjugation (Lee et al. 2010). The effect 
glucuronidation and sulphation is uncertain although inhibition has been reported (Price 
et al. 1986) . Extrapolation to humans is difficult because a number of the studies arise 
from rats, which present different metabolite patterns to humans.  
Studies in humans demonstrate increased CYP450 activity in type I diabetics, particularly 
CYP1A2, but this is not seen in type II diabetics (Matzke et al. 2000). Conversely, activity 
of CYP2E1 increases in obese, type II diabetics, but not type I diabetics (Wang et al. 2003; 
Baek et al. 2006). However, poorly controlled type I diabetes is often accompanied with 
high concentration of ketones in the blood. Ketones are substrates of CYP2E1 and these 
high concentrations may induce this enzyme by prolonging the fast component of 
degradation, a similar effect to that of ethanol (Lieber 1997; Rumack 2002). 
In studies using paracetamol, Dajani showed increased half-life of paracetamol in type I 
diabetics through changes to volume of distribution, not clearance (Dajani et al. 1974). 
Adithan’s work agreed and also showed paracetamol clearance in type II diabetics 
reduced to less than half of the controls (Adithan et al. 1988). A study of Phase II 
metabolism in type II diabetics showed only lower clearance of paracetamol by 
sulphation, not glucuronidation, and increases to renal clearance of paracetamol (Kamali 
et al. 1993). While there are reports of induction and inhibition, of note is the induction of 
GSH synthesis by insulin, which is essential for NAPQI detoxification (Okouchi et al. 2006). 
This could oppose the increase in Phase I activity reported above (Lu 1999).  
Conversely, hyperglycaemia and insulin deficiency decrease GSH synthesis to levels that 
impair anti-oxidant defence (Urata et al. 1996). This may theoretically increase the risk of 
toxicity in overdose, but has not been reported. In otherwise healthy individuals, diabetes 
possesses no additional risk of paracetamol toxicity at licensed doses. 
“Surgical diabetes” in the post-operative patient may arise from the stress response, 
when the body becomes catabolic and rapidly resistant to the effects of insulin. The 
duration of diabetes is thought to factor in the nature of alterations to drug metabolism 
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(Sawant et al. 2006). As such, extrapolation of studies in types I and II diabetes to post-
operative, surgical diabetes is not possible because of the substantial differences in 
pathogenesis and time course. 
1.4.7 LIVER DISEASE 
Table 1.4-7 Summary of alterations to paracetamol disposition with liver disease 
 NAPQI Production GSH activity 
Liver disease   
Risks of paracetamol toxicity in patients with liver disease are balanced and are not 
thought to be any greater than the general population at licensed doses (Table 1.4-7). 
There is a reduction in CYP2E1 in patients with cholestatic forms of cirrhosis compared 
with unchanged or increased levels of CYP2E1 with non-cholestatic (e.g. ethanol) related 
cirrhosis (Tegeder et al. 1999). This would theoretically reduce the risk of toxicity, 
although in practice the drug is avoided or dose reduced to a maximum of 3g/day (Klasco 
2009). 
There are other changes to GSH synthesis in cirrhotic patients. GSH is required for the 
detoxification of NAPQI and GSH itself requires cysteine. In patients with cirrhosis one of 
the pathways of cysteine production, the transsulfuration pathway, does not function 
(Mato et al. 1994). This may predispose patients with liver disease to paracetamol 
toxicity, but as discussed above, this has not been shown clinically.  
1.4.8 GENDER 
Table 1.4-8 Summary of alterations to paracetamol disposition with gender 
 NAPQI Production GSH activity 
Male  - 
Small gender differences have been found in the pharmacokinetics of beta-blockers, 
caffeine, selective serotonin reuptake inhibitors, and verapamil (Fletcher et al. 1994; 
Meibohm et al. 2002), but most are not clinically significant (O'Shea et al. 1994). In the 
case of paracetamol, minor reductions to clearance are seen in females (Liukas et al. 
2011)(Table 1.4-8). The activity of some CYP450 enzymes has been shown to be higher in 
men than women, e.g., CYP1A2 and CYP2E1, with CYP3A4 being higher in women than 
men (Meibohm et al. 2002; Bies et al. 2003). However, interindividual differences in 
CYP450 activity are much greater than those due to gender and these changes are not 
always seen (Kim et al. 1995b; Bebia et al. 2004).  
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Gender differences in paracetamol glucuronidation and the activity of UGT1A6 have also 
been shown, with increases seen in males (Bock et al. 1994), whereas reduced reserves of 
inorganic sulphate and PAPS in females mean sulphate depletion due to administration of 
a substrate of sulphation may occur at a lower dose in females than males (Mulder 1986). 
GSH concentration in the liver is identical between genders as are rates of GSH synthesis 
(Mulder 1986).  
Other gender-related factors causing pharmacokinetic differences include the lower body 
weight and organ size, higher percentage of body fat, and lower glomerular filtration rate 
in women than in men (Fletcher et al. 1994; Meibohm et al. 2002; Bies et al. 2003). One 
review cautioned that the information on the effect of gender is mainly derived from rat 
studies because they are most pronounced in this species. They quote several studies that 
have shown the identification of sex-dependent difference in rats do not translate to the 
same xenobiotic handling differences in humans (Mugford et al. 1998). 
1.4.9 ETHNICITY 
Table 1.4-9 Summary of alterations to paracetamol disposition with ethnicity 
 NAPQI Production GSH activity 
African  - 
Ethnicity is not considered a significant risk factor for paracetamol toxicity, although some 
changes to disposition are seen. Critchley et al. examined the 24 hour urinary excretion of 
paracetamol and its metabolites following a single oral dose of 1.5 g in 111 Caucasians 
(Scotland), 67 West Africans (Ghana) and 20 East Africans (Kenya). They found reduced 
amounts of the Phase I conjugates of paracetamol amongst the Caucasians compared 
with Africans (p< 0.0005) indicating slightly reduced Phase I activity in the Africans (Table 
1.4-9). There were also differences in glucuronide conjugation with Caucasians 
conjugating significantly less than in the Africans, accounting for the increased amount 
excreted by the Phase I pathway. The authors conclude that these ethnic differences in 
paracetamol metabolism may be related to genetic or environmental factors including 
differences in diet and protein intake (Critchley et al. 1986). However, in studies using 
similar methods, no differences were seen between Caucasian and Chinese males living in 
South Australia (Osborne et al. 1991) or Caucasian and Oriental subjects in Canada (Patel 
1992). Prescott warns it may be difficult to distinguish the cause of ethnic variation 
between the effect of genetic, dietary or environmental factors (Prescott 1996).  
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1.5 THE CYTOCHROME P450 ENZYMES 
Cytochrome P450 (CYP450) enzymes are a very substantial and diverse superfamily of 
haemoproteins found in eukaryotes, bacteria and archaea (Nelson 2008). The name 
CYP450 is derived from the fact that these are coloured ('chrome') cellular ('cyto') 
proteins, with a "pigment at 450 nm", so named for the characteristic Soret peak formed 
by absorbance of light at wavelengths near 450 nm when the haem iron is reduced and 
complexed to carbon monoxide (Wijnen et al. 2007). They enzymatically metabolise a 
vast range of both exogenous and endogenous compounds. Usually they form part of 
multi-component electron transfer chains, called P450-containing mixed function oxidase 
systems (Wijnen et al. 2007).  
1.5.1 CLASSIFICATION 
CYP450 enzymes have been identified from all lineages of life, including mammals, birds, 
fish, insects, worms, sea squirts, sea urchins, plants, fungi, slime moulds, bacteria and 
archaea (Guengerich 1999). In humans the completion of the human genome sequence 
revealed the presence of 57 active CYP genes (Wijnen et al. 2007). These are displayed in 
Table 1.5-1 based on their major substrate.  
Table 1.5-1 Classification of all 57 human cytochrome P450 based on major substrate class (Guengerich et al. 2005) 
Sterols Xenobiotics Fatty Acids Eicosanoids Vitamins Unknown 
1B1  1A1 2J2 4F2 2R1 2A7 
7A1  1A2 4A11 4F3 24A1 2S1 
7B1  2A6 4B1 4F8 26A1 2U1 
8B1  2A13 4F12 5A1 26B1 2W1 
11A1  2B6  8A1 26C1 3A43 
11B1  2C8   27B1 4A22 
11B2  2C9    4F11 
17A1  2C18    4F22 
19A1  2C19    4V2 
21A2  2D6    4X1 
27A1  2E1    4Z1 
39A1  2F1    20A1 
46A1  3A4    27C1 
51A1  3A5     
 3A7     
CYP450 enzymes are further classified by their amino acid homology. Families are 
identified by an Arabic number and have at least 40% homology of amino acids, the 
subfamily is identified by a capital letter and has at least 55% homology and the gene 
product is identified by a further Arabic number. This classification system has replaced 
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nomenclature based on the substrate of the enzyme, e.g. cyclosporin oxidase and 
nifedipine oxidase are the same enzyme, P450 3A4 (Bruton et al. 2006).  
Human CYP450s are primarily membrane-associated proteins, located either in the inner 
membrane of mitochondria or in the endoplasmic reticulum of cells. While the highest 
concentrations of CYP450 are in the nose and the adrenal gland, the greatest mass is 
found in the centrilobular region of the liver (Wijnen et al. 2007). Their relative 
contribution to marketed drug metabolism is shown in Figure 1.5-1. 
The most common reaction catalysed by CYP450 is a mono-oxygenase reaction, i.e. 
insertion of one atom of oxygen into an organic substrate (RH) while the other oxygen 
atom is reduced to water (Equation 1.5-1). 
           
          
Equation 1.5-1 Most common reaction catalysed by CYP450 enzymes 
Of those whose function is currently known, most CYP450 enzymes present in humans 
are involved in the metabolism of sterols and vitamins A and D (Table 1.5-1) (Guengerich 
2006). About one quarter of the 57 CYP450 enzymes are considered to be involved 
primarily in the metabolism of “xenobiotic” (not normally in the body) chemical 
substances (Guengerich 2006). 
Five of the CYP450 enzymes carry out 90% of all CYP450 metabolism, making study in this 
area much simpler than if all 57 human CYP450 were involved (Frye 2004; Guengerich 
2006). Furthermore, these enzymes play a vital role in homeostasis (Lewis 2004; Wijnen 
et al. 2007). 
 
Figure 1.5-1 Contribution of CYP450 to overall drug Clearance 
(i) Contribution of each clearance pathway to overall clearance. (ii) Of metabolism as a clearance pathway, the 
contribution of individual enzyme systems to metabolism of marketed drugs is shown. UGT indicates uridine dinucleotide 
phosphate (UDP) glucuronosyl transferase; FMO, flavin-containing monooxygenase; NAT, N-acetyltransferase; MAO, 
monoamine oxidase; CYP, cytochrome P450. (iii) Of CYP 450 mediated metabolism of marketed drugs, the involvement 
of individual P450s metabolism is shown(Wrighton et al. 1992). 
Hepatic CYP450 are the most widely studied of the CYP450 enzymes because of their role 
in drug metabolism (Bruton et al. 2006). Here CYP450 enzymes are probably the most 
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important element of oxidative drug metabolism in humans (Guengerich 2006). The 
majority of CYP450 reactions: 
 Deactivate drugs; 
 Attenuate their biological activity; and 
 Accelerate their clearance from the body (Guengerich 2006).  
CYP450s can also activate compounds, which may have their own inherent 
pharmacological activity, or may modify cellular constituents and damage cells, as is the 
case with paracetamol and its metabolite NAPQI (Guengerich 2006). 
1.5.1.1 CAPACITY AND AFFINITY 
The metabolic reactions between a CYP450 enzyme and a substrate can be defined as 
either low affinity/high capacity or high affinity/low capacity. The affinity of an enzyme to 
a substrate refers to its preference for certain substrates. The rate at which the enzyme 
can metabolise substrate refers to its capacity. For example, CYP2D6 is a high affinity/low 
capacity enzyme: it prefers to metabolise specific substrates at low concentrations. As the 
concentration of a substrate increases, CYP2D6 becomes saturated and other, lower 
affinity, enzymes become involved in the metabolism of the substrate. Low affinity/high 
capacity CYP450 enzymes which commonly mop-up the spill over include CYP3A4, and 
CYP1A2 (Chen et al. 1998). While these classifications are true in the main, exceptions do 
exist; such an example is CYP2E1 which has high affinity/low capacity for some substrates 
and low/high for others (Kim et al. 2007). 
1.5.1.2 CYP450 AND DRUG METABOLISM 
1.5.1.2.1 CYP450 VARIATION; GENES AND THE ENVIRONMENT 
Unlike the CYP450 enzymes involved in homeostasis, the amount of xenobiotic 
metabolising CYP450 enzymes can vary widely in number and can even be completely 
absent, depending on an individual’s genome (Guengerich 1999). These polymorphisms 
are an important factor in determining an individual’s response to medication (Wijnen et 
al. 2007). The population can be divided into four subgroups based on their genotype: 
 Poor metabolisers (PM); 
 Intermediate metabolisers (IM); 
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 Extensive metabolisers (EM) and; 
 Ultrarapid metabolisers (UM) (Frank et al. 2007).  
Those with a PM genotype lack any functional allele, whereas EM subjects have one or 
two and UM subjects have more than two functional alleles. The IM genotype can arise 
from heterozygosity from a non-functional allele or the presence of alleles with reduced 
activity (Frank et al. 2007). 
The potential impact is shown for a theoretical drug in Figure 1.5-2. In this figure the 
upper trace represents that of an EM, the majority of the population, and the lower trace 
that of a PM. EMs metabolise drugs quickly and achieve a much lower steady state 
concentration. If the metabolite is active, or toxic, this rapid metabolism can lead to 
toxicity (Gasche et al. 2004). Conversely it can prevent therapeutic concentrations of the 
parent compound being maintained, requiring higher doses (Kirchheiner et al. 2004). As 
EMs constitute the majority of the population, drug dosing is based on their metabolism. 
In PMs, drug concentration accumulates with each administration as shown in the lower 
trace. PMs risk toxicity through parent compound accumulation (Lessard et al. 1999). 
 
Figure 1.5-2 Effect of variation in human CYP450 activity on plasma concentration.  
The effect of different metaboliser status on plasma concentration of a theoretical drug over time is shown. The top 
trace represents that of an extensive metaboliser and the bottom that of a poor metaboliser AUC indicates area under 
the curve(Guengerich 2006).  
Ethno-specificity is also involved in many cases. As an example the number of CYP2D6 PM 
ranges from 1-10% across ethnic groups, with the mean prevalence of 8.9% in white 
British, 3.9% amongst the French and as low as 1% of sub-continental Indians (Mamidi et 
al. 1999).  
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Although the majority (70-90%) of the variation in function is attributable to this genetic 
control (He et al. 2005), environmental factors, such as disease states, caffeine 
consumption, smoking, alcohol and concomitant drug use also impact on the enzymes 
actual activity (Harvison et al. 1988b; Prescott 2000a) and these were reviewed in Section 
1.4. 
Enzyme activity can be either increased or decreased, also referred to as enzyme 
induction and inhibition, respectively. Many clinically relevant drug interactions arise 
from this process. For example, a drug that inhibits the CYP450-mediated metabolism of 
another drug may cause the second drug to accumulate within the body and may result in 
toxicity. It is especially relevant to medicines with narrow therapeutic indices, such as 
some anti-arrythmics and anti-epileptics. Some of these factors were also discussed in 
Section 1.4.  
It is the sum of these influences, both genetic and environmental, which determine an 
individual’s actual enzyme activity, or phenotype. The effect of these are seen every day 
in a clinical environment; why a heavy smoker may need higher doses of benzodiazepine 
for sedation (Greenblatt et al. 1980), why the same dose of theophylline may be toxic for 
a non-smoker but ineffective for a smoker, or why a heavy alcohol drinker requires 
greater doses of opiate for pain relief and yet is at a greater risk of paracetamol toxicity 
(Frye et al. 1997; Ozdemir et al. 2000). As an explanation for these clinical observations, 
and the large differences in pharmacokinetics behind them, CYP450 enzymes can show a 
greater than 30 fold variation in function (Matzke et al. 2000; Carcillo et al. 2003; Zhou et 
al. 2004). The above examples show how important environmental factors are to 
determining an individual’s CYP450 activity.  
Because of the variability of these enzymes and their impact on drug metabolism, reliable 
measures of their activity play an important role in clinical studies of the current type. 
More practically, increased understanding of the variability of CYP450 enzymes may lead 
to the possibility of predicting and managing drug:drug interactions and explaining 
individual differences in response to or tolerability of medicines (Glue et al. 1999). 
It is not surprising then that knowledge of an individual’s CYP450 activity is becoming 
increasingly desirable in medical practice. While a genotype can be determined by arrays 
such as the AmpliChip (Roche Diagnostics, North America) or polymerase chain reaction 
(PCR) assays, from the examples above, it is clear that the genotype only accounts for a 
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fraction of the overall variation. Even in the absence of environmental influences, the 
genotype is inadequate in the majority of cases for predicting enzyme activity. As an 
example, CYP2D6 shows pronounced overlapping of genotype between IM and EM (Evans 
et al. 1991). For this reason, assessing the sum of genetic and environmental influences, 
or phenotyping, is the most accurate way to determine enzyme activity at the time of 
interest.  
1.5.2 ASSESSMENT OF CYP450 ACTIVITY 
As more is understood about drug metabolism in humans, there is increasing interest in 
assessing the role of CYP450 enzymes and how they are modulated. An individual’s 
phenotype at any given time is the sum of the effects of an individual’s genes and their 
environmental exposures (Section 1.4). Assessment of either influence alone is 
insufficient for accurate measurement.  
Phenotype can be assessed by three techniques:  
 Measuring mRNA or protein levels in liver biopsy for a specific CYP450 enzyme; 
 Exposing liver biopsy tissue to a probe drug; or 
 Administering a probe drug systemically and taking a blood or urine sample.  
The most common approach for assessment of CYP450 phenotype is the use of a probe 
drug whose clearance is dominated by the CYP450 enzyme of interest. This probe drug 
can be administered to a patient systemically (i.e. orally or intravenously), or can be 
exposed directly to liver tissue, obtained from a liver biopsy. While liver biopsies are 
considered the benchmark standard material for this assessment, the ethical and patient 
safety considerations of obtaining these samples are often insurmountable and systemic 
administration of probes in vivo have been shown to produce equivalent results (Tanaka 
et al. 2003).  
1.5.2.1 PROBES FOR CYP450 ACTIVITY 
The use of probe compounds to assess CYP450 enzyme activity began with non-specific 
probes such as antipyrine several decades ago (Breckenridge et al. 1973). Antipyrine is 
extensively metabolised by CYP450 enzymes and measuring its clearance following 
systemic administration is the benchmark as a general indicator of CYP450 mediated drug 
metabolism. However, it provides no specific information on individual CYP450 enzymes 
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(Breimer et al. 1990). As this area expanded, several rigorous in vivo pharmacokinetic 
studies found individual probe drugs for specific CYP450 enzymes, such as the clearance 
of caffeine as a means of assessment of the activity of CYP1A2 (Butler et al. 1992). 
While this provided huge advances to the understanding of the role of CYP450 enzymes, 
methods were cumbersome and inexact. Determining the clearance of a probe drug (area 
under the concentration time curve) (AUC(0-∞)), may be the most accurate way of 
determining an individual enzyme’s phenotype (Frank et al. 2007), but it is accompanied 
by several challenges, i.e. the activity of several enzymes other than the CYP450 under 
investigation contribute to clearance of the drug being measured. The rate of renal 
excretion may also be a factor which must remain constant for phenotype measurements 
to be comparable; this may be unachievable in all but the strictest of controlled 
environments, and all but impossible in the surgical patient.  
To avoid these complications, assessment of the partial clearance of the probe to its given 
CYP450 dependent metabolite can be performed. This approach requires multiple plasma 
samples and determination of recovery of the drug from the urine; both of which are time 
and cost intensive strategies, as well as uncomfortable for the test subject.  
Simplified metrics, such as those assessing the metabolic ratio of a probe drug to its 
metabolite at a certain time point, were developed to avoid these problems. Whereas the 
clearance of caffeine had been used to assess CYP1A2 activity, now the ratio of caffeine 
to paraxanthine (its primary metabolite) is used. This method was found to compare 
favourably with the more intensive strategies (Tucker et al. 1998), showing bimodal or 
trimodal distribution, reflecting the PM, IM and EM subgroups of enzyme activity (Frank 
et al. 2007). Moreover, this method is more economically and ethically viable (Frank et al. 
2007). 
Administering several individual probe compounds at the same time in a ‘cocktail’ was 
trialled to simplify and improve analysis, in an attempt to eliminate inter-day variation. 
The feasibility of cocktails was first shown in 1990 (Rogers et al. 2003), but, it was later 
found some of the probes affected the metabolism of other probes, invalidating the 
assessment. After considerable development, probe cocktails are now common place in 
drug research. Probes shown not to interact with other probes to provide good 
approximations of CYP450 activity are used (Fuhr et al. 2007).  
There are several desirable attributes for the ideal probe for CYP450 activity: 
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 The probe must have a known, quantifiable metabolic pathway that is principally 
or exclusively mediated by the CYP450 enzyme under investigation, so no 
interactions occur; 
 The action of the CYP450 enzyme in the clearance or metabolite formation being 
measured must be the rate limiting step. If other enzymes or processes (such as 
rate of excretion) are involved they must not be rate limiting; 
 If other processes, such as rate of excretion, are rate limiting they must remain 
constant for the assessment to remain valid; and 
 Probes for hepatic CYP450 enzymes should be completely metabolised by the liver 
and have a low hepatic extraction ratio (EH) in order to minimise influence of other 
factors, such as changes to hepatic blood flow or protein binding.  
This final point requires further expansion and can be explained by examination of the 
“well stirred” model of hepatic clearance. The well stirred model assumes that the liver is 
a single well stirred compartment and that unbound drug in the plasma is in equilibrium 
with unbound drug in the liver. Hepatic clearance (CLH) can therefore be described as 
Equation 1.5-2, where QH is hepatic blood flow, Clint is the intrinsic clearance of the drug 
and fu is the fraction of the drug unbound. 
    
         
          
 
Equation 1.5-2 Hepatic clearance and influence of hepatic blood flow 
Simplifying the model for low (EH<0.3) and high (EH>0.7), hepatic extraction ratio drugs 
will show which factors are the major influences of CLH. The hepatic extraction can be 
described as Equation 1.5-3. 
   
       
          
 
   
  
 
Equation 1.5-3 Hepatic clearance of drugs with high hepatic extraction ratios 
The liver is less efficient at clearing drugs with a low EH from the blood and therefore 
QH>>>fuCLint. As a result for these drugs the denominator can be simplified to QH. 
Applying this to allow further simplification of Equation 1.5-3 shows that for these drugs 
CLH ≈ fuCLint, revealing that CLH of drugs with a low EH depends on both fu and CLint. 
Accordingly, they should be minimally bound to plasma proteins to avoid complications 
from changes in volume of distribution, and be administered intravenously (Frye et al. 
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1997) in order to rely solely on the intrinsic metabolic activity of the responsible enzyme 
(De Vries et al. 1994). 
Other, more practical considerations, for the ideal probe include: 
 The probe must be safe and relatively pharmacologically benign at doses used; 
 The probe should be readily available commercially and registered as a 
therapeutic drug; 
 Analysis of the probe should be as simple as possible; 
 The probes should ideally show low intra-individual variability; 
 The time between administration of the probe and the taking of the sample 
should be short to minimise opportunities for introduction of sources of error (e.g. 
caffeine intake when caffeine is a probe) and inconvenience to patient and 
researcher; and 
 Pre-test restrictions should be minimal, i.e. fasting, abstaining from alcohol, 
caffeine or other dietary or lifestyle restrictions (Frye et al. 1997; Streetman et al. 
2000b; Zaigler et al. 2000; Frank et al. 2007). 
Several probes can be administered at the same time in a “cocktail”, offering several 
advantages, whilst also presenting their own set of challenges (Frye et al. 1997). When 
probes are given individually, there is often significant inter-day variability between 
samples due to a multitude of unquantifiable factors such as the influence of diet, 
exercise or the body’s circadian rhythms. The impact of this can be minimised by the 
administration of several probes at the same time, providing there is no interaction 
between them. An ideal cocktail is one that produces the same results as if each probe is 
administered separately (Frye et al. 1997). 
Components of a cocktail must not interact metabolically or clinically or cause analytical 
interference. Further validation is required to ensure that the accuracy of individual 
probes is not altered by the use of other probes in the cocktail and that independent 
phenotypic measures of the individual enzymes are still obtained (Berthou et al. 1995). 
The potential for these interactions can be minimised by keeping the doses as small as 
possible without compromising the assay detection limits. This also minimises any 
pharmacological activity. For example, chlorzoxazone, a probe for CYP2E1, was found to 
decrease the metabolism of caffeine, a probe for CYP1A2, by 20% when 500mg doses 
were given (Frye et al. 1997; Zhou et al. 2004), however, using a lower 250mg dose of 
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chlorzoxazone avoided this problem. Chlorzoxazone is metabolised by both CYP2E1 and 
CYP1A2, but CYP1A2 is only involved when CYP2E1 is saturated by higher doses (Frye et 
al. 1997). Other probes may induce the metabolism of another such as quinidine, a useful 
substrate of CYP2D6, but inducer of CYP3A4 (Zhou et al. 2004). 
Ideally sampling schedules should be kept as simple as possible and with multiple probes 
adjustment in the sampling time can be made without significant change in the accuracy 
of the exposure estimates (Campbell et al. 1987). Analytical interference can also be a 
problem as with the addition of each drug into the cocktail at least two additional 
compounds, the parent drug and the metabolite, will appear in the sample. Extraction 
and chromatographic modifications can overcome this. HPLC mass spectrometry based 
methods are about 100 times more sensitive and specific than HPLC-UV ones and provide 
lower limits of detection but the essential equipment is expensive and not often available 
in laboratories in a clinical setting (Guengerich 2006). 
It is important to note that many original studies in this area used non-human CYP450 
enzymes as an approximation of human enzymes. These enzymes are similar, but as an 
example, rat CYP1A2 are only 75% identical to human. For some substrates, rat and 
human 1A2 have nearly identical catalytic activity, whereas with others, human 1A2 has 
≥10 higher catalytic efficiency. There is also a greater variability in 1A2 levels in humans 
than rats. Many of these differences can be overcome by physiologically based 
pharmacokinetic modelling techniques that account for these differences (Guengerich 
2006). 
Probes are used in an attempt to gain knowledge about enzymes involved in drug 
metabolism so that the behaviour of other drugs can be predicted. The best probe drug 
for an individual CYP450 enzyme is metabolised exclusively by the CYP450 enzyme under 
investigation. Probes that have significant alternate pathways of metabolism (i.e. are 
metabolised by more than one CYP450 enzyme) may lead to erroneous conclusions 
(Swart et al. 2004).  
By understanding more about these processes there is the possibility of drug therapy 
being tailored to the individual patient’s metabolic parameters, so those who can tolerate 
a greater dose of a medicine get more and those who are predisposed to toxicity get a 
dose more appropriate to them.  
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The probes used to assess the activity of the four CYP450 enzymes relevant to this Thesis 
and justifications for their choice are discussed in the following section. 
1.5.3 PROBES USED IN THIS STUDY 
A summary of the CYP450 enzymes associated with Phase I paracetamol metabolism and 
their chosen probes are shown below in Table 1.5-2. Following this table is a review and 
evaluation of the enzyme probes for each enzyme. 
Table 1.5-2 Summary of CYP450 enzymes being assessed 
Enzyme Test Time Sample 
CYP1A2 Caffeine PO 100 mg  1 hour post dose Plasma 
CYP2D6 Dextromethorphan PO 30mg 4 hour post dose Plasma 
CYP2E1 Chlorzoxazone PO 250 mg  1 hour post dose Plasma 
CYP3A4 Midazolam IV 0.025mg/kg 4 hour post dose Plasma 
1.5.3.1 CYP1A2 
In addition to its role in the Phase I metabolism of paracetamol, CYP1A2 mediates the 
rate-limiting step in the metabolism of many other drugs including theophylline, 
clozapine, and tacrine, as well as in the bioactivation of procarcinogens (Simon et al. 
2001). CYP1A2 activity shows both pronounced intra- and interindividual variability. A 
major cause of this variability is related to smoking which causes enzyme induction. Other 
influences include drug intake and diet which can result in either induction or inhibition. 
In contrast to these exogenous factors, genetic influences on enzyme activity seem to be 
less pronounced. Therefore, phenotyping of CYP1A2, i.e. the determination of the actual 
activity of the enzyme in vivo, represents a useful approach both for scientific and clinical 
applications. CYP1A2 is almost exclusively expressed in the liver (Faber et al. 2005). 
1.5.3.1.1 CHOSEN PROBE- CAFFEINE 
Caffeine is the drug of choice for phenotyping CYP1A2 (Streetman et al. 2000a). It is 
relatively safe and possesses many favourable pharmacokinetic characteristics as a 
phenotyping probe. It is rapidly and completely absorbed from the gastrointestinal tract, 
distributed throughout the total body water, has low plasma binding, a short half-life, 
negligible first-pass metabolism, minimal renal elimination and first order elimination 
with almost entirely hepatic biotransformation (Fuhr et al. 1993; Kalow et al. 1993; 
Backman et al. 2008). Approximately 95% of caffeine’s systemic clearance is mediated by 
CYP1A2 (Kalow et al. 1993). The metabolism of caffeine is shown in Figure 1.5-3. 
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Caffeine (137X)
5-acetylamino-6-formylamino-3-methyluracil (AFMU)
5-acetyl-6-amino-3-methyluracil (AAMU)1-methylurate (1U)
1-methylxanthine (1X)
Unknown intermediate
Paraxanthine (17X)
CYP1A2
CYP1A2
CYP1A2 NAT2
XO Non-enzymatic
1,7-dimethylurate (17U)
CYP 2A6 and CYP 1A2
 
Figure 1.5-3 Predominant routes of caffeine metabolism 
(Streetman et al. 2000a) 
The caffeine metabolic ratio is also used as a marker for the assessment of liver 
dysfunction in patients with cirrhosis and is believed by some groups to be better than 
static determination of standard liver function tests (e.g. serum transaminases) (Jodynis-
Liebert et al. 2004). 
Plasma phenotyping compares the ratio of paraxanthine (17X, 1, 7-dimethylxanthine) 
with caffeine (1, 3, 7-trimethylxantine, 137X). This N-3 demethylation of caffeine accounts 
for up to 84% of the primary metabolism of caffeine at the doses used in vivo (Rost et al. 
1994; Frye et al. 1998b; Holland et al. 1998) and quantification of 137X partial clearance 
by 17X formation is the standard assessment of CYP1A2 activity if liver biopsy samples are 
not available (Kalow et al. 1993).  
The metabolite 17X is chosen for this purpose as only CYP1A2 is involved in its formation, 
whereas the formation of caffeine’s other metabolites involve CYP2E1 and CYP3A, in 
addition to CYP1A2. If these other metabolites are included, the involvement of these 
other enzymes compromises the accuracy of the assessment of CYP1A2 (Gu et al. 1992; 
Rost et al. 1994; Tassaneeyakul et al. 1994). Measuring the 137X/17X ratio has been 
shown to be more sensitive than a direct measurement of caffeine clearance (Jodynis-
Liebert et al. 2004) and these compounds are only found in plasma (Tanaka et al. 2003). 
1.5.3.1.2 SAMPLE TIME 
The metabolite 17X is both a product and a substrate of CYP1A2 and the goal of the 
17X/137X ratio is to measure 17X formation, or 17X as a product, not as a substrate. 
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Because of this, timing of sample collection is critically important since as time after the 
caffeine administration increases, 17X concentrations are more likely to reflect 17X 
degradation. 
1.5.3.1.3 DOSE OF CAFFEINE 
Most commonly used doses vary from 1-2mg/kg or 100-200mg (Kalow et al. 1993) 
because oral doses of >3mg/kg exhibit saturable pharmacokinetics and involve CYP2E1 
and CYP3A4 (Denaro et al. 1990). This results in poorer correlation with enzyme activity 
(Kalow et al. 1993; Tassaneeyakul et al. 1994). 
1.5.3.1.4 PHARMACOKINETIC PARAMETERS OF CAFFEINE 
In adults, caffeine has a Vd of 0.6L/kg, is 36% protein binding, has a half-life of five hours 
and Cmax between half and two hours following oral administration. It is excreted in the 
urine entirely as metabolised drug (Lacy et al. 2005).  
1.5.3.1.5 OTHER REPORTED PROBES OF CYP1A2 
Plasma samples are most often used for phenotyping CYP1A2, although urine and saliva 
sampling and a breath test have also been used (Fuhr et al. 1994).  
1.5.3.1.5.1 URINE SAMPLING 
Following plasma sampling, urine sampling is the next most cited method. While urine 
samples are far easier to obtain than plasma, this method for CYP1A2 assessment is 
fraught with technical difficulties: 
 Less than 2% of the caffeine dose is excreted unchanged so the ratio of caffeine to 
paraxanthine used for plasma assessment cannot be applied (Butler et al. 1992); 
 As a consequence, urine samples must be analysed for the ratio of four different 
metabolites in an eight hour urine collection (Georga et al. 2001); 
 The four metabolites being measured are amongst a total of 16 metabolites of 
caffeine found in urine. As a result, they are in low concentrations which may 
prevent direct analysis (Rostami-Hodjegan et al. 1996); 
 There are considerable structural similarities between the four metabolites, 
further hindering their analysis and extraction (Georga et al. 2001); 
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 The metabolites examined are either secondary or tertiary metabolites which are 
not exclusively formed by CYP1A2 (Fuhr et al. 1994) and as discussed above, this 
can impair the accuracy of the assessment of CYP1A2; 
 The validity of urine analysis relies on stable renal function and urine flow. 
Changes to renal function can invalidate the assessment because the four 
metabolites analysed are excreted in the urine very slowly, at rates much slower 
than glomerular filtration. Accordingly, the rate of excretion is the rate limiting 
step at which the metabolites appear in the urine, not their CYP1A2 mediated 
synthesis (Kalow et al. 1993). The problem arises because changes to renal 
function can affect the rate of excretion of each metabolite differently, and 
consequently this may alter their ratio in the urine, invalidating CYP1A2 
assessment; 
 Stable renal function and urine flow is difficult to achieve in healthy adults, given 
caffeine induces diuresis (Tang-Liu et al. 1982), and virtually impossible in major 
surgical patients who often have unstable renal function and hydration issues 
arising from surgery; and 
 Urine analysis is also more susceptible to influence by ethnicity and smoking, 
further contributing to poor correlation of the ratios (Fuhr et al. 1994; Tanaka et 
al. 2003).  
1.5.3.1.5.2 OTHER TESTS 
Saliva has been shown to correlate highly with systemic clearance and has been used for 
phenotyping CYP1A2. However some of the limitations of saliva testing are discussed in 
Section 1.2. 
Breath testing has also been used. Breath testing involves the administration of a precise 
dose of 13C-labeled caffeine and the measurement of the amount of 13C labelled carbon 
dioxide exhaled over two hours (Lambert et al. 1983; Lambert et al. 1986; Lambert et al. 
1990). This presents a number of challenges. While the first step in the process, the 
demethylation of the labelled 3-methyl group from caffeine is mediated by CYP1A2, there 
are a number of subsequent steps before the labelled carbon atom is exhaled from the 
lungs as carbon dioxide. All of these steps must remain non-rate-limiting for the 
assessment of CYP1A2 activity to be valid. This assessment also depends on respiratory 
quotient and therefore can be influenced by physical activity, smoking and diet (Lambert 
et al. 1983); none of these presumptions have been shown outside of healthy adults. 
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Additional barriers include sourcing the radio-labelled caffeine and accurately capturing a 
patients breath for two hours; both quite onerous tasks.  
Other, far more invasive tests measure CYP1A2 directly in liver biopsy samples. CYP1A2 
occurs in liver but not in blood cells. Hence assessment of its enzymatic presence using 
Western blot analysis or its formation by way of messenger ribonucleic acid (mRNA) 
determination is possible only by testing liver tissue, not by testing blood or other 
accessible tissue (Kalow et al. 1993). Accordingly these methods are unsuitable for 
frequent assessment of enzyme activity as is required in this Thesis.  
1.5.3.1.6 PROBLEMS WITH CAFFEINE AS A PROBE FOR CYP1A2 
Caffeine's main disadvantage as a probe for CYP1A2 is that it, along with other xanthines, 
is contained in many food and drinks. Intake of anything containing xanthine will interfere 
with the phenotyping (Rainska et al. 1992). This interference is more prominent in those 
who habitually drink coffee. It has been reported that habitual coffee drinkers are 
required to abstain for seven days before blood caffeine concentrations decline below the 
limit of detection, whereas for those who do not consume caffeine containing products, 
caffeine concentrations will fall to undetectable levels within three hours of a 500mg oral 
dose (Warren 1969). Because of the large amounts of caffeine consumed by humans it 
has also been found in ‘blank’ human plasma, which may interfere with preparation of 
control samples. Accordingly, some researchers advocate use of aqueous solutions of 
bovine albumin for control purposes to produce more accurate results than may be 
achieved with human plasma (Denaro et al. 1990).  
1.5.3.2 CYP2D6 
Aside from paracetamol, CYP2D6 is involved in the metabolism of about a quarter of all 
commonly prescribed medicines (Bertz et al. 1997) including anti-arrhythmics, 
antidepressants, neuroleptics, β-blockers and opioids (Lutz et al. 2004). It is often quoted 
for its large inter-individual and interethnic variation in activity and more than 80 allelic 
variants have been described (Zanger et al. 2004). These genetic polymorphisms can 
result in a 30 to 40 fold difference in the clearance of CYP2D6 substrates. Furthermore, 
this can cause extremes in drug concentration, both high and low, in the affected group 
of patients (Frank et al. 2007). This can lead to non-response in some and toxicity in 
others (Bertilsson et al. 2002; Kirchheiner et al. 2004) and no better example of this is 
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seen than in the response to codeine. Codeine is metabolised to morphine by CYP2D6 and 
it is this morphine that confers the majority of codeine’s analgesic activity. For the same 
dose of codeine, CYP2D6 poor metabolisers may receive no analgesic effect, whereas 
ultra-rapid metabolises may experience life-threatening opioid toxicity (Gasche et al. 
2004).  
CYP2D6 is mainly expressed in the liver but is also found in the lung and heart. CYP2D6 is 
stable over years. It is thought genetic determinants prevail over environmental factors in 
determining phenotype as CYP2D6 is not known to be affected by oral contraceptives or 
enzyme inducers such as rifampicin or ethanol(Bock et al. 1994). Neither gender, caffeine 
consumption, diabetes, menstrual cycle phase nor smoking have been shown to affect it 
(Matzke et al. 2000; Frank et al. 2007). However, there is some evidence CYP2D6 activity 
is modified by infection (Bertilsson et al. 2002), but not inflammation alone (Frye et al. 
2002). 
1.5.3.2.1 CHOSEN PROBE- DEXTROMETHORPHAN 
Dextromethorphan (DM) is probably the best probe drug for detecting CYP2D6 activity 
(Streetman et al. 2000a; Frank et al. 2007). DM metabolism is shown in Figure 1.5-4. 
Following absorption, DM is O and N-demethylated to dextrorphan (DX) and 3-
methoxymorphinan (3-MM). CYP2D6 mediated O-demethylation to DX accounts for more 
than 90% of DM metabolism and is the rate limiting step (Frank et al. 2007).  
3-Hydroxymorphinan (3-HM)
3-Methoxymorphinan (3-MM)
Dextromethorphan (DM)
Dextrorphan (DX)
CYP3A
N-demethylation
CYP2D6
O-demethylation
CYP2D6
O-demethylation
CYP3A
N-demethylation
 
Figure 1.5-4 Predominant routes of dextromethorphan metabolism 
1.5.3.2.2 SAMPLE TIME 
Oral clearance once again provides the best measure of CYP2D6 activity but this requires 
multiple samples over a long time to complete an AUC, which is expensive to perform and 
uncomfortable for the patient.  
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Single plasma samples can be used but the low analyte concentration requires very 
sensitive detection methods such as fluorescence detection or mass spectrometry. With 
these methods, correlations between the metabolic ratio in three or four hour post-dose 
plasma samples and oral clearance have been reported as high as r=0.74 (Hu et al. 1998; 
Chladek et al. 2000; Streetman et al. 2000b). 
1.5.3.2.3 DOSE OF DEXTROMETHORPHAN 
Doses of 20-30mg are most common with adverse effects associated with larger doses(Hu 
et al. 1998). Additionally, CYP2D6 becomes saturated at relatively low levels of substrate 
concentration, so doses are kept low to avoid the influence of other enzymes(Frank et al. 
2007). Streetman et al. conducted a dose finding study amongst 40 subjects for the 
purpose of phenotyping with doses ranging from 0.05-1.3mg/kg. They found inaccuracies 
in the results determined from the higher doses consistent with enzyme saturation. They 
concluded that 30mg could be used without concern for toxicity or the accuracy of the 
metabolic ratio to determine phenotype (Streetman et al. 1999). 
1.5.3.2.4 PHARMACOKINETIC PARAMETERS OF DEXTROMETHORPHAN 
DM undergoes rapid absorption with high bioavailability (Pender et al. 1991). Maximum 
concentrations are achieved in two hours. The elimination half-life of dextromethorphan 
is 2.5 hours and 4 hours for dextrorphan (Hollander et al. 1994). It is renally excreted 
mostly as demethylated metabolites (Pender et al. 1991). Absorption may be delayed by 
reductions to gastric emptying. 
1.5.3.2.5 OTHER REPORTED PROBES OF CYP2D6 
Saliva and urinary methods have also been used to probe for CYP2D6. The low analyte 
concentration in saliva makes the analysis difficult to perform and this method also lacks 
reproducibility (Hu et al. 1998; Frank et al. 2007). Poor correlations of saliva with 
established plasma and urinary measures also question the validity of this assessment 
technique.  
Urine collections ranging from 4 to 24 hours in duration have been used and in the 
literature most phenotyping studies involve an 8 hour urine collection, which does show 
good correlation with oral clearance (Evans et al. 1991; Schadel et al. 1995; Hu et al. 
1998; Kashuba et al. 1998b; Chen et al. 2003). However, there are some important 
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problems with urinary measures of the DM:DX ratio as a measure of CYP2D6 activity, 
which include: 
 Changes to urine pH causing up to a 20 fold variation in measured metabolite ratio 
(Kashuba et al. 1998a); 
 Excretion of dextrorphan being reduced in patients with impaired renal function 
(as mentioned in Section 1.3, the stress response temporarily impairs renal 
function in most surgical patients)(Kevorkian et al. 1996; Rostami-Hodjegan et al. 
1999); 
 Poor correlation with oral clearance (Borges et al. 2005) and; 
 Intra-individual coefficient of variation being reported as 37% on average 
(Kashuba et al. 1998a; Labbe et al. 2000).  
Debrisoquine and sparteine have also been used extensively and provide the most 
accurate result, but concerns about their availability and safety, limit their use (Streetman 
et al. 2000a). Tramadol has also been considered but requires further validation before it 
could be used and has safety concerns of its own. The metabolism of tramadol is also 
much more complicated than dextromethorphan. Metoprolol also provides a reliable 
result but the clinical effects of this drug limit its utility (Frank et al. 2007). 
1.5.3.2.6 PROBLEMS WITH DEXTROMETHORPHAN AS A PROBE FOR CYP2D6 
On repeated dosing accumulation may occur to a much greater extent in poor 
metabolisers (PM) than extensive metabolisers (EM) (Schadel et al. 1995). In studies using 
repeated doses where accumulation is an issue, saliva and serum samples may be more 
accurate. PM may also exhibit poor glucuronidation ability (Schadel et al. 1995). Due to 
the structural similarities, several opiates may interfere with the assay (Chen et al. 1990). 
Urinary pH may lead to a 20-fold variation in the measured 
dextromethorphan/dextrorphan metabolic ratio, however, correction factors have been 
developed that can adjust for changes in urinary pH (Ozdemir et al. 2004). Intra-individual 
variation in urinary dextromethorphan/dextrorphan metabolic ratios have been 
investigated (Kashuba et al. 1998a). This group found a coefficient of variation of 37% on 
average; however creatinine clearance and urinary pH were not taken into account which 
could improve these values.  
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DM and DX are present in very low concentrations in plasma and saliva samples. The 
compounds do not absorb UV light and therefore cannot be detected by conventional 
HPLC instruments with UV detection. The compounds do fluoresce so can be detected by 
a fluorescence detector in addition to mass spectrometry methods.  
1.5.3.3 CYP2E1 
The enzyme CYP2E1 is found mostly in the liver but also in several extra-hepatic tissues 
such as the kidney, lung and lymphocytes (Song et al. 1996; Lieber 1997). It exists on the 
plasma membrane when functionally active (Wu et al. 1992). It is involved in the 
metabolism of more than 70 endogenous and exogenous substrates including suspected 
carcinogens (Kharasch et al. 1993). Aside from paracertamol, the most important 
substrates are many inhaled anaesthetics, and ethanol (Song et al. 1996). There is no 
evidence of self-induction of CYP2E1 by paracetamol nor is there evidence of cumulative 
kinetics following prolonged use (Rumack 2002). While not a substrate, azole antifungals 
have been shown to induce CYP2E1. CYP2E1 is also involved in the metabolism of AA and 
has a minor role in gluconeogenesis (Song et al. 1996).  
The metabolites generated by CYP2E1 are often more toxic than the parent compound, 
commonly resulting in reactive free radical metabolites or oxidative species. These may 
cause DNA damage, generate protein adducts, cause lipid peroxidation, mobilise iron 
stores and may result in cytotoxicity (Song et al. 1996).  
There is considerable inter-individual variability in CYP2E1 activity. Many factors such as 
fasting, diabetes, obesity, hypophysectomy, alcohol, high fat diets and drug use influence 
CYP2E1 activity and this may contribute to the variability between individuals (Lieber 
1997). These were discussed in Section 1.4.  
Genetic factors may also be involved, as variations in the CYP2E1 gene have been 
described which are associated with altered enzyme activity or expression, although none 
of the polymorphisms described so far are useful for predicting an individual’s CYP2E1 
activity (Ernstgard et al. 2007). CYP2E1 also exhibits ethnic differences, having greater 
activity in Asians, particularly Taiwanese, compared with European and African Americans 
(Stephens et al. 1994). 
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1.5.3.3.1 CHOSEN PROBE- CHLORZOXAZONE 
Chlorzoxazone is the only CYP2E1 probe that has been widely studied (Desiraju et al. 
1983), is the only one currently available and has been proposed to be a nearly ideal 
probe (Ernstgard et al. 2007). Used clinically as a skeletal muscle relaxant for relief of 
painful musculoskeletal conditions, it is rapidly absorbed when given orally, attaining a 
peak at 38min ±3.3min after dosing (Frye et al. 1996; Ernstgard et al. 2004). The 
concentration then rapidly declines in a mono-exponential manner, suggesting rapid 
distribution and excretion. It is extensively metabolised and rapidly eliminated. Up to 90% 
of chlorzoxazone is oxidised by CYP2E1 to 6-hydroxychlorzoxazone which is then 
glucuronidated and excreted in the urine. Less than 1% of the drug is excreted into the 
urine unchanged with most (74 +/- 3.4%) of the dose excreted as the glucuronidated 
metabolite 6-hydroxychlorzoxazone (Desiraju et al. 1983). Such a high percentage 
indicates minimal influence of other elimination pathways. The 6-hydroxylation of 
chlorzoxazone provides a valid estimate of hepatic CYP2E1 activity and this can be found 
from a single point plasma ratio (Frye et al. 1996). The metabolism of chlorzoxazone was 
shown not to be affected by concurrent administration of paracetamol in a 
pharmacokinetic study (Ernstgard et al. 2004). 
1.5.3.3.2 SAMPLE TIME 
Plasma concentrations after 8 hours are generally undetectable indicating rapid 
elimination(Frye et al. 1996) although methods have been developed to detect 
chlorzoxazone as late as 10 hours after dosing (Desiraju et al. 1983). Two hours is 
considered to be ideal sampling time. High correlation between 2 and 4 hour metabolic 
ratios indicates 4 hours may also be acceptable but while ratios remain the same, the 
concentrations drop thereby increasing the influence of analytical errors. Two studies 
have found crushing the chlorzoxaone tablet improved absorption and similarly improved 
results (De Vries et al. 1994; Ernstgard et al. 2007). 
1.5.3.3.3 DOSE OF CHLORZOXAZONE 
As discussed in Section 1.5.2.1, chlorzoxazone has been found to affect the metabolism of 
caffeine when given at higher doses of 750mg, indicating its preferred enzyme, CYP2E1, 
had been saturated. In subjects with low body weight, 500mg is sufficient to saturate 
CYP2E1 (Frye et al. 1998a). This is avoided by using lower doses. However, it is suggested 
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that intra-individual variation reduces with increasing dose (Tanaka et al. 2003). In an 
attempt to find the ideal dose for phenotyping Frye et al. examined the effect of increase 
dose on kinetics. Their results of increases in the AUC and elimination half-life and 
reductions in the dose-normalised formation of 6OH-chlorzoxazone indicated saturation 
of CYP2E1 with higher doses and a non-linear disposition. They concluded that the use of 
a lower 250mg dose would avoid the complications associated with this non-linear 
elimination and its effect on phenotypic measures (Frye et al. 1998a). 
1.5.3.3.4 PHARMACOKINETIC PARAMETERS OF CHLORZOXAZONE 
Chlorzoxazone is rapidly absorbed following oral administration with a maximum 
concentration being achieved at 38min following a 750mg dose. It has a half-life of 66min 
and clearance 148 mL/min. 
1.5.3.3.5 OTHER REPORTED PROBES 
Measuring chlorzoxazone in other biological fluids has been examined. The solubility of 
the drug in the saliva and salivary glands is a crucial factor in the success of salivary 
monitoring. Chlorzoxazone is a relatively large and hydrophobic molecule and although 6-
hydroxychlorzoxazone is mostly glucuronidated or sulphated, the increase in size 
outweighs this increase in hydrophilicity. Because of these factors, the equilibration and 
equal partitioning of chlorzoxazone or 6-hydroxychlorzoxazone between plasma and 
saliva is not rapid enough to be clinically useful for monitoring (Ernstgard et al. 2007). 
Other methods to measure CYP2E1 activity in lymphocytes by the substrate p-nitrophenol 
or by flow cytometry, have also been investigated but were shown not to be as useful as 
chlorzoxazone metabolism (Ernstgard et al. 2007). 
1.5.3.3.6 PROBLEMS WITH CHLORZOXAZONE AS A PROBE FOR CYP2E1 
There may be a small contribution to chlorzoxazone metabolism by other CYP450 
enzymes. CYP1A has been shown to metabolise chlorzoxazone but it is of minor 
importance compared with human CYP2E1 in vivo (Desiraju et al. 1983).  
Chlorzoxazone metabolism may be affected by other confounders such as body weight. 
Ernstgard et al. in their review of chlorzoxazone use, showed that there was a significant 
correlation between metabolic ratio and body weight, lean body weight, body fat and 
body mass index (Ernstgard et al. 2004). Previous studies have also showed body weight 
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as a major contributor to inter-individual variability in the oral clearance of 
chlorzoxazone. The authors predict CYP2E1 activity is related to amount of body fat. In 
this paper, Ernstgard et al. postulated a connection between body fat, increased plasma 
insulin levels, increased fat catabolism, increased acetone and ketone body formation 
and, ultimately, increased CYP2E1. Ernstgard et al. also found no influence of moderate 
recent alcohol use, although alcoholics are known to metabolise chlorzoxazone five times 
more rapidly than healthy subjects. It is unclear if smoking impacts on CYP2E1 activity as 
it often accompanies alcohol use, although some induction in chlorzoxazone metabolism 
has been observed (Kroon 2007). 
No interfering peaks have been observed with the administration of midazolam and 
caffeine, as well as many other probes for other CYP450 enzymes. No interference was 
found in samples from several different patient population including patients with renal 
or hepatic disease, liver transplants or cancer (De Vries et al. 1994).  
In vivo 6-hydroxychlorzoxazone is rapidly glucuronidated following its formation and 
mainly exists as this conjugate in plasma and is entirely glucuronidated in urine. To 
accurately determine concentrations of 6-hydroxychlorzoxazone, samples must first 
undergo enzymatic hydrolysis to remove the glucuronide and expose the metabolite for 
detection (Lucas et al. 1993). Lucas showed approximately a threefold increase in the 
measured concentration of 6-hydroxychlorzoxazone after treatment with Helix pomatia 
juice. Treatment with β-glucuronidase showed yields 12% lower than with H. pomatia 
juice (Lucas et al. 1993). Unless exposed to enzyme hydrolysis, 6-hydroxychlorzoxazone in 
samples is below the limit of detection with some methods (Stiff et al. 1993). Incubation 
for 3 hours at 37°C is sufficient, with hydrolysis being complete after 2hrs of incubation. 
Longer incubations do not yield increased concentrations of 6OH-chlorzoxazone (Stiff et 
al. 1993). 
Chlorzoxazone is a low extraction ratio drug so clearance depends on metabolic activity 
and not hepatic blood flow (Guengerich 1999). Variation in absorption is thought to be 
one of the main contributors to inter-individual changes in metabolic ratio seen, with co-
efficient of variations commonly reported of 30-40% (Chen et al. 2002; Ernstgard et al. 
2004) and up to 52% in one study (Ernstgard et al. 2007). Accordingly changes to gastric 
emptying in surgical patients may have an impact.  
 138 
 
1.5.3.4 CYP3A 
CYP3A is the most clinically significant group of enzymes in human drug metabolism, 
being responsible for the metabolism of 60% of all therapeutic drugs and accounting for 
up to a quarter of all CYP450 enzymes in the liver. It is the major metabolic enzyme 
present in the human intestine (Thummel et al. 1994; Thummel et al. 1996; Lin et al. 
2001; Chaobal et al. 2005; Chung et al. 2006). In adults, CYP3A4 and 3A5 are the two most 
important isoforms with CYP3A7 only being found in foetal liver (Lin et al. 2001; 
McDonnell et al. 2005). Of these, CYP3A4 is the major isoform. CYP3A5 is subject to 
polymorphic expression and is only found in 20-30% of adult human livers, but having 
greater expression in the small intestine and kidneys (Lin et al. 2001). CYP3A4 and 3A5 
metabolise many of the same drugs but have different substrate intrinsic clearance and 
regioselectivity (Lin et al. 2001). Variations in CYP3A5 expression have been shown to 
have no effect on midazolam clearance (He et al. 2005) suggesting that CYP3A4 is 
predominantly responsible for the metabolism of midazolam when administered 
parenterally. 
Wide inter-individual variations in rate and extent of intestinal and hepatic CYP3A activity 
are seen in humans (Lin et al. 2001). Studies have shown up to a 48 fold variation in 
weight normalised clearance values between individuals (Lin et al. 2001). The expression 
of CYP3A may be affected by environmental, hormonal or genetic influences, however, 
relatively little is known about these homeostatic influences in comparison with what is 
known about the effects of drugs and diet (Rogers et al. 2002).  
1.5.3.4.1 CHOSEN PROBE- MIDAZOLAM 
Midazolam is a widely accepted and validated phenotyping probe for CYP3A and is one of 
the preferred in vivo probes by the US Food and Drug Administration (FDA) (Food and 
Drug Adminstration 1999). It has many of the attributes of an ideal CYP3A probe: 
 Its short half-life allows for estimation of the area under the curve (AUC and other 
pharmacokinetic end-points) within a reasonable time period; 
 It is exclusively metabolised by CYP3A4 to a primary metabolite, 1’-
hydroxymidazolam when parenterally administered; 
 It is not a PGP/multidrug resistant-1 substrate, which itself is subject to inhibition 
and induction, thereby potentially confounding results (Thummel et al. 1996); 
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 As it is subject to hydroxylation by both intestinal and hepatic CYP3A, oral 
formulations can be used to assess both intestinal and hepatic CYP3A activity and 
parenteral formulations to assess only the hepatic component (Tanaka et al. 
2003); 
 It has a low hepatic extraction ratio and clearance that is largely hepatic blood 
flow independent (Thummel et al. 1994); and 
 Its clearance correlates with CYP3A activity in liver biopsies and the clearance of 
other known CYP3A substrates such as cyclosporine (Chen et al. 2006; Chung et al. 
2006). It also reflects changes expected on co-administration with CYP3A inducers 
and inhibitors and in patients with severe liver disease (Chung et al. 2006). 
1.5.3.4.2 SAMPLE TIME 
Total midazolam clearance is an established in-vivo probe to assess the activity of CYP3A, 
however, accurate quantitation of midazolam clearance after midazolam administration 
requires the collection of serial blood samples (Lin et al. 2001). This is time consuming 
and costly. Similar to the other CYP450 probes discussed the use of a single time point to 
predict the integral plasma midazolam exposure (i.e. AUC) and indirectly in-vivo CYP3A 
activity has been investigated (Thummel et al. 1994; Thummel et al. 1996). This study 
showed that the optimal time for getting the best correlation between a single time point 
and AUC is the harmonic mean of the mean residence time (MRT). The study of 224 
healthy volunteers found the MRT for IV midazolam was 3.5 ± 1.6h and 3.4 ± 1.5h for oral 
midazolam, concluding that four hours was the best sampling time as the absorption and 
distribution would be essentially complete. A strong correlation (r=0.80) was shown 
between the four hour midazolam concentration and the IV midazolam AUC. Similar 
correlations remained when the study participants were given known CYP3A inducers and 
inhibitors, showing the usefulness of midazolam in drug interaction studies as an accurate 
assessment of CYP3A activity in altered states. 
Other studies have assessed the use of the ratio of 1`-hydroxymidazolam 
metabolite/midazolam concentration ratio at 30 minutes and one hour post dose with 
predicted correlations ranging from r=0.43 to r=0.87 (Dundee et al. 1984). However, the 
study using the four hour midazolam concentration had a much larger cohort. The 
metabolite 1`-hydroxymidazolam also undergoes rapid, potentially variable 
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glucuronidation in the liver and may introduce a further source of unpredictability (Food 
and Drug Adminstration 1999). 
1.5.3.4.3 DOSE 
The pharmacological effects of midazolam are dose limiting, but also have to be balanced 
with assay detection limits. Doses range from 0.025mg/kg for MS detection methods and 
up to 7mg dose for UV detection. Used clinically for sedation with amnesia, the relief of 
status epilepticus and induction of anaesthesia, the dose for its use as a probe must avoid 
the potential sedation and respiratory rate depression. The experience of clinical effects 
seems to have no effect on the validity of the probe. Those with previous exposure to 
benzodiazepines or alcohol tend not to be as sensitive to the pharmacodynamic effects of 
the drug.  
1.5.3.4.4 PHARMACOKINETIC PARAMETERS OF MIDAZOLAM 
Midazolam has a Vd ranging from 0.8-2.5 L/kg, being increased in congestive heart failure 
and chronic renal failure (Lacy et al. 2005). It is extensively protein bound (95%) and has a 
half-life of elimination of one to four hours, being prolonged in cirrhosis, congestive heart 
failure, obesity and the elderly. It is excreted in the urine, mainly as glucuronide 
metabolites (Lacy et al. 2005).  
1.5.3.4.5 OTHER REPORTED PROBES 
Simvastatin has also been used as a probe for CYP3A and was listed as a preferred 
substrate for the study of CYP3A drug interactions by the FDA (Prueksaritanont et al. 
2003). Approximately 80% of the metabolism of simvastatin to its metabolite, simvastatin 
acid, occurs via CYP3A with the remaining 20% via CYP2C8 (Chung et al. 2006) making it a 
less ideal probe for CYP3A. It also requires a similar sampling profile to midazolam. 
Simvastatin also lacks studies validating it through liver biopsy and there are few 
randomised controlled studies comparing it with established probes such as midazolam. 
One recent study showed weak correlations of phenotypic values between the two 
substrates, with simvastatin having far wider variability (Chung et al. 2006). The authors 
concluded simvastatin was a less accurate measure of CYP3A activity than midazolam and 
this variability occurred because simvastatin was less specific for CYP3A than midazolam 
(Chung et al. 2006) perhaps due to the influence of CYP2C8, a polymorphic enzyme. 
Simvastatin showed a double peak on its concentration-time profile indicating it may also 
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be subject to entero-hepatic recycling, which would also further complicate its analysis 
(Chung et al. 2006). Compared with midazolam, simvastatin is a non-validated, 
suboptimal CYP3A probe and its use as a CYP3A probe in preference to midazolam cannot 
be justified (Swart et al. 2004). 
1.5.3.4.6 PROBLEMS WITH MIDAZOLAM AS A PROBE FOR CYP3A4 
Midazolam is a hypnosedative and this does limit its usefulness in some settings and in 
some populations, with mild to moderate sedation often being reported (Chung et al. 
2006). There are also some reports of difference in metabolism between sexes (Lin et al. 
2001). 
A history of alcohol abuse and age have also been shown as covariates (Swart et al. 2004). 
Alcoholic cirrhosis can lead to an increased half-life of midazolam due to an increased Vd 
which is explained by a reduction of plasma protein binding (Swart et al. 2004). Compared 
with the effect of alcohol, the contribution of age is small (Swart et al. 2004).  
Midazolam has an intermediate to high hepatic extraction ratio which makes its 
pharmacokinetics susceptible to changes in hepatic blood flow (Swart et al. 2004).  
Once blood samples have been taken, some midazolam is lost with long periods of 
storage. El Mahjoub et al. showed around 90% of the original concentration of midazolam 
was measured in whole blood after 1 year of storage at -80°C and approximately 80% if 
stored at -20°C for the same period. No midazolam was detectable if the same was kept 
at room temperature (El Mahjoub et al. 2000). 
  
 142 
 
1.6 POPULATION STATISTICS 
As will be shortly discussed in Section 2.1, this study involved colorectal and breast cancer 
patients. The population statistics of these groups are outlined below. 
1.6.1 COLORECTAL CANCER 
1.6.1.1 PREVALENCE IN EUROPE AND IRELAND 
Colorectal cancers were the most commonly diagnosed cancer across the European Union 
(EU) in 2008, representing 13.6% of all cancers diagnosed. Ireland has one of the highest 
incidence rates of colorectal cancer in Europe with age standardised estimates for 2008 of 
66.9 per 100,000 for males and 42.9 for females. This compares with 54.9 and 35.9 for the 
UK, 54.8 and 36.4 for France and 27.4 and 17.1 for Greece (Ferlay et al. 2010).  
 
Figure 1.6-1 Newly diagnosed cases of colorectal cancer and percentage of all newly diagnosed cancers  
Number of newly diagnosed cases reported each year to the National Cancer Registry of Ireland (solid bar) and this 
number as a percentage of all cancers diagnosed in that year (dotted line). Source: (National Cancer Registry Ireland 
2010). 
Figures from the National Cancer Registry of Ireland list 2,271 newly diagnosed cases of 
colorectal cancers in 2009 (National Cancer Registry Ireland 2010). In Ireland this 
represents 7.6% of the total number of new cancers diagnosed in 2009, much lower than 
the 13.6% seen across the EU due to the even higher rates of other cancers in Ireland 
(National Cancer Registry Ireland 2010).  
The number of cases diagnosed with colorectal cancer in Ireland has increased by 
approximately 35% over the last fifteen years, which may reflect improvements in 
diagnosis, awareness and screening. The number of cases recorded by the National 
Cancer Registry of Ireland is shown in Figure 1.6-1 
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There have also been increases in the population of Ireland over this time which would 
have some impact, increasing the actual number diagnosed. Despite the increase in 
numbers diagnosed, the percentage of colorectal cancers of the total number of 
malignant cancers diagnosed in Ireland, also shown in Figure 1.6-1, has reduced over this 
time period.  
1.6.1.2 PATIENT CHARACTERISTICS 
Of the 2,271 newly diagnosed cases of colorectal cancer in Ireland in 2009, 1,342 
occurred in males and 929 in females (National Cancer Registry Ireland 2010). The actual 
number of cases of colorectal cancer diagnosed in 2008 collected by the National Cancer 
Registry of Ireland differs slightly from the estimates of Ferlay et al. given in section 
1.6.1.1. When the National Cancer Registry of Ireland rates were adjusted to meet the 
age of a theoretical European population, colorectal cancer diagnosis rates were 65.1 per 
100,000 males and 39.0 per 100,000 females. Both sets of age adjusted rates from Ferlay 
et al. (Ferlay et al. 2010) and the National Cancer Registry of Ireland (National Cancer 
Registry Ireland 2010) indicate that approximately two-thirds of those diagnosed with 
colorectal cancer are male. There are also important changes in rates of diagnosis in 
different age group. Data for age at time of diagnosis are shown in Figure 1.6-2.  
 
Figure 1.6-2 Age specific rates of newly diagnosed colorectal cancers in Ireland in 2009 
Data presented as cases per 100,000 of the population within that age group for each gender. Source: (National Cancer 
Registry Ireland 2010) 
This figure shows that colorectal cancer rates are highest in the 80-84 year old age group, 
with very few patients being diagnosed under 50 years of age. This has important 
ramifications for this Thesis in terms of the eligibility criteria for entry into the study, 
which, to paraphrase, required patients to be otherwise healthy aside from their 
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indication for surgery. It is to be expected the number of co-morbidities increase with age 
and this may lead to a greater rate of those who do not meet the entry criteria.  
1.6.1.1 DISEASE CHARACTERISTICS 
Locations of colorectal cancers newly diagnosed in Ireland in 2009 are displayed in Figure 
1.6-3. The National Cancer Registry of Ireland does not publish statistics that distinguish 
between locations of cancer in colon and, as a result, the majority of colorectal cancers 
are found within this region.  
Anus 2%
Colon 68%
Rectum 24%
Rectosigmoid 6%
 
Figure 1.6-3 Location of all newly diagnosed colorectal cancers in Ireland in 2009  
Data rounded to the nearest whole number. Source: (National Cancer Registry Ireland 2010) 
Locations of colorectal cancers also vary with age. These are displayed in Figure 1.6-4. 
 
Figure 1.6-4 Age specific location newly diagnosed colorectal cancers in Ireland in 2009 
Data presented as cases per 100,000 of the population within that age group for each location. Source: (National Cancer 
Registry Ireland 2010). 
Encompassing the largest area of the bowel, cancers of the colon make up the majority of 
diagnoses in all age groups, becoming increasingly prevalent in the later stages of life, 
peaking in the 80-84 year old age group. Rectal cancers are the second largest contributor 
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to colorectal cancer diagnoses, with relatively few rectosigmoid or anal cancers, however 
these represent a relatively exiguous anatomical area of the bowel.  
1.6.2 BREAST CANCER 
1.6.2.1 PREVALENCE IN EUROPE AND IRELAND 
Across the EU malignant breast cancer is the second most commonly diagnosed cancer in 
2008, representing 13.1% of all cancers diagnosed (Ferlay et al. 2010). In a recent report 
Ireland was listed as having the fourth highest incidence of breast cancer of 27 EU 
countries, with age standardised rates of 126.5 per 100,000 females. This compares to 
119.1 for the UK, 133.8 for France and 61.9 for Greece (Ferlay et al. 2010). There were 
2,766 newly diagnosed cases of malignant breast cancer reported to the National Cancer 
Registry of Ireland in 2009 which represented 9.3% of all malignant cancers diagnosed in 
that year (Figure 1.6-5). 
 
Figure 1.6-5 Newly diagnosed cases of breast cancer and percentage of all newly diagnosed cancers  
Number of newly diagnosed cases reported each year to the National Cancer Registry of Ireland (solid bar) and this 
number as a percentage of all cancers diagnosed in that year (dotted line). Source: (National Cancer Registry Ireland 
2010). 
Similar to colorectal cancer, the number of breast cancer cases diagnosed has steadily 
increased in the last fifteen years, although the increase in breast cancer cases has been 
more marked. There was a dramatic increase in 2008, when numbers of cases diagnosed 
increased by 12% on the previous year. This may reflect the effect of increased resources 
and national expansion of the national breast screening program “Breast Check” in 
Ireland, which commenced screening in December 2007. Unlike colorectal cancers, the 
percentage of breast cancers diagnoses of all malignant cancer diagnoses has increased 
from 8.0% in 1994 to 9.3% in 2009 (Figure 1.6-5). 
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1.6.2.2 PATIENT CHARACTERISTICS 
Of the 2766 newly diagnosed cases of breast cancer in Ireland in 2009, 2740 (99.1%) were 
female. When the Irish population statistics were adjusted to meet the age of a 
theoretical European population, the rate of malignancy of the breast being diagnosed 
was 125.23 per 100, 000 population for females and 1.17 per 100,000 males (Figure 
1.6-6).  
 
Figure 1.6-6 Age specific rates of newly diagnosed malignant breast cancers in Ireland in 2009 
Data presented as cases per 100,000 of the population within that age group for each gender. Source: (National Cancer 
Registry Ireland 2010) 
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2 METHODS 
2.1 PARACETAMOL METABOLISM STUDY 
This study was designed to detect changes to surgical patients’ paracetamol metabolism 
before and after surgery and determine the safety of higher doses of paracetamol. 
Following review of the literature discussed in this Thesis it was determined that the most 
effective way of establishing any changes and safety was through the review of: 
 Any changes to the kinetics of paracetamol, which would indicate a change in 
disposition (Section 2.2); 
 The detection of the stress response by reviewing the concentration of 
inflammatory cytokines known to affect drug metabolism (Section 2.3); 
 The measurement of αGST concentration, the most sensitive marker of early 
hepatotoxicity on the market (Section 2.4); and 
 The activity of CYP450 enzymes, the enzymes that contribute to paracetamol’s 
Phase 1 metabolism (Section 2.5); 
The methods for determining changes to paracetamol metabolism identified above 
required the collection of both blood and urine samples from patients and to determine 
the change caused by surgery, patient samples were required, prior to and following 
surgery. Accordingly, each patient recruited into this study was given paracetamol and 
had blood and urine samples taken on the evening before and for four days after their 
surgery (the protocol for which is described below).  
Drug metabolism is subject to a vast array of inter-individual differences arising from 
genetics and environmental influences. As discussed in Sections 1.3 and 1.4 these 
influences make the comparison between individuals very difficult because they are not 
applied to all individuals equally, nor are their drug metabolism’s affected to the same 
degree once an exposure to one of these influences has occurred. With this in mind this 
study compared preoperative to postoperative data from the same patient, using 
preoperative data as the control to reduce sources of variance. This allowed a more 
accurate assessment of the effect of surgery on drug metabolism. 
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2.1.1 THE PATIENTS 
Before the details of the study protocol are presented the justification for the patient 
groups is explained. 
The study began collecting patients scheduled for bowel resection into two groups: one 
group receiving high dose paracetamol (Group A) and the other receiving the licensed 
dose (Group B).  
Bowel resection patients were chosen because of: 
 Their need for good pain control postoperatively (to enable coughing, 
mobilisation etc.); 
 The effect on drug metabolism arising from the invasive and traumatic nature of 
their surgery, frequently involving manipulation of the gut and liver;  
 The malnourishment and prolonged perioperative fasting regularly seen in these 
individuals; and 
 Their prolonged hospital admission. 
Thus, these patients provided a “worst case scenario” for assessing changes to drug 
metabolism in surgical patients.  
Allocation to either group was done sequentially in groups of 10 patients. Doses were not 
randomised for four reasons: 
 This was a study primarily concerned with toxicity, not efficacy. A patient cannot 
have any influence on their own drug metabolism while in hospital;  
 Only one surgeon performed bowel resections at this hospital and he only worked 
with one anaesthetist. Following surgery all patients returned to the same ICU 
where they received the same level of nursing care;  
 Each patient provided their own control data from preoperative sampling; and 
 Randomisation would have necessitated frequent changes to dosing regimen, 
therefore conducting the study in blocks of patients eliminated the risk of dosing 
errors.  
This recruitment continued until half-way through Group B when reconfiguration of 
surgical services in the region in 2008 withdrew bowel resection surgery from this 
hospital (St John’s Hospital, Limerick (Hospital 1)).  
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The next most major surgery still carried out at Hospital 1 was mastectomy. To make the 
best of the situation they were chosen to give a comparator group (Group C) to bowel 
resection patients because: 
 They also have a need to good pain control postoperatively to allow restoration of 
function and reduce risk of chronic pain; and 
 Their surgery does not involve manipulation of the gut or liver, but is still 
considered intermediate in nature and can be of similar duration; and 
 Patients have short preoperative fasting and an early return to oral nutrition. 
However, it became clear that this patient group was unsuitable for this type of research 
primarily because they had poor IV access making the blood sampling detailed below 
difficult.  
It was decided to abandon this group and collect further bowel resection patients (Group 
D) in Mercy University Hospital, Cork (Hospital 2). This added a further 14 months to the 
research and presented significant challenges and some of these are detailed in the 
discussion. 
2.1.2 STUDY APPROVAL 
Ethics Committee approval was sought and gained from The Clinical Research Ethics 
Committee of the Cork Teaching Hospitals (Appendix 1 and 2). 
Clinical Trials approval was also sought and gained from the European Medicines Agency 
(EMEA) and the Irish Medicines Board (IMB) (Appendix 3). 
While application for ethics approval was straight forward, involving obtaining written 
approval from the host hospitals, application, provision of study protocols, presentation 
at meetings and answering of verbal and written questions, the application to the EMEA 
was significantly more laborious. This began with the application to apply for application 
for clinical trial approval, which was assessed on the investigators qualifications and 
experience. Once this was approved the application for clinical trial approval itself was 
nearly 100 pages in length which was completed online and then printed. The printed 
application was then submitted with key references and documents to the authority. This 
was followed by thorough inspection of every detail of the study by the EMEA and 
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resulted in further requested for information. Once these requirements were satisfied, 
approval was finally granted by the IMB as the agency with responsibility for Ireland.  
2.1.3 SAMPLE SIZE 
It was necessary to determine how many patients were required to enter the study to 
detect significant differences in paracetamol metabolism. The aspect of paracetamol 
metabolism of greatest interest was the difference between Phase II: Phase I paracetamol 
metabolite ratios before and after surgery. Generally, the number of participants required 
to detect significant differences is related to the size of that difference. Large differences 
can be detected with fewer participants whereas small differences need many more 
participants to detect them. A measure used to describe the size of this difference is 
called the ‘effect size’. The effect size can be used to determine sample size necessary to 
show a significant difference  
Changes to urinary metabolite ratio seen in previous work conducted by Kennedy in 1996 
were used in the effect size (d) calculation (Kennedy 1996). This was determined using 
Cohen’s d, as shown in Equation 2.1-1: 
 (               ) 
                                                               
                                                                         
 
Equation 2.1-1 Application of Cohen's equation for effect size 
The effect size (d) was shown to be 0.68. A power calculation was conducted which found 
that with and effect size of 0.68, 15 patients be required for 95% significance, which was 
consistent with previous work (Kennedy 1996). 
2.1.4 SAFETY 
At all times the safety and speedy recovery of the patient took priority over the conduct 
of the research study. The patients were informed at the time of consenting that they 
could withdraw at any time without hindrance to their subsequent medical care and this 
statement was also included in the consent form kept by the patient (Appendix 4). 
Low thresholds were set for derangement in liver function tests that were tested and 
reviewed twice daily. Any alterations resulted in withdrawal of trial doses and alterations 
to other analgesia were made to ensure continued comfort of the patient. 
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2.1.5 RECRUITMENT 
Prior to admission, all patients scheduled for elective surgery, who fulfilled the inclusion 
criteria, were identified to the Principal Investigator by the Admissions Co-ordinator 
(Hospital 1) or Surgeon’s Nurse Specialist (Hospital 2). A patient’s suitability for 
recruitment was ascertained by the Principal Investigator prior to consenting. This was 
done by checking previous laboratory values and medical notes to ensure the patient 
fulfilled all the inclusion criteria, but none of the exclusion criteria, as defined below. For 
all suitable patients, this information was presented to the anaesthetist supervising the 
research for their review and, if they agreed, the patient was eligible for admission into 
the study. 
2.1.5.1 INCLUSION CRITERIA 
All patients were eligible for inclusion into the study if they were admitted for any of the 
following procedures:  
 Bowel resection for non-malignant indication (e.g. Crohn’s disease, diverticulitis); 
 Bowel resection for malignancy of the gastro intestinal tract; or 
 Mastectomy (with or without axillary node clearance) for malignant indication, 
and fulfilled all of the following criteria, which were assessed at preadmission: 
 Normal liver and renal function; 
 Fitness to consent (age over 18); and 
 Medical fitness for inclusion as determined by physician. 
2.1.5.2 EXCLUSION CRITERIA 
Any patient fulfilling any of the criteria below was excluded from the study:  
 Type 1 diabetes; 
 Alcoholism (the daily consumption of >2 standard drinks in the previous week was 
used as a screening tool as definitions of alcoholism vary (Tonnesen et al. 1999)); 
 Deranged liver function greater than the upper limit of normal (INR, ALT, AST); 
 Deranged renal function (SCr>110umol/L); 
 Intolerance to oral medication; 
 Pregnancy; 
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 Vomiting; 
 Porphyria; 
 Hypersensitivity to any of the investigational medical products; 
 The use of any of the following medicines in the week before surgery: 
o Paracetamol, carbamazepine, hydantoin, imantinib, isoniazid, rifampicin, 
barbiturate; or 
 Those who, in the opinion of a physician, were too frail to be included in the study. 
2.1.6 ADMISSION INTO THE STUDY 
Patients who were suitable for inclusion into the study were admitted to the ward at least 
the evening prior to surgery. Patients were visited by the Principal Investigator and the 
nature of the study was explained to them before they were invited to participate. 
Patients were informed that complete abstention from caffeine containing foods or 
drinks was required during the study. The consent form was left with the patient and the 
Principal Investigator left the patient to review the information and discuss the study with 
relatives. The anaesthetist supervisor then visited the patient to answer any further 
questions and to consider their fitness to participate and to consent their participation in 
the study. If the patient fulfilled all the inclusion criteria but none of the exclusion criteria, 
the patient either accepted or declined the invitation to enrol in the study. 
If the patient agreed to participate in the study the consent form was signed by the 
patient, the anaesthetist supervising the research and the Principal Investigator 
(Appendix 4). A copy was given back to the patient for their record. At the time of 
consenting, the patient was asked to empty their bladder, and this urine was discarded. 
2.1.7 PRE-OPERATIVE PHASE OF THE STUDY- CYP450 ACTIVITY AND PARACETAMOL 
KINETICS 
2.1.7.1 CANNULATION AND FIRST BLOOD SAMPLE 
A 14 or 16G peripheral line (In-syte® Becton Dickinson, Madrid, Spain) was inserted into a 
forearm vein of the patient and flushed with 10mL normal saline (B Braun, Dublin, 
Ireland). One 3.5mL blood sample was then drawn off from the cannula, (being the dead 
space + 2mL) using a 5mL syringe and discarded to ensure reliability of the sample (Prue-
Owens 2006). A further 6mL of blood was immediately taken using a 10mL syringe which 
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was then transferred to two 2.7mL EDTA blood collection tubes (monovette® Sarstedt, 
Nümbrecht Germany). This transfer was done without delay to minimise clotting in the 
syringe and subsequent haemolysis. The blood collection tubes were labelled with the 
patient number, day of the study, time of the sample and initials of person who took the 
sample. 
Patency and aseptic sampling technique was maintained according to in-house standard 
operating procedures of each participating hospitals. 
2.1.7.2 DRUG ADMINISTRATION 
Relevant background information to the 4 drugs accompanying paracetamol which were 
administered as part of this study is detailed in Section 1.5. 
Two doses of paracetamol were used in the study and their allocation is shown in Table 
2.1-1.  
Table 2.1-1 Paracetamol dosing for each group 
Group Paracetamol Dose 
 Preoperative Intraoperative Posoperative 
A 1.5g single dose 2g single dose 1.5g every four hours 
B, C and D 1g single dose 2g single dose 1g every six hours 
As soon as the peripheral line was inserted a standard giving set was primed with the IV 
paracetamol (Perfalgan, 1g/100mL, Bristol-Myers-Squibb, Dublin, Ireland). The giving set 
was connected to the patient’s peripheral line and the infusion started at a rate to give 
the dose over 15min. Due to the poor availability of infusion pumps on the ward for 
Group A, a drop rate of 30drops/10secs was used to approximate the required flow rate 
of 10mL/min. The time was noted at the beginning and end of the infusion and recorded 
on the individualised patient data collection form (Appendix 6). 
Caffeine 100mg/2mL (Martindale Pharmaceuticals, Romford, UK) in a 5mL syringe and 
midazolam 1mg/0.5mL (Hypnovel, Roche, Basel, Switzerland) in a 2mL syringe were 
administered via the additive port on the giving set while the paracetamol infusion was 
running. Dextromethorphan 30mg/20mL (Benylin Non Drowsy, Pfizer, Dublin, Ireland) 
and Chlorzoxazone 250mg (Paraflex, AstraZeneca, Södertälje, Sweden) were given by 
mouth followed by 25mL of water. All five medicines were given as close together as 
possible, i.e. within 1-2 minutes, so that their administration times were considered the 
 154 
 
same. After the fifth patient of Group A, the IV caffeine became unavailable and two 
50mg caffeine tablets were used in its place (ProPlus, Bayer, Berkshire, UK).  
For those patients scheduled to receive 1.5g of paracetamol (as detailed in Table 2.1-1), 
the infusion pump was first set to administer 150mL. Once the first vial of paracetamol 
had been given it was removed from the giving set and the second was attached. In those 
few doses administered without infusion pumps, once the second vial had run to 5mm 
below the label of the vial the additional 500mg was deemed to have been given (this 
level was determined by removing the entire contents of a previous vial and replacing 
50mL) and the infusion was stopped. The giving set was detached from the peripheral 
line, the port on the line was cleaned using an alcohol wipe and the line flushed with 
10mL normal saline. Heparinised saline 10 IU/mL (5mL) (Hepsal CP Pharmaceuticals, 
Wrexham, UK) was used in those patients thought to have poor venous access by the 
anaesthetist. The anaesthetist remained in contact with the patients and the researcher 
for 15-30min until the effect of the midazolam was known. 
2.1.7.3 SUBSEQUENT BLOOD SAMPLES 
A second blood sample was taken fifteen minutes after the paracetamol infusion. A 
tourniquet was placed proximally to the peripheral line, the port was cleaned and 3.5mL 
of blood was collected using a 5mL syringe and discarded. A further 5.4mL was collected 
into two EDTA blood collection tubes either using a Sarstedt multi-adapter system 
(Sarstedt, Nümbrecht, Germany) or a 10mL syringe decanted into the EDTA tubes. A 
syringe was used in those with poor access to reduce the risk of the vein collapsing by 
using less suction in the vein. The tourniquet was removed and the time of the collection 
was noted. The port was cleaned and the line was flushed with 10mL saline or 
heparinised saline as described above. Further samples were collected as shown in Table 
2.1-2. The additional CYP450 analysis to be conducted on the 4 hour sample required a 
further 5.4mL of blood collected at this time point. 
Table 2.1-2 Daily sampling times (minutes after administration of monitored dose) and volume of blood needed at 
each sample (mL) 
 Day -1 Day 1 Day 2 Day 3 Day 4 Blood Volume (mL) 
Sa
m
p
le
 t
im
e 
(m
in
) 
0 0 0 0 0 5.4 
15 15    5.4 
30 30    5.4 
60 60 60 60 60 5.4 
90 90    5.4 
240 240 240 240 240 10.8 
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2.1.8 URINE SAMPLES 
As patients were not catheterised pre-operatively, they were asked to collect the entire 
volume of their urine in four hourly aliquots. The importance of collecting the entire 
volume was stressed to patients. To make this as easy as possible, urine collection 
containers labelled with the times of collection interval were placed in all toilets 
accessible to the patient. Patients unable to collect their urine directly into the collection 
container were offered a disposable bed pan from which urine was decanted into the 
collection container. Patients using bed pans were asked not to pass faeces into the same 
container or put toilet paper into the container, however this was unavoidable for some 
patients. In those cases where faecal matter was present, the urine was still collected into 
a separate container and the volume recorded. If samples were heavily contaminated 
with faeces the urine volume was approximated and were discarded as the possibility of 
contamination arising from biliary excretion of drugs could not be excluded.  
It was important the urine collection coincided with the dosing of the study medicines. To 
facilitate this the first postoperative urine collection was ‘rounded up’ to the nearest 
required interval and recorded as pre-operation until that time, even though it may have 
been longer than four hours.  
2.1.9 POSTOPERATIVE PHASE OF STUDY 
2.1.9.1 DAY OF SURGERY (DAY 0) 
2.1.9.1.1 INTRAOPERATIVELY 
The following was performed for all study participants during the intraoperative period: 
 IV paracetamol 2g was administered intraoperatively (Table 2.1-1); 
 Record of the following was taken: 
o Blood/fluid (Appendix 7); 
o Anaesthetics administered (Appendix 8); and 
o The operation performed, its duration, any liver manipulation that took 
place and any associated events or complications (Appendix 8). 
2.1.9.1.2 POSTOPERATIVELY 
The following was performed for all study participants on their return from theatre: 
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 IV paracetamol was administered according to Table 2.1-1; 
 Fluid balance was recorded; 
 Pain scores were recorded every hour 
 Alternative analgesic usage was recorded; and 
 Pharmacodynamic tests (Table 2.1-3) were performed 
In addition, urine was collected every 4 hours. All patients returned from theatre with 
urinary catheters in situ. While catheterised, all urine was collected from the catheter bag 
at four hourly intervals and then processed as described in Section 2.1.10.2 
No blood samples were taken for the study on the day of surgery. This was for several 
reasons: 
 Pharmacokinetics could not be accurately predicted from samples obtained on 
this day. Pharmacokinetic equations exist in either single dose or steady state 
form. On this day paracetamol concentrations would not have reached steady 
state, but would have been above those from a single dose. Typically, five drug 
half-lives must pass before steady state can be assumed. 
 Patients who lost large volumes of blood intra-operatively would not have been fit 
for further blood sampling 
 The timing of a patients return to theatre could not be predicted and would have 
led to inconsistencies between patients. 
2.1.9.2 DAYS 1-4 POST OPERATIVELY 
For any enrolled patient not fulfilling any of the attrition criteria (Section 2.1.9.3), the 
study continued for four postoperative days. This length was the maximum period it was 
considered IV paracetamol use could be justified in clinical practice, given the known 
problems with postoperative oral absorption. Four postoperative days was also the 
minimum duration of inpatient stay following major bowel surgery.  
The following was performed for all study participants during the postoperative period on 
days 1–4 inclusively: 
 IV paracetamol was administered at regular intervals throughout the day 
according to Table 2.1-1; 
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 Plasma samples were drawn usually from the 10pm dose each day according to 
Table 2.1-2; 
 Chlorzoxazone 250mg, caffeine 100mg, dextromethorphan 30mg and midazolam 
1mg were co-administered with the monitored 10pm paracetamol dose; 
 All urine was collected every 4 hours, the total volume was measured and 
recorded and two x 25mL aliquots were taken; 
 Fluid balance was recorded; 
 Pain scores were recorded every hour. Daily best, worst and average pain in last 
24hrs, pain now were also recorded; 
 Alternative analgesic usage was recorded; and 
 Pharmacodynamic tests (Table 2.1-3) were performed and checked daily. 
After surgery patients in Groups A, B and D may have had a central line inserted into the 
vena cava through the jugular vein. When this was present it was used for both drug 
administration and blood sampling. To avoid contamination of the blood samples, 
arrangements were made with the nursing staff that paracetamol was only given through 
the distal line and blood samples were taken from the proximal line. Alternatively, if a 
peripheral line was still available, the paracetamol was given through that line. When 
taking samples from the central line, all fluids running through it were stopped and their 
lines clamped as per local hospital protocols. The allocated port was cleaned and 4 mL of 
blood withdrawn and discarded. The required sample was then taken, the port cleaned 
and the line flushed with 10mL of normal saline using pulsatile flushes of 2mL pushes. In 
patients without a central line, the sampling technique was the same as on day 0, with 
contra-lateral lines being used for paracetamol administration and blood sampling where 
available. Again, all fluids were stopped and lines clamped during blood sampling. Urine 
collection continued as on day 0 until at least 8 hours after the last dose of 
dextromethorphan on day 4. 
Any other non-paracetamol containing analgesia that was administered to the study 
patients was recorded as per protocol. 
2.1.9.3 ATTRITION CRITERIA 
During the course of the study, Patients were removed immediately if they fulfilled any of 
the following criteria: 
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 An AST or ALT level three times above the upper limit of normal; 
 Any other sign of paracetamol toxicity or allergy (e.g. thrombocytopaenia); 
 Loss of fitness for inclusion as determined by a physician; 
 Loss of venous access as to prevent timely blood sampling without excessive 
discomfort to the patient; or 
 The patient withdrew their consent (Section 2.1.13.2) 
Any patient who fulfilled any of the attrition criteria did not receive further investigational 
doses of paracetamol, however, they were monitored for the original proposed study 
period and their data were included in the final analysis.  
2.1.10 PROCESSING OF SAMPLES  
2.1.10.1 PLASMA  
Within one hour of collection, plasma samples were taken to the laboratory centrifuge 
and spun at 3000g for 10min. The plasma layer was then pipetted off using a 3mL pasture 
pipette into labelled 1.25mL plastic screw top collection tubes (Sarstedt, Nümbrecht 
Germany). The labels contained the patient number, day of study, sample number, time 
of collection and the initials of the person who took the sample. These plasma samples 
were frozen in lots according to the sampling day at -20C until the patient had 
completed the study, when the samples were transferred to a -80C freezer in the School 
of Pharmacy, University College Cork. 
2.1.10.2 URINE 
The total volume of urine excreted within each four hour time period was measured using 
a 1L cylindrical flask and recorded (Appendix 6). Two 25mL samples were taken, labelled 
with the total volume, sample period, day of the study and patient number and frozen 
along with the preceding days plasma at -20C until the patient had completed the study, 
when the samples were transferred to a -80C freezer in the School of Pharmacy, 
University College Cork.  
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2.1.11 OTHER SAMPLING- PHARMACODYNAMIC INFORMATION  
The following tests were conducted primarily to ensure the safety of the study participant 
but to also provide information regarding the onset time of any hepatotoxicity that 
occurred while it was still subclinical (Table 2.1-3). 
To monitor safety during the study, LFT’s AST, ALT, INR and bilirubin were done daily 
during the treatment phase. Monitoring continued on alternate days for the rest of the 
admission. The daily t=0hr plasma sample was used for αGST and IL-1 and IL-6 levels. 
Once daily testing of these substances were chosen due to the cost of the sampling kits 
and on advice from the manufacturer of the kits (Shaw 2009). 
Table 2.1-3 Pharmacodynamic testing 
Test Frequency Rationale 
GST Daily An intracellular protein found in hepatocytes in all 
regions of the liver lobule. Specific marker for the 
detection of early (yet subclinical) hepatotoxicity 
ALT + AST Daily Marker of hepatocyte damage, released rapidly, 
peaks early and returns to normal quickly because of 
its short half-life once the injury has ceased 
INR Daily Marker of more substantial hepatocyte damage 
Serum creatinine Daily Marker of renal function which may impact on the 
clearance of paracetamol and its metabolites 
Interleukin-6 (IL-6) Daily Correlates with inflammation and CYP450 activity 
2.1.12 DEMOGRAPHIC AND CLINICAL DATA 
The following information was also collected from the patient or their medical notes 
(Appendix 9): 
 Nutrition status: 
o Height, weight at time of admission for calcuation of BMI; 
o Previous week’s meal plan; 
o Any recent weight loss; 
o Any recent periods of fasting or malnutrition; 
 Review of Systems: 
o Note any co-morbidities, ASA status; 
o Pain scores (VNRS) ‘best’, ‘worst’, ‘average pain in last 24hrs’ and ‘pain 
now’ scores were recorded daily; 
 Other clinical data: 
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o Primary diagnosis; 
o Any concomitant disease; 
o Drug history and any regular medication; 
o Smoking history; and 
o Preoperative laboratory investigations (serum sodium, potassium, 
urea, and creatinine, alkaline phosphatase, bilirubin (total), bilirubin 
(conjugated) and alanine aminotransferase (ALT). 
2.1.13 ADVERSE EVENT REPORTING AND HANDLING WITHDRAWALS 
2.1.13.1  ADVERSE EVENTS 
Adverse events were classified as either an ‘adverse event’ or a ‘serious adverse event’. 
Any patient fulfilling either adverse or serious adverse event criteria did not receive any 
further paracetamol doses and alteration to other analgesia was made to ensure 
continuing comfort of the patient. 
Additionally, all patient reported adverse events were noted. 
2.1.13.1.1 ADVERSE EVENT 
 ALT or AST measurements greater than five times the upper limit of normal, or  
 Any other event that causes morbidity that was thought to be related to the 
study. 
Adverse events were not reported until after consultation with the anaesthetist 
supervising the research and further confirmation, by subsequent analysis of paracetamol 
concentrations and other markers of hepatotoxicity, that the adverse event was a result 
of the patient’s participation in the study. Reporting was delayed due to the possibility of 
other factors causing alteration to liver function associated with surgery but not related 
to paracetamol administration.  
2.1.13.1.2 SERIOUS ADVERSE EVENT 
 ALT or AST measurements greater than ten times the upper limit of normal;  
 INR>2; or 
 Any other event that is life threatening or fatal thought to be related to the study. 
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Serious adverse events were reported immediately after consultation with the Consultant 
directly involved in this research project. 
2.1.13.1.3 REPORTING OF EVENTS 
If an event occurred it was to be reported to the Irish Medicines Board and host hospital 
on the adverse event reporting form on the Irish Medicines Board website: 
www.imb.ie/EN/SafetyQuality/OnlineForms/ClinicalTrial-SeriousAdverseEvent.aspx 
2.1.13.2 WITHDRAWALS 
Patients were informed at the time of consenting that they would be withdrawn from the 
study at any time if they fulfil any of the attrition criteria or if they chose to, for any 
reason, or for no reason at all. Their data were handled as described in Section 2.1.9.3 
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2.2 PARACETAMOL AND METABOLITE ASSAY 
Paracetamol is a weak organic acid with a pKa of 9.5 (Prescott et al. 1971). It is well 
known for its poor aqueous solubility, being moderately soluble in hot water, aqueous 
alkaline solutions and polar organic solvents such as methanol and acetone. Because of its 
small distribution volume and administration in gram doses, the concentration in 
biological fluid of paracetamol, along with its Phase II metabolites, are high, and remain in 
the mg/L range for several hours following a therapeutic dose (Rawlins et al. 1977). 
Along with its metabolites, paracetamol has been analysed by almost every analytical 
technique and the compounds present few detection problems individually. Common 
methods used include enzyme linked immunoassay, spectrophotometry and thin layer, 
gas and high performance liquid chromatography (TLC, GC and HPLC). Because of the 
complex nature of plasma and urine, some form of chromatographic separation or 
solvent extraction is necessary to minimise interference by other drugs and endogenous 
compounds.  
HPLC with octadecylsilica as a means of separation was first reported in the late 1970’s 
(Knox et al. 1977; Knox et al. 1978). Today HPLC is the most cited method in the literature 
for separating mixtures of analgesic drugs and related compounds (Kazakevich et al. 
2007). HPLC also meets the rigorous requirements for precision, specificity and sensitivity 
required by medical regulatory authorities (Moffat et al. 2011). While HPLC is useful in 
research and industrial environments for determining paracetamol concentrations, it is 
less useful in clinical environments where fast results are necessary for therapeutic 
decision. Here spectrophotometric and immunoassays are more common. However, 
these techniques often require costly, highly specialised instruments and do not allow for 
the simultaneous analysis of compounds, making them unsuitable for the analysis in this 
Thesis (Bosch et al. 2006).  
The HPLC methods for analysis of paracetamol and its metabolites have recently been 
extensively reviewed (Bosch et al. 2006; Kaushik et al. 2006). HPLC of paracetamol has 
historically always utilised a gradient method to enable simultaneous analysis of 
paracetamol and its metabolites in a reasonable time frame. Typically a phosphate or 
acetate buffer is used in the mobile phase along with a weak organic solvent such as 
methanol, iso-propanol or acetonitrile. Solvent extraction is rarely performed, but when 
done commonly utilises ethyl-acetate. In plasma samples, perchloric acid (PCA) and 
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acetonitrile are the most frequently used for protein removal. Urine samples are often 
diluted with mobile phase or water up to 50 fold. Internal standards are normally not 
used, but when they are, theophylline, phenacetin and 3-hydroxyacetanilide are among 
the most common. 
2.2.1 MATERIALS 
Paracetamol, potassium phosphate, perchloric acid and formic acid were purchased from 
Sigma (St. Louis, Missouri, United States of America (USA)). Paracetamol glucuronide, 
sulphate, cysteine and mercapturate and paraxanthine were purchased from Toronto 
Research Chemicals (Ontario, Canada). HPLC grade acetonitrile and water were purchased 
from Fisher Scientific (Leicestershire, UK). All other chemicals were of analytical grade or 
higher. The mobile phases were filtered through HA filters (0.45μm Millipore, Bedford, 
Massachusetts, USA) before use. 
Polypropylene 1.5mL Eppendorf tubes (Sarstedt, Nümbrecht, Germany) and 100µL low 
volume inserts (Fisher Scientific, Dublin, Ireland) were used to prevent loss of polar 
compounds due to adsorption onto the un-silanised glassware available.  
Drug free plasma was obtained from the Irish Blood Transfusion Service (St. Finbarr’s 
Hospital, Cork, Ireland) and drug-free urine was obtained in-house. 
2.2.2 APARATUS 
The HPLC separation was performed using a Waters® 2695 Alliance HPLC system, 
equipped with a Waters® 2996 Photodiode Array (PDA) Detector and column oven 
(Waters Corporation, Milford, USA). Chromatograms were captured and processed using 
Empower Pro interface (Empower 2, Waters Corp., Milford, USA). 
Weights of analytical compounds under 5mg were measured using a MX5 Microbalance 
(Mettler-Toledo Inc., Ohio, USA) while larger weights were measured using an Adventurer 
Pro AS-214 balance (Ohaus, Nänikon, Switzerland). Centrifugation was undertaken in a 
Mikro 120 centrifuge (Hettich, Tuttlingen, Germany). Vortex mixing utilised a Lab Dancer 
S42 at a fixed speed of 2800RPM (VWR, Pennsylvania, USA) 
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2.2.3 METHODS- PLASMA 
2.2.3.1 CHROMATOGRAPHIC METHOD DEVELOPMENT 
Initial attempts at analysing paracetamol and its metabolites were based on the method 
reported by Al-Obaidy et al. (Al-Obaidy et al. 1995), using 20mM orthophosphoric acid 
and acetonitrile (4:96, v/v adjusted to pH3.5). However, the Phenomenex Synergi 4m 
Hydro-RP 250x4.6mm column with a Phenomenex SecurityGuard precolumn 
(Phenomenex, Cheshire, UK) available for this research was not suitable for this method 
as it had a much smaller internal diameter and accordingly, the run times were too long. 
After a further review of the literature, the method used by Reith et al. (Reith et al. 2009) 
was selected as the column was similar to the one available for this research. The column 
was heated to 30°C to both reduce the impact of any fluctuation in temperature in the 
laboratory and improve chromatographic peak shape (Yan et al. 2000).  
Chromatography was optimised with alterations to the composition of the mobile phases, 
their gradient and flow rate. The final conditions eluted the compounds of interest with a 
gradient mobile phase consisting of 0.1M KH2PO4 + 1%v/v formic acid (A) and acetonitrile 
+ 1%v/v formic acid (B). The gradient had initial conditions of 95:5 (A:B) for the first 2.5 
minutes, which was then reduced to 91:9 by 10 minutes, and decreased linearly to 77:33 
by 20 minutes which was then maintained until 21 minutes. Re-equilibration to initial 
conditions followed for 4 minutes before injection of the next sample. The flow rate 
remained constant at 1.0mL/min.  
These mobile phase ratios resulted from the adaptation of the method of Reith et al. 
(Reith et al. 2009), who used two mobile phases containing all three elements: KH2PO4, 
formic acid and acetonitrile in different ratios. The method used in this study split the 
mobile phases into the aqueous and organic components. This allowed for greater 
flexibility during method development, taking advantage of the Waters® 2695’s 
quaternary pump. However, KH2PO4 is not generally considered compatible with 
acetonitrile due to salt precipitation (Kazakevich et al. 2007). Therefore, rapid changes of 
organic solvent were avoided to prevent this.  
Needle wash and seal wash solution was 5%v/v methanol in water which was kept at 50°C 
to improve buffer removal. Wash cycles using this solution were incorporated at the end 
of every run to prevent buffer salt build-up. The sample injection volume was 25L and 
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the autosampler compartment was kept at 4°C. All chromatograms were captured using 
PDA spectra from 220-300nm and the wavelengths of interest later extracted using 
Empower Pro.  
2.2.3.2 UV ABSORBANCE 
UV absorbance of a molecule arises from excitation of its electrons by the irradiating light. 
Excitation of the molecule is dependent on its electronic structure and only usually occurs 
in the presence of unsaturated compounds or loan pairs of electrons (Shriner et al. 1980). 
Only these molecules have sufficiently stable excited states to give rise to absorption in 
the near UV range (Silverstein et al. 1991).  
Traditionally, single wavelength UV detectors were set at the absorbance maxima of the 
compound of interest, showing an absorbance peak as the compounds pass through the 
detector. Such a chromatogram of the paracetamol compounds at 242nm is shown in 
Figure 2.2-1.  
 
Figure 2.2-1 Sample chromatogram of paracetamol and its metabolites captured at 242nm in human plasma.  
The elution order was paracetamol glucuronide, paracetamol cysteine, paracetamol sulphate, paracetamol and 
paracetamol mercapturate respectively.  
Additionally, a PDA detector has the ability to scan across the whole near UV spectrum 
virtually simultaneously, providing absorbance spectra of the analyte at a range of 
wavelengths as it passes through the detector (Silverstein et al. 1991). It can be seen from 
Figure 2.2-1 that the only thing distinguishing one peak from another is the elution time, 
whereas examination of the peak spectra of paracetamol and its metabolites reveals 
some additional differences (Figure 2.2-2). 
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By only absorbing in the presence of some functional groups with free electrons, the PDA 
spectra can provide some information about constituents of a molecule (Silverstein et al. 
1991). All paracetamol molecules possess an N-acetyl aryl amide group, which produce 
strong absorption around 240nm. Only the thiol conjugates, paracetamol cysteine and 
mercapturate showed absorption at 297nm as a result of the aryl thioether and carboxylic 
acid groups on their side chains (Shriner et al. 1980). While it is possible to use molecular 
features to predict UV absorption, or vice versa, this is more of an art than a science 
because: 
 Most functional groups absorb UV weakly, or not at all;  
 Closely positioned functional groups affect the absorbance of one another; 
 Many functional groups absorb in the same region; and 
 Absorption is affected by the polarity of the solvent. 
However, absorbance spectra are useful to confirm the identity of the eluting compound 
or the presence of co-eluting peaks and were used to determine selectivity and specificity 
of this assay. Ultimately the wider availability of mass spectrometry and nuclear magnetic 
resonance have superseded PDA spectra for compound identification (Shriner et al. 1980; 
Silverstein et al. 1991).  
2.2.3.3 PREPARATION OF STOCK SOLUTIONS 
Stock solutions were prepared in 1.5mL Eppendorf tubes by adding a known quantity of 
compound to water for HPLC to give a final concentration of 1mg/mL. Resultant solutions 
were then vortex mixed for 30 seconds and sonicated for 5 minutes. Following sonication, 
samples were dated and stored at -20°C in batches until required for analysis.  
2.2.3.4 SAMPLE PREPARATION DEVELOPMENT 
2.2.3.4.1 PROTEIN REMOVAL 
Biological samples frequently contain proteins. When mixed with mobile phase, proteins 
still present can precipitate and collect at the head of the HPLC column, leading to its 
degradation and resulting in poor chromatography. Therefore, samples for HPLC analysis 
must be free of proteins before injection onto the HPLC column.  
Three of the most common methods of separating the compounds of interest from 
plasma proteins are: 
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1. Protein precipitation, centrifugation and injection of the resulting supernatant; 
2. Addition of solvents into which compounds of interest are miscible but proteins 
are not, followed by separation and injection of the solvent; or 
3. Solid-Phase Extraction. 
For paracetamol analysis, protein precipitation was chosen because the compounds of 
interest were in high concentrations and not bound to plasma proteins. This method was 
simple, quick and cheap and was adapted from Jensen et al. (Jensen et al. 2004) and Reith 
et al. (Reith et al. 2009).  
From the beginning of the method development, efficient use of plasma was of primary 
importance. Methods above used up to 0.5mL per sample but given the number of 
planned analyses to be performed on each sample collected for this project, this volume 
had to be reduced. Additionally, any chemical added for precipitation of proteins diluted 
the concentration of paracetamol compounds in the sample, making them harder to 
detect, so it was necessary to keep added volumes low. 
2.2.3.4.1.1 CHOICE OF AGENT 
Protein precipitation was the first step in all methods reviewed. Chemicals, 
concentrations and volumes varied amongst papers (Blanchard 1981; Polson et al. 2003; 
Souverain et al. 2004; Hendriks et al. 2008). PCA and acetonitrile were the most common 
agents and these were chosen for further investigation. PCA was used at a concentration 
of 30%v/v to prevent chemical hydrolysis of paracetamol metabolites back to the parent 
drug. To determine which of the two most commonly cited agents was the most suitable 
for plasma protein precipitation, the following experiment was undertaken with triplicate 
samples (Figure 2.2-3): 
3x 1mL blank 
plasma in 1.5mL 
Eppendorf
100µL 30% PCA + 
100µL 
acetonitrile 
added
C
200µL of 30% 
PCA added
A
Vortex and 
centrifuge
Vortex and 
centrifuge
Observe 
supernatant
Observe 
supernatant
200µL of 
acetonitrile 
added
B
Vortex and 
centrifuge
Observe 
supernatant
Clear Solution. 
Large white pellet
Straw coloured 
solution. Small 
pellet
Clear Solution. 
Large white pellet
 
Figure 2.2-3 Experimental design to determine protein precipitant 
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Each Eppendorf was vortex mixed for 30 seconds and centrifuged at 14000RPM 
(c.17500G) for 5 minutes. The results of this were:  
 Samples (A) produced a clear, colourless solution with a large white pellet of 
protein precipitant at the bottom of the tube;  
 Samples (B) produced a straw coloured solution with a small white pellet; and 
 Samples (C) produced the same result as Samples (A). 
It was concluded that, volume for volume, PCA was more efficient at precipitating plasma 
protein. To confirm this finding, further experiments were conducted doubling and then 
quadrupling the volume of acetonitrile. The same results were found. Given the necessity 
to restrict volumes of additive, PCA was chosen to precipitate proteins in future samples.  
2.2.3.4.1.2 DETERMINATION OF VOLUME 
The exact volume of PCA 30%v/v also varied in the literature (Blanchard 1981; Polson et 
al. 2003; Souverain et al. 2004; Hendriks et al. 2008). An experiment was also designed to 
determine the optimal volume and is shown in  
Figure 2.2-4.  
3x 1mL blank 
plasma in 1.5mL 
Eppendorf
100µL of 30% 
PCA added
C
200µL of 30% 
PCA added
A
150µL of 30% 
PCA added
B
Clear Solution. 
Large white pellet
50µL of 30% PCA 
added
D
200µL of 30% 
PCA added to 
supernatant
Clear Solution. 
No pellet
Clear Solution. 
Small white pellet
Mix
Centrifuge and 
Observe
Mix
Centrifuge and 
Observe
Clear Solution. 
Large white pellet
200µL of 30% 
PCA added to 
supernatant
Clear Solution. 
No pellet
Mix
Centrifuge and 
Observe
Mix
Centrifuge and 
Observe
Clear Solution. 
Large white pellet
200µL of 30% 
PCA added to 
supernatant
Clear Solution. 
No pellet
Mix
Centrifuge and 
Observe
Mix
Centrifuge and 
Observe
Clear Solution. 
Large white pellet
200µL of 30% 
PCA added to 
supernatant
Mix
Centrifuge and 
Observe
Mix
Centrifuge and 
Observe
 
Figure 2.2-4 Experiment design to optimise volume of PCA added 
Samples were again vortex mixed for 30 seconds and centrifuged at 14000RPM for 5 
minutes. Following the first centrifugation, all samples became a clear colourless solution 
with a large white pellet of protein precipitant at the bottom of the tube. To ensure 
complete precipitation of proteins, the supernatant of each sample was removed into a 
fresh Eppendorf tube and a further 200L of PCA 30% was added. Samples were mixed 
and centrifuged as before.  
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Samples A, B and C returned a clear solution with no visible pellet. The presence of a 
protein pellet in sample D indicated that protein was still present in solution before the 
second addition of acid and that 50uL of PCA 30%v/v was insufficient for removal of all 
proteins from 1mL of human plasma. It was concluded that the volume of PCA 30%v/v 
must be at least 10% of the volume of the plasma sample for adequate protein removal. 
Blank plasma used in these analyses was donated by fit and healthy volunteers, as 
determined by screening undertaken by the Irish Blood Transfusion Service. This group 
was likely to have at least the same quantities of plasma protein as study participants 
who are undergoing surgery for cancer or other disease of the bowel, as the effect 
disease has on plasma protein concentration, if any, is to lower the total concentration. 
This would suggest plasma protein precipitation methods developed from blank plasma 
could be applied to study participants without consuming plasma samples for validation.  
2.2.3.4.2 EXTRACTION EFFICIENCY 
Although protein removal was optimised, it was necessary to assess if this method altered 
the concentration of paracetamol measured in the sample and if this effect was 
consistent across the concentration range. This was determined by the extraction 
efficiency. Extraction efficiency compares absorption peak areas of a compound in a 
dilution series suitable for direct injection with a plasma dilution series after the plasma 
samples have had their proteins removed (Figure 2.2-5). Mobile phase at initial conditions 
was used as diluent. 
2.2.3.4.2.1 PREPARATION OF STANDARDS 
Stock solution of paracetamol (1mg/mL) was diluted with blank plasma to give a 
concentration of 40g/mL. A seven point concentration range from 40g/mL to 
0.625g/mL was obtained by diluting 750L of the sample (paracetamol 40g/mL) with a 
further 750L of blank plasma and vortexing mixing for 30 seconds, followed by five 
subsequent serial dilutions. The same dilution series was prepared using diluent in place 
of plasma. All samples were prepared in triplicate.  
2.2.3.4.2.2 PREPARATION OF STANDARDS FOR INJECTION 
Plasma: 200L of sample was added to a 1.5mL Eppendorf tube followed by 20L of 
30%v/v PCA. Tubes were vortex mixed for 30 seconds followed by centrifugation at 14000 
RPM for five minutes.  
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Diluent: Samples were prepared as for plasma except that 20L of diluent was added in 
place of the perchloric acid (Figure 2.2-5). 
Stock solutions of 
paracetamol
Diluted in plasma 
to 40-0.625µg/mL
Diluted in diluent 
to 
40-0.625µg/mL
Perchloric acid 
added 
Additional diluent 
added
Vortex and 
centrifuge
Inject 
supernatant
Vortex and 
centrifuge
Inject 
supernatant
 
Figure 2.2-5 Extraction efficiency method 
The supernatant of each sample was transferred to 100µL low volume inserts (Fisher 
Scientific, Dublin, Ireland) and then placed inside an autosampler vial (1.5mL screw neck 
vial, AGB Scientific, Dublin, Ireland) for HPLC analysis. An external standard was not added 
as no extraction occurred. HPLC analysis was conducted with the conditions described 
above (Section 2.2.3.1). 
2.2.3.5 ASSAY VALIDATION 
2.2.3.5.1 LIMITS OF DETECTION AND QUANTIFICATION 
Limits of detection (LOD) and limits of quantification (LOQ) were determined from the 
chromatograms of a dilution series of each compound in blank plasma, prepared and 
analysed in five replicates according to Section 2.2.3.4. LOD were the lowest 
concentration at which the signal to background noise ratio was 3:1, based on peak 
height. LOQ were the lowest concentration at which the signal to background noise ratio 
was 10:1, tests for precision and accuracy were passed, and the peak area was at least 
twice that of the LOD peaks (Shah et al. 1992; Bressolle et al. 1996). 
2.2.3.5.2 PRECISION AND ACCURACY 
Inter and intra batch variations were determined from low, middle and high 
concentrations for each compound (Table 2.2-1).  
Table 2.2-1 Concentrations used for the determination of precision and accuracy values for each compound 
Compound Low concentration 
(µg/mL) 
Mid concentration 
(µg/mL) 
High concentration 
(µg/mL) 
Paracetamol glucuronide 0.625 10 80 
Paracetamol sulphate 0.625 5 40 
Paracetamol 0.625 5 40 
Paracetamol cysteine 0.3125 5 20 
Paracetamol mercapturate 0.625 5 20 
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Values were determined over five samples of each concentration in the first batch (intra-
day variation) and from one sample from a further five batches (inter-day variation). 
Values were calculated over a batch rather than a day in accordance with accepted 
validation practices as batches routinely ran over more than one day (Shah et al. 1991; 
Bressolle et al. 1996). 
2.2.3.5.3 CALIBRATION CURVES 
Calibration curves were prepared by plotting the peak area versus the concentration of 
each compound. These were analysed within each batch during analysis from standards 
placed after every fifth patient sample. Stock solutions of 1mg/mL were serially diluted 
with blank plasma to give a calibration curve constructed over the expected range of 
concentrations in patient samples as shown in Table 2.2-2. Calibration samples had a 
minimum plasma content of 98%. These were then prepared for analysis as described in 
Section 2.2.3.4.  
Table 2.2-2 Concentrations used to construct calibration curves in plasma (µg/mL) 
Paracetamol 
glucuronide 
Paracetamol 
sulphate 
Paracetamol Paracetamol 
cysteine 
Paracetamol 
mercapturate 
   0.3125  
0.625 0.625 0.625 0.625 0.625 
1.25 1.25 1.25 1.25 1.25 
2.5 2.5 2.5 2.5 2.5 
5 5 5 5 5 
10 10 10 10 10 
20 20 20 20 20 
40 40 40   
80     
The linear regression equations were calculated with:  
       
Equation 2.2-1 Linear regression equation 
To prove a linear equation was the most appropriate for regression, calibration curves 
had to be proven to be linear. Calibration curves were accepted as linear if analysis of the 
validation samples showed the correlation co-efficient was not significantly different from 
1, the slope was significantly different from 0 and the intercept was not significantly 
different from 0. Significant differences were deemed to have occurred if the 95% 
confidence interval of the mean excluded the value in question (i.e. 1 for correlation 
coefficient and 0 for the other parameters). 
 173 
 
2.2.3.5.4 STABILITY 
Stock solution of paracetamol was diluted to 10µg/mL with blank human plasma and 
stored with patient samples in the same polypropylene containers at -80°C and at -20°C, 
4°C and bench-top room temperature (≈20°C). These were analysed and compared with 
calibration curves derived from freshly prepared samples.  
2.2.3.6 ANALYSIS 
Pharmacokinetic calculations were performed using Microsoft Excel® v12.0.6 (Microsoft, 
Redmon, Washington, USA) and statistical analysis was carried out using Statistical 
Package for Social Sciences (SPSS) v15.0 (SPSS, Chicago, Illinois, USA). 
2.2.4 METHODS- URINE 
2.2.4.1 CHROMATOGRAPHIC METHOD DEVELOPMENT 
Using the method developed for plasma samples, clear separation was obtained for 
paracetamol and its metabolites in spiked samples. However, this method was not 
optimal for urine analysis because: 
1. The concentrations of the paracetamol compounds were much higher in urine so 
it was possible to identify and quantify paracetamol mercapturate, which was 
below the LOQ in most plasma samples; and  
2. The plasma method used a gradient mobile phase to elute the compounds of 
interest within a reasonable time of 25 minutes. However, the increasing organic 
content of the gradient programme altered the chromatographic baseline, 
rendering identification and integration of absorbance peaks arising from 
paracetamol mercapturate at physiological concentrations problematic and 
unreliable (Figure 2.2-6).  
Using an isocratic method with different combination of the phosphate buffer and 
acetonitrile of the plasma method gave a flat baseline. However, on the Phenomenex 
Synergi column, isocratic combinations would either compromise the separation of the 
first four compounds (paracetamol glucuronide, paracetamol cysteine, paracetamol 
sulphate, and paracetamol) or cause the elution time of paracetamol mercapturate to be 
very long.  
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Recent developments in HPLC column technology (e.g. pore-, particle-size and 
subsequent increases to the number of theoretical plates), have significantly improved 
chromatography (Majors 2008). A replacement for the Phenomenex Synergi column was 
required for this analysis and an Agilent Zorbax Rapid Resolution C18 1.8µm 2.8x56mm 
column was found suitable (Agilent Technologies, California, USA). It was chosen because 
the <2.0µm particle size allowed for increased separation and peak resolution of the first 
four compounds but the shorter column length would reduce the retention time of the 
paracetamol mercapturate. In addition, the column’s reduced particle size increased 
resolution even at low flow rates with corresponding savings of HPLC solvent. 
To develop the method, the mobile phases and initial conditions as used for plasma 
samples (acidified 0.1M phosphate buffer and acetonitrile) were used. However, 
paracetamol glucuronide co-eluted with the solvent front (Figure 2.2-6).  
 
Figure 2.2-6 Chromatogram (242nm) of paracetamol and metabolite on Agilent column with plasma assay conditions 
Chromatogram shows effect of gradient mobile phase in changes to baseline. Separation of peaks is poor and elution of 
paracetamol mercapturate on sloping baseline makes integration difficult. 
The proportion of acetonitrile was reduced to 3%, the column manufacturer’s stated 
minimum organic component to prevent collapse of the stationary phase’s C18 moiety, 
but this still did not allow sufficient retention of paracetamol glucuronide from the 
solvent front. The mobile phases were changed to water and methanol, both acidified 
with formic acid to 1%v/v. Methanol has about 1/3 the elutropic strength of acetonitrile 
on C18 solid phases, and is more polar (Kazakevich et al. 2007). These properties increase 
the retention times of polar analytes relative to mobile phases containing acetonitrile. 
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The effect of this change is shown in Fig 2.2-7 where the assay using methanol elutes 
paracetamol glucuronide after the solvent front  
 
Figure 2.2-7 Chromatogram (242nm) of paracetamol and metabolites using 97% aqueous and 3% methanol (black 
trace) or 3% acetonitrile (blue trace).  
Acetonitrile trace offset on y-axis. 
Buffer was not added to the water component as salt precipitation was an issue in the 
plasma assay, with frequent system washes required to prevent this occurring. Initial 
method development focussed on optimising paracetamol mercapturate and 
paracetamol glucuronide retention. Paracetamol mercapturate was retained too long, 
necessitating a long run-time and paracetamol glucuronide co-eluted with the solvent 
front. Elution of analytes with the solvent front compromises identification and 
quantification of compounds. Initial combinations did reduce the retention times of 
paracetamol mercapturate and improved the peak shape but during the development, 
the analyte peaks were observed to be fronting. This can signify variable ionisation states 
of the analyte existing in the mobile phase, causing inconsistent partitioning with the 
stationary phase. While it was anticipated acidification of the mobile phases was 
sufficient to prevent this, the re-introduction of the phosphate buffer was necessary to 
eliminate any variation in ionisation, and this improved peak shape markedly.  
Potassium phosphate is soluble in methanol and accordingly, precipitation of the buffer 
salts was less of an issue than when acetonitrile was used. As a precaution though, to 
protect the instrument from the corrosive effects of the buffer salts, an end-of-run wash 
cycle was again incorporated.  
While the elution of paracetamol mercapturate had been resolved the separation of the 
first four compounds now proved troublesome. After several runs it was found a 
combination of 97%v/v 0.1M phosphate buffer and 3%v/v methanol gave sufficient 
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separation. This was the minimum organic component of the mobile phase 
recommended by the manufacturer. Validation was completed as for plasma analysis. 
2.2.4.2 SAMPLE PREPARATION 
In healthy individuals urine does not contain any proteins. However, neat urine contains 
high quantities of salts and their concentration can saturate the PDA. Accordingly, 50L of 
urine samples was diluted with 950L of HPLC grade water before injection, directly into 
the HPLC vial (Goicoechea et al. 1995; Di Girolamo et al. 1998; Jensen et al. 2004; Reith et 
al. 2009). The vial was capped and vortexed for 30 seconds. As no extraction was 
performed and the quantity of urine in the diluted sample so low, paracetamol standards 
were diluted with water, rather than urine, to provide calibration curve data. 
  
 177 
 
2.3 CYTOKINE ASSAY 
The activation of the stress response in the study patients was determined by the 
concentration of inflammatory cytokines in their plasma samples. Given their low 
concentrations and protein nature, a multiplex electrochemiluminescense assay (MSD 
Gaithersburg; Maryland; USA) was chosen as it is highly sensitive, specific, requires no 
sample pre-treatment and can process several samples concurrently. 
2.3.1 ASSAY PRINCIPLE 
The assay used for this analysis uses the same principle as other “sandwich” 
immunoassays:  
1. An antibody for a target protein coats the surface of a well; 
2. The target protein is added and binds to the antibody on the well surface; 
3. A detection antibody is added which also binds to the target protein forming 
an antibody sandwich around the target protein; and 
4. The detection antibody contains a label (Ruthenium Ru) that emits light when 
electrochemically stimulated. The amount of light produced is proportional to 
the amount of secondary antibody captured within the antibody sandwich, 
and therefore provides a quantitative measure of the amount of the target 
protein present. 
A Meso-Scale-Discovery (MSD) assay was chosen as it provided the most amount of 
information from the smallest sample volume. There are a few idiosyncrasies of MSD 
assays that allow this. The antibody for the specific protein target is coated on an 
electrode (or “spot”) in the plate well, rather than the whole well. In the case of the assay 
used here a multiplex assay was used, which contained four spots in each well. This 
allowed four cytokines, IFN-γ, IL-1β, IL-6, and TNF-α to be assayed in the same well at the 
same time from a single small-volume sample without requiring any additional steps over 
a conventional ELISA (Figure 2.3-1). 
The 96-well plates were supplied with the spots pre-coated, each with their specific 
cytokine capture antibody. The wells were blocked with a supplied diluent to prevent 
non-specific interactions and then plasma sample was added. The cytokines present in 
the sample bound to the capture antibodies immobilised on their respective spots. A 
detection antibody solution was then added that contained a blend of cytokine 
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antibodies, each labelled with the electrochemiluminescent MSD SULFO-TAG®. Unlike 
conventional ELISAs that use detection labels that fluoresce when exposed to light, 
electrochemiluminescence detection uses labels that emit light when electrochemically 
stimulated. This reduces background signals because the stimulation mechanism 
(electricity) is decoupled from the signal (light). Multiple excitation cycles of each label 
amplify the signal to enhance light levels and improve sensitivity.  
  
Figure 2.3-1 Spot diagram showing placement of analyte capture antibody and schematic of assay principle. 
The labelled detection antibodies then bind to the cytokines, which were already bound 
to the capture antibody, thus completing the sandwich. MSD read buffer was then added 
to provide the appropriate chemical environment for electrochemiluminescence. The 
plate was then loaded into an MSD sector instrument for analysis. Inside the sector 
instrument, a voltage was applied to the electrodes that caused the labels bound to the 
electrode surface to emit light. The intensity of emitted light from each spot provided a 
quantitative measure of IFN-γ, IL-1β, IL-6, and TNF-α present in the sample. 
2.3.2 MATERIALS 
ELISA kits (Pro-inflammatory Panel 1 (4-plex) catalogue number K15009C-2) were 
purchased from Meso Scale Delivery Gaithersburg, Maryland, USA. The contents of the 
kits is detailed in Table 2.3-1. Water for HPLC (Fisher Scientific, Dublin, Ireland) was used 
as deionised water. Phosphate buffered saline plus 0.05% Tween-20 (PBS-Tween) was 
purchased from Sigma-Aldridge (St Louis, Missouri, USA) and made according to 
manufacture’s instructions. Tubes for reagent preparation (50mL and 15mL) and 1.5mL 
micro-centrifuge tubes for preparing serial dilutions were obtained from Sarstedt 
(Sarstedt, Nümbrecht, Germany).  
1  2  
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Table 2.3-1 Contents of Pro-inflammatory panel kit 
Item Description Storage Number in kit 
Multi-Spot 96 well 4 Spot Human Pro-Inflammatory I Plate 2–8°C 4 
SULFO-TAG Detection Antibody Blend (50X) 2–8°C  1 vial (375μL) 
Human Pro-Inflammatory Calibrator Blend (1μg/mL each) <-70°C  5 vials (15μL ea) 
Diluent 2 <-10°C  1 bottle (40 mL) 
Diluent 3 <-10°C 1 bottle (25 mL) 
Read Buffer T (4X) RT 1 bottle (50 mL) 
2.3.3 APARATUS 
Meso Scale Delivery Sector Imager 2400 was used as the detection device. The imager 
was attached to computer running Meso Scale Delivery’s Discovery Workbench® v3.0.17 
software. 
2.3.4 ASSAY PROTOCOL 
The assay was run as per kit recommendations with one modification on the advice of the 
manufacturer: 
 The assays were incubated with sample overnight to allow the reactions to reach 
equilibration and achieve better sensitivity. 
Otherwise the standard serum assay protocol provided in by the manufacturer was 
followed. The protocol used is summarised here: 
1. Preparation of calibrator samples: A serial dilution of Calibrator Blend was 
performed by diluting calibrators in Diluent 2; 
2. Addition of Diluent 2: 25μL of Diluent 2 was pipetted to cover the entire bottom 
of each well. The plate was sealed and incubated for 30 minutes with vigorous 
shaking (800RPM) at room temperature; 
3. Addition of Sample or Calibrator: 25μL of each Calibrator or Sample Solution was 
placed into the wells. The plate was sealed and incubated for 2 hours with 
vigorous shaking (800RPM) at room temperature; 
4.  Washing and Addition of Detection Antibody Solution: The plate was washed 
three times with 300μL PBS + 0.05% Tween-20 into each well, tapping out the 
liquid onto paper towels after each wash. A 25μL aliquot of the 1X Detection 
Antibody Solution was placed into each well of the MSD plate. The plate was 
sealed and incubated for 2 hours with vigorous shaking (800RPM) at room 
temperature; and 
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5. Washing and Reading: The plate was again washed three times with 300μL PBS + 
0.05% Tween-20. Then to each well, 150μL of Read Buffer T was added. The plate 
was analyzed on the sector imager immediately after addition of Read Buffer.  
Care was taken to ensure that bubbles were avoided at all stages, including the use of 
positive pipetting, as bubbles interfere with the reaction and reading.  
2.3.5 DATA ANALYSIS 
Data were analysed using Meso Scale Delivery’s  orkbench software and curves fitted 
using the built-in 4PL fit with 1/y2 weighting y = b2 + ((b1 - b2) / (1 + (x / b3)^b4)). 
2.3.6 PLATE CONFIGURATION 
Each spot was in the same position in every well as shown in Figure 2.3-2. A sample plate 
layout is shown in Figure 2.3-3 
 
Figure 2.3-2 Layout of assay spots in plate wells 
 1 2 3 4 5 6 7 8 9 10 11 12 
A stdA stdA 1A0 1A0 1A1 1A1 2A0 2A0 2A1 2A1 2A2 2A2 
B stdB stdB 2A3 2A3 2A4 2A4 3A0 3A0 3A1 3A1 3A2 3A2 
C stdC stdC 3A3 3A3 3A4 3A4 4A0 4A0 4A1 4A1 4A2 4A2 
D stdD stdD 4A3 4A3 4A4 4A4 5A0 5A0 5A1 5A1 5A2 5A2 
E stdE stdE 5A3 5A3 5A4 5A4 6A0 6A0 6A1 6A1 6A2 6A2 
F stdF stdF 6A3 6A3 6A4 6A4 7A0 7A0 7A1 7A1 7A2 7A2 
G stdG stdG 7A3 7A3 7A4 7A4 8A0 8A0 8A1 8A1 8A2 8A2 
H stdH stdH 8A3 8A3 9A0 9A0 9A1 9A1 9A2 9A2 9A3 9A3 
Figure 2.3-3 Layout of plate 1 showing standards (red) and patient samples (yellow) 
Abbreviations: std= standard. Patient samples shown as patient number, group letter and sample day.  
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2.3.7 RESULTS 
The image of plate 1 captured by the sector imager is shown in Figure 2.3-4 showing the 
various intensities of light emitted by the calibration standards and samples. As shown in 
the schematic Figure 2.3-3, the calibration standards are in the wells to the left.  
 
Figure 2.3-4 Image of plate 1 from sector reader from showing light intensities of various assayed samples 
2.3.7.1 VALIDATION 
Alongside patient samples, standard curves were prepared in duplicate in each plate for 
all cytokines assayed. Standard curves were constructed based on omitted light intensity 
(Figure 2.3-5). The concentration of the cytokines in each sample was calculated by 
plotting its intensity on the standard curve from their respective plates (Figure 2.3-6). 
Standard curves also provided limit of detections which also provided validation data 
 
Figure 2.3-5 Standard curve for IFN-γ from plate 1 
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Figure 2.3-6 Standard curve of IFN-γ showing location patient samples from plate 1 
Limits of detection (LOD) were calculated and defined as 2.5 standard deviations above 
the background. They are given in Table 2.3-2 and compared with values published by the 
manufacturer. 
Table 2.3-2 Limits of detection in pg/mL 
Cytokine Typical LOD Plate 1 Plate 2 Plate 3 Plate 4 
IFNγ 0.4 0.91 2.85 2.83 2.41 
IL-1β 0.2 0.38 0.89 1.0 0.49 
IL-6 0.7 0.42 0.34 0.4 0.36 
TNFα 0.5 0.76 0.65 0.64 0.64 
All of the LOD’s are similar to quoted limits and are reproducible, indicating intra-plate 
reproducibility as shown in Figure 2.3-7. No sample matrix issues were observed.  
 
Figure 2.3-7 Plot of standard curve for TNF-α from all plate  
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2.4 α GLUTATHIONE S-TRANSFERASE ASSAY  
Alpha glutathione S-transferase (αGST) is a Phase II detoxification enzyme protein found 
in high concentration in hepatocytes, where it constitutes 2-5% of all soluble protein 
(Trull et al. 1994; Clarke et al. 1997; Nagral et al. 1997). Its function in paracetamol 
metabolism was discussed in Section 1.2. Because it is in such high concentrations in 
these cells it appears rapidly in the plasma when hepatocytes are injured and become 
leaky. Measuring the appearance of αGST in plasma is used in drug development and 
clinical disease management for early detection of liver damage and it is considered the 
most sensitive parameter of liver tissue damage following paracetamol administration 
(Beckett et al. 1985; Trull et al. 1994; Redl et al. 1995; Chouker et al. 2005) 
As a measure of paracetamol induced hepatotoxicity, αGST has several advantages over 
transaminase enzymes, alanine aminotransferase (ALT) and aspartate aminotransferase 
(AST), conventionally used for this assessment: 
 αGST has a half-life in circulation of 90 minutes, significantly shorter than 
transaminases AST (17±5 hours) and ALT (47±10 hours) (Kasper et al. 2008). 
Consequently, αGST levels return to baseline values quickly when damage to 
hepatocytes ceases, enabling the detection of the onset and cessation of 
hepatocyte injury (Beckett et al. 1993; Trull et al. 1994);  
 αGST is more sensitive than transaminases being measurable at low levels of 
hepatocyte injury and lower concentrations of toxin (Clarke et al. 1997); 
 Because αGST is found in high concentrations in hepatocytes, statistically 
significant elevation occurs sooner than other markers of hepatotoxicity(Beckett 
et al. 1993). Accordingly, it may identify preclinical toxicity that is not detected 
using transaminases (Murray et al. 1992a; Sivilotti et al. 2002); 
 αGST is only released from hepatocytes and is therefore more discriminating than 
transaminases, which can be released from a variety of tissues (Murray et al. 
1992a; Kumle et al. 2003); 
 αGST is equally distributed in both the centrilobular and periportal regions of the 
liver (Sundberg et al. 1993). In contrast, transaminases are not distributed 
uniformly, with concentrations higher in the periportal region than the 
centrilobular (Beckett et al. 1993). Since the centrilobular hepatocytes are the 
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most susceptible to damage, αGST is a more sensitive indicator of hepatic 
damage.  
An ELISA αGST assay was chosen as the method of choice for the detection of hepatocyte 
injury over transaminase enzyme assays due to its advantages outlined above. The upper 
limit of the reference range for those without hepatic damage is 11.4μg/L (Rees et al. 
1995). 
2.4.1 ASSAY PRINCIPLE 
This ELISA used a sandwich assay principle similar to that used for the measurement of 
cytokines. This ELISA was more conventional than the ELISA used for the cytokine assay as 
the entire lower surface of each well was pre-coated with anti-αGST IgG antibodies by the 
manufacturer. A schematic of the assay principle is shown in Figure 2.4-1.  
 
Figure 2.4-1 Spot diagram displaying αGST enzyme-linked immunoassay and schematic of assay principle 
Diluted plasma samples were added to each well and any αGST present in the sample 
bound to the αGST-antibodies coating the well surface. Enzyme-conjugate was added, 
followed by substrate. The enzyme used was horse-radish peroxidase (HRP), which 
oxidises the substrate, the chromogen 3,3′,5,5′-tetramethylbenzidine (TMB), changing it 
from colourless to blue (Josephy et al. 1982; Josephy et al. 1983). TMB is the most 
popular substrate for HRP detection in ELISA as it is very sensitive and is more quickly 
oxidised than other HRP substrates, resulting in faster colour development (Liem et al. 
1979). Upon addition of the stop solution, sulphuric acid, TMB becomes yellow with a 
maximum absorbance at 450nm (Josephy et al. 1982; Josephy et al. 1983). Absorbance of 
the wells was read at 450nm with a reference 655nm. The absorbance intensity was 
proportional to the amount of αGST present in the sample. 
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2.4.2 MATERIALS 
Four ELISA kits (HEPKIT-Alpha) were purchased with the same lot number (Argutus 
Medical, Dublin, Ireland). The contents of the kits is detailed in Table 2.3-1. Water for 
HPLC (Fisher Scientific, Dublin, Ireland) was used as deionised water. Tubes for reagent 
preparation (50mL and 15mL) and 1.5mL micro-centrifuge tubes for preparing serial 
dilutions were obtained from Sarstedt (Sarstedt, Nümbrecht, Germany).  
Table 2.4-1 Contents of HEPKIT-Alpha 
Item Description Storage Number in kit 
Anti αGST IgG coated 96 well microassay plate 2–8°C 1 
GST Calibrator stock solution 2–8°C  1 vial (200μL) 
Positive Control  2–8°C  1 bottle (4.5mL) 
Conjugate concentrate (anti αGST IgG conjugated to HRP) 2–8°C  1 vial (300μL) 
Wash Concentrate (20x PBS Tween-20) 2–8°C  1 bottle (55 mL) 
TMB substrate 2–8°C  1 bottle (11 mL) 
Stop solution 0.5 mol/L 2–8°C  1 bottle (11 mL) 
2.4.3 APARATUS 
Plates were read using a Biorad 680 Microplate Reader(Biorad, California, USA) measuring 
absorbance at 450nm with a reference filter at 655nm. Data were captured using Biorad 
Microplate Manager Software V5.2.1(Biorad, California, USA). 
2.4.4 ASSAY PROTOCOL 
The assay was run according to the assay protocol published by the manufacturer with one 
modification on the advice of the manufacturer’s representative: 
 The recommended reference filter 630nm was not available. A 655nm filter was used 
in its place. 
2.4.4.1 PREPARATION OF REAGENTS  
All reagents were bought to room temperature (20.2°C), mixed well and checked to be 
free of crystals before use. 
2.4.4.1.1 WASH SOLUTION (PBST)  
The wash solution was prepared by diluting 50mL of the 20x concentrated solution with 
950mL of deionised water. The salt crystals in the concentrated solution were dissolved 
prior to dilution by gentle warming and agitation of concentrate at 37°C for 30 minutes.  
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2.4.4.1.2 CALIBRATORS  
Calibrators were prepared from the αGST stock solution as follows: 
Calibrator A: 25μL Calibrator Stock+ 2500μL  ash Solution. Using labelled micro-
centrifuge tubes, Calibrator A was further diluted to prepare the remaining calibrators as 
shown in Table 2.4-2. Calibrators were used within 30 minutes of preparation.  
Table 2.4-2 Concentration and preparation of calibrators 
Equivalent Calibrator 
Concentration 
Calibrator Volume  μL   Wash Solution Volume  μL   
40μg/L (A)  500 (A)  -  
20μg/L (B)  500 (A)  500  
10μg/L (C)  500 (B)  500  
5μg/L (D)  500 (C)  500  
2.5μg/L (E)  500 (D)  500  
1.25μg/L (F)  500 (E)  500  
0μg/L (G)  -  500  
2.4.4.1.3 SAMPLE PREPARATION 
Samples were diluted 1:5 by adding 50μL of plasma to 200μL of wash solution in a blank 
microassay plate.  
2.4.4.1.4 CONJUGATE 
Immediately prior to use the conjugate concentrate was diluted 1:51 by adding 980μL 
conjugate to 49mL of wash solution. 
2.4.4.2 ASSAY PROCEEDURE 
All reagents were delivered at the midpoint of the side of the wells with care not to 
scratch the side with the pipette tip. Positive pipetting was used to prevent introduction 
of bubbles. 
1. Addition of Sample or Calibrator: 100μL of each calibrator (A-G) and the control were 
added in duplicate to each plate in rows 1 and 2 as shown in Figure 2.4-2. Samples 
were then added, also in duplicate, in the remaining wells. The plates were sealed and 
incubated at room temperature for 60 minutes with vigorous shaking (800RPM VWR 
Plate Shaker, VWR Scientific, Cambridge, UK). After 55 minutes of incubation the 
conjugate was prepared; 
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2. Washing and Addition of Enzyme Conjugate Solution: At the end of the incubation 
the wells were washed four times with 250μL of the wash solution, tapping out the 
liquid onto paper towels after each wash. 100μL of the conjugate solution was then 
added to each well. The plates were incubated again at room temperature for 30 
minutes with vigorous shaking (800RPM); and 
3. Washing, Addition of Substrate, Stop Solution and Plate Reading: The plates were 
washed again as in step 2. To each well 100μL of substrate was added and the plates 
were incubated in the dark (inside a drawer) for 15 minutes exactly. Immediately 
afterwards, 100μL of the stop solution was added to each well. Plates were read 
immediately with the microplate reader at 450nm with 655nm as reference. 
2.4.5 DATA ANALYSIS 
Data were captured using Microplate manager software. Mean absorbance was 
calculated for each calibrator, control and sample. Calibration curves were constructed by 
plotting A450/655nm on the x axis and [αGST] (μg/L) on the y axis. A polynomial line of best 
fit was determined using the equation Equation 2.4-1: 
           
Equation 2.4-1 Equation for line of best fit for αGST standards 
The equations of these lines were then used for determining sample αGST concentration. 
The actual concentration was then determined by multiplying the calculated 
concentration by the dilution factor of 5. The concentration of the positive control was 
read directly from the curve as it was not diluted. The positive control was checked 
against the reference value specific for the kit. 
2.4.6 PLATE CONFIGURATION 
A sample plate layout is shown in Figure 2.4-2. 
 1 2 3 4 5 6 7 8 9 10 11 12 
A stdA stdA 5C1 5C1 6C0 6C0 6C1 6C1 6C2 6C2 6C4 6C4 
B stdB stdB 7C0 7C0 1D0 1D0 1D1 1D1 2D0 2D0 2D1 2D1 
C stdC stdC 2D2 2D2 2D3 2D3 2D4 2D4 3D0 3D0 3D1 3D1 
D stdD stdD 3D2 3D2 3D3 3D3 3D4 3D4 4D0 4D0 4D1 4D1 
E stdE stdE 4D2 4D2 4D3 4D3 4D4 4D4 5D0 5D0 6D0 6D0 
F stdF stdF 7D0 7D0 8D0 8D0 8D1 8D1 8D2 8D2 8D3 8D3 
G stdG stdG 8D4 8D4 9D0 9D0 10D0 10D0 10D1 10D1 10D2 10D2 
H CTRL CTRL 10D3 10D3 10D4 10D4 11D0 11D0 11D3 11D3 11D4 11D4 
Figure 2.4-2 Layout of plate 3 showing standard samples (red) and patient samples (yellow) 
Abbreviations: std= standard. Ctrl= positive control. Patient samples shown as patient number, group letter and sample 
day.  
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2.4.7 RESULTS 
A photo of plate 3 was taken immediately after reading and is shown in Figure 2.4-3. 
Plates developed colour as shown in response to the presence of αGST.  
 
Figure 2.4-3 Photo of αGST  LISA plate 3 immediately after reading.  
Development of yellow colour indicates presence of αGST in sample 
2.4.7.1 VALIDATION 
Alongside patient samples, calibrator samples A-G were assayed in duplicate on each 
plate to produce a standard curves. Aside from determining αGST in patient samples, 
standard curves were used to provide the limit of detection and compared across plates 
to provide validation data. A sample curve is shown in Fig 2.2-4. 
 
Figure 2.4-4 Standard curve for αGST from plate 3  
Limits of detection (LOD) were determined as 2.5 standard deviations above the 
background. They are given in Table 2.4-3 and compared with values published by the 
manufacturer. 
Table 2.4-3 Limit of detection of αGST  µg/L  on each plate compared to provided reference value 
 Typical LOD Plate 1 Plate 2 Plate 3 Plate 4 
αGST  µg/L) 0.25 0.247248 0.261624 0.097255 0.308198 
y = -0.0007x2 + 0.0816x + 0.0775 
R = 0.9995 
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All LOD are similar or better than quoted limits. No sample matrix issues were visually 
observed. To analyse for inter-plate reproducibility means and standard errors were 
calculated and are detailed in Table 2.4-4.  
Table 2.4-4 Mean and standard error values of standard curve samples 
Concentration 
 μg/L) 
Mean absorbance 
(450/655nm) 
Standard deviation Standard error (%) 
1.25 .1775 .01500 0.084507 
2.50 .2800 .01414 0.050508 
5.00 .4750 .01915 0.040313 
10.00 .8450 .03000 0.035503 
20.00 1.3775 .03403 0.024707 
40.00 2.1800 .02708 0.012422 
Graphs of standard curves from all plates were also prepared (Figure 2.4-5). 
 
Figure 2.4-5 Standard curve for αGST from all plates.  
Graph (A) shows regression line based on mean values from all plates with dotted line representing 95% confidence 
interval of mean values. No value lies outside of the confidence interval. Graph (B) shows the standard curves for each 
plate, virtually superimposed, with all curves lying within the confidence interval. 
The equation of the lines of best fit were: 
Table 2.4-5  quations of lines of best fit for αGST standard curves 
Plate Equation Correlation (r) 
1 y = -0.0007x2 + 0.0819x + 0.1009 0.999649939 
2 y = -0.0007x2 + 0.0816x + 0.0775 0.999549899 
3 y = -0.0006x2 + 0.076x + 0.0813 0.999449849 
4 y = -0.0007x2 + 0.0806x + 0.072 0.999899995 
Assessing the mean and standard error values, all are below 10%, indicating there is very 
little variability between plates. Visually, the lines of best fit for each plate are virtually 
superimposed. From the equations, the intercepts are also virtually identical. To confirm 
this, an analysis of covariance was conducted on the absorbance values to test for 
homogeneity of the regression lines and to test the equality of the error variance. The 
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results of the Levene’s test confirm equal variance between samples F(3, 24)=0.025, 
p=0.995. Testing concentrations across the plates also gave non-significant results with 
F(6, 21)=1.647 p=0.184. These results confirm that there was no significant differences 
between plates. Each observation was independent, variance homogenous (as shown by 
Levene’s tests) and distribution was normal. 
Positive control samples were also included with each kit and assayed in duplicate on 
each plate. Each kit gave the concentration of the quality control sample as a range from 
7.6-12.6ug/L. Results of the plate are considered valid if the calculated value of the 
positive control is within the provided range. The calculated concentrations are provided 
in Table 2.4-6. 
Table 2.4-6 Calculated concentrations of positive control samples determined in each plate (±standard deviation of 
duplicate samples) compared with provided reference range 
Positive Control Reference range Plate 1 Plate 2 Plate 3 Plate 4 
αGST  µg/L  7.6-12.6 9.48±1.06 10.19±0.94 10.32±0.54 9.86±0.54 
The positive control values were within the reference range on all plates, confirming the 
validity of the results. 
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2.5 LCMS ASSAY 
Four medicines: caffeine, dextromethorphan, chlorzoxazone and midazolam were used to 
probe the activity of four CYP450 enzymes, 1A2, 2D6, 2E1 and 3A4, as discussed in 
Sections 1.5. Separate assays for each of these probes are readily available in the 
literature but this would have required significant volumes of blood for this study (Tanaka 
et al. 2003; Zhou et al. 2004; Fuhr et al. 2007). Obtaining such large volumes of blood 
from very sick patients in the acute stage of recovery was unrealistic as it could impede 
their recovery and was also difficult from an ethical and practical standpoint. Accordingly, 
minimising the blood collected from these patients was of paramount importance. As 
such, an assay that could determine the concentration of all of the compounds of interest 
in small blood-volume samples, rather than separate assays involving larger blood 
volumes, was not only an attractive prospect from an efficiency point of view but was also 
an ethical and clinical necessity.  
In determining the activity of the CYP450 enzymes of interest, the concentration of the 
four probe drugs and their primary metabolites in plasma samples were measured. An 
internal standard was used resulting in analysis of nine compounds in total. This 
presented several analytical challenges: 
 The expected concentrations of these drugs and metabolites were below the 
sensitivity limits of HPLC with UV detection; 
 Only one of the drugs and metabolites could be detected by fluorescence, 
rendering fluorescence detection unsuitable; 
 ELISA plates were not available for the detection of all of the compounds, 
simultaneously or as individual assays. ELISAs that were available required too 
much sample for the separate analysis of all eight compounds arising from the 
probe drugs (i.e. ELISA does not require an addition of an internal standard); and 
 Mass spectrometry (MS) is sensitive enough to detect the compounds at the 
concentration levels expected and is commonly used for this type of research. 
However, MS methods in the literature either analysed the compounds in 
separate runs, or in varying combinations with other drugs or used other probe 
drugs that were purposely avoided in this study (e.g. metoprolol). No method was 
reported at the time of this analysis that examined the concentration of all the 
compounds of interest simultaneously (Zhu et al. 2001; Jerdi et al. 2004; Fuhr et 
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al. 2007; Kumar et al. 2007; Lahoz et al. 2007; Zhang et al. 2008; Ghassabian et al. 
2009; Liu et al. 2009).  
Unlike UV or fluorescence detection, MS determines the mass to charge ratio of charged 
particles and determines their abundance as they pass through the detector. MS has two 
main advantages over photometric detection: 
 MS can be several thousand times more sensitive; and (Polettini 2006) 
 Co-eluting peaks can be identified by their individual molecular weights. 
Accordingly, chromatographic separation of compounds is less important than 
with UV detection and as a result, run times can be shorter (Silverstein et al. 
1991). 
For the reasons stated above a MS method was the most appropriate technique for 
this particular analysis. Access to a MS was given through the generous support of the 
Analytical Chemistry Department, UCC. To minimise the time required using the liquid 
chromatogram/mass spectrometer (LCMS), development of the sample preparation 
method was completed on the same HPLC instrument used in Section 2.2. 
2.5.1 SAMPLE PREPARATION AND EXTRACTION 
Sample preparation for LCMS is more demanding than for HPLC. Similar approaches can 
be taken to those discussed in Section 2.2, utilising one of four techniques: direct 
injection, protein precipitation before injection, liquid-liquid extraction and solid phase 
extraction. For this analysis, the aims of the extraction process were to produce a sample 
suitable for injection that used one of these four methods and, in addition: 
 Contained all compounds of interest, unconjugated and extracted in high 
amounts; 
 Was free of proteins and salts; 
 Was of reduced volume, concentrated from the original sample; 
 Was free of particulate residue; 
 Could be produced repeatedly; and 
 Was capable of scaling up for the preparation of the several hundred samples 
taken for this analysis.  
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Direct Injection
Plasma proteins damage instrument.
Concentrations below limit of detectIon. Buffer from 
deconjugation would not be removed
Solid Phase Extraction
Allows for concentration
Free of proteins and buffers
Can’t extract all compounds from one sample. 
Large amount of sample required. 
Expensive
Liquid-liquid extraction
Allows for concentration
Free of proteins and buffers
Possible to extract all compounds from one sample
Sample volume variable
Labour intensive but cheap
Protein precipitation
Aqueous supernatant hard to concentrate. 
Buffer for β-glucuronidase would suppress ionisation in LCMS
Low and variable analyte recovery due to co-precipitation.
Final sample must be:
Unconjugated
Concentrated
Free of proteins
Free of buffers 
Free of particulates
Repeatable
Scalable
Plasma 
sample
 
Figure 2.5-1 Aims of sample preparation and factors that influenced choice of extraction method 
The important factors that influenced what extraction method was chosen are shown in 
Figure 2.5-1. The background to these aims listed above are briefly discussed in sequence 
below: 
Contained all compounds of interest, unconjugated, extracted in high 
amounts; 
The first step of sample preparation was to deconjugate the compounds from other 
molecules added to them during the drug metabolism process.  
Drugs are frequently conjugated to other groups during the metabolism process, most 
commonly to a glucuronide moiety (Daali et al. 2008). This was the case with most of the 
compounds under investigation. Glucuronide conjugation interferes with analysis in two 
ways:  
1. It increases the water solubility of the compound making it harder to extract from 
plasma with organic solvent; and  
2. It increases the molecular weight of the compound, altering its MS signal (which is 
based on a molecular mass to charge ratio) so that the conjugated compounds 
would not be seen in their expected mass to charge range. 
While the molecular weight could be approximated for a glucuronidated compound (by 
adding the weight of a glucuronide group to the molecular weight of the compound of 
interest), and therefore be detected by LCMS, no analytical standards were available for 
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the glucuronide conjugates to produce standard curves and enable the calculation of their 
concentration. It was therefore necessary to de-conjugate these compounds from their 
glucuronide.  
There are several methods in the literature that facilitate glucuronide deconjugation, 
most commonly acid hydrolysis (Daali et al. 2008) or the use of a β-glucuronidase enzyme 
(Kaushik et al. 2006). Acid hydrolysis is difficult to limit to the desired deconjugation 
reaction and may cause degradation of other compounds, whereas β-glucuronidase is 
specific to the deconjugation of glucuronide. There are several sources of β-glucuronidase 
but the most commonly used and readily available is derived from the juice of the snail 
Helix pomatia. Optimal activity of this enzyme requires shaking, incubation and a buffered 
acidic environment; a summary of the conditions used in relevant papers is given in 
Appendix 14.  
The inclusion of buffer salts presented problems for the LCMS, which are discussed 
further below. Inclusion of a buffer into the sample preparation excluded direct injection 
of the sample and any simple protein precipitation method of sample preparation, as the 
buffer would still be present in the final sample. Only solid phase or liquid-liquid 
extraction methods remained as options. After reviewing the literature and contacting 
product specialists at various suppliers, there was no one solid phase cartridge that could 
extract all the compounds being analysed, and sample requirements were too great for 
separate extractions. This left liquid-liquid extraction as the only option. 
Was free of proteins and salts; 
The problems arising from the protein content of plasma samples that makes them 
unsuitable for direct injection in HPLC systems were discussed in Section 2.2. These 
problems are magnified in LCMS systems. Due to the sensitive nature of detection, 
proteins present in plasma samples can, at worst, permanently damage the instrument, 
but more commonly leave ‘ghost signals’ that indicate the presence of a compound even 
though none is present in the injected sample. These signals can remain long after the last 
injection. Salts in samples also cause problems. MS requires the ionisation of the 
compound being analysed and the presence of salts hampers this ionisation. Therefore 
samples that contain salts can suppress this ionisation and also permanently damage the 
instrument, so these also must not be present in samples.  
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Was of reduced volume, concentrated from original sample; 
The concentration of some of the compounds of interest was expected to be so low, it 
was desirable to increase their concentration by reducing the final volume of the sample. 
This required the solvents used in the extraction process to be volatile and capable of 
evaporation to dryness. Following this evaporation, a reduced volume of a solvent could 
be used to reconstitute the sample’s evaporation residue. 
Was free of particulate residue; 
To protect the column and MS from any residual proteins and particulates, the only way 
to ensure particulate removal was to filter the samples. Several product specialists were 
contacted before the final product was chosen. 
Could be produced repeatedly; 
Results of the extraction process were required to be reproducible across the expected 
concentration range. Inconsistencies would invalidate the results. An internal standard 
was required to validate this and account for any variation. Phenacetin was chosen for 
this purpose as incorporating an internal standard for each compound would have been 
extremely cumbersome and problematic for the analysis. Phenacetin was widely used in 
the literature in similar types of analysis as a surrogate internal standard for all 
compounds of interest.  
Was capable of scaling up for the preparation of the several hundred 
samples taken for this analysis; 
The sample preparation process had to be scalable to facilitate analysis of the several 
hundred samples within the period of access to the LCMS. It also had additional 
requirements: 
1. Preparation must be limited to a 2mL Eppendorf tube to prevent sample loss 
through adherence to the sides of larger tubes, and to fit available laboratory 
equipment; and 
2. Use a minimum volume of extraction solvent to prevent long evaporation times 
as these would require large volumes of nitrogen gas to evaporate the samples. 
The availability of this gas was limited, frequently running out at the weekend. 
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2.5.2 EXTRACTION DEVELOPMENT 
2.5.2.1 MATERIALS 
2.5.2.1.1 ANALYTICAL COMPOUNDS 
Caffeine, chlorzoxazone, paraxanthine and phenacetin were purchased from Sigma-
Aldrich (St. Louis, Missouri, United States of America (USA)). Dextromethorphan, 
dextrophan, 6-OH-chlorzoxazone and 1-OH-midazolam were purchased from Toronto 
Research Chemicals (Ontario, Canada). Midazolam was the generous gift of Hoffman-La-
Roche AG (Basel, Switzerland). As midazolam is a Schedule Four Controlled Drug, a license 
to import (Appendix 10) and a license to possess (Appendix 11) midazolam were 
necessary and these were obtained from the Department of Health and Children. 
2.5.2.1.2 SOLVENTS AND BUFFERS AND OTHER MATERIALS 
HPLC grade acetonitrile, methanol and water were purchased from Fisher Scientific 
(Leicestershire, UK). Potassium phosphate (puriss), sodium acetate (puriss), β-
glucuronidase powder (type H-1, 1.96MU/g), analytical grade formic acid 88%, glacial 
acetic acid, diethyl ether, dichloromethane, chloroform and 2-propanol were purchased 
from Sigma-Aldrich (St. Louis, Missouri, USA). The mobile phases were filtered through 
type HA filters (0.45μm Millipore, Bedford, Massachusetts, USA) to remove particulate 
matter before use. These filters were chosen as they were compatible with the mobile 
phases being used.  
2.5.2.2 CHROMATOGRAPHIC CONDITIONS 
For development of sample preparation, separation of all the above listed analytical 
compounds in a single run was performed on a Phenomenex Synergi 4m Hydro-RP 
250x4.6mm column with a Phenomenex SecurityGuard precolumn held at 30°C 
(Phenomenex, Cheshire, UK). A gradient mobile phase combined 0.1M KH2PO4 + 1% 
formic acid (A) with acetonitrile + 1% formic acid (B) (Table 2.5-1).  
Table 2.5-1 Chromatographic conditions for HPLC assay for optimisation of LCMS sample preparation 
Time %A Flow rate (mL/min) 
0 85 1 
16.75 68 (nonlinear) 1 
17 85 1 
21 85 1 
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The gradient had initial conditions of 85:15 (A:B) which declined at a non-linear curve of 5 
to 68:32 (A:B) by 16.75 minutes. The initial conditions were then restored by the 17th 
minute and maintained for a further four minutes. The flow rate remained constant at 
1.0mL/min.  
2.5.2.3 APPARATUS 
Samples were centrifuged using a Mikro 120 Centrifuge (Hettich, Tuttlingen, Germany) at 
14000 RPM. Compounds were analysed using an ATI Unicam UV/Vis spectrometer 
(Unicam Analytical Systems, Madison, USA). Samples were incubated with an Apollo 
shaker oven HP50 (CLP, Northampton, UK) set at 37°C and 20RPM. Extracted solvents 
were evaporated using a TurboVap LV concentration workstation (Caliper LifeSciences, 
Massachusetts, USA) at 40°C under a gentle flow of nitrogen gas until dryness. Final 
samples were filtered using Multiscreen Solvinert 0.45µm low binding hydrophilic 
polytetrafluoroethylene filters and Multiscreen vacuum manifold (Millipore, 
Massachusetts, USA) at 15-20mmHg. 
Analysis of samples during the sample preparation method development was conducted 
using a Waters 2695 Alliance HPLC system (Waters Corporation, Milford, USA) equipped 
with a 2996 Photodiode Array (PDA) Detector, 2475 Multi Wavelength Fluorescence 
Detector and column oven. Chromatograms were captured and processed using 
Empower Pro interface (Empower 2, Waters Corp., Milford, USA).  
2.5.2.4 OVERVIEW 
A summary of factors relevant to the application of liquid-liquid extraction to this work is 
shown in Figure 2.5-2. 
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Compounds must be unionised to 
extract Liquid-liquid extraction
Compounds have different 
physiochemical properties.
Their extraction varies with solvent, pH 
and volume of solvent
Sample volume collected insufficient 
to analyse each compound separately. 
Need simultaneous extraction
From literature
diethylether, dichloromethane, 
chloroform, 2-propanol most common 
extraction solvents
Sample pH and solvent choice must 
be combine to improve extraction of 
various compounds
Volumes must be kept fit within 2mL 
eppendorf tube and be optimised to 
extract maximum amount of 
compound for each addition.  
Figure 2.5-2 Summary of factors affecting liquid-liquid extraction 
This method of sample preparation relies of the varying solubilities of the compounds of 
interest and the contaminants present in the plasma sample. Compounds must be ionised 
to extract and, given the varying physicochemical properties of the compounds being 
measured, this presented the biggest analytical challenge to this research. The literature 
was searched for further details of the compounds solubilities and these are summarised 
in Table 2.5-2 below. Where exact values were unavailable, solubilities are given as freely 
soluble (1 part in 1–10); insoluble (1 part in more than 10000); or sparingly soluble (1 part 
in 30–100) (Lund 1994). Molecular weights, necessary for LCMS analysis, were obtained 
from the Agilent Mass Hunter workstation Acquisition 2.00 software (Agilent 
Technologies, Massachusetts, USA) based on each molecule’s empirical formula.  
Several experiments were undertaken to understand, develop and optimise the 
extraction of the nine compounds of interest. Each of these experiments is summarised 
with key findings and graphs to support the conclusions where relevant in Table 2.5-3 
further below.  
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Table 2.5-2 Structural and solubility details of compounds under investigation 
Abbreviations: MR= molecular weight; (M+H)+= MR of ionised compound; Abs= UV absorbance maxima or fluorescence 
excitation/emission wavelengths; LogP=octanol:water partition coefficient; H2O=water; EtOH=ethanol; 
CHCl3=chloroform; (C2H5)2O=diethyl ether; Free=freely soluble; Ins=insoluble; Spr=sparingly soluble. References: 1-
(Toronto Research Chemicals 2007), 2-(Sigma-Aldrich 2009); 3-(Moffat et al. 2011); 4-(Lund 1994) 
Compound pKa MR (M+H)
+
 Abs LogP Solubility 
Phenacetin  
2.23 
179.09 
180.1 
244nm
3
 1.6
3
 H2O 1:1300
3
 
EtOH 1:15
3
 
CHCl3 1:14
3
 
(C2H5)2O 1:90
3
 
Caffeine  
143 
194.08 
195.09 
273nm
3
 -0.07
3
 H2O 1:46
3
 
EtOH 1:66
3
 
CHCl3 1:5.5
3
 
(C2H5)2O 1:530
3
 
Paraxanthine  
8.82 
180.16 
181.07 
271nm
2
 -0.2
2
 H2O  
EtOH  
CHCl3  
(C2H5)2O  
Dextromethorphan  
8.33 
271.19 
272.2 
λex/em 
280/ 
315nm
3
 
3.97
3
 H2O 1:60
3
 
EtOH 1:10
3
 
CHCl3 Free
3
 
(C2H5)2O Ins
3
 
Dextrorphan  
 
257.18 
258.19 
λex/em 
280/ 
315nm
1
 
3.1
1 
H2O  
EtOH  
CHCl3  
(C2H5)2O  
Chlorzoxazone  
8.03 
169 
170 
280nm
3
 1.6
3
 H2O Spr
3
 
EtOH 1:20
3
 
CHCl3 1:250
3
 
(C2H5)2O 1:60
3
 
6-OH-chlorzoxazone  
 
184.99 
186 
297nm
1
  H2O  
EtOH  
CHCl3  
(C2H5)2O  
Midazolam  
6.23 
325.08 
326.09 
219nm
3
 4.3
3
 H2O Ins
4
 
EtOH Free
4
 
CHCl3 Free
4
 
(C2H5)2O Free
4
 
1-OH-midazolam  
 
341.07 
342.08 
246nm
1
  H2O  
EtOH  
CHCl3  
(C2H5)2O  
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Table 2.5-3 Summary of experiments in development of liquid-liquid extraction method for CYP450 probe drugs. 
Each experiment is summarised in term of Aim, Experiment (a brief summary of the experiment and conditions), Findings (the key findings from the experiment) and Implication (what was learnt from 
the experiment that was relevant to the assay development and future work). Abbreviations used: DEE- diethyl ether; DCM- dichloromethane; CL- chloroform; P- 2-propanol; CLP- a mixture of 
chloroform and 2-propanol; N2- nitrogen gas; HPLC- high pressure liquid chromatography; PDA- photodiode array; AQ- aqueous; ACN- acetonitrile; PCA- perchloric acid; NaAc- Sodium acetate; PH- 
phenacetin; CA- caffeine; PX- paraxanthine; DM- dextromethorphan; DX- dextrorphan; CZX- chlorzoxazone; 6CZX- 6-hydroxy-chlorzoxazone; MDZ- midazolam; 1MDZ- 1-hydroxy-midazolam; PO4 
potassium phosphate buffer; MeOH- methanol; 
HPLC method developed for simultaneous 
determination. Initial conditions 85:15 
AQ:ACN.
Experiment FindingsAim Implication
0.5mL of DEE, DCM, CL and P added to 
separate HPLC vials and timed to 
evaporate to dryness under gentle stream 
of N2.
P component of extraction solvent must be 
small or offset by other more volatile 
solvents.
DEE to be stored at -80°C to reduce 
evaporation.
Extraction of parent compounds (not 
metabolites), 20µg/mL, each in 100µl 
water tested from 500µL of four different 
solvents: DEE, DCM, CL, P and most 
common solvent in literature, chloroform 
and 2-propanol (9:1) mixture (CLP). 
Sample vortex mixed, centrifuged, organic 
layer separated and evaporated to 
dryness under N2 gas (extracted).  
Reconstituted 1mL in water.
Results compared to standard curves. 
Analysis by spectrophotometer.
Analysis of by spectrophotometer took too 
long, results inconsistent.
Simultaneous method needed.
Water spiked with all compounds to 10µg/
mL. 1mL of each solvent added and 
extracted
Solvent evaporated and reconstituted in 
mobile phase initial conditions. 
Extraction varied with compound and 
solvent. No one perfect solvent.
Consideration must be given to adjusting 
pH to have compounds un-ionised.
Stock solutions containing all compounds 
at 125µg/mL made. Dilution of 80µL of this 
solution with 920µL of plasma gives 
plasma spiked with 10µg/mL of all 
compounds (spiked plasma).
Maximum UV absorbance determined for 
each compound.
PDA set to scan for UV maxima of each 
compound.
P very slow to evaporate (45 min), 
followed by CL (27min) DCM (8min) and 
DEE (4min).
Consider adding a base during extraction 
to increase extraction of bases.  Given 
buffering capacity of plasma, experiments 
to determine base required should be in 
plasma.
Repeated extractions may be necessary.
Only DEE forms supernatant, others form 
subnatant under aqueous layer. 
Supernatant much easier to work with than 
subnatant.
No solvent completely extracted any 
compound.
DEE evaporated so quickly it is difficult to 
pipette a volume accurately.
DCM was best overall, but extracted 
bases poorly.
1. Determine 
evaporation of each 
solvent
2. Determine 
Solubility of 
compounds in 
solvents
Key Graphs
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500µL of spiked plasma added to 1000µL 
of NaAc. Add 1M NaOH in 10µL amounts 
to achieve pH 2 units above pKa of 
strongest base. Repeat extraction in 
previous step.
NaAc buffer 0.2M pH 4.75 necessary for 
β-glucuronidase activity. Literature shows 
buffer volume must be ≥2x sample 
volume.
Extraction of DX decreases with addition 
of buffer. Adding acid ionises basic 
compounds which then cannot extract into 
solvent.
Add base before final extraction to remove 
ionisation of bases
500µL of spiked plasma added to 1000µL 
of NaAc and 500µL of DCM. Extract, 
evaporate and reconstitute.
500µL spiked plasma added to 30µL of 
0.33, 0.66 and 1M NaOH. (High 
concentration used to minimise additional 
volume). 30µL water added to controls 
500µL of DCM added and extracted. Two 
further 500µL DCM extractions completed. 
Organic recovered separately, dried and 
reconstituted in 200µL mobile phase. 
Analysed separately to see recovery from 
each step.
CZX and PX extract poorly, 10-20% of 
controls.
The three extraction steps recover 
approximately 75, 20, 5% respectively of 
total recovery at each step. 
Basic and neutral compounds extract well, 
>80% of controls.
 Extraction not significantly affected by 
base strength.
Protein precipitant may be required to form 
harder protein pellet. Adding acid would do 
this and also improve extraction of acidic 
compounds. From paracetamol assay 
volume of PCA 30% required was 10% of 
sample volume, but total removal of 
proteins from plasma is not required, only 
solidification of precipitating proteins to 
make organic subnatant easier to access. 
What is the correct volume for this 
application? Are there alternative 
methods?
Second extraction step contributes 
significantly to recovery, third step less 
important.
Protein precipitate forms diffuse layer 
above organic subnatant. Protein sticks to 
pippette tip making clean extraction of 
organic layer difficult.
Adding base unionises and improves 
extraction of bases.
One step extraction not possible.
Smallest volume of PCA sufficient for this 
purpose.
Poor peak shape on chromatogram 
impairs integration. Significant tailing seen. 
May be effect of pH.
Rerun above with 0.01M phosphate buffer 
as aqueous mobile phase.
Introduce phosphate buffer into aqueous 
mobile phase.
After vortexing all samples form a creamy 
homogenous liquid. Following centrifuging, 
solid protein pellet formed between 
aqueous supernatant and organic 
subnatant of all samples which makes 
removal of organic much easier.
25, 50 and 100µL of 30% PCA added to 
1mL spiked plasma (5µg/mL) followed by 
500µL DCM. Organic extracted and 
evaporated to dryness and reconstituted in 
200µL mobile phase.
pH of sample with 25µL PCA is 1.
Peak shape markedly improved. Recovery 
of acids >80% but bases <20%. Volume of 
PCA does not affect recovery.
Upon reconstituting dried solution in 
mobile phase, white supernatant formed 
and stuck to pipette tips making clean 
sample transfer to HPLC difficult. 
pH9-10 achieved after 120µL addition. 
This pH may be too acidic and risk 
hydrolysing compounds. Also need to 
account for effect of buffer required for β-
glucuronidase activity. 
Extraction of bases improved.
3. Determine 
extraction from 
plasma
4. Improve extraction- 
precipitate protein
5. Incorporate buffer 
for  β-glucuronidase 
activity
6. Improve extraction 
of bases
Experiment FindingsAim Implication Key Graphs
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Previous experiment repeated using pH 4, 
7 and 10 buffer containing all probes at 
10µg/mL. Also included Chloroform/2-
Propanol 9:1 mixture (P) also commonly 
reported. 
500µL of spiked plasma added to 1mL of 
NaAc buffer. Four samples have 500µL 
DCM added, another four have 500µL 
CLP added. Solvents extracted. 120µL 
NaOH added to remaining aqueous 
solution and solvents crossed over for the 
second extraction to give the following 
combinations (1
st
-2
nd
): DCM-CLP, DCM-
DCM, CLP-CLP, CLP-DCM. Organics 
evaporated in Turbovap at 40°C for 45min 
and reconstituted in ACN.
Repeated previous experiment using 
either acetonitrile or methanol as 
reconstituting solvent in final step. 
ACN chosen as reconstituting solvent.
Would using acetonitrile (ACN) or 
methanol (MeOH) (commonly used for 
protein precipitation) as reconstituting 
solvent cause these proteins to precipitate, 
making them easier to avoid when 
pipetting?
Both sets of samples free of protein. 
Reconstitution with ACN gives clearer 
solution.
Access to Turbovap. All samples now in triplicate instead of 
duplicate.
 ?Some effect of plasma on 6CZX and DX 
preventing extraction. Go back to aqueous 
samples to get better assessment of the 
effect of pH on their extraction- ?buffering 
capacity of plasma or protein binding 
making 6CZX and DX extraction difficult to 
assess.
Peak fronting in chromatograms impairing 
integration- ?as a result of using ACN to 
reconstitute evaporation residue. 
CLP now an option again (took too long to 
evaporate by hand). 
8. Determine 
superiority of DCM or 
CLP CLP generally superior over DCM at 
extraction especially for bases following 
addition of NaOH. 
Extraction still mostly ≤65%. 6CZX not 
found in any sample, DX<10%.  
Reduce injection volume.
DEE vastly superior for extraction of acidic 
compounds. 
Compounds in much lower concentrations 
than controls- compounds are leaving 
sample- ?Problem with reconstitution.
Reconstitute in mobile phase removes 
peak fronting.
Recovery poor in all samples. Examine left 
over aqueous samples after extraction- 
lower 6CZX or DX concentration indicates 
better extraction.
Reducing pH to 4 in previous experiment 
increases extraction of 6CZX. Does 
repeating previous experiment using 
phosphate buffer of pH2.9 further improve 
recovery? Method as previous but 
reconstituted mobile phase. 
6CZX and DX spiked into buffer 0.5mL pH 
4, 7, 10 buffers to give 10µg/mL. Each 
sample extracted with 0.5mL of one of 
three solvents, DEE, DCM and CLP. 
Solvents extracted and evaporated and 
reconstituted in ACN.
DX extracted best at pH 10 into CLP.
 6CZX extracted best at pH 4 into DEE.
9. Improve extraction 
of 6CZX and DX
10. Improve extraction 
of 6CZX
Lowering pH 4.75 to 2.9 does not improve 
recovery of 6CZX.
Stick with chloroform rich mixture.
DX extracts best into CLP or DEE at pH 
10.
pH achieved by additional NaAc buffer 
sufficient for extraction of acids. 
1MDZ; best at high pH, no strong impact of solvent. Extracting 50-70%
6CZX; strong effect of pH, 4≥7>>10, solvent DEE (70%)>CLP (50%)>>DCM (24%)
CA; Small pH effect, 4<7<10, strong effect of solvent  P; (83%)>CLP (81%)>DCM (67%), DEE (10%)
CZX; Strong pH effect 10>>7≈4, some solvent  effect P (83%)=CLP (83%)>DCM (76%)>DEE(62%)
DM; solvent effect increases with pH. Best extraction at high pH. CLP=P (83%)> DCM (68%)> DEE (56%)
DX; Strong effect of pH 10>>>7=4. No solvent effect P (86%)≥ CLP (84%)≥ DEE (83%)≥ DCM (81%)
MDZ; pH effect varies with solvent. DEE best at pH 10 (81%), other solvents do not vary with pH (≈60%)
PX; Strong pH effect 4>7>>10. Strong solvent effect P (53%)≥CLP (50%)>>DCM (24%)>>DEE (5%)
PH; Small effect of pH 4≥7≥10. Moderate solvent effect P (82%)≥CLP (81%)>DCM (72%)>DEE (51%).
Chloroform/2-Propanol mixtures have ≈ 
extraction. 9:1 mix takes longer to 
evaporate. Recovery still ≤65%.11. Determine effect 
of pH
Centrifuge samples at 14000RPM for 
10min to try and solidify precipitant.
No change to precipipant.
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Adding DEE does not improve extraction. 
Erroneously first extraction with CLP has 
superior yield to DEE+CLP as if DEE 
impaired extraction. This experiment was 
repeated and results confirmed.
DEE does not add to the extraction as the 
first step.
240µL required.Advised that pH7 would be optimal for 
allowing all compounds to simultaneously 
extract into solvent. What volume of 1M 
phosphate buffer  pH 7.6 (PO4) would be 
sufficient to neutralise 500µL of 0.2 NaAc 
buffer?
6CZX extracts especially poorly
250µL NaAc buffer containing all 
compounds at 10µg/mL added to 250µL of 
either CLP or DEE. Extract organic. Add 
120µL PO4 and a further 250µL CLP to all 
samples. Add 120µL NaOH followed by a 
further 250µL CLP.
Concern over DX extraction and variation 
of pH after addition of fixed volume of 
NaOH. Would a buffer help?
K2HPO4/KH2PO4 buffer was used because 
it also has buffer activity upon addition of 
NaOH at pH10-12. Add middle extraction 
for weak acids/bases. 
13. Determine 
superiority of CLP or 
DEE
12. Neutralise sample
14. Improve extraction 
of bases
To scale up method to 500µL of plasma 
was exceed capacity of 2mL eppendorf. 
Can volume of additions be reduced?
Drop PCA from the proceedure (risk of 
hydrolysis compounds).
Use MeOH to reconstitute evaporation 
residue.
Remove DEE from final extraction.Negligible amounts found in final DEE 
extraction.
White precipitate still forms between PO4 
and NaOH addition.
MeOH markedly improves recovery >90%, 
except for 6CZX , and does not alter peak 
shape.
Reconstitution of evaporation residue in 
mobile phase compared to reconstitution 
in MeOH.  125µL water containing all 
probes 10µg/mL added to 125µL NaAc 
and PCA 10µL. 250µL CLP added and 
extracted followed by 120µL of PO4 and a 
further 250µL CLP added and extracted. 
30µL NaOH then added followed by 
addition and extraction of another 250µL 
CLP and lastly the addition and extraction 
of 250µL DEE. Two sets of triplicate 
samples produced; 1 set reconstituted in 
mobile phase, the other in MeOH.
Some compounds have poor aqueous 
solubility, but all have good solubility in 
MeOH. 
All samples now mixed for 10min at 
1400RPM.
?Precipitant from buffers (note no plasma 
present in sample unlike earlier 
experiment that noted this problem). Try 
adding small volume of PCA.
White precipitate making uncontaminated 
removal of extraction solvent difficult. 
Reduced variation between replicate 
samples with longer mixing.
Caffeine and Paraxanthine show strong 
relationship with mixing time, with greater 
extraction on longer mixing. Other 
compounds show no improvement.
250µL water containing all probes to 10µg/
mL added to 250µL NaAc buffer. 250µL 
CLP added and extracted. 250µL PO4 was 
added followed by addition and extraction 
of 250µL CLP. 50µL NaOH was added 
followed by a further addition and 
extraction of 250µL CLP. Sample were 
either vortex mixed for 30 seconds or 
shaken at 1400RPM for either 1min or 
10min. 
In one set of samples a shaker was used 
instead of a vortex. This greatly improved 
extraction.
Only small amounts of DX and DM came 
out in DEE. No other compound found in 
thrid extraction. Need to change from 
DEE?
Average recovery:
1MDZ; 61%
6CZX; 32%
CA; 76%
CZX; 69%
DM; 72%
DX; 66%
MDZ; 55%
PX; 38%
PH; 77%.
Extraction of 6CZX and PX main issues. Incorporate base prior to final extraction to 
increase extraction of basic compounds.
250µL NaAc buffer containing all 
compounds at 10µg/mL added to 250µL of 
CLP. Extract organic. Add 120µL PO4 and 
a further 250µL CLP. Extract organic. Add 
50µL of 4M NaOH and 250µL DEE. 
Extract organic. Evaporate and 
reconstitute in mobile phase.
15. Compare mixing 
methods
16. Does using 
methanol to 
reconstitute 
evaporation residue 
improve extraction?
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Reintroduce DEE earlier in process for 
6CZX and PX extraction.
No major effect.Does concentration of drugs influence 
their extraction? Prepare 100µL plasma 
samples containing PX and CZX at 
concentrations of 10, 5, 1, 0.5, 0.1µg/mL. 
Add 100µL NaAc, 6µL PCA, 200µL CLP. 
Extract CLP, evaporate and reconstitute in 
100µL MeOH. 
6CZX extraction <60%.Alter initial HPLC conditions and gradient 
to improve resolution of 6CZX and DX.
Plasma reduces recovery to >70%, except 
for 6CZX and PX at <45%.
DX and DM show better extraction from 
water. All other compounds difference 
≤5%.
For 500µL plasma and 500µL NaAc 
volume of 1M PO4 required for pH 7-8 = 
400µL. To increase pH 10-12 with 4M 
NaOH volume required 80µL.
Volumes of PO4 and NaOH required 
checked
Two sets of samples run 1) 500µL plasma 
spiked to 10µg/mL 2) 500µL water spiked 
to 10µg/mL. Each added to 500µL NaAc 
and 30µL PCA followed by addition and 
extraction of 1mL CLP. 400µL PO4 added 
followed by addition and extraction of 
500µL CLP. 80µL NaOH then added 
followed by final addition and extraction of 
500µL of CLP. Reconstitute evaporation 
residue in MeOH.
?DX and DM extraction effected by buffers 
in plasma- pH not manipulated as much as 
in water- based samples.
Extraction of  6CZX and PX now only 
problems.
Large solvent volume only important when 
PX extraction occurs (first extraction).
PX proportional to solvent volume, PX 
most hydrophilic. Others not affected.
125µL of water spiked to 10µg/mL of all 
compounds added to 125µL NaAc. 
Extraction with either 125, 250 or 500µL of 
CLP. 120µL PO4 added followed by repeat 
extraction using previous volume. 30µL of 
NaOH added along with a final extraction 
of CLP with the same volume. Evaporation 
residue reconstituted in MeOH.
17. Role of solvent 
volume
18. Examine effect of 
plasma
19. Examine effect of 
compound 
concentration
20. Improve PX and 
6CZX extraction
Changes to mixing and reconstitution 
procedures have improved recovery.
Most compounds extracting 65-90%- Only 
DX extracts poorly at 40% but only one 
extraction- no added base in this 
experiment.
?affinity of DEE for 6CZX strong, needing 
less than 250µL for extraction.
Other compounds, do not show any 
significant effect on changing ratio of 
solvent.
CA and PX rely on CLP for extraction and 
extract poorly into DEE.
Both CA and PX show strong relationship 
with CLP volume, with extraction 
decreasing as CLP volume decreases.
Repeat using plasma containing all 
probes.
Discovered in literature- PCA known to 
reduce recovery through binding to 
precipitating protein. ACN does not do 
this. Try ACN instead.
?Volume of DEE required >>750µL.
Increasing DEE component did not alter 
6CZX extraction.
?More as a result of reducing CLP volume.
Increasing DEE component reduces PX 
extraction.
Organic layer from 750µL and 500µL 
additions of CLP form subnatant, 250µL 
addition forms supernatant. 
3 sets of 250µL plasma containing 10µg/
mL PX and 6CZX added to 250µL NaAc 
and 15µL PCA. Each set had one of the 
solvent combinations added and 
extracted: 750µL CLP+250µL DEE; 500µL 
CLP+500µL DEE; 250µL CLP+750µL 
DEE. 
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ACN seems to partition with organics, 
increasing organic volume to 1100µL from 
first extraction.
125µL plasma containing all compounds 
added to 125µL NaAc followed by 250µL 
ACN or 10µL PCA. 750µL and 125µL DEE 
added to both samples and extracted 
followed by 100µL PO4. 500µL CLP then 
added and extracted followed by 25µL 
NaOH and a final addition and extraction 
of 500µL CLP.
Recovery increases overall by ≈ 10%.
Replace PCA with ACN as precipitant.Both volumes of ACN provide acceptable 
protein precipitation. 
125µL of plasma spiked with all 
compounds to 10µg/mL added to 125µL 
NaAc in two sets. First set has ACN 250µL 
added, second has 500µL. Both followed 
by 250µL CLP which is extracted and 
evaporated. 
21. Improve PX and 
6CZX extraction- use 
ACN as precipitant
22. Compare ACN to 
PCA
Repeat above with 1mL of CLP at both 
extractions.
Method does not have same total volume 
of CLP- did not account for CLP from 
second extraction in previous method.
Would a two extraction method without 
addition of buffer be equivalent?
125µL plasma containing all compounds 
added to 125µL NaAc followed by 250µL 
ACN and 750µL CLP and 125µL DEE. 
Organics extracted. 25µL NaOH added 
followed by addition and extraction of 
750µL CLP.
ACN improves extraction 5-20% for all 
compounds except CA which ≈.
?PCA causes buffer salts to precipitate. 
?Can this step be removed.
Following centrifugation immediately prior 
to removal of second set of organic ?white 
crystals seen at bottom of sample tube 
where PCA was used as precipitant.
?Removal of ACN with organic in first 
extraction allows proteins to re-suspend. 
Proteins appear almost dissolved and do 
not contaminate pippette tip.
Following addition of organic for second 
extraction protein pellet dispersed into 
aqueous phase- this occurred more 
prominently in with ACN samples.
Protein precipitation of both precipitants 
adequate.
Average recovery with ACN as precipitant:
1MDZ; 95%
6CZX; 91%
CA; 80%
CZX; 96%
DM; 92%
DX; 88%
MDZ; 92%
PX; 77%
PH; 88%.
23. Simplify method
Average recovery with two extractions:
CA; 63%
PX; 58%
All other compound extraction >75%.
Average recovery improves:
CA; 68%
PX; 70%
All other compound extraction >75%.
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Confirms earlier results when mixed with 
CLP. DEE has strong extraction for 6CZX.
Increasing DEE does not improve 
extraction.
Conditions for β-glucuronidase activity 
checked. 
?Saturation of solvent at lower volumes, 
?at larger solvent volumes mixing may be 
less efficient.
Recovery from 1000µL<<2x 500µL 
recovery. 
Repeat previous experiment with 500µLx2 
vs 1000µL and 750µLx2 vs 1500µL 
volumes of CLP.
May not be transferable to larger solvent 
volumes- ?solvents saturated at these 
lower volumes. Need to examine effects of 
larger volumes.
Repeated extraction does not significantly 
improve recovery over single extraction of 
equivalent volume at these volumes 
(2x250µL≈1x500µL).
Recovery increases with increasing 
solvent volume but effect tails off so 
750µL≈1000µL, except for PX which 
shows linear relationship from 20% up to 
≈60%.
Is there and effect of solvent volume- is 
2x250µL extractions superior to 1x500µL? 
Five sets of 125µL spiked plasma (10µg/
mL) were prepared. 125µL NaAc and 
250µL ACN added to each. One of the 
CLP volumes added to each set 250µL, 
250µL followed by another 250µL, 500µL, 
750µL, 1000µL. Solvents extracted, 
evaporated and reconstituted in MeOH.
24. Improve PX and 
6CZX extraction- CLP 
volume
Four sets of samples increasing to 500µL 
plasma. Add 100µL 2M NaAc, 500µL 
ACN, 800µL CLP. To each set add 25, 50 
or 100µL DEE. Organic phase extracted 
and reconstitute in 500µL MeOH.
In most cases extraction did not improve 
by increasing solvent volume about 
6xsample volume, except for paraxanthine 
which continued to improve but tailed off 
after solvent volumes exceed 6xsample 
volume.
25. Optimise DEE 
volume
All compounds extract >80%.
Use 250µL CLP in final extraction. Add 
remaining solvent to second extraction 
(cannot be added to first extraction as the 
would exceed sample tube capacity).
No significant difference between 500µL 
and 250µL CLP volumes.
Only 1MDZ and DX affected by reduction 
in final CLP extraction, DX mostly, 
reducing only ≈10% across range 500µL 
to 50µL range. 
Only compounds that extract in basic 
conditions are 1MDZ and DX. Only very 
small amount of 6CZX, CA, CZX, DM, 
MDZ and PH are seen in final extraction.
Four sets of 500µL plasma containing all 
compounds 10µg/mL. 100µL 2M NaAc 
added along with 500µL ACN 450µL CLP 
and 25µL DEE. Organic phase extracted 
and a further 550µL CLP added and 
extracted followed by the addition of 
100µL NaOH. To each set of samples a 
final 500, 250, 100 or 50µL CLP was 
added and extracted. 
PX extraction dependent on CLP volume- 
is third extraction necessary again?
Constraints: Turbovap cannot evaporate 
organic volumes >2mL… ACN partitioning 
into organic phase so total extraction 
solvent must be <1.5mL.
Average recovery reduces:
PX; 51%.
26. Reintroduce 
middle extraction
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Lower MeOH content samples have 
symmetrical peaks.
Reducing MeOH content reduces recovery 
by 5-10%.
Repeat method in two sets. Process both 
sets the same until the final step. Dissolve 
evaporation residue of one set in MeOH 
and the second set in MeOH/water 50:50. 
Column on LCMS much shorter than 
previously used. The shorter column does 
not allow for the same degree of mixing 
and suspect the MeOH base of the sample 
is carrying the compounds through the 
column- causing the peak fronting. Try 
reducing MeOH content in solution that 
dissolves evaporation residue.
Extraction good by peak fronting impairs 
integration.
Samples prepared as above- different 
column used in LCMS.
Final method:
500µL plasma added to a 2mL eppendorf tube. 
100µL 2M NaAc containing 2000u β-glucuronidase was added, vortex mixed for 30 seconds and incubated overnight in a shaker oven at 37°C and 40RPM.
500µL ACN with 10µg/mL internal standard PH was added at end of incubation
450µL CLP and 25µL DEE was added and mixed for 10minutes at 1400 RPM and then centrifuged at 14000 RPM for 10 minutes. All of organic phase was removed
A further 800µL CLP was added and extracted as above. 
To remaining aqueous sample 100µL NaOH and a final 500µL CLP was added and organic layer extracted. 
All organics extracted were combined into a 2mL eppendorf and evaporated to dryness in a Turbovap under a gentle stream of nitrogen in a water bath at 40°C
To residue 250µL of MeOH was added and sonicated for 10minutes followed by mixing at 1400RPM for a further 10minutes.
27. Confirm final 
method
28. Stop peak fronting
Use MeOH/water 50:50 to dissolve 
samples.
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2.5.2.5 Β-GLUCURONIDASE ACTIVITY 
Once the extraction method had been finalised, the last the step in the development of this sample preparation was the optimisation of glucuronide 
deconjugation. As discussed in Section 2.5.1, some of the analytes are extensively glucuronidated in vivo as part of their metabolism and elimination 
processes. Glucuronide moieties conjugated to analytes alter their m/z and this would affect their detection by LCMS. As it was intended to 
quantitate these analytes it was necessary to ensure complete deconjugation of the glucuronide. Section 2.5.1 also contains the justification for the 
use of β-glucuronidase for this deconjugation. Like many hydrolytic enzymes, β-glucuronidase requires specific conditions for optimal activity; chiefly 
amongst these are pH 4.5-5 and temperature of 37°C for molluskan sources (Appendix 14). Control of pH was achieved by dissolving the β-
glucuronidase powder in 2M acetate buffer adjusted to pH4.75. Acetate buffer was chosen as it had good buffering capacity around the pH range 
required for β-glucuronidase activity and, following addition of NaOH, a secondary buffering capacity around pH 10. This alkali environment was 
desirable in the latter stages of the extraction method described above. Temperature was maintained by incubating the samples in a shaker oven at 
37°C. Other factors requiring optimisation included:  
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 Ratio of buffer: sample volume; 
 Effect of substrate concentration; 
 Whether activity was dependent on amount of β-glucuronidase or its concentration; 
 Amount of β-glucuronidase per sample; 
 Temperature of incubation; and 
 Length of incubation. 
The optimisation of these factors used the only analytical glucuronide conjugate readily available, paracetamol glucuronide, as analytical glucuronide 
conjugates of the probe drugs/metabolites are not commercially available. The hydrolysis of paracetamol glucuronide back to paracetamol was 
achieved by incubation with freshly prepared solutions of β-glucuronidase (20000u (10.38mg)/mL 2M acetate buffer, pH 4.75). β-glucuronidase was 
freshly prepared with each experiment because the hydrolytic activity of the enzyme was not stable (Kaushik et al. 2006). Both paracetamol and 
paracetamol glucuronide were detected using the assay previously described (Section 2.2) and complete conversion was deemed to have occurred 
when no paracetamol glucuronide was found. All samples were prepared in triplicate along with controls containing acetate buffer without the 
addition of β-glucuronidase. A summary of the method development is shown in Table 2.5-4. This resulted in the overnight incubation of 1000u β-
glucuronidase in 100µL of 2M acetate buffer per 500µL patient plasma sample. Three measures were taken to ensure these deconjugation reaction 
conditions would achieve complete hydrolysis of the probe drugs/metabolites in the actual patient samples: 
 The concentration of paracetamol glucuronide used in this method development was 10-100 fold greater (100µg/mL) than the sum of probe 
drugs/metabolites under investigation in the patient samples; 
 The amount of β-glucuronidase included in the patient samples was at least five times more than was required to fully hydrolyse these more 
concentrated 100µg/mL of paracetamol glucuronide samples; and 
 The period of incubation used (overnight) was at least three times longer than that necessary for the complete deconjugation of the 
100µg/mL of paracetamol glucuronide samples. 
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Table 2.5-4 Summary of experiments to optimise β-glucuronidase activity (abbreviations as in previous figure) 
1. Optimise conditions 
for β-glucuronidase 
activity
Oven did not heat. As all samples in 
triplicate run one of three of each set. 
Incubate other two of each set for a further 
8 hours and run.
Six sets of 100µL plasma samples spiked 
with 100, 50, 10, 5, 1 and 0.5µg/mL of PG. 
50µL BG added to all samples. Samples 
vortex mixed and incubated overnight in 
shaker oven overnight at 37°C. At end of 
incubation 10µL PCA added, mixed and 
centrifuged, supernatant injected.
Concentration of P proportional to dilution 
by additional NaAc.
2:1 ratio of sample:NaAc sufficient to 
achieve pH within enzyme activity limits.
No influence of NaAc volume on 
deglucuronidation.
No PG found in samples- No P present in 
controls.
Three samples sets of 100µL plasma 
containing 10µg/mL PG added to 50µL of 
BG. To two sets of samples an additional 
50 or 150µL of NaAc added. Samples 
incubated in shaker oven overnight at 
37°C. 10µL PCA added, samples vortex 
mixed for 30seconds and centrifuged. 
Supernatant injected. 
Activity determined using conversion of 
paracetamol glucuronide (PG) to 
paracetamol (P). 1000u β-glucuronidase 
dissolved in 50µL NaAC (BG).
No PG present in all incubated samples 
regardless of PG concentration.
All unincubated samples had poor β-
glucuronidase activity. 
No advantage incubating samples beyond 
5 hours. 
1-3 hour samples have almost complete 
deconjugation but some variation. 5 and 
18 hour sample have complete 
deconjugation in all samples. 
Five sets of 100µL plasma containing PG 
100µg/mL. 50µL BG added and mixed. 
Incubate each set in shaker oven at 37°C 
for 1, 2, 3, 5 and 18hrs. At end of 
incubation 10µL PCA added, mixed and 
centrifuged, supernatant injected. 
All samples converted all PG to P.
BG very potent. Suspect carryover of BG 
from pipette tip while pipette NaAc 
sufficient to convert PG to P.
100µL of plasma containing PG 100µg/
mL. Add BG 50, 40, 30, 20, 10, 0µL made 
up to 50µL with NaAc. Samples vortex 
mixed and incubated overnight in shaker 
oven overnight at 37°C. At end of 
incubation 10µL PCA added, mixed and 
centrifuged, supernatant injected. 
Even samples with no BG added 
converted all PG to P. Controls all PG as 
normal.
Volume of sample did not overcome β-
glucuronidase activity. 
Three sets of 50µL BG and 25µL PG 1mg/
mL added to 75, 225 or 475µL plasma. 
Samples vortex mixed and incubated 
overnight in shaker oven overnight at 
37°C. At end of incubation 10µL PCA 
added, mixed and centrifuged, 
supernatant injected.
Temperature critical to β-glucuronidase 
activity.
2. Determine effect of 
NaAc volume
3. Determine effect of 
PG concentration- 
and duration of 
incubation
4. Determine effect of 
plasma volume on β-
glucuronidase activity
5. Determine effect of 
varying amount of β-
glucuronidase
6. Determine effect of 
incubation time on β-
glucuronidase activity
Experiment FindingsAim Implication
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2.5.3 PATIENT SAMPLES 
Once the extraction method was shown to be successful the analysis was transferred to 
the LCMS for the analysis of patient samples. 
2.5.3.1 MATERIALS 
Materials used for the method development were also used for the analysis of patient 
samples. In addition Fisher Optima® LC/MS grade water and acetonitrile were used in 
combination with Optima® LC/MS grade formic acid (Fisher Scientific, Leicestershire, UK) 
as the mobile phase for the LC/MS. 
2.5.3.2 APPARATUS 
Apparatus used for the method development were also used for the analysis of patient 
samples. In addition, the analysis of patient samples was conducted using an Agilent 1200 
HPLC attached to Agilent 1200 series DAD SL detector and a Agilent 6510 Quadrupole 
time-of-flight (Q-TOF) mass spectrometer, with an electron spray ionisation (ESI) ion 
source (Agilent Technologies, Massachusetts, USA). Data were acquired on Agilent Mass 
Hunter workstation Acquisition 2.00, analysed on Agilent Mass Hunter workstation 
Qualitative Analysis 2.00 and quantitated using Agilent Mass Hunter workstation 
Quantitative Analysis 2.00.  
2.5.3.3 CHROMATOGRAPHIC CONDITIONS 
Separation was performed on an Agilent XDB C18, 1.8um, 4.6x50mm column, heated on 
the heating block to 35°C. A linear gradient method was employed using 95% water 5% 
acetonitrile 0.1% formic acid (A) and 95% acetonitrile 5% water 0.1% formic acid (B) as 
shown in Table 2.5-5. Solvents are often premixed in LCMS systems to prevent use of 
100% acetonitrile, which can damage and occlude the narrow bore tubing utilised in 
LCMS systems. 
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Table 2.5-5 Chromatographic conditions for LCMS assay 
Time %B Flow rate (mL/min) 
0.75 7.0 0.600 
3.00 25.0 0.600 
5.00 30.0 0.600 
7.00 30.0 0.600 
7.50 90.0 0.600 
9.00 90.0 0.600 
9.50 7.0 0.600 
2.5.3.4 SAMPLE PREPARATION 
Polypropylene 1.5mL and 2.0mL Eppendorf tubes and 50mL sample tubes (Sarstedt, 
Nümbrecht, Germany) were used for all sample preparation. Samples were inserted into 
HPLC sample vials containing 100µL low volume inserts (Fisher Scientific, Dublin, Ireland). 
Reference samples of nominal concentration were prepared in Solvent A. The Injection 
volume was 10µL. 
2.5.3.5 MASS SPECTROMETER PARAMETERS 
The parameters of the mass spectrometer were optimised for the detection of the 
analytes of interest. As the mass of these analytes was known, acquisition was in MS 
mode only in the m/z range of 100-1000. This causes the instrument to behave as a TOF, 
selecting ions in the desired m/z range without fragmentation in the collision cell. 
Initially the effects of changes to drying gas flow rate on the detector response were 
examined. Drying gas flow rate will affect the ionisation of the sample as it leaves the 
nebuliser. Each analyte was prepared in diluent to 0.1mg/L. 6L was chosen as the ideal 
flow rate (Figure 2.5-3), however, this caused condensation inside the ESI unit. After 
attempts to prevent this by reducing the mobile phase flow rate were unsuccessful, a gas 
flow of 10L/min was chosen as a compromise.  
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Figure 2.5-3 Effect of drying gas flow rate on LCMS detector response 
Shown as mean +standard deviation from 1mg/L sample in diluent 
Due to time constraints only midazolam response was optimised further as it was 
expected to be in the lowest concentration. The remaining conditions role and optimal 
status were as follows:  
 Gas temperature effects ionisation in the ESI. There was very little difference 
across the temperatures assessed with the optimal being 340°C (Figure 2.5-4). 
 
Figure 2.5-4 Effect of drying gas temperature on detector response 
Shown as mean +standard deviation from 1mg/L sample in diluent 
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 Capillary voltage provides the pull of charged ions from the earthed ESI unit into 
the charged MS capillary. There was only minor change and 4000V was chosen 
(Figure 2.5-5). 
 
Figure 2.5-5 Effect of capillary voltage on detector response 
Shown as mean +standard deviation from 0.1mg/L sample in diluent 
 Fragmentor voltage in TOF only mode determines the energy applied to the ion 
stream to exclude ions outside the chosen m/z range. It was selected as 210V. 
 
Figure 2.5-6 Effect of fragmentor voltage on detector response 
Shown as mean +standard deviation from 0.1mg/L sample in diluent 
Additional settings were the rate of acquisition at 2 spectra/second and nebuliser 
pressure of 50 PSIG. 
 
 214 
 
  
 215 
 
3 RESULTS 
3.1 PATIENT DEMOGRAPHICS 
3.1.1 SUMMARY OF PATIENT DEMOGRAPHICS FOR ALL GROUPS 
Demographic information was collected from each group. The description of each group was given in Section 2.1.1. This information is summarised 
below in Table 3.1-1 and continued in Table 3.1-2. All groups were broadly similar in age, although Group A had the highest mean age (63.2±11.0yrs). 
Group C was the youngest (47.7±8.1yrs), reflecting the different diagnosis of this group. Group D was, on average, the youngest of the groups 
undergoing bowel surgery although this group had the largest standard deviation (Table 3.1-1). 
Table 3.1-1 Summary table of patient demographics 
Summary data are presented as mean and standard deviation (Mean (SD)) for continuous data, Count and per cent of group (Count (%)) for categorical data and median and interquartile range 
(Median (IQR)) for discrete, non-normal data. Other abbreviations: BMI- Body Mass Index; Drinker- broken down by number of self-reported standard drinks consumed per average week- “+” ≥1, 
<10/week; “++” ≥10, <20/week; “+++”≥20/week;  ancer- if malignancy was main indication for surgery. 
Group N Age (Years) 
Mean (SD) 
BMI (kg/m2) 
Mean (SD) 
Male 
Count (%) 
Smoker 
Count (%) 
Drinker 
Median (IQR) 
Cancer 
Count (%) 
A 10 63.2 (11.0) 28.6 (5.6) 8 (80) 0 (0) + (0,++) 10 (100) 
B 4 57.9 (3.3) 25.4 (2.4) 2 (50) 4 (100) + (+,+) 4 (100) 
C 8 47.7 (8.1) 23.3 (4.0) 0 1 (12.5) 0 (0,0) 8 (100) 
D 11 52.3 (20.9) 27.6 (4.3) 8 (72.7) 3 (27.3) + (0,++) 7 (63.6) 
Based on the BMI results, all the groups except for Group C could be classified as overweight (i.e. BMI>25 kg/m2). The average BMI of Group C (23.2 
kg/m2) was within the healthy weight range. In many cases the patients in Group C had completed courses of chemo or radiotherapy prior to 
enrolling in the study which may have resulted in weight loss prior to the study. The majority of the patients in the study were male, except for 
Group C, again reflecting the diagnosis of those in Group C. There were very few smokers in the study, with the exception of Group B in which all 
patients smoked. Patients did not smoke during the study itself as this was not permitted by the hospitals involved. There was a wide range of 
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alcohol consumption amongst the patients, with patients in Groups A and D having the highest average consumption. There were no drinkers in 
Group C. Unlike all the other groups, many of the patients in Group D had a diagnosis other than cancer as the main reason for surgery.  
Table 3.1-2 Summary table of patient demographics (continued) 
Other abbreviations (In addition to those used in the previous table) ASA status- (American Society of Anaesthesiologists (ASA) physical status 
Group Duration of Surgery (hr) 
Median (IQR) 
Number of preoperative medicines 
Median (IQR) 
ASA status 
Median (IQR) 
Total Paracetamol dose (g) 
Median (IQR) 
A 3 (2.5, 3.4) 2 (0, 7.5) 1.5 (1, 2) 42.5 (41.4, 43.6) 
B 2.25 (1.9, 2.5) 0 (0, 0.25) 1 (1, 1) 21 (21, 21) 
C 2.25 (2, 2.6) 0 (0, 0.25) 1 (1, 1.3) 21 (21, 21) 
D 5 (4.6,5.6) 0 (0, 2.5) 1 (1, 2) 20 (19.5, 20) 
Group D had the longest surgery time (median 5 hrs; IQR 4.6-5.6), reflecting the more time consuming nature of laparoscopic surgery undergone by 
the majority of this group, whereas Groups A, B and C were broadly similar in duration of surgery (Table 3.1-2). Group A had the highest number of 
preoperative medicines (median 2; IQR 0-7.5) which is also reflected in their higher median ASA status. No medicines taken preoperatively were 
known to alter paracetamol metabolism. During the course of the study, Group A had twice the amount of paracetamol than the other groups. This is 
slightly less than may be anticipated given the dosing schedules for each group, however, the median for Group A (42.5; IQR 41.4-43.6) was brought 
down by the first patient who was withdrawn from the study early.  
As discussed in Section 2.1, reconfiguration of surgical services ended bowel resections at the first hospital. To continue collection bowel resection 
patients the study was moved to a second hospital (Hospital 2). Groups A, B and C were recruited from Hospital 1, whereas Group D was from 
Hospital 2. 
3.1.2 PATIENT DEMOGRAPHICS OF GROUP A 
Group A consisted of 10 patients undergoing major bowel resection. The demographics of this group are detailed in Table 3.1-3.  
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Table 3.1-3 Group A Patient demographics 
Presented as mean and standard deviation (SD), number and per cent (%) of group or median and interquartile range (IQR) as indicated. All other abbreviations are as in previous tables.  
Patient Age Sex Weight (kg) Height (m) BMI (kg/m2) Cancer Smoker Drinker Pre-op 
medications 
ASA status 
1A 87 M 96 1.8 29.63 Y N N 9 2 
2A 65 F 87 1.64 32.35 Y N N 3 2 
3A 67 M 129 1.78 40.71 Y N ++ 6 2 
4A 62 M 83 1.63 31.24 Y N + 9 2 
5A 52 M 92 1.85 26.88 Y N +++ 1 2 
6A 73 F 58 1.62 22.10 Y N N 8 1 
7A 58 M 67 1.69 23.46 Y N ++ 0 1 
8A 54 M 89 1.71 30.44 Y N N 0 1 
9A 51 M 68 1.68 24.09 Y N +++ 0 1 
10A 58 M 79 1.79 24.66 Y N + 2 1 
Mean (SD) 63.2 (11)  84.8 (19.7) 1.71 (0.08) 28.56 (5.57)      
Count (%)      10 (100) 0 (0)    
Median (IQR)        + (++) 2 (0, 7.5) 1.5 (1, 2) 
This group received the high dose of paracetamol, 1.5g every four hours. The majority of all patients were male (80%) and aside from patients 1 and 
6, all patients were aged in their 50’s and 60’s. This is younger than expected from the data given by the National Cancer Registry of Ireland for 
colorectal cancer patients (National Cancer Registry Ireland 2010). BMI varied widely amongst the group, with six being overweight and four of these 
being classified obese. All patients in this group had a malignancy as their main indication for surgery. None were smokers but two were heavy 
drinkers. There was also a wide range in the number of preoperative medicines, which in most cases was reflected in a higher ASA status (Table 
3.1-3). 
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Table 3.1-4 Group A patient demographics (continued) 
All abbreviations explained in previous tables 
Patient Main Procedure Duration of Surgery (hr) Paracetamol dose (g) Plasma Samples Urine Samples 
1A Transverse colectomy 3.5 11 16 16 
2A Extended hemicolectomy 2 44 24 37 
3A Anterior resection 3 39.5 26 30 
4A Anterior resection 5 41 26 33 
5A Anterior resection 3 42.5 26 32 
6A Left hemicolectomy 1.5 41 24 31 
7A Anterior resection 3 41 25 31 
8A Left hemicolectomy 2.5 41 11 27 
9A AP resection 2.5 42.5 21 35 
10A AP resection 4.5 36.5 18 28 
Median (IQR)  3 (2.5, 3.4) 42.5 (41.4, 43.6) 24 (19, 26) 31 (29, 33) 
The majority of surgery involved an anterior resection, followed by colectomies (Table 3.1-4). The full set of plasma samples was collected from the 
majority of the patients in this group with the exception of patients 1 and 10 who withdrew from the study early for reasons given in Table 3.1-11. 
The majority of patients in this group had central lines which were also used for obtaining blood samples. Complete urine collections were also 
obtained in 9 of the 10 cases in this group from urinary catheters which were present for the duration of the study for all patients. Although not 
recorded, the majority of these patients were not ambulating until Day 3 or 4, remaining on complete bed-rest until then. Most were fasted until the 
third day when a light diet of soup and ice cream was commenced. All patients remained in the ICU until at least the evening of Day 3, where they 
received one-to-one nursing care.  
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3.1.3 PATIENT DEMOGRAPHICS OF GROUP B 
Group B consisted of four patients undergoing the same surgical procedures as Group A, but receiving the licensed dose of intravenous paracetamol, 
1g every six hours. The reconfiguration of regional surgical services ended recruitment into this group prematurely and consequently, only four 
patients were recruited (Table 3.1-5). This group was also younger that the national average (57.9±3.3 yrs) (National Cancer Registry Ireland 2010) 
and closer to the healthy range of BMI with less variation than Group A. All had a malignancy as their primary indication for surgery and all were 
smokers. There was a low rate of alcohol consumption amongst all in this group and they had a lower average ASA status than Group A (Table 3.1-5). 
Table 3.1-5 Group B Patient demographics 
All abbreviations explained in previous tables 
Patient Age Sex Weight(Kg) Height(m) BMI(kg/m2) Cancer Smoker Drinker Pre-op 
medications 
ASA status 
1B 60 M 79 1.78 24.93 Y Y + 0 1 
2B 61 F 64 1.68 22.68 Y Y + 1 1 
3B 54 M 87 1.85 25.42 Y Y + 0 1 
4B 55 F 87 1.75 28.41 Y Y + 0 1 
Mean (SD) 57.9 (3.3)  79.3 (10.8) 1.77 (0.07) 25.36 (2.36)      
Count (%)      4 (100%) 4 (100%)    
Median (IQR)        + (0) 0 (0, 0.25) 1 (1, 1) 
All of Group B required colectomy, with two additionally receiving a cholecystectomy. This was slightly above the national average (National Cancer 
Registry Ireland 2010) but being a small group it is difficult to apply to population trends. The duration of surgery was also shorter than for Group A. 
Patient 2 in this group did not consent to give blood samples but complete sets of blood and urine were obtained all other patients (Table 3.1-6) 
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Table 3.1-6 Group B patient demographics (continued) 
All abbreviations explained in previous tables 
Patient Surgery Duration of Surgery (hr) Paracetamol dose (g) Plasma Samples Urine Samples 
1B Left hemicolectomy, cholecystectomy 1.75 20 19 30 
2B Sigmoid colectomy, cholecystectomy 2 20 - 29 
3B Left hemicolectomy 2.5 20 21 31 
4B Right hemicolectomy 2.5 20 21 30 
Median (IQR)  2.25 (1.9, 2.5) 21 (21, 21) 20 (14, 21) 30 (29.7, 30.3) 
3.1.4 PATIENT DEMOGRAPHICS OF GROUP C 
Group C contained patients undergoing mastectomy who received the licensed dose of paracetamol of 1g every six hours. The mean age 
(47.7±8.1yrs) of this group was younger than all other groups and younger than the national average of those with breast cancer (Table 3.1-7). They 
were all female. The mean BMI (23.27kg/m2) was within the healthy range as were all patients except for one obese patient. Only one patient was a 
smoker, who was also a heavy drinker. Very few took medications preoperatively and only two were ASA 2. All patients except for patients 4 and 8 
received chemotherapy prior to their surgery. 
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Table 3.1-7 Group C Patient demographics 
All abbreviations explained in previous tables 
Patient Age Sex Weight (kg) Height (m) BMI (kg/m2) Cancer Smoker Drinker Pre-op medications ASA status 
1C 41 F 62.3 1.67 22.33 Y Y +++ 0 1 
2C 42 F 67.2 1.74 22.20 Y N N 0 1 
3C 45 F 72 1.67 25.82 Y N N 0 1 
4C 52 F 88 1.66 31.93 Y N N 1 2 
5C 64 F 54 1.67 19.36 Y N N 0 1 
6C 41 F 62 1.74 20.48 Y N N 4 2 
7C 52 F 63 1.67 22.59 Y N N 0 1 
8C 41 F 65 1.74 21.47 Y N N 0 1 
Mean (SD) 47.7 (8.1)  66.7 (10) 1.7 (0.1) 23.3 (4.0)      
Count (%)      8 (100) 1 (12.5)    
Median (IQR)        0 (0, 0) 0 (0, 0.25) 1 (1, 1.25) 
All patients underwent a mastectomy with all but one having concomitant axillary node clearances (Table 3.1-8). The duration of surgery varied from 
1.5 to 3 hours. While all patients received the full paracetamol doses, plasma collection was very problematic in this group as none of these patients 
had central lines postoperatively, and most being post-chemotherapy had poor venous access. Urine samples were also problematic as only a few 
patients had urinary catheters for longer than the first postoperative day and female patients had trouble collecting all of their own urine. 
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Table 3.1-8 Group C patient demographics (continued) 
All abbreviations explained in previous tables 
Patient Surgery Duration of Surgery (hr) Paracetamol dose (g) Plasma Samples Urine Samples 
1C Mastectomy, Axillary Node Clearance 2 20 22 13 
2C Mastectomy, Axillary Node Clearance 1.5 20 8 18 
3C Mastectomy, Axillary Node Clearance 2 20 6 19 
4C Mastectomy, Axillary Node Clearance 2 21 19 28 
5C Mastectomy, Axillary Node Clearance 3 20 12 27 
6C Mastectomy, Axillary Node Clearance 2.5 20 15 27 
7C Mastectomy, Axillary Node Clearance 3 20 6 13 
8C Mastectomy 2.5 20 - 7 
Median (IQR) 2.3 (2, 2.6) 21 (21, 21) 9 (5, 13) 20 (12, 27) 
3.1.5 PATIENT DEMOGRAPHICS OF GROUP D 
Group D was a continuation of Group B, being composed of patients undergoing colorectal surgery; however, as noted above, Group D patients were 
recruited from Hospital 2. Under a different surgeon there was a different approach to colorectal surgery. At Hospital 2 colorectal surgery patients 
underwent an enhanced recovery programme where they received high protein drinks supplements pre and post operatively and were returned to 
light diets the morning following surgery, if it was tolerated. Patients were also encouraged to ambulate on the day following surgery and as part of 
that tubing for IV lines and urinary catheters were removed on this or the second day. In addition, the majority of the procedures were laparoscopic. 
Similar to Groups A and B, the average age of this group was less than national averages (52.3±20.9 yr). The average BMI for the group was in the 
overweight range (27.63±11.76 kg/m2). Unlike all other groups, several of the patients who underwent surgery did not have malignant disease as the 
main indication for surgery. Few were smokers although several were alcohol drinkers. The number of preoperative medications also varied widely 
along with ASA status (Table 3.1-9). 
 223 
 
Table 3.1-9 Group D Patient demographics 
All abbreviations explained in previous tables 
Patient Age Sex Weight (kg) Height (m) BMI (kg/m2) Cancer Smoker Drinker Pre-op 
medications 
ASA 
status 
1D 42 M 58.9 1.67 21.12 N N N 0 1 
2D 61 M 93 1.74 30.72 N N ++ 9 2 
3D 60 M 65 1.68 23.03 N Y +++ 0 1 
4D 52 M 89 1.8 27.47 Y N ++ 3 2 
5D 52 F 74 1.68 26.22 Y N N 0 1 
6D 73 M 93 1.62 35.44 Y N N 0 1 
7D 33 F 90 1.66 32.66 N N + 10 2 
8D 65 M 82 1.72 27.72 Y Y ++ 0 1 
9D 70 M 69 1.72 23.32 Y Y + 2 2 
10D 66 M 73 1.67 26.18 Y N ++ 0 1 
11D 60 F 79 1.62 30.10 Y N N 0 1 
Mean (SD) 52.3 (20.9)  78.7 (11.8) 1.69 (0.1) 27.6 (4.3)      
Count (%)      7 (64%) 3 (27%)    
Median (IQR)        + (0,++) 0 (0, 2.5) 1 (1, 2) 
Similar to Group A there were a larger number of rectal cancers than would be expected in the general population although some of those in this 
group underwent this surgery for inflammatory bowel diseases or congenital malformation (Table 3.1-10). Being laparoscopic, these surgeries were 
of much longer duration than the open surgeries in Groups A and B (median (IQR) duration hours: Groups A and B 2.5 (2, 3.125), Group D 5 (4.5, 
5.75)). Obtaining plasma samples was also problematic as only two had central lines in place, however, for the most part, urine collections were 
successful. 
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Table 3.1-10 Group D patient demographics (continued) 
All abbreviations explained in previous tables 
Patient Surgery Duration of Surgery (hr) Paracetamol dose(g) Plasma Samples Urine Samples 
1D Sigmoid colectomy (open) 4.5 19 11 20 
2D Panproctocolectomy, hernia repair (lap) 5.75 18 24 22 
3D Anterior resection (lap) 4.75 19 22 27 
4D Anterior resection (lap) 4.25 19 20 24 
5D Anterior resection (lap) 5.5 19 6 18 
6D Anterior resection (lap) 5 19 6 25 
7D Sub-total colectomy (open) 5.5 19 6 20 
8D Anterior resection (lap) 4.5 19 25 23 
9D Anterior resection (lap) 6 18 6 13 
10D Anterior resection (lap) 6 18 24 21 
11D Anterior resection (lap) 4.75 19 15 24 
Median (IQR) (9 laparascopic, 2 open) 5 (4.5, 5.75) 20 (19.5, 20) 15 (6,23) 22 (20,24) 
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3.1.6 WITHDRAWALS AND COMPLICATIONS 
Table 3.1-11 details withdrawals and complications recorded during the study period. 
Only one patient withdrew consent for participating in the study due to unpleasant 
sensations and dreams that occurred following the administration of midazolam. The 
majority of patients who were withdrawn were as a result of poor venous access for 
blood sampling. Other patients were withdrawn due to nausea or vomiting that 
prevented the administration of the oral medicines used in the study and two were 
withdrawn for reduction in renal function (Table 3.1-11). 
Table 3.1-11 Withdrawals or complications 
Patient Complication 
1A Renal failure- withdrawn day 2 
8A Poor IV access- limited sampling post-op, no bloods day 4 
10A Unpleasant dreams following midazolam- withdrew day 4 
2B Consented for urine only- no bloods 
1C Dehydration post-op- urine not produced for some intervals 
2C Poor IV access- no bloods from day 2 
3C Poor IV access- no bloods post op 
5C Poor IV access- no bloods from day 2 
7C Poor IV access- no bloods post op 
8C Poor IV access- no bloods 
1D Poor IV access- no bloods from day 2 
5D Persistent nausea and vomiting- no bloods post op 
6D Renal failure post-op– withdrawn post op, urine collected 
7D Poor IV access- no bloods post op 
9D Poor IV access- no bloods post op 
11D Poor IV access- no bloods days 1 and 2 
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3.2 PARACETAMOL ANALYSIS VALIDATION 
3.2.1 PLASMA 
Chromatograms were obtained for all patient plasma samples. A sample chromatogram is 
shown in Figure 3.2-1. 
 
Figure 3.2-1 Sample chromatogram of absorbance of paracetamol and its metabolites in plasma  
Chromatogram is from injection of a plasma standard containing 20µg/mL of paracetamol and its metabolites captured 
at 242nm. The elution order and times (mins) were paracetamol glucuronide (6.82), paracetamol cysteine (9.47), 
paracetamol sulphate (10.27), paracetamol (12.63) and paracetamol mercapturate (17.49). 
3.2.1.1 HPLC VALIDATION 
3.2.1.1.1 SPECIFICITY/SELECTIVITY 
Specificity of the assay for paracetamol and its metabolites was examined to ensure that 
endogenous compounds in the patient’s plasma samples did not co-elute and interfere 
with the compounds of interest. This was validated by the absence of interfering 
chromatographic peaks in blank human plasma and from the pre-dose plasma samples 
obtained from the first six patients in Group A (Shah et al. 1992). Selectivity was 
confirmed by peak contours from the PDA (Figure 2.2-2) (Bressolle et al. 1996). 
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Figure 3.2-2 PDA spectra of peaks from Figure 3.2-1.  
From left: paracetamol glucuronide, paracetamol cysteine, paracetamol sulphate, paracetamol and paracetamol mercapturate respectively. In addition to peaks at around 242nm, Paracetamol 
Cysteine and Mercapturate have absorbance peaks at 297nm 
3.2.1.1.2 CALIBRATION CURVES 
Calibration curves were prepared as detailed in Section 2.2  
Linearity of the calibration curve was shown by: 
 The intercept not being statistically different from 0; 
 The slope being statistically different from 0; and  
 The regression coefficient not being statistically different from 1.  
Table 3.2-1 shows all calibration curves passed tests for linearity. 
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Table 3.2-1 Tests of linearity of calibration curves 
Linearity  Intra-batch Inter-batch 
  Mean 95% CI Mean 95% CI 
Paracetamol 
glucuronide 
Intercept 19616.4 ± 26705.31 5074.356 ± 24228.202 
Slope 52565.64 ± 1633.775 53761.53 ± 3070.789 
Correlation 1 ± 0.001 1 ± 0 
Paracetamol 
sulphate 
Intercept 3493.638 ± 9192.73 8306.097 ± 9772.053 
Slope 39322.89 ± 1212.024 40346.56 ± 2374.88 
Correlation 1 ± 0.001 1 ± 0.001 
Paracetamol  Intercept 3464.38 ± 32134.941 25566.72 ± 32763.734 
Slope 90259.51 ± 13237.234 79346.08 ± 7792.874 
Correlation 1 ± 0 1 ± 0.001 
Paracetamol 
cysteine 
Intercept 4719.723 ± 5954.201 4820.502 ± 5733.96 
Slope 29537.71 ± 1366.425 27697.47 ± 2046.41 
Correlation 0.999 ± 0.001 0.999 ± 0.001 
Paracetamol 
mercapturate 
Intercept 1375.735 ± 2282.031 2501.135 ± 3142.974 
Slope 28157.31 ± 406.278 27752.9 ± 1151.106 
Correlation 1 ± 0 1 ± 0 
3.2.1.1.3 EXTRACTION EFFICIENCY 
A seven point dilution series of paracetamol was prepared in triplicate for both plasma 
and diluent and analysed according to Section 2.2. Extraction efficiency was determined 
by dividing plasma sample peak area by the peak area of its respective diluent 
concentration. Figure 3.2-3 shows extraction from plasma was linear with good 
correlation (R>0.99) across the concentration range. This indicates extraction of 
paracetamol from plasma with this method was consistent over concentrations tested.  
 
Figure 3.2-3 Paracetamol extraction efficiency 
Table 3.2-2 shows extraction efficiency was also high and consistent with an average of 
80% extraction efficiency across the concentration range. The extraction method was also 
proven to be reliable as the per cent relative standard deviation (%RSD) figures was 
comparable between the plasma and diluent samples with no trends being observed.  
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Table 3.2-2 Paracetamol extraction efficiency calculation 
Concentration 
(g/mL) 
Diluent 
Avg peak area 
%RSD Plasma 
Avg peak area 
%RSD Extraction 
Efficiency 
40 4234101.41 0.256 3472697.13 0.329 82.017 
20 2083704.68 1.019 1703640.25 0.333 81.76 
10 1051986.77 1.343 837982.57 0.198 79.657 
5 528783.63 1.052 417076.94 1.015 78.875 
2.5 274278.35 0.736 227213.91 0.426 82.841 
1.25 144025.91 0.608 117132.30 2.457 81.327 
0.625 84736.31 0.589 67936.76 1.256 80.174 
    Average 80.95 
These findings were considered acceptable as: 
1. Extraction efficiency was consistent and repeatable across the concentration 
range; and  
2. Extraction efficiency was above levels where losses due to poor extraction 
can lead to calibration curves with small slopes and which can produce 
unreliable results (Bressolle et al.) (Table 3.2-2). 
3.2.1.1.4 PRECISION AND ACCURACY 
Inter and intra batch variations were calculated from high, middle and low concentrations 
for each compound as discussed in Section 2.2. Precision and accuracy were calculated as 
the per cent RSD and per cent recovery respectively and are shown in Table 3.2-3. Values 
were accepted if below 15%, except at the LOQ, when precision and accuracy were 
accepted if less than 20% (Shah et al. 1992; Bressolle et al. 1996). All values passed the 
acceptance criteria. Although still within acceptable limits, lower concentrations generally 
performed worse than middle and high concentrations as the impact of interference from 
the sample matrix was proportionally greater. Paracetamol mercapturate preformed 
worst of all compounds, in keeping with its late elution and poor peak shape.  
The lower concentration of 0.3125µg/mL was originally included as the lower value for 
this compound but this concentration failed tests for precision. Accordingly, the LOQ was 
raised to 0.625 µg/mL, which fell within acceptable limits (Shah et al. 1992). For 
paracetamol mercapturate the increase in LOQ resulted in only six standards being used 
to construct the standard curve. As standard curves are required to contain a minimum of 
five values this was still acceptable (Bressolle et al. 1996). 
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Table 3.2-3 Validation results for plasma HPLC assay 
 LOQ LOD Conc Precision (%RSD) Accuracy (% recovery) 
 
µg/mL 
Intra-
batch 
Inter-
batch 
Intra-batch Inter-
batch 
Paracetamol 
glucuronide 
0.3125 0.156 0.625 9.279 8.948 97.945 98.022 
10 3.802 2.858 102.87 107.477 
80 1.104 3.304 100.347 101.229 
Paracetamol 
sulphate 
0.625 0.156 0.625 4.881 6.967 102.777 95.622 
5 3.81 5.201 101.533 98.679 
40 1.213 2.335 100.598 99.882 
Paracetamol  0.3125 0.156 0.625 6.081 6.466 104.102 94.616 
5 2.069 2.269 97.794 101.692 
40 7.297 7.209 100.114 100.766 
Paracetamol 
cysteine 
0.3125 0.156 0.3125 9.922 12.461 90.121 87.439 
5 2.822 4.204 98.415 99.174 
20 2.258 3.287 100.117 100.4 
Paracetamol 
mercapturate 
0.625 0.156 
 
0.625 11.055 15.432 88.152 86.197 
5 3.47 2.276 101.871 102.459 
20 0.917 1.912 99.955 99.892 
3.2.1.1.5 STABILITY 
Stability of paracetamol in human plasma was examined. There was no evidence of 
degradation of paracetamol in storage for the conditions and durations tested (Table 
3.2-4). 
Table 3.2-4 Stability of paracetamol 
Storage Condition Duration Found ±SD  
(µg/mL) 
Precision  
(RSD %) 
Accuracy  
(%) 
Freezer -80°C 18 months 9.907 ±0.423 3.881 99.002 
Freezer -20°C 6 months 10.191 ±0.306 2.736 101.907 
Fridge 4°C 1 week 10.165 ±0.432 3.876 101.65 
Bench top 24 hours 10.104 ±0.347 3.126 101.04 
3.2.2 URINE 
3.2.2.1 HPLC VALIDATION 
The HPLC assay for urine analysis was revalidated as the chromatographic conditions 
were different to those of the plasma assay. Specifity, LOQ, LOD, precision and accuracy 
were determined in the same manner as described in Section 3.2.1.1.  
3.2.2.1.1 SPECIFICITY/SELECTIVITY 
The order of elution was different to the plasma analysis, with paracetamol cysteine and 
sulphate switching elution order (Figure 3.2-4).  
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Figure 3.2-4 Sample chromatogram of absorbance of paracetamol and its metabolites  
Chromatogram is from injection of a 20µg/mL solution, captured at 242nm. The elution order and times (mins) were 
paracetamol glucuronide (1.86), paracetamol sulphate (2.56), paracetamol cysteine (3.01), paracetamol (3.30) and 
paracetamol mercapturate (12.86) respectively. 
Identity of the peaks was confirmed by UV spectra, as seen in Figure 3.2-5.  
 
Figure 3.2-5 PDA spectra of compound peaks.  
From left: Paracetamol Glucuronide; Paracetamol Sulphate; Paracetamol Cysteine; Paracetamol; Paracetamol 
Mercaptopurate. The additional absorbance peaks of Paracetamol Cysteine and Mercapturate occur at around 297nm 
3.2.2.1.2 CALIBRATION CURVES 
Linearity was assessed as detailed in Section 2.2. Table 3.2-5 shows all calibration curves 
passed tests for linearity. 
Table 3.2-5 Tests of linearity of calibration curves 
Linearity  Intra-batch Inter-batch 
  Mean 95% CI Mean 95% CI 
Paracetamol 
glucuronide 
Intercept 6481.754 ± 11450.589 4940.385 ± 14343.605 
Slope 60309.22 ± 1078.379 60195.84 ± 1030.175 
Correlation 1 ± 0 1 ± 0 
Paracetamol 
sulphate 
Intercept -1145.34 ± 12817.482 2167.087 ± 10390.411 
Slope 108429.9 ± 1170.996 107687.5 ± 1927.475 
Correlation 1 ± 0 1 ± 0 
Paracetamol  Intercept -8070.76 ± 14594.39 3991.286 ± 34133.937 
Slope 147483 ± 3405.818 145076.7 ± 9248.016 
Correlation 1 ± 0 1 ± 0 
Paracetamol 
cysteine 
Intercept 4798.094 ± 6104.336 3959.116 ± 7028.147 
Slope 29389.54 ± 1451.676 28797.85 ± 1718.671 
Correlation 1 ± 0 0.998 ± 0.004 
Paracetamol 
mercapturate 
Intercept -774.736 ± 5550.438 2266.339 ± 10125.641 
Slope 32156.99 ± 2697.149 32054.07 ± 5265.747 
Correlation 0.999 ± 0.001 1 ± 0.001 
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3.2.2.1.3 PRECISION AND ACCURACY 
Whilst defrosting the first set of urine samples an amount of yellow coloured flocculent 
precipitate settled at the bottom of the urine sample container. Initially care was taken 
not to disturb the precipitate and the sample was drawn from the clear, yellow urine. It 
was assumed that, given their solubility, the paracetamol compounds under investigation 
would be homogenously dissolved in the urine. During the validation, five of the closed 
urine sample containers were inadvertently knocked over and agitated just prior to 
preparation for injection. These samples were then shown to have markedly higher 
concentrations of paracetamol metabolites than their previous analysis, although all 
other non-agitated samples and standards absorbed the same (Figure 3.2-6). Graph F of 
this figure also demonstrated that while the measured concentrations on compounds had 
reduced, all compounds were affected to approximately the same degree, and the 
metabolite ratio was not altered. It was suspected the defrosting process created a 
solvent stratification and a resulting inhomogeneous analyte distribution within the 
sample container. All subsequent samples were vigorously shaken prior to sampling. 
Validation then proceeded. Results from this validation are shown in   
Table 3.2-6 and were found to be within acceptable limits (Shah et al. 1992).  
Table 3.2-6 Validation  
 LOQ LOD Conc Precision(%RSD) Accuracy(% recovery) 
 µg/mL  Intra-
batch 
Inter-
batch 
Intra-batch Inter-
batch 
Paracetamol 
glucuronide 
0.3125 0.156 1.25 5.252 3.788 99.018 112.534 
10 1.079 0.542 99.906 99.616 
80 0.972 1.248 100 100.263 
Paracetamol 
sulphate 
0.625 0.156 0.625 7.183 9.642 101.322 96.766 
5 1.531 1.601 99.529 100.337 
40 0.501 1.134 99.997 99.987 
Paracetamol  0.3125 0.156 0.625 10.078 10.508 98.746 95.696 
5 0.448 0.373 100.136 100.195 
40 1.065 3.162 100.031 99.976 
Paracetamol 
cysteine 
0.3125 0.156 0.3125 7.576 14.447 91.133 118.922 
5 1.058 8.718 97.825 96.429 
20 2.023 2.387 100.464 100.822 
Paracetamol 
mercapturate 
0.625 0.3125 
 
0.3125 10.738 17.851 117.801 112.277 
5 3.683 8.544 103.452 102.78 
20 3.614 7.568 99.556 99.512 
 
 233 
 
 
 
Figure 3.2-6 Effect of shaking urine sample on the amount of analyte measured 
Graphs show paracetamol (A) and its metabolites (paracetamol glucuronide (B), paracetamol cysteine (C), paracetamol 
sulphate (D), paracetamol mercapturate (E)) measured in five different urine samples. First bar (blue) shows the amount 
in measured in the sample before shaking and the second bar (red) the amount after shaking. While the amount 
recovered was reduced, graph F shows the ratio of the metabolites and their relative concentration was maintained.  
3.2.3 SUMMARY 
Two assays for HPLC were developed and validated. Both were found to surpass 
validation requirements.  
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3.3 URINE RESULTS 
Urine analysis is a useful tool for assessing changes to drug metabolism as the metabolic 
products of most drugs, including paracetamol, are mainly excreted in the urine (Siegers 
et al. 1984). Metabolites are usually found in high concentrations and sample preparation 
of urine is usually straight forward. While studies of paracetamol’s metabolism and 
disposition frequently show considerable inter-subject variation, the fractional urinary 
recovery of each of paracetamol’s conjugates remain remarkably constant within each 
subject (Clements et al. 1984; Kietzmann et al. 1990). Fractional urinary recovery can be 
used to prepare metabolic ratios that assess the relationship between drug metabolites 
and/or parent compounds and provide insight into changes of drug metabolism. These 
ratios are a composite measure and depend on both metabolic partial clearance and 
renal partial clearance. For the metabolic ratio to be accurate as a tool to assess changes 
to metabolic partial clearance of any drug, renal partial clearance must remain relatively 
constant. When this is achieved, changes to fractional urinary recovery can be attributed 
to something other than random intra-individual variation (Miners et al. 1992).  
Paracetamol, although freely filtered at the glomerulus, is subject to substantial, but 
incomplete, tubular resorption (Miners et al. 1992). Tubular reabsorption can potentially 
cause significant alterations to renal partial clearance of drugs and is dependent on two 
factors: 
 Urine pH (compounds must be unionised to be resorbed); and  
 Urine flow rate (resorption efficiency decreases with increased urine flow) (Miners 
et al. 1992).  
Paracetamol is a weak acid (pKa 9.5) and is essentially unionised at all urinary pH values; 
accordingly renal partial clearance of paracetamol is independent of urinary pH (Forrest 
et al. 1982; van der Marel et al. 2003). However, during periods of severe dehydration 
and reduced urine flow, paracetamol’s partial renal clearance is reduced (Miners et al. 
1992). This can have a large effect on metabolic ratios that contain the excretion of 
unchanged paracetamol and obscure changes to metabolic partial clearances.  
Conversely, the increased solubility and active tubular secretion of the major urinary 
metabolites exempt them from the factors that affect paracetamol’s partial renal 
clearance. As a result their elimination is independent of urine flow and urine pH 
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(Kietzmann et al. 1990; Miners et al. 1992). Additionally, excretion of paracetamol and its 
metabolites are also independent of creatinine clearance (Kietzmann et al. 1990). 
It is a central hypothesis of this Thesis that paracetamol metabolism changes around the 
time of surgery. This hypothesis was to be tested in the following manner: 
 Quantification of factors known to affect fractional urinary recovery (changes to 
urine volume and percentage of the dose recovered in the urine); 
 Assessment of the contribution of paracetamol and each of the metabolites to 
overall dose recovery; 
 Determination of the contribution of sulphate containing metabolites to the 
overall dose recovery; 
 Preparation of a metabolic ratio to examine changes to the Phase II and Phase I 
pathways involved in paracetamol’s metabolism; and 
 Assessment of the factors that potentially impact on this metabolic ratio.  
3.3.1 ANALYSIS OF RESULTS- PREAMBLE 
Urine was collected every four hours from each patient in the study. This resulted in 
nearly 1000 urine samples for analysis. Information from each sample included: 
1. Patient and patient group; 
2. Sample time and day; 
3. Volume of urine excreted over collection period; and 
4. The concentration of paracetamol and each of its four metabolites of interest. 
These values were then used to calculate amounts and ratios of excreted metabolites. For 
the purposes of analysis of the urine results, concentrations which were determined to be 
below the LOD were set to 0 and concentrations between the LOQ and LOD were set to 
half the LOD. (Shah et al. 1992) 
With at least 30 samples per patient, collected from samples taken every four hours over 
a five day period, clear trends emerged graphically, however summarising the data for 
meaningful statistical analysis was difficult. As an example, Group A’s urinary paracetamol 
glucuronide concentrations are presented in Figure 3.3-1.  
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Figure 3.3-1 Box plot of Group A Paracetamol Glucuronide concentration from all samples  
Concentration displayed as measured in four hour urine collections. Green line marks first sample obtained following 
surgery. Samples numbers are given as day.sample 
 
Table 3.3-1 Sampling intervals, corresponding pooled intervals, (used in statistical analysis), and graph intervals 
Sample Day 
Notes on interval timing 
Sample Interval 
(hr) 
Pooled 
Interval 
Graph 
Day 
Graph Sample 
No. 
Preoperative day 
Time taken from beginning 
of preoperative paracetamol 
dose 
0-4hrs -1 -1 -4 
4-8hrs   -3 
8-12hrs   -2 
12-16hrs   -1 
Day of Surgery 
Times by clock 
1400-1800 0 0 5 
1800-2200   6 
Day 1 Postop 
Times by clock 
2200-0200 1 1 1 
0200-0600   2 
0600-1000   3 
1000-1400   4 
1400-1800   5 
1800-2200   6 
Day 2 Postop 
Times by clock 
2200-0200 2 2 1 
0200-0600   2 
0600-1000   3 
1000-1400   4 
1400-1800   5 
1800-2200   6 
Day 3 Postop 
Times by clock 
2200-0200 3 3 1 
0200-0600   2 
0600-1000   3 
1000-1400   4 
1400-1800   5 
1800-2200   6 
Day 4 Postop 
Times by clock 
2200-0200 4 4 1 
0200-0600   2 
0600-1000   3 
1000-1400   4 
1400-1800   5 
1800-2200   6 
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An analysis of variance, such as a Friedman’s test, on these data would almost certainly 
show a significant difference at p<0.05 occurred across the study. However, with up to 34 
samples per patient, determining where the significant differences occurred in a full post 
hoc test would require nearly 600 Wilcoxon signed rank tests. While useful for displaying 
graphical trends, the clinical relevance of statistical results from one four hour interval to 
another was questionable. Consequently, results for descriptive and statistical purposes 
were pooled. As much of the literature investigating multiple dose paracetamol excretion 
uses 24 hour urine collections, 24 hour intervals were also chosen for the pooling of 
samples for this Thesis. The results for each patient’s four hourly samples were summed 
over each 24 hour interval as shown in Table 3.3-1. To coincide with study drug 
administration, each “day” began at 2200 hours as opposed to midnight. The same data 
in Figure 3.3-1 are shown after pooling was performed in Figure 3.3-2.  
 
Figure 3.3-2 Box plot of Group A Paracetamol Glucuronide concentration after pooling of sample times  
Concentration displayed after samples pooled across day. Green line marks first sample obtained following surgery.  
The concern with pooling data in this way is the loss of variance, which can arise from the 
“smoothing out” of changes to metabolite concentration that occur from one four hour 
sample to the next. The effect of any loss of variance occurring from the pooling was 
assessed graphically and examples are shown below (Figure 3.3-3). The left plot shows 
boxes and whiskers that vary between each other in size and length, demonstrating the 
differences in paracetamol glucuronide concentrations that occur over the day. This is lost 
when the values are summed as shown in the right-hand plot. Friedman’s tests were 
conducted to assess if the variation between the four-hour samples within a 24 hour set 
of samples (such as those in the left plot in Figure 3.3-3) were statistically significant and 
the majority were.  
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Figure 3.3-3 Box plot of Group A Paracetamol glucuronide Concentration on Day 1 before (left) and after pooling 
(right) 
These revealed that there were significant differences between the sample intervals even 
within each 24hr period. Accordingly, the statistical results that arise from these pooled 
values that were used in the analysis below are likely to underestimate the statistical 
significance of differences. Consequently, data are also presented graphically. While 
statistical analysis necessitated pooling values, graphical and regression analysis used the 
full data set (4hr samples). In graphs, sample and day numbers correspond to the times 
shown in Table 3.3-1. The critical level of significance used in this analysis is α≤0.05. 
3.3.2 DISTRIBUTION OF URINE RESULTS 
For each patient group, the summed results for each day were checked for normality 
visually by preparing a histogram with normal curve superimposed, a Q-Q plot and a box 
and whisker plot. In addition, formal normality tests were conducted using the 
Kolmogorov-Smirnov test (D). No result consistently passed normality tests across the 
groups.  
Based on the shape of the histograms, the log10 of the daily values were taken and 
normality tests repeated. While generally improving normality visually, there was still 
clear deviation in the histograms and Q-Q plots and the Kolmogorov-Smirnov tests were 
still significant. For completeness, other transformations were attempted including the 
natural log, inverse, square and square root of the values, but none improved the 
distribution beyond that of the log10 transformation. As normal distributions could not be 
obtained from these transformations, non-parametric methods were used for the 
description and testing of differences within variables across the samples collected.  
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3.3.3 URINE VOLUME 
The volume of urine was expected to change over the course of recovery as a result of the 
stress response and the challenges to fluid balance presented by surgery. Crucially, 
reductions to urine output can affect the excretion of each of paracetamol’s metabolites 
differently. The total volume of urine collected over each four-hour interval was 
measured and summed for each 24hr interval. This figure was then divided by 24 to give 
average hourly urine output for each 24hr interval. 
Descriptive statistics for the urine output are shown. Exact Friedman’s tests were used to 
assess differences across all days of the study and again over the postoperative days 
alone. This was followed by one or two tailed Wilcoxon signed rank tests, where 
appropriate, for post hoc analysis.  
3.3.3.1 GROUP A 
A total of 293 urine samples were collected from patients in Group A. The group median 
volumes and IQRs of each four-hour sample are shown in Figure 3.3-4. It can be seen that 
urine output changed considerably over the course of the study. Before and for the day 
and a half following surgery, median urine volumes were consistent, between 40 and 
70mL/hr. Following this oliguria, diuresis occurred with outputs rising swiftly to reach a 
maximum median of 309mL/hr. Outputs then plateaued (Figure 3.3-4) onto Day 4.  
 
Figure 3.3-4 Four hourly urine volumes collected over study (median±IQR) Group A 
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Initially IQRs were small, most notably on the day following surgery; however, the 
increases in median outputs later in the study were accompanied by widening IQRs. The 
median and IQRs for the summed daily values are presented in Table 3.3-2. Large 
increases in output were noticed on Day 3 and 4, accompanied by widening IQRs.  
Table 3.3-2 Median and interquartile ranges for the summed daily urine volume 
mL/hr Day -1 Day 1 Day 2 Day 3 Day 4 
Median 
(IQR) 
62,  
(44, 85) 
51 
(35, 63) 
92 
(65, 141) 
168 
(127, 239) 
151 
(136, 251) 
To examine for changes between the distributions of urine volume over the course of the 
study exact Friedman’s tests were used on summed urine volumes. All values were first 
examined, followed by only postoperative volumes. The results are shown in Table 3.3-3. 
These results confirm what was observed graphically, that there were significant 
differences in urine volumes across the whole study (χ2=29.067, p<0.000) and also just 
over the postoperative period (χ2=20.067, p<0.000).  
Table 3.3-3 Friedman’s test e amining differences in urine volume across study 
*
= significant difference at p<0.05 
χ2  p  24.800 (<0.000)* 
χ2 (p)Postop only 20.067 (<0.000)* 
As the direction of change of urine volume was unknown, post hoc tests were conducted 
using 2-tailed, exact Wilcoxon signed rank tests to examine on what days significant 
differences in urine output occurred. Tests between the preoperative day and 
postoperative days were conducted, along with examining the first postoperative day and 
all the subsequent postoperative days (Table 3.3-4). To limit the size of the Bonferroni 
correction and Type I error, comparisons for the following days were not conducted.  
Table 3.3-4 Group A, post hoc pair-wise analysis (p) of urine volume 
*
= significant difference at p<0.05 
Group A  
1 0.037*  
2 0.064 0.01* 
3 0.008* 0.004* 
4 0.008* 0.004* 
Day -1 1 
All comparisons showed highly significant differences. However, as there were 7 
comparisons in the post hoc analysis, a Bonferroni correction of α/7 needed to be 
applied. This reduced the critical level of significance to p>0.0072, leaving only the 
comparisons between Day 1 and Days 3 and 4 below this level. Differences were of 
 241 
 
greater significance between the extreme ends of the study, in keeping with the values 
shown in Figure 3.3-4. 
3.3.3.2 GROUP B 
Urine output for Group B shows a similar pattern to Group A (Figure 3.3-5). Urine volumes 
were consistently low (30-40mL/hr) before and until the end of the first postoperative 
day. Thereafter diuresis developed with median outputs increasing to over 250mL/hr 
(sample 3.3) with one individual producing 400mL/hr in one four hour period (Patient 4, 
sample 3.6) and 5.6L that day. The descriptives for the summed values are presented in 
Table 3.3-5 and Figure 3.3-5. 
Table 3.3-5 Median and interquartile ranges for the summed daily urine volume 
*
= significant difference at p<0.05 
mL/hr Day -1 Day 1 Day 2 Day 3 Day 4 
Median 
(IQR) 
23  
(18, 45) 
32  
(26, 77) 
117  
(57, 192) 
173  
(84, 221) 
150  
(102, 209) 
 
Figure 3.3-5 Four hourly urine volumes collected over study (median±IQR) Group B 
Table 3.3-6 shows that there were significant differences in urine volumes across the 
whole study and within the postoperative period alone.  
Table 3.3-6 Friedman’s test e amining differences in urine volume across study 
*
= significant difference at p<0.05 
χ2  p  10.667 (0.004) 
χ2  p Postop only 8.100 (0.033)* 
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To determine the combinations of days that were significantly different, post hoc tests 
were conducted using Wilcoxon signed rank tests. These results are in Table 3.3-7. 
Despite trends being seen in Figure 3.3-4 and shown in Table 3.3-6, no significant results 
were found in post hoc tests, illustrating the increased sensitivity of a repeated measures 
test like Friedman’s test. 
Table 3.3-7 Group B, post hoc pair-wise analysis (p) of urine volume 
*
= significant difference at p<0.05 
Group B  
1 0.109  
2 0.109 0.068 
3 0.109 0.068 
4 0.109 0.068 
Day -1 1 
3.3.3.3 GROUP C 
The changes in urine production across the study period were less in Group C than other 
groups; however, the variation within each sample period was greater (Figure 3.3-6). This 
group collected their own urine for the majority of the study as they were only 
catheterised for a brief period following surgery. There was also less distinction between 
the perioperative and postoperative urine output. 
 
Figure 3.3-6 Four hourly urine volumes collected over study (median± IQR) Group C 
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Summed daily outputs were also reduced compared with other groups and were 
comparatively consistent over the duration of the study (Table 3.3-8).  
Table 3.3-8 Summed daily urine volume- Median (LQ, UQ) 
mL/hr Day -1 Day 1 Day 2 Day 3 Day 4 
Median 
(IQR) 
80  
(40, 155) 
112  
(55, 133) 
52  
(19, 89) 
71 
(40, 93) 
76  
(35, 101) 
The Friedman’s test showed that there were no significant differences in urine output 
found in either comparison (Table 3.3-9).  
Table 3.3-9 Friedman’s test e amining differences in urine volume across study 
*
= significant difference at p<0.05 
χ2  p  8.480 (0.066) 
χ2 (p)Postop only 6.840 (0.075) 
Because Friedman’s tests exclude cases list-wise, post hoc tests were conducted to 
include the full data set, as these tests exclude pair-wise. This revealed that urine output 
was significantly higher on the first postoperative day than the rest of the postoperative 
period, however, once the Bonferroni correction was applied, these values lost their 
statistical significance (Table 3.3-10). This was the opposite of that seen in the previous 
two groups of patients.  
Table 3.3-10 Group C, post hoc pair-wise analysis (p) of urine volume 
*
= significant difference at p<0.05 
Group C  
1 0.735  
2 0.237 0.05* 
3 0.345 0.043* 
4 0.345 0.043* 
Day -1 1 
3.3.3.4 GROUP D 
Urine outputs in Group D were greater than the other groups undergoing similar surgery 
types (Groups A and B) until Day 4 when they fell below. Similar to Groups A and B, there 
was a reduction in urine output and IQRs immediately postoperatively, but for a shorter 
period of time (Figure 3.3-7). Urine volumes were also more consistent across the study 
than Groups A+B, not exhibiting the same diuresis seen in these other groups. Variability 
in urine volume for each four-hour sample was wide, but consistent. 
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Figure 3.3-7 Four hourly urine volumes collected over study (median±IQR) Group D 
The maximum median output of 275mL/hr was achieved earlier than other groups 
(sample 2.5), and the individual greatest output was from Patient 6D, who produced 
467.5mL/hr for sample 4.2 (a total of 1870mL was measured in this four hour sample). 
The consistency in urine output was clearly reflected in the daily median outputs shown 
in Table 3.3-5, which varied very little on Days 1, 2, and 3, and fell away on Day 4. IQRs 
were large but also remain consistent.  
Table 3.3-11 Summed daily urine volume- Median (LQ, UQ) 
mL/hr Day -1 Day 1 Day 2 Day 3 Day 4 
Median 
(IQR) 
61  
(55, 87) 
110  
(66, 137) 
107  
(83, 134) 
113  
(73, 149) 
50  
(18, 114) 
Friedman’s tests were again conducted and revealed no significant results (Table 3.3-12). 
Table 3.3-12 Friedman’s test e amining differences in urine volume across study 
*
= significant difference at p<0.05 
χ2  p  6.500 (0.167) 
χ2 (p)Postop only 4.200 (0.242) 
For the reasons mentioned in Section 3.3.3.3, post hoc tests were still conducted. These 
showed significant differences in the comparison of the preoperative urine volume with 
Day 1, 2 and 3 postoperatively. This is consistent with the values shown in Table 3.3-11, 
however, as in previous groups, these values were not statistically significant (Table 
3.3-13) once the Bonferroni correction had been applied. 
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Table 3.3-13 Group D, post hoc pair-wise analysis (p) of urine volume 
*
= significant difference at p<0.05 
Group D  
1 0.019*  
2 0.014* 0.638 
3 0.049* 0.695 
4 0.641 0.547 
Day -1 1 
3.3.3.5 GROUP B+D 
As a combination of two groups already discussed, this group exhibited trends similar to 
that of Group D, who make up the majority of patients. The influence of Group B was to 
lower median urine outputs preoperative and Day 1 postoperatively, increasing them for 
subsequent days (Figure 3.3-8). IRQs remained largely similar to those of Group D. Peak 
median output occurred in interval 3 on Day 3 to just over 200mL/hr. Following the 
trends seen in Figure 3.3-8, the summed outputs increase steadily from the preoperative 
day until Day 4 when they decline for the first time. IQRs show accompanying increases 
and are mostly symmetrical about the median until Day 4 when they show a positive 
skew (Table 3.3-14). 
 
Figure 3.3-8 Four hourly urine volumes collected over study (median±IQR) Group B+D 
The skew indicates asymmetry of the distribution derived from the fact that the urine 
outputs above the median are of greater magnitude, stretching further away from the 
median, than those beneath it, which are clustered closer to the median (Table 3.3-14).  
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Table 3.3-14 Summed daily urine volume- Median (LQ, UQ) 
mL/hr Day -1 Day 1 Day 2 Day 3 Day 4 
Median 
(IQR) 
56  
(22, 84) 
91  
(34, 129) 
107  
(80, 154) 
129  
(77, 171) 
79  
(39, 158) 
Once again Freidman’s tests were conducted, but did not show significant results (Table 
3.3-15). As previously, two tailed post hoc tests were conducted.  
Table 3.3-15 Friedman’s test e amining differences in urine volume across study 
*
= significant difference at p<0.05  
χ2  p  8.436 (0.072) 
χ2  p Postop only 4.900 (0.186) 
These show that the preoperative output was significantly lower than that of Days 1, 2 
and 3, which was maintained even after the Bonferroni correction had been considered. 
There was no significant difference at p<0.05 between the outputs of the postoperative 
days (Table 3.3-16).  
Table 3.3-16 Group B+D, post hoc pair-wise analysis (p) of urine volume 
*
= significant difference at p<0.05 
Group B+D  
1 0.005*  
2 0.002* 0.151 
3 0.008* 0.135 
4 0.365 0.470 
Day -1 1 
3.3.4 PERCENTAGE OF DOSE RECOVERED IN THE URINE 
The molar amounts of all metabolites of paracetamol in each urine sample were summed 
and divided by the paracetamol dose to give the per cent of the dose recovered in the 
urine. As paracetamol dose and administration intervals varied preoperatively and 
postoperatively, and between groups, determining what dose to divide the recovered 
amounts by was calculated as follows: 
 For preoperative samples, as they arose from a single dose of paracetamol, the 
amounts of metabolite in all preoperative urine samples were summed together, 
divided by the dose of paracetamol administered (paracetamol 1g=6.6mmol, 
1.5g=9.9mmol) and are reported as a single preoperative value “All”; or 
 For postoperative samples, as they arose from steady state, the amounts of 
metabolite were again summed, but were divided by the dose administered over 
the four-hour urine collection period. This was determined by summing the total 
24hr paracetamol dose and dividing by six, the number of four-hour collection 
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intervals that occurred within a 24hr period. Therefore, for Group A, the sum 
amount of metabolite in each sample was divided by 9g/6 = 1.5g = 9.9mmol. For 
the remaining groups, the sum of metabolites was divided by 4g/6 = 0.67g = 
4.4mmol.  
For the daily per cent recovered figures, metabolite amounts for the whole day were 
summed and divided by the 24hr paracetamol dose (59.5mmol for Group A, 26.5mmol for 
other groups). In this analysis, changes to dose recovery postoperatively could indicate 
changes to excretion, confounding the interpretation of changes to metabolic ratio. 
3.3.4.1 GROUP A 
Changes to urinary dose recovery are shown in Figure 3.3-9. Recovery of dose 
preoperatively is poor with a median of 61.5% for Day-1.  
 
Figure 3.3-9 Per cent of administered paracetamol dose recovered in the urine from four hourly collection 
Results shown as median % (±IQR) 
Following surgery, recovery increased and remained consistent, with the median peaking 
on Day 2, at 106% of dose. There was no obvious pattern relating to time of day or time 
since surgery. IQRs increase in the later days of the study and appear largely symmetric. 
Daily values exhibited a similar pattern to those seen graphically from the 4hr samples. 
Median values (Table 3.3-17) remained consistent, up to 94% on Day 2, as did IQRs which 
stretch beyond the 100% recovery of dose from Day 2 until the end of the study.  
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Table 3.3-17 Summed daily recovery of dose in the urine - Median (LQ, UQ) 
% Day -1 Day 1 Day 2 Day 3 Day 4 
Median 
(IQR) 
63.17 
(52.02, 
83.98) 
79.96 
(59.03, 
86.85) 
94.27 
(78.59, 
107.68) 
82.57 
(74.73, 
106.09) 
75.81 
(38.89, 
106.74) 
Analysis of these values using an exact Freidman’s tests (Table 3.3-18) showed that the 
distribution of the postoperative values was significantly different. 
Table 3.3-18 Friedman’s test e amining differences in urinary recovery of dose across study 
*
= significant difference at p<0.05 
χ2  p  7.378 (0.116) 
χ2  p Postop only 8.333 (0.036)* 
A post hoc analysis was undertaken using exact 2-tailed Wilcoxon sign-rank tests (Table 
3.3-19). For reasons mentioned in Section 0, a significant difference at p<0.05 was found 
in increase of Day -1 values to Day 2 values (p=0.027), which was not detected by the 
Friedman’s test, although these failed to reach the level of significance after the 
Bonferroni correction. The significant result from the Friedman’s test in the analysis of 
the postoperative days arose from the increase from Day 1 to Day 2 which shows a 
significance of p=0.01. This also failed to reach significance after the Bonferroni correction 
had been applied 
Table 3.3-19 Group A, post hoc pair-wise analysis (p) of urinary recovery of dose 
*
= significant difference at p<0.05 
Group A  
1 0.232  
2 0.027* 0.01* 
3 0.25 0.164 
4 0.652 0.734 
Day -1 1 
3.3.4.2 GROUP B 
Following surgery, urinary recoveries of paracetamol were consistently around the 100% 
value (Figure 3.3-10). The highest median recovery was 134% on the evening of the day of 
surgery, when patients would have received a loading dose intraoperatively and lowest in 
the first sample taken on Day 3. Considering the lower recoveries found in the samples 
either side of this one, and that it was collected after all patients had had their urinary 
catheters removed, this may indicate incomplete evacuation of urine within each four 
hour period and accumulation of the dose in the bladder. This is supported by the 
fluctuations in urine output seen in Figure 3.3-5. Preoperative recovery was again low at 
approximately 40% of the administered dose. Further inspection of the values that 
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contributed to this summed value shown, revealed that, while other patients were 
excreting 60-80% of the dose in the first preoperative four hour urine collection, patients 
in Group B excreted approximately 20% of the dose. 
 
Figure 3.3-10 Per cent of administered paracetamol dose recovered in the urine from four hourly collection 
Results shown as median % (±IQR) 
While the second urine sample contained a slightly higher metabolite concentration than 
most other groups, it still only contributed a further 20% to the recovery. The descriptives 
of the daily values in Table 3.3-20 reflect this consistency in dose recovery, with medians 
varying less than four per cent over the postoperative period.  
Table 3.3-20 Summed daily recovery of dose in the urine - Median (LQ, UQ) 
% Day -1 Day 1 Day 2 Day 3 Day 4 
Median 
(IQR) 
22.79 
(14.20, 
31.30) 
98.89 
(88.94, 
110.49) 
101.21 
(87.95, 
116.53) 
104.535 
(89.361, 
115.174) 
102.165 
(92.49, 
109.436) 
The clear difference between preoperative and postoperative recovery seen graphically is 
reflected in the highly significant result of the Friedman’s tests reported Table 3.3-21. 
Also in line with the graphical observations is the lack of significant difference between 
the postoperative days. Post hoc tests were conducted but the combinations used 
previously failed to show significant differences (data not shown). 
Table 3.3-21 Friedman’s test e amining differences in urinary recovery of dose across study 
*
= significant difference at p<0.05 
χ2  p  11.467 (0.001) 
χ2 (p)Postop only 3.000 (0.432) 
 250 
 
3.3.4.3 GROUP C 
Recovery of the dose in the urine of Group C patients varied widely over the duration of 
the study (Figure 3.3-11). This group were only briefly catheterised in the immediate 
postoperative period and spent the majority of the study collecting their own urine. As 
with the previous group, the greatest dose recovery was from the first postoperative 
sample, when a median of 176% of the dose was measured. The lowest recovery, 54%, 
was obtained at the end of Day 2 postoperatively, as was the case with Group B. IQRs of 
nearly 100% (sample 2.2) were also the greatest of any group and reflected the dose 
recovery of over 200% of two patients in this sample period. 
 
Figure 3.3-11 Per cent of administered paracetamol dose recovered in the urine from four hourly collection 
Results shown as median % (±IQR) 
Despite the variation described above and seen in Figure 3.3-11, descriptive values 
obtained from daily recovery were remarkably consistent, however, large IQRs were still 
seen, most notably on Days-1 and 2 when it was approximately 60% (Table 3.3-22). 
Table 3.3-22 Summed daily recovery of dose in the urine- Median (LQ, UQ) 
% Day -1 Day 1 Day 2 Day 3 Day 4 
Median 
(IQR) 
84.38 
(37.91, 
100.37) 
96.34 
(71.46, 
114.54) 
78.31 
(29.29, 
96.43) 
92.08 
(66.63, 
104.66) 
81.51 
(64.00, 
114.07) 
Freidman’s tests were conducted and no significant results were obtained (Table 3.3-23).  
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Table 3.3-23 Friedman’s test e amining differences in urinary recovery of dose across study 
*
= significant difference at p<0.05 
χ2  p  2.880 (0.613) 
χ2  p Postop only 2.280 (0.561) 
3.3.4.4 GROUP D 
As previously, urinary recovery from the preoperative dose was low (median 47%) (Figure 
3.3-12). Following surgery, values showed some variation although no pattern occurs in 
relation to time of day or time since surgery. Values spike in sample 4.2 following a trough 
in the four previous samples. In most cases, this corresponded with catheter removal.  
 
Figure 3.3-12 Per cent of administered paracetamol dose recovered in the urine from four hourly collection 
Results shown as median % (±IQR) 
Descriptives for the daily values show that median recoveries were less than 100% and 
were their lowest on the first and last day of the study (Table 3.3-24). However, several 
individual time points show median recoveries at or near 100% in Figure 3.3-12. IQRs 
were less than seen in other groups, but failed to extend to 100%. 
Table 3.3-24 Summed daily recovery of dose in the urine - Median (LQ, UQ) 
% Day -1 Day 1 Day 2 Day 3 Day 4 
Median 
(IQR) 
46.648 
(24.542, 
62.456) 
84.807 
(70.769, 
85.826) 
78.695 
(48.55, 
92.132) 
78.163 
(57.625, 
91.724) 
58.357 
(25.412, 
67.368) 
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Freidman’s tests showed a significant difference at p<0.05 in the comparison including 
preoperative values, but did not detect a significant difference at p<0.05 within the 
postoperative period alone (Table 3.3-25).  
Table 3.3-25 Friedman’s test e amining differences in urinary recovery of dose across study 
*
= significant difference at p<0.05 
χ2  p  14.6 (0.02)* 
χ2  p Postop only 7.050 (0.068) 
Post hoc tests were conducted and show the dose recovery on Day -1 was significantly 
lower than Days 1, 2, and 3 (Table 3.3-26). The comparison with Day 2 was below the 
critical level of significance after the Bonferroni correction.  
Table 3.3-26 Group D, post hoc pair-wise analysis (p) of urine volume 
*
= significant difference at p<0.05 
Group   
1 0.001*  
2 0.019* 0.577 
3 0.002* 0.557 
4 0.641 0.148 
Day -1 1 
3.3.4.5 GROUP B+D 
As previously, the result of combining these two groups is mainly dominated by Group D 
values, as they make up the larger proportion of the examined values (Figure 3.3-13).  
 
Figure 3.3-13 Per cent of administered paracetamol dose recovered in the urine from four hourly collection 
Results shown as median % (±IQR) 
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The effect of adding Group B was to slightly raise the median recoveries and increase 
IQRs (Figure 3.3-13). Descriptives of the summed daily values also reflect the influence of 
Group D, again failing to reach 100%, although upper quartiles now approach or exceed 
full recovery of the dose (Table 3.3-27). There is no clear trend indicating recovery 
changes over time.  
Table 3.3-27 Summed daily recovery of dose in the urine - Median (LQ, UQ) 
% Day -1 Day 1 Day 2 Day 3 Day 4 
Median 
(IQR) 
40.4 
(22.2, 
62.086) 
85.316 
(76.222, 
91.976) 
84.702 
(55.565, 
98.595) 
86.816 
(66.939, 
103.847) 
61.164 
(56, 
107.153) 
Freidman’s tests showed significant differences across the study when preoperative 
values were included, but not within postoperative values alone (Table 3.3-28).  
Table 3.3-28 Friedman’s test e amining differences in urinary recovery of dose across study 
*
= significant difference at p<0.05 
χ2  p  16.56 (0.01)* 
χ2  p Postop only 3.982 (0.277) 
As with Group D, post hoc tests showed the preoperative dose recovery to be significantly 
lower than Days 1, 2 and 3, and these all surpassed the required level of significance after 
the Bonferroni correction had been applied (Table 3.3-29).  
Table 3.3-29 Group C, post hoc pair-wise analysis (p) of urine volume 
*
= significant difference at p<0.05 
Group   
1 0.000*  
2 0.005* 0.542 
3 0.000* 0.635 
4 0.193 0.123 
Day -1 1 
3.3.5 CONTRIBUTION OF METABOLITES TO RECOVERY 
Overall, there was very little change shown to the amount of paracetamol dose recovered 
in the urine during the steady-state period postoperatively. While the total amount of 
metabolites recovered did not change, the five compounds contributing to this recovery 
may have varied. Alterations to the pattern of metabolite excretion is as, if not more, 
important to this Thesis than the amounts of metabolites recovered as it can indicate 
alterations to the drug metabolism processes. It was therefore import to evaluate the 
contribution of each of the metabolites to the total urinary recovery. For the purposes of 
statistical analysis, recoveries of paracetamol cysteine and paracetamol mercapturate 
were combined into one value, “Phase I products”, as both are derived from NAPQI. To 
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compare the contribution of the metabolites, the amount of each metabolite was divided 
by the total amount of all metabolites recovered in that urine sample. Accordingly values 
are reported as “% contribution to recovery”. Each metabolite was then assessed as with 
previous sections, with Friedman’s tests with and without the day before surgery, and, if 
appropriate, followed by post hoc tests.  
3.3.5.1 GROUP A 
Several trends appear in the relative contribution of paracetamol metabolites to the 
overall dose recovery in this group (Figure 3.3-14).  
 
Figure 3.3-14 Contribution of each metabolite to overall recovery 
Values reported as group medians. Abbreviations used: PGlu= paracetamol glucuronide; PSul= paracetamol sulphate; 
PCys= paracetamol cysteine; PMer= paracetamol mercapturate; P= paracetamol 
Comparing the first urine sample with the last, noticeable changes included: 
 Paracetamol sulphate reduced from 25 to 10%; 
 Paracetamol glucuronide increased from 56 to 71%; 
 The combined Phase I metabolites decreased slightly from to 12 to 10%, having 
reached a maximal contribution of 26% in sample 4, Day 1; and 
 Unchanged paracetamol remained relatively constant, increasing from to 7 to 8%. 
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Values were summed as with previous sections. Exact Friedman’s tests were used to 
assess the statistical significance of the resultant values across each day of the study. The 
results in Table 3.3-30 show that there were highly significant differences in the relative 
contribution of each metabolite across all days of the study and within the postoperative 
period alone. 
Table 3.3-30 Results of Friedman’s test  
*
= significant difference at p<0.05 
Group A Paracetamol Glucuronide Paracetamol Sulphate Phase I products 
χ2  p  18.756 (<0.000)* 26.933 (<0.000)* 21.333 (<0.000)* 
Postop only χ2  p  14.6 (0.001)* 15.8 (<0.000)* 13.667 (0.001)* 
To determine the nature of the Friedman’s test results, post hoc tests were carried out 
using two-tailed, exact Wilcoxon signed rank tests (Table 3.3-31).  
Table 3.3-31 Group A, post hoc pair-wise analysis (p) of urine volume 
*
= significant difference at p<0.05 
Group A Paracetamol Glucuronide  Paracetamol Sulphate  Phase I Products 
1 0.846   0.027*   0.002*  
2 0.193 0.037*  0.002* 0.002*  0.002* 0.77 
3 0.012* 0.004*  0.004* 0.004*  0.02* 0.008* 
4 0.02* 0.004*  0.004* 0.027*  0.91 0.012* 
Day -1 1  -1 1  -1 1 
For paracetamol glucuronide, the increased contributions from Day-1 to Days 3 and 4 
were statistically significant, as was the increase between Day 1 and all other 
postoperative days. Once the Bonferroni correction had been applied, only the 
comparison between Day 1 and Day 3 and 4 remained significant. Paracetamol sulphate 
showed significant reductions between the preoperative and all postoperative days, with 
all but Day 1 remaining significant after Bonferroni correction. The reduction between 
Day 1 and Days 2, 3 and 4 postoperatively were also significant with Days 2 and 3 
surpassing the rigours of the Bonferroni correction. There were significant increases in 
Phase I products between the preoperative day and Days 1, 2 and 3; Days 1 and 2 
remaining so after Bonferroni correction. There were significant reductions in Phase I 
contribution between Day 1 and Days 3 and 4, with no comparison remaining significant 
after Bonferroni correction. 
3.3.5.2 GROUP B 
Trends in metabolite contribution are less marked in Group B (Figure 3.3-15): 
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 Paracetamol glucuronide started at 43% of the recovery, peaked at 60% in sample 
2, Day 4 and reduced to 51% in the final sample;  
 Paracetamol sulphate began by contributing 31%, gradually reducing to 13% in 
sample 3, Day 3 and increased slightly to 16% at the end of the study; and  
 Phase I metabolites began contributing 15% to the recovery, peaked at 36% just 
before the end of the study in sample 5 Day 4, before reducing to 29% in the last 
urine sample.  
 
Figure 3.3-15 Contribution of each metabolite to overall recovery 
Values reported as group medians. Abbreviations used: PGlu= paracetamol glucuronide; PSul= paracetamol sulphate; 
PCys= paracetamol cysteine; PMer= paracetamol mercapturate; P= paracetamol 
Daily summed values were tested using the Friedman’s test (Table 3.3-32). Two significant 
differences arose in the increase of paracetamol glucuronide and decrease of 
paracetamol sulphate between preoperative and postoperative values.  
Table 3.3-32 Results of Friedman’s test 
*
= significant difference at p<0.05 
Group B Paracetamol 
Glucuronide 
Paracetamol 
Sulphate 
Phase I products 
χ2  p  9.067 (0.028)* 10.400 (0.005)* 2.933 (0.469) 
Postop only χ2  p  6.300 (0.094) 5.8 (0.052) 1.200 (0.753) 
However, as this group only contained four patients no significant differences arose in the 
post hoc tests of these values (Table 3.3-33).  
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Table 3.3-33 Group B, post hoc pair-wise analysis (p) of urine volume 
*
= significant difference at p<0.05 
Group B Paracetamol Glucuronide  Paracetamol Sulphate  Phase I Products 
1 0.5   0.109   0.109  
2 0.25 0.25  0.109 0.068  0.285 0.273 
3 0.25 0.125  0.109 0.068  0.285 0.465 
4 0.25 0.125  0.109 0.068  0.285 0.715 
Day -1 1  -1 1  -1 1 
3.3.5.3 GROUP C 
Contributions of metabolites in Group C appeared relatively consistent across the study 
(Figure 3.3-16). Observations included: 
 Contribution of paracetamol sulphate was low from the beginning (19%), and 
reduced to 12% in the final urine sample; 
 Paracetamol glucuronide began at 54% and increased to its maximum 
contribution at 65% in the last sample on the day of surgery. After falling slightly, 
contributions remained consistently around the high 50%/low 60% values until 
finishing at 61%; and 
 There was an unusually high contribution of Phase I metabolites from the 
beginning of the study (19%), which increased to 30% by sample 3 on Day 1 and 
remained around 25% until the final sample.  
 
Figure 3.3-16 Contribution of each metabolite to overall recovery 
Values reported as group medians. Abbreviations used: PGlu= paracetamol glucuronide; PSul= paracetamol sulphate; 
PCys= paracetamol cysteine; PMer= paracetamol mercapturate; P= paracetamol 
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Values were again summed into daily intervals. Table 3.3-34 shows the results of the 
Friedman’s tests that were conducted. This shows that there were statistically significant 
differences in paracetamol glucuronide and Phase I metabolite contributions across all 
days of the study and within the postoperative period only. There were no differences 
seen for paracetamol sulphate.  
Table 3.3-34 Results of Friedman’s test 
*
= significant difference at p<0.05 
Group C Paracetamol 
Glucuronide 
Paracetamol 
Sulphate 
Phase I products 
χ2  p  15.52 (<0.000)* 7.52 (0.107) 13.6 (0.002)* 
Postop only χ2  p  10.2 (0.007)* 1.08 (0.857) 9 (0.02)* 
Table 3.3-35 shows the results of the post hoc tests conducted on these values. For 
paracetamol glucuronide, the statistical significance of the Friedman’s test arose from the 
decrease between the preoperative day and Days 2, 3 and 4. No comparison remained 
significant after Bonferroni correction. Significant differences at p<0.05 were seen in the 
pair-wise tests for paracetamol sulphate in the decrease from the preoperative day to 
Days 1, 2 and 3, but these also did not remain significant following Bonferroni correction. 
Further, significant differences were also seen in the increase of Phase I products 
between the preoperative day and Days 1 and 3 and in the reduction of Phase I products 
between Day 1 and 4. None of these surpassed the critical level of significance once the 
Bonferroni correction had been applied. 
Table 3.3-35 Group C post hoc pair-wise analysis (p) of urine volume 
*
= significant difference at p<0.05 
Group C Paracetamol Glucuronide  Paracetamol Sulphate  Phase I Products 
1 0.219   0.031*   0.016*  
2 0.016* 0.078  0.016* 1  0.078 0.195 
3 0.043* 0.438  0.125 0.625  0.043* 0.313 
4 0.043* 0.043*  0.043* 0.625  0.125 0.043* 
Day -1 1  -1 1  -1 1 
3.3.5.4 GROUP D 
Clear trends emerged in the relative contributions of metabolites in Group D (Figure 
3.3-17). These include: 
 Steady reduction in contribution of paracetamol sulphate from 26% on the day of 
surgery to 9.6% on Day 4 sample 5; 
 Consistent contribution of paracetamol glucuronide remaining around 60%; and 
 Increased Phase I products from 14% preoperatively, to 25% in sample 6 on Day 3. 
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Figure 3.3-17 Contribution of each metabolite to overall recovery 
Values reported as group medians. Abbreviations used: PGlu= paracetamol glucuronide; PSul= paracetamol sulphate; 
PCys= paracetamol cysteine; PMer= paracetamol mercapturate; P= paracetamol 
Summed daily values were assessed for variance using Friedman’s tests (Table 3.3-32). All 
metabolites showed significant differences over the entire study and within the 
postoperative period alone.  
Table 3.3-36 Results of Friedman’s test 
*
= significant difference at p<0.05 
Group D Paracetamol 
Glucuronide 
Paracetamol 
Sulphate 
Phase I products 
χ2  p  13.5 (0.005)* 28.4 (<0.000)* 18.1 (<0.000)* 
Postop only χ2  p  12.75 (0.002)* 18.6 (<0.000)* 7.65 (0.049)* 
Post hoc tests were also conducted (Table 3.3-37). Significant differences arose from the 
increase in paracetamol glucuronide contribution between the beginning (preoperative 
and Day 1) and end of the study (Days 3 and 4), although none remained significant after 
Bonferroni correction. Conversely, all comparisons of paracetamol sulphate were highly 
significant; both the reduction from preoperative contributions to all postoperative 
values and again the further reduction from Day 1 to the following postoperative days. 
Only the comparisons with Day 4 just failed to meet the requirements of the Bonferroni 
correction. Phase I products increased significantly between the preoperative and all 
postoperative days, but do not show a significant change between Day 1 and Days 2, 3 or 
4. In these comparisons, all but the increase between Day -1 and 4 remain significant 
after Bonferroni correction. 
 260 
 
Table 3.3-37 Group D post hoc pair-wise analysis (p) of urine volume 
*
= significant difference at p<0.05 
Group D Paracetamol Glucuronide  Paracetamol Sulphate  Phase I Products 
1 0.898   0.001*   0.003*  
2 0.638 0.52  0.001* 0.001*  0.001* 0.32 
3 0.037* 0.047*  0.002* 0.002*  0.002* 0.695 
4 0.023* 0.049*  0.008* 0.008*  0.016* 0.461 
Day -1 1  -1 1  -1 1 
3.3.5.5 GROUP B+D 
Trends emerge once again in this combination group (Figure 3.3-18): 
 Paracetamol glucuronide began at 59% and fell to 50% in the first postoperative 
sample. Gradual increases followed to its peak contribution of 63% in sample 3, 
Day 3, before it fell again to 52% in the final sample; 
 Paracetamol sulphate began at 20%, increased to 26% in the first postoperative 
sample and then gradually reduced to around 11% by the end of the study; and 
 Phase I contributions increased steadily from 13% to around 25% and remained at 
this level for the remainder of the study.  
 
Figure 3.3-18 Contribution of each metabolite to overall recovery 
Values reported as group medians. Abbreviations used: PGlu= paracetamol glucuronide; PSul= paracetamol sulphate; 
PCys= paracetamol cysteine; PMer= paracetamol mercapturate; P= paracetamol 
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Table 3.3-38 shows the results of the Friedman’s tests conducted on the summed daily 
values. This shows highly significant differences for all comparisons aside from the 
examination of the Phase I products across the postoperative days.  
Table 3.3-38 Results of Friedman’s test 
*
= significant difference at p<0.05 
Group B+D Paracetamol 
Glucuronide 
Paracetamol 
Sulphate 
Phase I products 
χ2  p  17.36 (0.001)* 33.68 (<0.000)* 21.12 (<0.000)* 
Postop only χ2  p  12.709 (0.003)* 23.182 (<0.000)* 4.091 (0.266) 
Post hoc test results are also shown (Table 3.3-39). These confirm the observations made 
from Figure 3.3-18: There were significant increases in the proportion of paracetamol 
glucuronide between the first two days and the last two. All but the decrease between 
Day -1 and 4 failed to surpass the requirements of the Bonferroni correction. Paracetamol 
sulphate showed highly significant reductions between both of the first two days and all 
other days of the study. There were also highly significant increases in Phase I products 
between the preoperative day and all other days.  
Table 3.3-39 Group B+D, post hoc pair-wise analysis (p) of urine volume 
*
= significant difference at p<0.05 
Group 
B+D 
Paracetamol Glucuronide  Paracetamol Sulphate  Phase I Products 
1 0.735   <0.000*   0.001*  
2 0.305 0.241  <0.000* <0.000*  <0.000* 0.542 
3 0.009* 0.017*  <0.000* <0.000*  <0.000* 0.685 
4 0.006* 0.014*  0.002* 0.001*  0.004* 0.898 
Day -1 1  -1 1  -1 1 
3.3.6 CONTRIBUTION OF SULPHATE CONTAINING METABOLITES 
As paracetamol sulphate, cysteine and mercapturate rely on inorganic sulphate for their 
formation, changes to their contribution to urinary recovery across the study were also of 
interest. Inorganic sulphate is mostly derived from dietary protein and body stores of 
GSH. GSH is necessary for the conjugation of NAPQI. Reductions to this value in fasting 
individuals could indicate exhaustion of body stores GSH, and potentially the reduction in 
NAPQI conjugation. 
3.3.6.1 GROUP A 
A consistent downward trend emerges in the role of sulphate metabolites in urinary 
recovery of Group A (Figure 3.3-19). The contribution peaked just after surgery at 45.5% 
and fell steadily to 17.6% in the second to last sample. Within these results there was a 
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high degree of variability between participants with wide IQRs noticeable in the last two 
thirds of the study. 
 
Figure 3.3-19 Per cent of urinary metabolites excreted as sulphate derived compounds.  
Results shown as median % (±IQR) 
Metabolite amounts were summed into daily values and the percentage recalculated. 
Descriptives of these values are shown in Table 3.3-40, which also repeat the downward 
trend seen in Figure 3.3-19. 
Table 3.3-40 Summed daily recovery of sulphate derived metabolites in the urine- Median (LQ, UQ) 
% Day -1 Day 1 Day 2 Day 3 Day 4 
Median 
(IQR) 
36.185 
(29.189, 
42.704) 
39.657 
(34.002, 
50.449) 
28.171 
(23.641, 
40.135) 
21.269 
(16.862, 
30.455) 
21.591 
(15.228, 
32.218) 
Friedman’s tests were conducted across the entire study and in the postoperative period 
only using these daily values (Table 3.3-41). Both comparisons showed highly significant 
differences across the days tested.  
Table 3.3-41 Friedman’s test e amining differences in urinary recovery of sulphate derived metabolites across study 
*
= significant difference at p<0.05 
χ2  p  23.911 (<0.000)* 
χ2  p Postop only 17.933 (<0.000)* 
Post hoc tests were performed using two tailed, exact Wilcoxon signed rank tests (Table 
3.3-42). Highly significant differences were seen in the comparison of the early days of 
the study with the last two days, confirming the trends observed in Figure 3.3-19. These 
were the only comparisons to remain significant after Bonferroni correction.  
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Table 3.3-42 Post hoc pair-wise analysis (p) of urinary recovery of sulphate derived metabolites 
*
= significant difference at p<0.05 
Group A  
1 0.139  
2 0.093 0.01* 
3 0.008* 0.004* 
4 0.012* 0.004* 
Day -1 1 
3.3.6.2 GROUP B 
Figure 3.3-20 shows less of a decline in contribution of sulphate derived metabolites for 
Group B than with Group A, but still one is apparent, especially on Day 1. From their peak 
of 46.5% early on the first postoperative day, values fell and remained around 36% for all 
of the second and most of the third postoperative day. The sulphate contribution then 
recovers slightly to finish on 40.5%. 
 
Figure 3.3-20 Per cent of urinary metabolites excreted as sulphate derived compounds.  
Results shown as median % (±IQR) 
As previously, daily values were calculated and their descriptives are presented in Table 
3.3-43. These show the largest reduction from the second postoperative day. 
Table 3.3-43 Summed daily recovery of sulphate derived metabolites in the urine- Median (LQ, UQ) 
% Day -1 Day 1 Day 2 Day 3 Day 4 
Median 
(IQR) 
37.583 
(35.866, 
53.753) 
44.400 
(36.761, 
57.324) 
37.264 
(32.868, 
46.601) 
38.408 
(31.999, 
44.873) 
38.979 
(30.499, 
52.344) 
The statistical significance of the reductions observed in the descriptive values was tested 
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with Friedman’s tests (Table 3.3-44). No significant differences were seen. Post hoc tests 
also did not show significant changes (data not shown).  
Table 3.3-44 Friedman’s test e amining differences in urinary recovery of sulphate derived metabolites across study 
*
= significant difference at p<0.05 
χ2  p  6.133 (0.189) 
χ2  p Postop only 5.700 (0.127) 
3.3.6.3 GROUP C 
In comparison with the previous groups, Group C showed very little alteration in the 
recovery of sulphate metabolites (Figure 3.3-21).  
 
Figure 3.3-21 Per cent of urinary metabolites excreted as sulphate derived compounds.  
Results shown as median % (±IQR) 
Daily values were prepared as with previous groups. The contribution began at 39.3% and 
remained within 5% of this value for the remainder of the study. Median values are 
consistent in the high 30%s but fall slightly on the last day of the study (Table 3.3-45). 
Table 3.3-45 Summed daily recovery of sulphate derived metabolites in the urine- Median (LQ, UQ) 
% Day -1 Day 1 Day 2 Day 3 Day 4 
Median 
(IQR) 
39.293 
(31.996, 
42.749) 
39.873 
(35.175, 
44.382) 
37.349 
(33.166, 
43.405) 
39.381 
(33.995, 
46.481) 
35.953 
(33.073, 
40.678) 
Table 3.3-46 shows the results of Friedman’s tests. Only the comparison within the 
postoperative period showed a significant difference at p<0.05, however, the comparison 
across all days of the study shows evidence of an association with a p=0.056.  
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Table 3.3-46 Friedman’s test e amining differences in urinary recovery of sulphate derived metabolites across study 
*
= significant difference at p<0.05 
χ2  p  8.8 (0.056) 
χ2  p Postop only 9 (0.02)* 
As could be expected from the values in Table 3.3-45, the post hoc analysis shows only 
one significant difference at p<0.05, between Day 1 and Day 4 (Table 3.3-47).  
Table 3.3-47 Post hoc pair-wise analysis (p) of urinary recovery of sulphate derived metabolites 
*
= significant difference at p<0.05 
Group C  
1 0.176  
2 0.398 0.263 
3 0.345 0.5 
4 0.138 0.043* 
Day -1 1 
3.3.6.4 GROUP D 
Figure 3.3-22 shows Group D’s gradual decline in the contribution of sulphate containing 
metabolites to overall urinary recovery. Starting at 35.9% preoperatively, values increased 
to 44% at the end of Day 1 and then fell to 29.9% by the beginning of the third day. 
Values then recovered to 34.0% by the end of the study. 
 
Figure 3.3-22 Per cent of urinary metabolites excreted as sulphate derived compounds.  
Results shown as median % (±IQR) 
Daily values showed a similar pattern of decline, with median values reducing by 8% 
between Day 1 and 3 which was then maintained into Day 4 (Table 3.3-48). IQRs were 
wide at the beginning of the study, but as the contribution of sulphate metabolites 
reduced so did the IQR. 
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Table 3.3-48 Summed daily recovery of sulphate derived metabolites in the urine- Median (LQ, UQ) 
% Day -1 Day 1 Day 2 Day 3 Day 4 
Median 
(IQR) 
35.927 
(27.675, 
41.189) 
41.969 
(33.881, 
46.898) 
36.964 
(36.282, 
39.085) 
33.973 
(30.78, 
36.962) 
33.824 
(32.453, 
36.915) 
Table 3.3-49 shows Friedman’s tests results conducted on these values. Significant 
differences were seen in both comparisons, with the postoperative only comparison 
showing a highly significant difference.  
Table 3.3-49 Friedman’s test e amining differences in urinary recovery of sulphate derived metabolites across study 
*
= significant difference at p<0.05 
χ2  p  12 (0.011)* 
χ2  p Postop only 11.55 (0.005)* 
Table 3.3-50 shows one significant difference at p<0.05 in the increase between the 
preoperative day and the first postoperative day. Two more significant differences were 
seen in the reduction of contribution between Day 1 and Days 3 and 4. However, these p 
values do not achieve significance after Bonferroni correction. 
Table 3.3-50 Post hoc pair-wise analysis (p) of urinary recovery of sulphate derived metabolites 
*
= significant difference at p<0.05 
Group D  
1 0.019*  
2 0.091 0.182 
3 0.799 0.027* 
4 0.674 0.05* 
Day -1 1 
3.3.6.5 GROUP B+D 
 
Figure 3.3-23 Per cent of urinary metabolites excreted as sulphate derived compounds.  
Results shown as median % (±IQR) 
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Once again the Group B+D comparison shows trends largely similar to Group D, with a 
small increase postoperatively, followed by a slight decline in values (Figure 3.3-23). Daily 
values peaked on Day 1 at 43.2% and fell gradually to Day 4 (34.1%) (Table 3.3-51). 
Table 3.3-51 Summed daily recovery of sulphate derived metabolites in the urine- Median (LQ, UQ) 
% Day -1 Day 1 Day 2 Day 3 Day 4 
Median 
(IQR) 
35.927 
(28.79, 
41.671) 
43.241 
(33.944, 
47.394) 
37.264 
(36.509, 
40.553) 
35.113 
(31.752, 
38.975) 
34.056 
(33.095, 
42.332) 
Friedman’s tests examined for significant differences across all days of the study and 
across the postoperative period only. Both tests showed significant results (Table 3.3-52). 
Table 3.3-52 Friedman’s test e amining differences in urinary recovery of sulphate derived metabolites across study 
*
= significant difference at p<0.05 
χ2  p  13.92 (0.004)* 
χ2  p Postop only 12.273 (0.004)* 
Table 3.3-53 shows the results of the pos-hoc tests. Significant differences arose in the 
increase from Day-1 to Day 1 and the decrease from Day 1 to Day 3 and 4. However, none 
of these results achieve significance after the Bonferroni correction was applied. 
Table 3.3-53 Post hoc pair-wise analysis (p) of urinary recovery of sulphate derived metabolites 
*
= significant difference at p<0.05 
Group B+D  
1 0.013*  
2 0.133 0.074 
3 0.480 0.008* 
4 0.575 0.01* 
Day -1 1 
3.3.7 RATIO OF METABOLITES PHASE II: PHASE I  
As discussed in the introduction to this results section, changes to urine flow can have a 
significant impact on the fractional urinary recovery of paracetamol. As shown in Section 
3.3.3, there were significant changes to urine flow across the study and this could 
potentially invalidate this type of metabolic ratio. Because the fractional urinary recovery 
of paracetamol’s metabolites was comparatively free from the factors that affect the 
recovery of paracetamol itself, ratios that compared the recovery of Phase II to Phase I 
products in the urine were prepared. As such, it is the most useful indicator of changes in 
contribution of each metabolic pathway to the overall clearance of paracetamol. 
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3.3.7.1 GROUP A 
Figure 3.3-24 shows a steep reduction in metabolite ratio from a preoperative value of 
8.5 to 2.6 in sample 3, Day 1.  
 
Figure 3.3-24 Ratio of Phase II: Phase I metabolites of paracetamol (median ±IQR) 
The ratio then increased gradually to its preoperative value by the end of Day 3, peaking 
at 10.5 in sample 4 Day 4. IQRs increased sharply from the preoperative to first 
postoperative sample, and then gradually declined to their narrowest on Day 2. Daily 
ratios were again calculated. Descriptives are shown in Table 3.3-54 and a box plot 
derived from these values is shown in Figure 3.3-25. 
Table 3.3-54 Ratio of metabolites in daily urine 
Shown as median (LQ, UQ) 
 
Figure 3.3-25 Box plot of metabolite ratio 
Ratio Median (IQR) 
Day -1 8.54 (7.12, 11.28) 
Day 1 2.99 (2.33, 5.55) 
Day 2 3.80 (1.99, 4.23) 
Day 3 5.50 (5, 7.63) 
Day 4 8.68 (5.52, 10.8) 
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Friedman’s tests on these values are shown (Table 3.3-55) which shows the differences 
observed achieved statistical significance.  
Table 3.3-55 Friedman’s test e amining differences in urinary recovery of dose across study 
*
= significant difference at p<0.05 
χ2  p  21.956 (0.000)* 
χ2  p Postop only 13.4 (0.002)* 
Post hoc tests using exact Wilcoxon matched pairs were again performed to compare the 
preoperative day with all postoperative days and also the first postoperative day to the 
remaining postoperative days. Prior research indicated the ratio only went down 
following surgery and accordingly only one tailed tests were used in the comparison of 
preoperative and postoperative values(Kennedy 2009a). However, as the direction of 
change from the first postoperative day to the other postoperative days was unknown, 
two tailed tests were used. Table 3.3-56 shows the results of these tests.  
Table 3.3-56 Group A, post hoc pair-wise analysis (p) of urine volume 
*
= significant difference at p<0.05 
Group A  
1 0.001*  
2 0.001* 0.846 
3 0.004* 0.012* 
4 1.000 0.012* 
Day -1 
(1 tailed) 
1 
(2 tailed) 
The decrease between the preoperative day and Days 1, 2 and 3 were all highly significant 
and all surpass Bonferroni correction. The two tailed tests showed the ratio increased 
significantly between Day 1 and Days 3 and 4 postoperatively, but these are not above 
the p value required for significance after the Bonferroni correction is considered. 
3.3.7.2 GROUP B 
There was a gradual reduction in metabolite ratio from 7.9 preoperatively to 3.8 in the 
last urine sample (Figure 3.3-26). The consistency of this decline was interrupted by a 
brief increase at the beginning of Day 2, peaking at 5.5, before declining again. 
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Figure 3.3-26 Ratio of Phase II: Phase I metabolites of paracetamol (median ±IQR) 
The daily values were again calculated and the descriptives (Table 3.3-57) and box plot 
(Figure 3.3-27) arising from these are shown. The median values showed a clear reduction 
from the preoperative sample. Postoperative ratios remain relatively constant.  
Table 3.3-57 Ratio of metabolites in daily urine 
Shown as median (LQ, UQ) 
 
Figure 3.3-27 Box plot of metabolite ratio 
Ratio Median (IQR) 
Day -1 5.52 (4.05, 8.89) 
Day 1 3.09 (2.22, 4.06) 
Day 2 2.44 (2.09, 3.18) 
Day 3 3.06 (2.49, 3.23) 
Day 4 2.43 (2.03, 2.92) 
  
Freidman’s tests were also conducted (Table 3.3-58). Given the small number of patients 
in this group, the finding of a significant difference at p<0.05 between all days of the 
study was unexpected. No significant difference at p<0.05 was seen in the comparison of 
the postoperative days. Post hoc tests were conducted and did not show any significant 
difference at p<0.05 (data not shown). 
Table 3.3-58 Friedman’s test e amining differences in ratio of Phase II:I metabolites in daily urine 
*
= significant difference at p<0.05 
χ2  p  7.6 (0.042)* 
χ2  p Postop only 5 (0.207) 
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3.3.7.3 GROUP C 
Group C began with the lowest preoperative ratio of all groups at 4.6 (Figure 3.3-28). This 
ratio fell gradually to 2.2 halfway through the first postoperative day and remained 
between 2.5 and 3.0 for the remainder of the study. 
 
Figure 3.3-28 Ratio of Phase II: Phase I metabolites of paracetamol (median ±IQR) 
Daily ratios were determined and descriptives (Table 3.3-59) and a box plot (Figure 
3.3-29) were prepared. These show the reduction from preoperative values and also 
show little variability in the data between patients, as IQRs were narrow. 
Table 3.3-59 Ratio of metabolites in daily urine 
Shown as median (LQ, UQ) 
 
Figure 3.3-29 Box plot of metabolite ratio 
Ratio Median (IQR) 
Day -1 4.578 (3.387, 6.224) 
Day 1 2.425 (2.028, 2.922) 
Day 2 3.086 (2.224, 4.055) 
Day 3 2.435 (2.092, 3.176) 
Day 4 3.058 (2.494, 3.232) 
  
Freidman’s tests (Table 3.3-60) were conducted on the daily values.  
Table 3.3-60 Friedman’s test e amining differences in urinary recovery of dose across study 
*
= significant difference at p<0.05 
χ2  p  10.72 (0.018)* 
χ2  p Postop only 8.76 (0.023)* 
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Significant differences were seen in both comparisons. Post hoc tests showed the 
decrease between the preoperative day and Days 1, 2 and 3 reached significance. In the 
comparisons of Day 1 and the remaining postoperative days, only the increase between 
Day 1 and Day 4 reached significance (Table 3.3-61). However, none of these comparisons 
achieve significance after the Bonferroni correction was applied. 
Table 3.3-61 Group C, post hoc pair-wise analysis (p) of urine volume 
*
= significant difference at p<0.05 
Group C  
1 0.016*  
2 0.023* 0.109 
3 0.031* 0.313 
4 0.063 0.043* 
Day -1 
(1 tailed) 
1 
(2 tailed) 
3.3.7.4 GROUP D 
The ratio in this group began at 6.1 and fell sharply to 2.3 at end of Day 1. The ratio 
remained consistent from this point, ranging between 3 and 3.5 (Figure 3.3-30). 
 
Figure 3.3-30 Ratio of Phase II: Phase I metabolites of paracetamol (median ±IQR) 
Four hourly values were summed and used to produce the descriptive statistics (Table 
3.3-62) and boxplot (Figure 3.3-31) shown. Median daily values show a marked reduction 
in ratio and remain consistent postoperatively. Variability between patients also reduced 
postoperatively as shown by the narrow IQRs. 
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Table 3.3-62 Ratio of metabolites in daily urine 
Shown as median (LQ, UQ) 
 
Figure 3.3-31 Box plot of metabolite ratio 
Ratio Median (IQR) 
Day -1 6.064 (3.877, 9.827) 
Day 1 2.967 (2.618, 4.095) 
Day 2 2.891 (2.408, 3.067) 
Day 3 3.278 (2.859, 3.475) 
Day 4 3.322 (2.945, 3.816) 
  
Friedman’s tests were conducted on these daily values and both comparisons showed 
statistically significant differences across the days they examined (Table 3.3-63). A greater 
degree of significance was observed when the preoperative value was included.  
Table 3.3-63 Friedman’s test e amining differences in urinary recovery of dose across study 
*
= significant difference at p<0.05 
χ2  p  17.1 (0.000)* 
χ2  p Postop only 7.65 (0.049)* 
Post hoc tests showed significance in the decrease between the preoperative ratio and all 
postoperative ratios, with the comparison with all but Day 4 remaining so after 
Bonferroni correction. However, the postoperative comparisons did not show any 
evidence of a significant change (Table 3.3-64). 
Table 3.3-64 Group D, post hoc pair-wise analysis (p) of urine volume 
*
= significant difference at p<0.05 
Group D  
1 0.002*  
2 0.000* 0.067 
3 0.001* 0.922 
4 0.02* 0.641 
Day -1 
(1 tailed) 
1 
(2 tailed) 
3.3.7.5 GROUP B+D 
The ratio in this combined group largely reflected the contribution of Group D, with the 
most notable difference being the increase in IQR, especially in towards the end of the 
study (Figure 3.3-32). The preoperative ratio was slightly increased to 6.3, but followed a 
similar trend, decreasing until the end of Day 1 and remaining fairly constant for the 
remainder of the study. 
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Figure 3.3-32 Ratio of Phase II: Phase I metabolites of paracetamol (median ±IQR) 
Values were pooled into daily intervals and used to prepare the descriptives (Table 
3.3-65) and box plot shown (Figure 3.3-33). As described above, this is largely similar to 
Group D with a marked reduction following surgery. The main effect of the addition of 
Group B is the widening of IQRs and the appearance of outlying values shown in Figure 
3.3-33. 
Table 3.3-65 Ratio of metabolites in daily urine 
Shown as median (LQ, UQ) 
 
Figure 3.3-33 Box plot of metabolite ratio 
Ratio Median (IQR) 
Day -1 6.064 (3.807, 10.154) 
Day 1 2.948 (2.537, 4.177) 
Day 2 2.945 (2.317, 3.429) 
Day 3 3.212 (2.545, 3.49) 
Day 4 3.322 (2.325, 3.83) 
  
Table 3.3-66 shows the results of the Friedman’s tests performed on these ratios. As 
could be predicted from Figure 3.3-33 significant differences were seen in the comparison 
of all days of the study but not within the postoperative period alone. 
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Table 3.3-66 Friedman’s test e amining differences in urinary recovery of dose across study 
*
= significant difference at p<0.05 
χ2  p  20.96 (0.000)* 
χ2  p Postop only 5.509 (0.146) 
Post hoc tests (Table 3.3-67) show highly significant reductions between the preoperative 
ratio and all the postoperative days. As predicted by the Friedman’s test, no significant 
differences were seen in the postoperative comparisons. 
Table 3.3-67 Group B+D, post hoc pair-wise analysis (p) of urine volume 
*
= significant difference at p<0.05 
Group B+D  
1 0.001*  
2 0.000* 0.135 
3 0.000* 1 
4 0.005* 0.966 
Day -1 
(1 tailed) 
1 
(2 tailed) 
3.3.8 FACTORS EFFECTING RATIO OF PHASE II: PHASE I PRODUCTS 
From the above results there appeared to be a clear difference in metabolic ratio 
following surgery. There are, however, a number of other factors amongst surgical 
patients that could affect the urinary concentration of metabolites, aside from surgery 
itself. These were examined below to see if they were a strong influence, potentially 
obscuring what appeared to be the effect of surgery.  
In addition to those detailed below, the effects of age and BMI on the metabolic ratio 
were also assessed using a Spearman’s correlation; however the number of patients in 
each group were too low for this to give meaningful results.  
3.3.8.1 GENDER 
Graphs of the metabolite ratio for males and females patients were produced for Group A 
and Groups B+D (Figure 3.3-31). No gender analysis was performed on Group C as all 
patients were female. 
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Figure 3.3-34 Changes in metabolite ratio across study period for males and females in Group A (top) and B+D 
(bottom) 
There were no clear differences in metabolite ratio between genders in either figures and 
both genders followed a very similar course (Figure 3.3-34) although the ratio tended to 
be higher in Group A females. As an estimate of the relationship between genders, two 
tailed Spearman’s correlations were prepared for the two groups based on the median 
values for each gender (Table 3.3-68). The metabolic ratio of males in Group A was highly 
correlated with, and accounted for 68% of the variability of the females’ metabolic ratio. 
In Group B+D, while there was evidence of an association, it was not statistically 
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significant and therefore a difference in metabolic ratio between genders could not be 
ruled out. 
Table 3.3-68 Results of Spearman’s correlation of metabolic ratios between genders 
*
= significant difference at p<0.05 
 Ρ ρ2 Sig (2 tailed) 
Group A 0.826 0.682 <0.000 
Group B+D 0.319 0.102 <0.148 
 
Figure 3.3-35 Correlation of median metabolic ratio between genders in Group B+D before (left) and after (right) 
ranking 
R
2
 values relate to Pearson’s correlation co-efficients, which is equivalent to the Spearman’s correlation co-efficient 
when based on ranked data (right plot) 
Examination of the left graph in Figure 3.3-35 does visually show a relationship. However, 
because the metabolite ratios were non-parametric, the correct means of assessment 
was with a Spearman’s correlation which uses ranked data. The problem with ranking 
data in small data sets is weakening of correlations because the magnitude of the values 
is not taken into account (Figure 3.3-35). A Pearson’s correlation on the unranked data 
did show a significant correlation, but this is not an appropriate test for non-parametric 
data. Accordingly, a further test of Group B+Ds data was necessary to determine if the 
genders were significantly different. A Mann-Whitney test was used to determine this and 
no significant difference between genders at p<0.05 was found (z=0.276, p=0.783). 
3.3.8.2 DOSE RECOVERED IN THE URINE 
A second potential influence is the amount of the dose recovered in the urine within any 
given interval. A relationship between these would indicate that some metabolites are 
more readily excreted in the urine than others causing the metabolic ratio to vary with 
dose recovery, which itself varied across the study (Section 3.3.4). 
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To examine the relationship, dot plots were first prepared plotting the four-hourly ratios 
against the per cent of dose recovered in the same urine samples (Figure 3.3-36). No 
relationship was apparent in any group.  
 
Figure 3.3-36 Dot plots of metabolite ratio and urinary dose recovery, showing values arising from each day 
Spearman’s correlations were then carried out on these values (Table 3.3-69).  
Table 3.3-69 Results of Spearman’s correlation between of metabolite ratio and urinary dose recovery 
*
= significant difference at p<0.05 
 N Ρ ρ2 Sig (2 tailed) 
Group A 245 -0.187 0.035 0.003* 
Group B 77 -0.042 0.002 0.714 
Group C 133 -0.150 0.023 0.086 
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Group D 219 -0.069 0.005 -0.069 
Group B+D 296 -0.063 0.004 0.283 
Only Group A showed a significant association, however with only 3.5% of the variability 
of the metabolic ratio being explained by dose recovery, the influence was very minor.  
3.3.8.3 URINARY OUTPUT 
As with dose recovery, the possibility of urinary output influencing the metabolic ratio 
was also investigated. Dot plots were prepared (Figure 3.3-37) followed by Spearman’s 
correlations (Table 3.3-70) as in the previous section. Graphically, no relationship 
appears, nor does there appear to be any difference in distribution amongst the days of 
the study. 
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Figure 3.3-37 Dot plots of metabolite ratio and urine volume, showing values arising from each day 
The Spearman’s correlations revealed a highly significant relationship occurring in Group 
A, however urine volume only accounted for 16% of the variance of metabolic ratio 
(leaving the remaining 84% to be explained by other factors). No other group showed a 
significant relationship or co-efficient of determination.  
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Table 3.3-70 Results of Spearman’s correlation between of metabolite ratio and urinary dose output 
*
= significant difference at p<0.05 
 N Ρ ρ2 Sig (2 tailed) 
Group A 245 0.403 0.162 0.000* 
Group B 77 0.147 0.022 0.201 
Group C 133 0.076 0.006 0.386 
Group D 219 0.005 0.000 0.936 
Group B+D 296 0.078 0.006 0.183 
3.3.8.4 SAMPLE INTERVAL (TIME OF DAY) 
The possibility of diurnal differences was also investigated. Dot plots were prepared 
contrasting the metabolic ratio against the day of the study.  
 
Figure 3.3-38 Dot plots of metabolite ratio and study day showing values arising from each sample interval 
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For each day of the study the six sample intervals were given a different colour. Banding 
of the colours in the graph would indicate a circadian variation (Figure 3.3-38). As no clear 
patterns of colour banding emerged in Groups A, B and C there was no evidence of 
diurnal variation in metabolic ratio in these groups. In Groups D and B+D some banding 
did appear to occur, with interval 6 appearing to cluster around the bottom of Days 1, 2 
and 3. Further examination of the data revealed this was a product of the order which the 
data points are applied or “stacked” on the graph by the statistical software, and that all 
data clustered around this point. To confirm this for Group B+D, day numbers were 
removed from metabolic ratio results, and a box plot was prepared from these data that 
contained interval numbers only. This showed that no interval’s metabolic ratio sits 
clearly above any other interval (Figure 3.3-39). Additionally, a Friedman’s test was 
conducted to establish if there was any statistical evidence of difference between the 
intervals, and none was seen (χ2 22.576, p=0.319) (data not shown). 
 
Figure 3.3-39 Box plot of metabolite ratio for each sample interval across all days 
3.3.8.5 METABOLITES 
Because four compounds contribute to the metabolic ratio, the question arises regarding 
how changes to a metabolite concentration affect the metabolite ratio, and whether one 
metabolite had a predominant effect on the ratio. To ascertain this, the metabolic ratio 
was plotted against the amount of each metabolite in the urine (the two Phase I products 
were again summed to give a single value as previously discussed). To determine the 
nature of their interaction a line of best fit was applied. Spearman’s correlation 
coefficients were also determined to assess the strength of the association between each 
metabolite and the metabolic ratio (Table 3.3-71). While partial correlations may have 
provided more information about these relationships, they cannot be used on non-
parametric data.  
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Table 3.3-71 Results of Spearman’s correlation between metabolite ratio and amount of each metabolite in urine 
*
= significant difference at p<0.05 
 Paracetamol Glucuronide Paracetamol Sulphate Phase I products 
Group Ρ ρ2 Sig (p) Ρ ρ2 Sig (p) Ρ ρ2 Sig (p) 
A 0.126 0.016 (0.031)* -0.047 0.002 (0.422) -0.665 0.442 (<0.00)* 
B 0.406 0.165 (<0.00)* 0.373 0.139 (<0.00)* -0.739 0.546 (<0.00)* 
C -0.050 0.003 (0.546) 0.011 0.000 (0.894) -0.418 0.175 (<0.00)* 
D 0.074 0.005 (0.258) 0.143 0.020 (0.028)* -0.450 0.203 (<0.00)* 
B+D 0.175 0.031 (0.002)* 0.162 0.026 (0.003)* -0.540 0.292 (<0.00)* 
Figure 3.3-40 shows the dot plot for all groups.  
 
 
Figure 3.3-40 Contribution of each metabolite to metabolic ratio and lines of best fit for each group 
Abbreviations: PGlu= paracetamol glucuronide; PSul= paracetamol sulphate; Phase I: total of paracetamol cysteine and 
paracetamol mercapturate.  
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In Group A, the slope of the line of best fit for both Phase II metabolites was fairly flat, 
indicating very little of the variation in metabolite amount explained the variation in 
metabolite ratio. There was also a high dispersion on either side of the best fit line, 
especially in the case of paracetamol glucuronide. This indicated the best fit line itself was 
a poor reflection of the data. Phase I metabolites cluster to the left of the graph and were 
represented by a best-fit line with a step negative slope, indicating that as amounts of 
Phase I values increased, metabolic ratio fell. The results of the correlation in Table 3.3-71 
showed highly significant correlations between the metabolite ratio and paracetamol 
glucuronide and Phase I metabolites. However, while the correlation of the Phase I 
products appears strong (ρ2=44.2%), the coefficient of determination for paracetamol 
glucuronide is small, accounting for just 1.6% of the variation in metabolite ratio.  
For Group B the associations appeared stronger, displaying generally the same directional 
relationship between metabolites and ratio as Group A. Highly significant relationships 
were seen between all metabolites and metabolic ratio. Coefficients of determination 
were greater than in Group A, with Phase I metabolites one again showing the strongest 
relationship, accounting for 54.6% of the variance of metabolic ratio in this group.  
Group C metabolites clustered together towards the origin of the graph and did not show 
any clear relationships with metabolic ratio. As previously, a significant correlation 
between Phase I metabolites and metabolic ratio was found, but it accounted for only 
17.5% of the variation.  
A similar clustering of data was seen in Group D with no clear associations emerging 
visually. Correlation revealed that there were two significant relationships: a weak 
correlation with paracetamol sulphate; and a stronger correlation with Phase I amounts 
which explained 20.3% of the variation.  
Group B+D showed no relationships between metabolic ratio and any metabolite visually. 
Correlation showed significant relationships with all three metabolites, however the 
relationship with the Phase I metabolites was very weak. A stronger relationship was seen 
with the Phase I metabolites, accounting for 29.2% of the variation.  
In summary, the strongest relationship determined by correlation was consistently that 
between metabolic ratio and Phase I metabolites.  
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3.3.8.6 REGRESSION 
It was intended to use a multivariate method on the data from all samples to examine the 
relationship between the Phase II to Phase I metabolites ratio and the other variables; 
initially urine volume, sample number and total amount in the urine. Such analysis was 
attempted using multiple regression. Although the data going into the multiple regression 
model do not have to be normally distributed, the residuals from the generated model 
must. Analysis of the residuals showed that this assumption was violated. This finding 
applied across all groups and a sample is presented from Group A in Figure 3.3-41. This 
shows how the distribution of the residuals from Group A is non-normal, with a skewed 
histogram and deviation in the P-P plot from the normal line. This indicated that the 
model was invalid and could not be relied on for the description of the data.  
 
Figure 3.3-41 Histogram (left) and P-P plot (right) testing normality of regression residuals for Group A.  
Data failed tests for normality as histogram (left) was well outside imposed normal curve and P-P plot (right) did not fall 
along the line of normality. 
3.3.9  SUMMARY  
Several changes were seen to the pattern of excretion of paracetamol metabolites 
following surgery. These changes were most discernible in the high dose group, Group A, 
in whom the large metabolic capacity of glucuronide metabolism was seen. Group A also 
had increased excretions of paracetamol cysteine, one of the metabolites derived from 
the toxic intermediary NAPQI, in addition to marked reductions in paracetamol sulphate. 
Similar patterns of change were shown in Group B and D, although to a lesser degree, 
while the way paracetamol was excreted in Group C did not appear to change noticeably.  
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3.4 PLASMA RESULTS 
Plasma analysis is essential for determining accurate drug pharmacokinetics and most 
pharmacokinetic parameters are derived from a plasma concentration time series. 
Paracetamol is found in high concentrations in plasma as it has a low Vd and, as 
previously discussed in Section 2.2, its extraction from plasma is relatively straight 
forward. In addition to these pharmacokinetic values, when concentrations are at steady 
state, comparison of single time-point concentrations of paracetamol in plasma between 
days can also provide information about changes to drug disposition. For the purposes of 
this study, chromatograms were obtained, as described in Section 2.2 (Figure 3.4-1).  
 
Figure 3.4-1 Sample chromatogram of absorbance of paracetamol and its metabolites in patient plasma  
Chromatogram obtained from injection of patient 5A plasma (30min after dose on day 1) at UV 242nm and shows 
compound and retention time (mins). Retention times (in minutes) for paracetamol and its metabolites were: 
paracetamol glucuronide 6.78; paracetamol cysteine 9.37; paracetamol sulphate 10.31; paracetamol 12.46; and 
paracetamol mercapturate 16.18 
These were used to determine the concentrations of paracetamol and its metabolites in 
plasma samples taken at the times shown in Table 2.1-1. As with the urine data, 
concentrations below the LOD were set to zero and concentrations between the LOQ and 
LOD were set to half the LOD (Shah et al. 1992). Plasma concentrations were then 
converted to molar concentrations. Although paracetamol was administered at regular 
intervals throughout each day postoperatively, only one dose interval per day was 
monitored with plasma sampling, postoperatively, this was usually the 10pm scheduled 
dose. The following plasma samples were taken as shown in Table 2.1-1:  
 A full pharmacokinetic profile following the one preoperative paracetamol dose;  
 A second full pharmacokinetic profile following the 10pm paracetamol dose on 
the first postoperative day; and 
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 Samples at 0, 1 and 4hrs following the 10pm paracetamol dose on subsequent 
postoperative days. 
Accordingly data presented for Days 2, 3 and 4 arise only from the 0, 1 and 4 hour 
samples taken on those days. 
Concentrations were used to calculate various pharmacokinetic parameters on the 
preoperative and first postoperative day. On days 2, 3 and 4 the 1 and 4 hour samples 
were then tested for changes over the duration of the study. Plasma concentrations of a 
typical patient are presented in Figure 3.4-2. 
 
Figure 3.4-2 Plasma and metabolite concentrations for Patient 4B  
Concentrations shown as measured over monitored dose interval on each day of the study. Data shown for days 2, 3 and 
4 arise from 0, 1 and 4hr samples. Abbreviations: PS- paracetamol sulphate; PM- paracetamol mercapturate; PG- 
paracetamol glucuronide; PC- paracetamol cysteine; P- paracetamol 
Statistical tests were performed using PASW Statistics 18, Release Version 18.0.0 (SPSS, 
Inc., 2009, Chicago, Illinois), with a critical level of significance of α=0.05. The distribution 
of paracetamol and metabolite concentrations, and the pharmacokinetic values derived 
from them, were checked visually for normality and by using the Kolmogorov-Smirnov 
test (D). Data did not fulfil conditions for normality and accordingly non-parametric tests 
were used. The critical level of significance was 0.05.  
3.4.1 PARACETAMOL HALF-LIFE 
Half-lives (t½) were determined for the day before and the day after surgery using 
Equation 3.4-1.  
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Equation 3.4-1 Plasma half life 
t½ is a translation of the co-efficient of elimination (k) determined from the slope of the 
elimination phase of the semilogarithmic concentration vs. time plot. It is the relationship 
between the rate of elimination and the amount of drug in the body (Equation 3.4-2). 
  
                    (    )
               (    )
  
  
  
 
Equation 3.4-2 Elimination rate constant determined by clearance (Cl), concentration (C) and distribution volume (Vd) 
The half-lives are displayed in Figure 3.4-3 along with a trend line for each patient. 
 
Figure 3.4-3 Pre and postoperative half-lives (hours) 
Graphs (clockwise from top left): Group A, B, C and D 
The postoperative half-lives for Group A almost uniformly increased, with only patients 
3A and 10A exhibiting slight decreases (Pt3A- pre 1.62, post 1.64; Pt10A- pre 1.60, post 
1.58). No other group showed such a consistent trend with most other patients’ half-lives 
remaining the same or slightly decreasing. This is also reflected in the descriptive statistics 
(Table 3.4-1) where again Group A showed an increase in half-life.  
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One tailed exact Wilcoxon signed-rank tests were conducted to examine the changes to 
this paired data for significance (Table 3.4-1). This confirmed that Group A was the only 
group to exhibit a significant change.  
Table 3.4-1 Half-life descriptives and statistical analysis 
Descriptives are presented as median (lower quartile, upper quartile) in hours. Wilcoxon matched pair results are 
presented as Z statistic and p value. * indicates significant result, where p<0.05. 
Group Day -1 Day 1 
 
Difference 
between days 
Day -1=1 
Wilcoxon matched 
pairs.  
A 1.75 (1.59, 2.11) 2.13 (1.80, 3.25) 0.62 (0.02, 1.6) 2.100 p 0.020* 
B 1.97 (1.64, 2.11) 2.09 (1.49, 3.14) 0.15 (0.02, 0.16) 0.000 p 0.625 
C 1.94 (1.60, 3.43) 1.89 (1.25, 2.27) 0.12 (0.01, 0.23) 1.342 p 0.250 
D 2.06 (1.82, 2.40) 1.89 (1.63, 2.19) 0.07 (-0.22, 0.25) 0.944 p 0.219 
3.4.2 PARACETAMOL AREA UNDER THE CONCENTRATION VS. TIME CURVE 
The area under the concentration versus time curve (AUC) relates both dose and 
clearance (Equation 3.4-3). 
    
    
  
 
Equation 3.4-3 Relationship between AUC, dose and clearance (CL) 
AUC was calculated over a dose interval (0-τ) at steady state with the trapezoid rule from 
the concentration time curve (Equation 3.4-4). 
       ∑(       )  
(       )
 
   
   
 
Equation 3.4-4 Calculation of AUC using trapezoid rule 
0-τ=dose interval, t=time, c=concentration, n=total number of concentration points, i= ith concentration time value  
AUC for a single dose was determined out to infinity (0-∞). At steady state: 
              
Equation 3.4-5 Relationship between single dose and steady state AUC 
Determining AUC(0-∞) for a single dose requires the calculation of the area from the last 
measured concentration (Clast) until it reaches zero. This was achieved by the division of 
(Clast) by the constant k, which was then added to AUC(0-τ) 
               (
     
 
) 
Equation 3.4-6 Calculation of AUC0-∞ for a single dose 
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The AUC was determined for the day before (Equation 3.4-6) and the day after surgery 
(Equation 3.4-4) and then divided by dose. These are shown in Figure 3.4-4. The AUC 
increased for the majority of Group A patients, although there was a marked reduction 
for patient 1A. For most patients in the other groups the AUC remained constant or 
reduced slightly. A significant increase in AUC was shown for Group A (Table 3.4-2). 
  
Figure 3.4-4 Pre and postoperative AUC (mg.hr/L.mg) 
Graphs (clockwise from top left): Group A, B, C and D 
No other significant changes were seen. 
Table 3.4-2 AUC values before and after surgery 
Group Day -1 AUC (IQR) 
 mg.hr/L 
Day 1 AUC (IQR) 
mg.hr/L 
Wilcoxon matched 
pairs. Day -1=1, Z  
A 0.041 (0.032, 0.054) 0.049 (0.037, 0.077) 1.820 p 0.039* 
B 0.039 (0.025, 0.052) 0.040 (0.022, 0.057) 0.535 p 0.375 
C 0.045 (0.042, 0.079) 0.045 (0.03, 0.719) 1.342 p 0.250 
D 0.042 (0.029, 0.054) 0.038 (0.032, 0.039) 0.405 p 0.406 
3.4.3 CLEARANCE 
Clearance is a measure of the amount of drug which is removed per unit volume per time 
period. Equation 3.4-2 shows the relationship between k (the co-efficient of elimination), 
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the rate at which a drug is cleared, and Vd (the volume of distribution), the theoretical 
volume into which a drug is dispersed. It is calculated by the rearrangement of Equation 
3.4-3. Clearance values are shown in Figure 3.4-5 
 
Figure 3.4-5 Pre and postoperative Clearance (L/hr) 
Graphs (clockwise from top left): Group A, B, C and D 
For Group A all patients showed reduction in clearance, except for patient 1A who 
showed a large increase. There were no strong trends in the other groups, with most 
patients showing little or no change at all, aside from patient 2D, who showed a marked 
reduction, and patient 3D who showed an increase. 
Based on these values there were no significant changes exhibited (Table 3.4-3). 
Table 3.4-3 Clearance (L/hr) values before and after surgery 
Group Day-1 (IQR) Day 1 (IQR) Wilcoxon matched 
pairs. Day -1=1 
A 24.56 (18.68, 31.21) 20.60 (13.05, 26.90) 1.540 p 0.074 
B 25.46 (19.34, 39.82) 25.27 (17.67, 44.94) 0.000 p 0.625 
C 22.40 (14.00, 23.68) 22.41 (14.56, 19.74) 1.342 p 0.250 
D 24.09 (18.54, 34.87) 26.66 (25.49, 31.47) 0.135 p 0.500 
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Calculating the differences between preoperative and postoperative Cl values showed 
patient 1A’s Cl to lie well outside the distribution of the rest of Group A. Treating patient 
1A as an outlier and removing it from the analysis meant that Group A produced a 
significant difference (2.336 p=0.008). 
3.4.4 VOLUME OF DISTRIBUTION 
Volume of distribution (Vd) was also determined for the day before (Equation 3.4-7) and 
the day after surgery (Equation 3.4-8).  
   
  
 
 
Equation 3.4-7 Calculation of Volume of Distribution for a single dose 
     
   
       
 
Equation 3.4-8 Calculation of Volume of Distribution at steady state (Vdss) 
f=-bioavailability of dose, Css=concentration at steady state 
Where 
    
   
    
 
Equation 3.4-9 Calculation of Concentration at steady state 
There were reductions shown in Vd in all groups for most patients with the exceptions of 
patients 1A and 3D. Only the differences in Group A were significant but clear trends were 
observed in all other groups (Table 3.4-4, Figure 3.4-6). 
Table 3.4-4 Vd (L/kg) before and after surgery 
*=significant difference 
Group Day-1 (IQR) Day 1 (IQR) Wilcoxon matched 
pairs. Day -1=1 
A 0.77 (0.65, 0.89) 0.48 (0.38, 0.70) 2.240 p 0.012* 
B 0.97 (0.63, 1.08) 0.63 (0.52, 0.88) 1.604 p 0.125 
C 0.88 (0.76, 1.11) 0.71 (0.42, 1.33) 1.342 p 0.250 
D 0.89 (0.77, 1.17) 0.75 (0.58, 0.92) 1.753 p 0.063 
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Figure 3.4-6 Pre and postoperative Vd(L/kg) 
Graphs (clockwise from top left): Group A, B, C and D 
3.4.5 MEAN RESIDENCE TIME 
Mean residence time is an approximation of how long an “average” molecule of drug 
stays in the body. It is determined as shown in Equation 3.4-10.  
    
    
   
 
Equation 3.4-10 Calculation of Mean Residence Time (MRT) 
AUMC= area under the moment curve, AUC= area under the curve 
This value can also be used to approximate half-life. 
  
 ⁄
           
Equation 3.4-11 Calculation of half-life using MRT 
There was close agreement between the half-lives calculated using the coefficient of 
elimination and those using MRT.  
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Figure 3.4-7 MRT before and after surgery 
This suggests the disposition kinetics of paracetamol can be approximated by a one 
compartment model. Half-lives derived from the coefficient of elimination that are 
distinctly greater than those determined using MRT indicate multiple compartments that 
cannot be predicted using the simple methods here.  
All patients in Group A exhibited increases in MRT (Figure 3.4-7).  
There were no strong trends in the other groups although there was a tendency for MRT 
to decrease, as depicted in Table 3.4-5. 
Table 3.4-5 Pre and postoperative MRT (hours) 
*=significant difference 
Group Day-1 (IQR) Day 1 (IQR) Wilcoxon matched 
pairs. Day -1=1 
A 2.32 (2.11, 2.88) 3.10 (2.49, 4.69) 2.521 p 0.004* 
B 2.76 (2.29, 2.94) 2.79 (2.06, 4.49) 0.000 p 0.625 
C 2.73 (2.23, 4.95) 2.64 (1.72, 2.92) 1.342 p 0.250 
D 3.04 (2.55, 3.38) 2.64 (2.10, 3.13) 1.214 p 0.156 
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3.4.6 PARACETAMOL CONCENTRATION IN PLASMA ONE HOUR POST DOSE 
Plasma samples taken one hour after paracetamol dosing were analysed. They are 
presented with and without normalisation for dose (Figure 3.4-8). Dose normalised values 
(y) were obtained by multiplying Group A’s measured concentration (x) by the 24 hourly 
paracetamol dose the other groups received (4g) divided by Group A’s dose (9g), so that 
y=(4g/9g)x=0.444x. 
  
Figure 3.4-8 Plasma paracetamol (mmol/L) at one hour with (left) and without (right) normalisation for dose 
The left graph in Figure 3.4-8 shows the extent of accumulation associated with Group A’s 
higher dose. When normalised for dose, trends emerge. For most groups, paracetamol 
concentrations increased until the middle of the study and then appear to decline.  
Differences between distributions were checked with Friedman’s two-way analysis of 
variance by ranks for statistical significance using exact tests (Table 3.4-6).  
Table 3.4-6 Plasma paracetamol concentration (mmol/L  1 hour post dose as median  IQR  and results of Friedman’s 
test 
*
= significant difference 
Group Day -1 Day 1 Day 2 Day 3 Day 4 χ2 (p) 
A 0.102 (0.072, 
0.113) 
0.169 (0.126, 
0.232) 
0.224 (0.16, 
0.272) 
0.15 (0.134, 
0.243) 
0.156 (0.135, 
0.174) 
11.6 
(0.012)* 
B 0.061 (0.046, 
0.071) 
0.078 (0.048, 
0.112) 
0.088 (0.017, 
0.113) 
0.077 (0.063, 
0.101) 
0.056 (0.049, 
0.07) 
4 
(0.475) 
C 0.081 (0.064, 
0.087) 
0.097 (0.085, 
0.109) 
0.03 (0.009, 
0.051) 
0.05 (0.05, 
0.05) 
0.058 (0.033, 
0.084) 
3 
(0.460) 
D 0.06 (0.042, 
0.074) 
0.071 (0.068, 
0.09) 
0.075 (0.06, 
0.11) 
0.072 (0.052, 
0.115) 
0.067 (0.02, 
0.087) 
5.6 
(0.258) 
The Friedman’s test revealed a significant difference across Group A. A post hoc test was 
conducted with exact Wilcoxon matched pairs tests (Table 3.4-7). 
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Table 3.4-7 Group A, post hoc pair-wise analysis (p) 
*
= significant difference 
Group A    
1 0.005*    
2 0.008* 0.173   
3 0.015* 0.594 0.139  
4 0.021* 0.021* 0.028* 0.139 
Day -1 1 2 3 
Significant differences were seen between day -1 (preoperative day) and all others days, 
and Day 4 and Days -1, 1 and 2 (Table 3.4-7). This reflects the parabolic shape of the 
concentration distribution across the days of the study. While many individual tests 
exceed the critical α=0.05 level of significance, statistical devotees would insist the 
Bonferroni correction again be applied to these repeated tests to reduce the chance of a 
Type I error (i.e. chance of a false positive). Because there are 10 comparisons, 
considering the Bonferroni correction in this test reduces the critical level of significance 
to 0.005, so that only the increase between Day -1 and 1 remains statistically significant. 
Wilcoxon matched pairs tests were also conducted for the other three groups. As 
expected from the Friedman’s two-way analysis of variance, only Group A showed any 
pairwise differences.  
3.4.7 PARACETAMOL CONCENTRATION IN PLASMA FOUR HOURS POST DOSE 
A similar analysis was conducted for the four hour post dose concentration of 
paracetamol in plasma (Figure 3.4-9).  
 
Figure 3.4-9 Plasma paracetamol (mmol/L) at four hours with (left) and without (right) normalisation for dose 
Patterns are less clear on analysis of this sample time. The left graph in Figure 3.4-9 shows 
a stark increase in paracetamol concentration in Group A following surgery which then 
appears to reduce over the course of the study. Dose normalisation (right graph Figure 
3.4-9) does not reveal any obvious patterns; however, a similar shape to the one hour 
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concentration emerges, with increases after surgery and declining over subsequent days. 
This effect is most notable in Groups A and B. Once again a significant difference was seen 
in the distribution of concentrations for Group A (Table 3.4-8). 
Table 3.4-8 4 hour plasma paracetamol concentration (mmol/L) as median (IQR) with Friedman’s test results 
*
= significant difference 
Group Day -1 Day 1 Day 2 Day 3 Day 4 χ2 (p) 
A 0.041 (0.025, 
0.052) 
0.107 (0.07, 
0.127) 
0.104 (0.064, 
0.149) 
0.063 (0.049, 
0.108) 
0.044 (0.039, 
0.063) 
18.533 
(0.00)* 
B 0.025 (0.014, 
0.034) 
0.036 (0.014, 
0.064) 
0.042 (0.025, 
0.072) 
0.032 (0.031, 
0.06) 
0.024 (0.018, 
0.033) 
7.467 
(0.096) 
C 0.026 (0.023, 
0.046) 
0.038 (0.034, 
0.050) 
0.034 (0.014, 
0.048) 
0.043 (0.018, 
0.053) 
0.041 (0.023, 
0.045) 
0.406 
(0.354) 
D 0.023 (0.017, 
0.035) 
0.037 (0.028, 
0.073) 
0.026 (0.018, 
0.048) 
0.027 (0.011, 
0.062) 
0.038 (0.02, 
0.053) 
4.267 
(0.432) 
Another post hoc analysis was undertaken (Table 3.4-9) 
Table 3.4-9 Group A Post hoc pair-wise analysis (p) 
*
= significant difference 
Group A    
1 0.005*    
2 0.008* 0.314   
3 0.093* 0.123 0.036*  
4 0.050* 0.017* 0.012* 0.161 
Day -1 1 2 3 
Similar to the one hour time sample, the preoperative sample from Group A was different 
from other days’. There were also significant differences between each of Day 1 and Day2 
with Day 4. Also similar to the one hour time sample, the application of the Bonferroni 
correction causes all but the increase between Day -1 and Day 1 to loose significance. 
3.4.8 ACCUMULATION OF PARACETAMOL IN GROUP A 
Samples were collected at t=0 and t=4hrs for all patients 
 
Figure 3.4-10 Difference between t=4 and t=0 paracetamol concentration 
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For Group A, who received paracetamol every four hours, this represented the beginning 
and end of the dosage interval and these were compared for evidence of accumulation. 
Confirming the data above, the largest accumulation across the dose interval occurred on 
the first dose on the day before surgery (Figure 3.4-10). On the days following surgery, 
the median value reduced to the point where on Days 3 and 4 the paracetamol 
concentrations were lower at the end of the dose interval than at the beginning. A 
Friedman’s test was also conducted on these data showing a statistically significant 
difference. 
Table 3.4-10 Difference between t=0 and t=4 concentrations  mmol/L  as median  IQR  and results of Friedman’s test 
*
= significant difference 
Group A Day -1 Day 1 Day 2 Day 3 Day 4 χ2 (p) 
Median 
IQR 
0.037 
0.024, 0.049 
0.006 
-0.013, 0.009 
0.005 
-0.004, 0.019 
-0.008 
-0.035, 0.025 
-0.005 
-0.036, 0.01 
10.88 
(0.015)* 
The negative median values indicate concentrations actually reduced over the dosage 
interval (i.e. between the time 0 and time 4 hour samples). A post hoc test was again 
conducted using one tailed exact Wilcoxon signed ranks tests (Table 3.4-11). The 
significant differences occurred between the preoperative and postoperative days. While 
none of the postoperative days are significantly different from each other, there is some 
evidence of a trend between them (p=0.078). However, applying the Bonferroni 
correction eliminated the statistical significance of all these results. 
Table 3.4-11 Results of post hoc test of differences between t=0 and t=4 concentrations (p) 
*
= significant difference 
Group A    
1 0.008*    
2 0.074 0.410   
3 0.008* 0.273 0.527  
4 0.031* 0.281 0.078 0.500 
Day -1 1 2 3 
3.4.9 PLASMA METABOLITE CONCENTRATIONS 
All metabolites studied are readily excreted in the urine. As a result, plasma does not 
accurately reflect metabolite ratios as the metabolites’ rates of formation are different 
from one another. Glucuronide and sulphate metabolites appear rapidly in plasma as they 
arise directly from a Phase II reaction on paracetamol. Conversely, paracetamol cysteine 
and mercapturate arise from a Phase II reaction on NAPQI, itself a Phase I product of 
paracetamol. Therefore NAPQI formation will delay the rate of paracetamol cysteine and 
mercapturate formation. The concentrations of paracetamol and these metabolites in 
plasma over the entire study are presented below for each group (Figure 3.4-11).  
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Figure 3.4-11 Paracetamol and metabolite concentrations (mmol/L) 
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Figure 3.4-11 Continued. Paracetamol and metabolite concentrations (mmol/L) 
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Some patterns appear from Figure 3.4-11. In Group A paracetamol and paracetamol 
glucuronide concentrations peak on Days 2 and 3 but there are no accompanying changes 
in the concentrations of paracetamol sulphate or the Phase I conjugates. Visually, 
concentrations of paracetamol sulphate or the Phase I conjugates remain relatively 
consistent across all groups, despite Group A having over twice the daily dose of 
paracetamol of the other groups.  
 
Figure 3.4-12 Median plasma paracetamol concentrations (mmol/L) 
Presented as median +/- quartiles preoperatively (red line) and Day 1 postoperatively (blue line).  
Paracetamol glucuronide concentrations accumulated in Group A, appearing to reach 
their highest concentration on Day 2 from which point they appeared to decline. The fact 
that paracetamol glucuronide concentrations accumulated and in later intervals exceeded 
those of paracetamol itself, indicates that paracetamol glucuronide rate of formation is 
greater than its rate of elimination, i.e. that its half-life is greater than that of 
paracetamol.  
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Further analysis was conducted comparing the kinetics of the preoperative to 
postoperative days and these graphs are shown in Figure 3.4-12.  
For Group A, the median Cmax of paracetamol increases from 0.254 mmol/L 
preoperatively to 0.296mmol/L on Day 1 postoperatively, an approximate increase of 
17%. The preoperative Cmax arising from a single dose in other groups is consistent 
between groups at around 0.1mmol/L. There appeared to be much less accumulation of 
paracetamol in Groups B, C and D (Figure 3.4-12) although as a percentage of 
preoperative Cmax, the increase is greater than of Group A (Table 3.4-12). 
Table 3.4-12 Difference between median Cmax (mmol/L) values 
Group Day-1 Cmax (mmol/L) Day 1 Cmax (mmol/L) Difference (mmol/L) % Increase 
A 0.140 0.243 0.103 73.4 
B 0.092 0.13 0.037 40.6 
C 0.116 0.184 0.068 58.8 
D 0.105 0.128 0.024 22.4 
3.4.10 CONCENTRATIONS WITHIN DOSE INTERVAL 
The concentrations of paracetamol and each metabolite were compared to examine the 
relationship between time of dose and formation of metabolites and the difference 
between steady state and single dose metabolite concentrations.  
3.4.10.1.1 PHASE I PRODUCTS 
The same process was followed for paracetamol cysteine and mercapturate. Neither 
metabolite was found in measurable concentrations following the preoperative 
paracetamol dose. Paracetamol cysteine was found following the postoperative dose 
although the concentration did not change over time, showing no increase with the 
administration of paracetamol. Concentrations in Group A, while still low (0.03mmol/L 
approximately), were about twice those of the other groups. Slight amounts of 
paracetamol mercapturate were detected postoperatively but again the concentration 
was not affected by paracetamol administration. There was no visually apparent 
difference between groups. These graphs are contained in Appendix 13. 
3.4.10.1.2 PARACETAMOL GLUCURONIDE 
Concentrations of paracetamol glucuronide are shown on the day before and day after 
surgery for each group (Figure 3.4-13). Preoperatively, all groups showed increases in 
paracetamol glucuronide concentration following the dose, until the 1.5 hour sample. 
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From this point, concentrations appeared to plateau. There was a substantial increase 
between preoperative and postoperative concentrations in Group A, with accumulations 
to a lesser degree seen in the other groups. Paracetamol glucuronide was detected prior 
to the administration of paracetamol postoperatively.  
 
Figure 3.4-13 Median plasma paracetamol glucuronide concentrations (mmol/L) 
Presented as median +/- quartiles preoperatively (red line) and day 1 postoperatively (blue line).  
3.4.10.1.3 PARACETAMOL SULPHATE 
Concentrations of paracetamol sulphate are also shown (Figure 3.4-14). Preoperative and 
postoperative concentrations are almost identical, not showing any significant increase 
between the single dose and steady state conditions. There was also very little difference 
between groups, despite the much higher dose given in Group A. There were slight 
increases of paracetamol sulphate concentration following the paracetamol dose but 
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these plateaued within 30 minutes for all groups. Paracetamol sulphate was also detected 
prior to the administration of paracetamol postoperatively.  
 
Figure 3.4-14 Median plasma paracetamol sulphate concentrations (mmol/L) 
Presented as median +/- quartiles preoperatively (red line) and day 1 postoperatively (blue line).  
3.4.11 SUMMARY 
Paracetamol’s plasma half-lives were seen to increase in Groups A and B which lead to 
statistically significant increases in exposure to paracetamol in Group A. Clearance and Vd 
were examined for their contribution to these changes. Reductions in clearance were 
large in Group A, while all other groups remained static. More noticeable were reductions 
to Vd which were seen in all groups and achieved statistical significance in Group A. Over 
the postoperative course one and four hour post-dose concentrations appeared to 
accumulate in all groups until Day 2, long after steady state was expected, from which 
time the appeared to decline approaching preoperative concentrations.   
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3.5 CYTOKINE RESULTS 
The concentration of cytokines IL-1β, IL-6, TNFα and IFNγ were measured in daily patient 
samples by the ELISA methods described in Section 2.3. 
Cytokines release and peak at different times following surgical trauma and 
concentrations following major abdominal surgery have been previously reported 
(Roumen et al. 1993a) (Section 1.3.1.2). TNF-α and IL-1β are key pro-inflammatory 
cytokines and are amongst the first to be released, and along with IFN-γ they stimulate 
the release of other cytokines including IL-6 (Dinarello 2000). Together, all four cytokines 
investigated in this study activate the hypothalamic-pituitary-adrenal axis by stimulating 
the release of corticotrophin releasing hormone (CRH), suppressing appetite and inducing 
pyresis. In the liver, they stimulate the acute phase response, leading to an increase in C-
reactive protein and a number of other mediators. They also induce insulin resistance in 
the liver and peripheral tissues. IL-6 is the most important cytokine for this research as it 
correlates well with surgical trauma, the stress response and the subsequent changes to 
drug disposition (Roumen et al. 1993a; Veenhof et al. 2011).  
3.5.1 DISTRIBUTION OF CYTOKINE RESULTS 
The distributions of the cytokine concentrations for each group were assessed graphically 
(examples shown in Figure 3.5-1 and 2) and with a formal normality test (Table 3.5-1). 
 
Figure 3.5-1 Graphs depicting distribution of IL-1β values from Group A on the preoperative day. 
(Left) Histogram with normal curve superimposed shows distribution skewed to the left; (Right) Box plot shows median 
bar is not centrally placed in the box and tails do not extend from the box symmetrically. Both graphs indicate the data 
are non-parametric. 
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Figure 3.5-2 Q-Q plots of IL-1β distribution 
(Left) Q-Q plot shows IL-1β values are not placed along the line of normality; (Right) The de-trended Q-Q plot shows an 
exaggerated deviation from the normal line. Both graphs indicate the data to be non-parametric. 
Kolmogorov-Smirnov tests examine if the data were significantly different from a normal 
distribution. In Table 3.5-1, a significance value of less than 0.05 indicated a significant 
variation from a normal distribution i.e. that the data were non-parametric. No group of 
cytokine results consistently showed evidence of normality. Attempts to normalise the 
data by log, square root and reciprocal transformations did not improve the results of 
these normality tests. 
Table 3.5-1 Results of Kolmogorov-Smirnov test D with (df) degrees of freedom for all cytokines. 
Abbreviations: D- Kolmogorov-Smirnov test statistic; df- degrees of freedom; Sig- significance. *=Significance. 
 Group A Group B Group C Group D 
 D (df) Sig. D (df)  Sig. D (df) Sig. D (df) Sig. 
IL-1β 0.253 (45) 0.000* 0.381 (15) 0.000* 0.236 (23) 0.002* 0.299 (39) 0.000* 
IL-6 0.373 (45) 0.000* 0.166 (15) 0.200 0.371 (23) 0.000* 0.332 (39) 0.000* 
TNF-α 0.154 (45) 0.009* 0.116 (15) 0.200 0.191 (23) 0.029* 0.148 (39) 0.031* 
IFN-γ 0.307 (45) 0.000* 0.118 (15) 0.200 0.347 (22) 0.000* 0.110 (33 ) 0.200 
To assess differences between days of the study, paired tests were used. While it is 
important to consider the distribution of each cytokine concentration as a group, as 
shown above, when conducting paired analysis it is more relevant to consider the 
distribution of the residuals. The residuals are the absolute value of the difference 
between the values in the paired analysis. Their distribution also failed tests of normality 
and an example of IL-1β is shown (Table 3.5-2).  
Table 3.5-2 Formal normality tests of the residuals for IL-1β 
 Group A Group B Group C Group D 
 D (df) Sig D (df)  Sig D (df) Sig D (df) Sig 
Day -1 v 1 0.277 (10) 0.028 0.439 (4) 0.001 0.387 (8) 0.001 0.353 (11) 0.000 
Day -1 v 2 0.516 (10) 0.000 0.439 (4) 0.000 0.325 (8) 0.013 0.353 (11) 0.000 
Day -1 v 3 0.515 (10) 0.000 0.439 (4) 0.001 0.455 (8) 0.000 0.351 (11) 0.000 
Day -1 v 4 0.428 (10) 0.000 0.449 (4) 0.001 0.391 (8) 0.001 0.352 (11) 0.000 
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Accordingly, non-parametric tests were used for cytokine analysis. Quartiles were 
calculated using weighted averages X(n+1)p. The results of the analysis of each cytokine are 
now presented in the following sections.  
3.5.2 IL-1β 
IL-1β is released from blood monocytes and tissue macrophages upon activation as part 
of the initial inflammatory response. As a primary inflammatory mediator IL-1β 
concentrations were expected to peak soon after incision and with a short half-life, 
resolve quickly in the absence of continuing inflammation (Roumen et al. 1993a). 
3.5.2.1 DESCRIPTIVES 
The median and interquartile ranges of all the groups for each cytokine are presented in 
the following tables and accompanied by box plots of their distribution. The assay had a 
lower LOD of 0.19pg/mL and an upper LOD of 2500pg/mL. As can be seen in the graphs 
that follow, the elevations of IL-1β were comparatively minor, with the highest measured 
concentration across all groups of 14.29pg/mL. Nearly half (41.8%) of IL-1β 
concentrations were at or below the LOD (0.19pg/mL). 
3.5.3 GROUP A 
 
Figure 3.5-3 Box plot for IL-1β concentration- Group A 
Table 3.5-3 Descriptives for IL-1β Group A 
IL-1β Group A 
(pg/mL) N Median (IQR) 
Day -1 10 0 (0 ,0.159) 
Day 1 10 0.250 (0.074, 1.029) 
Day 2 9 0 (0, 0.216) 
Day 3 9 0.160 (0, 0.484) 
Day 4 7 0.810 (0.306, 1.034) 
 
Group A began with 10 patients (Figure 3.5-3 and Table 3.5-3). There were only very small 
fluctuations in IL-1β concentrations, peaking on the day after surgery, falling the following 
day to baseline values and returning to slightly elevated values towards the end of the 
study. There was little variation within the study group over the five sampling days.  
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3.5.3.1.1 GROUP B 
  
Figure 3.5-4 Box plot for IL-1β concentration- Group B 
Table 3.5-4 Descriptives for IL-1β Group B 
IL-1β Group B 
(pg/mL) N Median (IQR) 
Day -1 3 0.213 (0.106, 7.249) 
Day 1 3 0 (0, 0.044) 
Day 2 3 0 (0, 0) 
Day 3 3 3.636 (2.511, 3.70) 
Day 4 3 0 (0, 0) 
 
Group B had three patients who gave blood samples (Figure 3.5-4 and Table 3.5-4). The 
small sample size limits its statistical inference. Large variability was noticeable on the 
preoperative day. This was caused by one patient who had elevated IL-1β prior to surgery 
as shown by the length of the whisker on the first box. This concentration of IL-1β may be 
expected in the presence of inflammation. Postoperatively, IL-1β concentrations were 
below the LOD for all days except Day 3 when all patients experience similar elevation in 
IL-1β concentration. 
3.5.3.1.2 GROUP C 
 
Figure 3.5-5 Box plot for IL-1β concentration- Group C 
Table 3.5-5 Descriptives for IL-1β Group C  
IL-1β Group C 
(pg/mL) N Median (IQR) 
Day -1 7 1.097 (0.890, 1.599) 
Day 1 5 0 (0, 0.095) 
Day 2 4 0.506 (0, 3.415) 
Day 3 2 2.958 (0.807, 4.033) 
Day 4 3 0 (0, 1.539) 
 
Group C began with seven patients but complete sample sets were collected from only 
two patients (Figure 3.5-5 and Table 3.5-5). This group also exhibited detectable IL-1β 
concentrations preoperatively. Only one patient had detectable concentrations of IL-1β 
on the first day after surgery. Following this, concentrations rose on Days 2 and 3 and fell 
to baseline on Day 4. As patients dropped out from this group variability increased.  
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3.5.3.1.3 GROUP D 
 
Figure 3.5-6 Box plot for IL-1β concentration- Group D 
Table 3.5-6 Descriptives for IL-1β Group D 
IL-1β Group D 
(pg/mL) N Median (IQR) 
Day -1 11 0 (0, 0.201) 
Day 1 6 0.150 (0, 1.030) 
Day 2 5 0.492 (0.085, 1.840) 
Day 3 6 0.274 (0.091, 1.074) 
Day 4 6 0.564 (0.107, 1.066) 
 
Group D began with 11 patients (Figure 3.5-6 and Table 3.5-6). There was negligible 
inflammation prior to surgery. Concentrations of IL-1β remained low until the second 
postoperative day falling on Day 3 and 4. There was little variability across the study aside 
from Day 3.  
3.5.3.2  CHANGES TO IL-1β CONCENTRATION 
3.5.3.2.1 ALL GROUPS  
Visual observation of Figure 3.5-3 through to Figure 3.5-6 does not reveal any obvious 
trend in IL-1β concentration across the study for any group. To confirm this, a Friedman’s 
test (χ2) was used to assess if the distribution of each of the days were the same. A 
significant result indicates differences between distribution of one or more of the study 
days (Table 3.5-7).  
Table 3.5-7 Results of Friedman test for concentration of IL-1β 
Abbreviations: N-number in group; χ
2
-Friedman test statistic; df- degrees of freedom; Sig- significance. Significant values 
are indicated by *. 
 N χ2 df Sig. 
Group A 7 12.195 4 0.0151* 
Group B 3 8.000 4 0.0916 
Group C 2 4.445 4 0.3492 
Group D 5 4.553 4 0.3363 
Group A achieved a significant result indicating that there were significant changes in the 
distribution of the IL-1β concentrations across the days of the study. A post hoc analysis 
was conducted using a one tailed  ilcoxon’s matched pairs test (Z) to determine where 
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the difference indicated by the significant result in the Friedman’s test occurred. One tail 
was used because IL-1β concentrations were only expected to be increased by surgery. 
While no difference occurred in the other groups, a repeated measures test such as 
Friedman’s requires a value to be present on all of the days of the test for the patient to 
be included in the analysis i.e. if one sample out of the five was missing that patient was 
excluded. This reduced the number of patients included in this analysis considerably 
giving a poor reflection of the amount of data gathered (Table 3.5-7). To improve this, a 
paired analysis was also conducted. To minimise the Type 1 error and the size of the 
Bonferroni correction, only the preoperative day was compared with the other days of 
the test. This resulted in four comparisons between the five tests, with the Bonferroni 
correction reducing the critical level of significance from 0.05 to 0.0125 (i.e. α/4) (Table 
3.5-8). 
Table 3.5-8 Results of Wilcoxon matched pairs test for IL-1β concentrations 
Values shown as Z (significance). Significant values are indicated by *.  
IL-1β Group A Group B Group C Group D 
Day N Z (sig) N Z (sig) N Z (sig) N Z (sig) 
-1 v 1 10 1.836 (0.066) 3 1.069 (0.285) 7 2.366 (0.018) 11 1.779 (0.075) 
-1 v 2 9 1.604 (0.109) 3 1.342 (0.18) 4 0.73 (0.465) 5 1.461 (0.144) 
-1 v 3 9 1.183 (0.237) 3 0 (1) 2 0.447 (0.655) 6 1.363 (0.173) 
-1 v 4 7 1.859 (0.063) 3 1.342 (0.18) 3 0.535 (0.593) 6 2.023 (0.043) 
These results show no significant changes in IL-1β concentration between the 
preoperative and any of the postoperative days of the study. This would indicate the 
significant result seen in Group A’s Friedman’s test arose from differences between days 
within the postoperative phase that were not undertaken in this paired analysis. Further 
analysis revealed this to be the case with the results of a Wilcoxon matched pairs test 
between Group A Days 3 and 4 of 2.197 (0.028), showing that the concentration of IL-1β 
was actually significantly higher on Day 4 than on Day 3, contrary to what would be 
expected. However once the Bonferroni correction was taken into account, this result lost 
its significance (Table 3.5-8).  
Two other results approached significance during the matched pair analysis summarised 
in Table 3.5-8, but both lost significance upon incorporation of the Bonferroni correction. 
In Group C the IL-1β concentration trended to being higher preoperatively than on Day 1 
postoperatively, and Group D showed a trend for Day 4 postoperatively to be higher than 
the preoperative sample.  
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3.5.3.3 CHANGES TO IL-1β CONCENTRATION AS PERCENTAGE OF PREOPERATIVE VALUE 
Some previous reports of cytokine concentrations following surgery have reported values 
as a percentage of baseline concentration (Veenhof et al. 2011). Although interesting, 
these results are to be interpreted with caution as working with percentages can skew 
results. However, the advantages of this method are the potential reduction in inter-
individual variation as the percentage increase is calculated for each patient. To facilitate 
this analysis, those with concentrations reported as zero were set at the LOD of the assay.  
 
Figure 3.5-7 Dual axis graphs showing median values of IL-1 β concentration  solid bars, left y a is  and median 
percentage change in IL-1 β concentration when compared to preoperative values. 
The graphs above show how a percentage change can exaggerate differences (Figure 
3.5-7). In the first graph of Group A, the increases on the final day of the study appear 
considerably larger than that of the increase to the actual cytokine concentration. 
Conversely, the increases seen on Day 3 for Group B appear diminished due to the 
elevated IL-1β concentration measured at the baseline in this group. To assess if this 
transformation of the data resulted in any change to the statistical analysis, the same 
analsysis previously undertaken for concentrations of IL-1 β was repeated. 
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As the transformation was applied to all days of the study, the distribution was 
unchanged and therefore the results of the Friedman’s test were identical to those in 
Table 3.5-7.  
The results of the Wilcoxon matched pairs test are summarised in Table 3.5-9. Some 
greater differences did arise in these results including the statistically significant increase 
between the preoperative and first postoperative day in Group A. Groups C and D both 
had results approaching significance for the same comparison.  
Table 3.5-9 Results of Wilcoxon matched pairs test for percentage change of IL-1β concentrations between the 
preoperative day and consecutive days.  
Values shown as Z (significance). Significant values are indicated by *.  
IL-1β Group A Group B Group C Group D 
Day N Z (sig) N Z (sig) N Z (sig) N Z (sig) 
-1 v 1 10 2.549 (0.011*) 3 0 (1) 7 2.366 (0.018) 11 1.955 (0.051) 
-1 v 2 9 1.604 (0.109) 3 1.342 (0.180) 4 0.365 (0.715) 5 1.461 (0.144) 
-1 v 3 9 1.992 (0.046) 3 1.069 (0.285) 2 0.447 (0.655) 6 1.753 (0.080) 
-1 v 4 7 2.197 (0.028) 3 1.342 (0.180) 3 1.069 (0.285) 6 2.23 .043) 
3.5.4 IL-6 
T-cells and macrophages activated by IL-1β and TNF-α secrete IL-6 soon after trauma. IL-6 
is also released by unrelated processes such as exercise and obesity, which may affect 
baseline concentrations (Roumen et al. 1993a; Fain 2010). It has both pro and anti-
inflammatory activity, promoting IL-1α and IL-10 and inhibiting TNF-α and IL-1 (Heinrich 
et al. 2003).  
IL-6 concentrations correlate well with trauma severity following surgery and have been 
used as a predictor of survival (Gebhard et al. 2000). Unlike other cytokines, IL-6 can cross 
the blood/brain barrier where it initiates PGE2 synthesis in the hypothalamus, a 
prostaglandin central to paracetamol pharmacology, causing pyresis (Roumen et al. 
1993a). 
3.5.4.1 DESCRIPTIVES 
The median and interquartile ranges of all the groups for each cytokine are presented in 
the following tables below accompanied by box plots of their distribution. The assay had a 
lower LOD of 0.42pg/mL and an upper LOD of 2500pg/mL. Much higher levels of IL-6 were 
measured than of IL-1β, with the highest across all samples of 421.60pg/mL. None of the 
121 samples examined were at or below the LOD. 
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3.5.4.1.1 GROUP A 
 
Figure 3.5-8 Box plot for IL-6 concentrations- Group A 
Table 3.5-10 Descriptive statistics for IL-6 Group A  
IL-6 Group A 
(pg/mL) N Median (IQR) 
Day -1 10 3.025 (1.607, 4.339) 
Day 1 10 35.192 (29.838, 133.137) 
Day 2 9 16.216 (10.602, 29.614) 
Day 3 9 11.167 (9.185, 14.797) 
Day 4 7 9.298 (7.944, 14.489) 
 
 
Although there was a small degree of elevation preoperatively, Group A exhibited a 
marked increase in IL-6 concentration on Day 1 postoperatively (Figure 3.5-8 and Table 
3.5-10). The box plot shows two outlying data points on Day 1, shown as 11 and 14, which 
belong to patient one and four respectively. Patient one went on to develop a leaking 
anastomosis and sepsis and died two weeks later. Patient four also had complications, 
also developing a leaking anastomosis, eventually requiring the formation of a colostomy 
and nearly a month of intensive care.  
The median concentration more than halved on Day 2 and continued to decline more 
gradually on Days 3 and 4. The outlying points 24, 34 and 44 on these later days all belong 
to patient four described above. Although this patient’s IL-6 concentrations declined in a 
similar manner to those of the rest of the group, they still fell outside of the group’s 
upper quartile. Patient one had been withdrawn from the study due to his complications 
and accordingly, IL-6 concentrations were not available after Day 1. 
The variation on Day 1 was far greater than any other day. On the following days data is 
clustered much closer around the median. 
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3.5.4.1.2 GROUP B 
 
Figure 3.5-9 Box plot for IL-6 concentration- Group B  
Table 3.5-11 Descriptive statistics for IL-6 Group B  
IL-6 Group B 
Day -1 3 1.034 (0.754, 2.915) 
Day 1 3 29.100 (26.920, 56.019) 
Day 2 3 20.234 (8.179, 22.498) 
Day 3 3 8.619 (5.183, 25.602) 
Day 4 3 13.995, (7.587, 15.137) 
Day -1 3 1.034 (0.754, 2.915) 
 
As discussed in the results for IL-1β, it is difficult to draw trends because of the size of this 
group. Similarly to Group A, IL-6 concentrations in Group B increased sharply from 
amounts just above the LOD preoperatively to concentrations which where thirtyfold 
higher on Day 1 (Figure 3.5-9 and Table 3.5-11). The concentration reduced gradually on 
Day 2 and three, increasing slightly on Day 4. The variation was greatest on Day 1 but the 
size of this group diminishes the usefulness of this measure. 
3.5.4.1.3 GROUP C 
 
Figure 3.5-10 Box plot for IL-6 concentration- Group C 
Table 3.5-12 Descriptive statistics for IL-6 Group C  
IL-6 Group C 
Day -1 7 1.097 (0.696, 1.692) 
Day 1 5 8.127 (3.378, 15.700) 
Day 2 4 6.134 (3.004, 27.445) 
Day 3 2 43.225 (9.199, 57.410) 
Day 4 3 31.546 (2.227, 44.752) 
Day -1 7 1.097 (0.696, 1.692) 
 
The pattern of changes to IL-6 concentration for Group C was unlike any other group 
(Figure 3.5-10 and Table 3.5-12). There was a high concentration of IL-6 measured 
preoperatively. Concentrations of IL-6 fell to their lowest levels on Day 1, remaining low 
on Day 2. On the third day there was a rapid increase in median concentration. 
Concentrations fell, but still remain markedly elevated on Day 4. Because of the dropout 
of patients from this group it is difficult to draw conclusions about cytokine trends. On 
Day 3, samples were obtained from only patients 1 and 4, both of whom had complicated 
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recoveries, with Patient 4 having the highest concentration of IL-6 of all patients in the 
study on this day (74.18pg/mL). A sample from an additional patient on Day 4 reduced 
the median concentration but did not eliminate the effect of these two other patients 
resulting in another high median concentration.  
3.5.4.1.4 GROUP D 
 
Figure 3.5-11 Box plot for IL-6 concentration- Group D 
Table 3.5-13 Descriptive statistics for IL-6 Group D  
IL-6 Group D 
(pg/mL) N Median (IQR) 
Day -1 11 1.350 (0.946, 3.649) 
Day 1 6 34.674 (16.464, 152.832) 
Day 2 5 19.578 (12.977, 26.223) 
Day 3 6 13.239 (6.762, 62.996) 
Day 4 6 13.836 (2.960, 25.505) 
 
Concentrations of IL-6 for Group D began consistently low across the group as shown by 
the low median and small interquartile range (Figure 3.5-11 and Table 3.5-13). 
Concentrations increased steeply on Day 1, increasing further on Day 2. On Day 1 an 
outlier from Patient 1 was seen about 20 times higher than the group median at 
417.20pg/mL. This patient underwent more extensive and one of the only two open 
surgeries in his group to correct a long standing congenital abnormality within his gastro-
intestinal tract.  
Median concentrations of IL-6 fell by Day 3, and remained relatively constant on Day 4. 
There was a large reduction in interquartile range from Day 3 through to Day 4. Another 
outlier appeared on Day 4 from patient 11. At 47.77pg/mL, Patient 11’s concentration on 
this day was four times that of their IL-6 concentration on the previous day (11.81pg/mL) 
and that of the group median. This patient had an uncomplicated recovery. 
3.5.4.2 CHANGES TO IL-6 CONCENTRATION 
3.5.4.2.1 ALL GROUPS  
Visual observation of the box plots revealed much greater variation in IL-6 concentration 
across the days of the study than seen with IL-1β. For most groups there was a clear 
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increase in the IL-6 concentration on the day following surgery. To confirm if this variation 
was real or due to chance a Friedman’s test (χ2) was used (Table 3.5-14).  
Table 3.5-14 Results of Friedman test for concentration of IL-6 
Abbreviations used: N-number in group; χ
2
-Friedman test statistic; df- degrees of freedom; Sig- significance. Significant 
values are indicated by *. 
IL-6 N χ2 df Sig. 
Group A 7 26.629 4 0.000* 
Group B 3 10.400 4 0.034* 
Group C 2 7.600 4 0.107 
Group D 5 8.480 4 0.075 
Groups A and B show significant differences in IL-6 concentration over the course of the 
study. As with IL-1β, a post hoc analysis was conducted using a one tailed  ilcoxon’s 
matched pairs test (Z) to identify on which pair of days statistically significant differences 
occurred. One tailed tests were again used as inflammation was only expected to increase 
as a result of surgery, and as before, to minimise the size of the Bonferroni correction 
only the pre-operative day was compared with each post-operative day. Once the 
Bonferroni correction was taken into account Group A showed significant differences 
between pre-operative concentrations and Days 1, 2 and 4 (Table 3.5-15).  
Table 3.5-15 Results of Wilcoxon matched pairs test for IL-6 concentrations 
Values shown as Z (significance). Significant values are indicated by *.  
IL-6 Group A Group B Group C Group D 
Day N Z (sig) N Z (sig) N Z (sig) N Z (sig) 
-1 v 1 10 2.803 (0.005)* 3 1.604 (0.109) 7 2.366 (0.018) 11 2.934 (0.003)* 
-1 v 2 9 2.666 (0.008)* 3 1.604 (0.109) 4 0.365 (0.715) 5 1.483 (0.138) 
-1 v 3 9 2.666 (0.008)* 3 1.604 (0.109) 2 1.342 (0.18) 6 2.201 (0.028) 
-1 v 4 7 2.366 (0.018) 3 1.604 (0.109) 3 1.069 (0.285) 6 1.572 (0.116) 
 
As the comparisons of the preoperative day with Day 2 and 3 gave exactly the same Z and 
significance value, this was checked by manual calculation. Like most non-parametric 
tests, the Wilcoxon matched pairs test is based on ranking of data rather than comparing 
the data’s actual value. In this analysis the same number of positive ranks occurred in 
both comparisons, resulting in the same Z and significance values. This also explained the 
results shown for Group B, as all postoperative values were greater than the preoperative 
values.  
Group D also showed a significant difference between the Day -1 and Day 1 adding to a 
general trend across all groups. Ignoring the Bonferroni correction brought Group C into 
this trend.  
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3.5.4.3 CHANGES TO IL-6 CONCENTRATION AS PERCENTAGE OF PREOPERATIVE VALUE 
As with IL-1β, IL-6 concentrations were transformed to a percentage of preoperative 
baseline concentration and analysed using the same procedure (Figure 3.5-12). 
 
Figure 3.5-12 Dual axis graphs showing median values of IL-6 concentration (solid bars, left y axis) and median 
percentage change in IL-6 concentration when compared with preoperative values. 
Once again the results demonstrate this method’s ability to skew data based on 
preoperative cytokine concentrations and this is demonstrated clearly in the differences 
between groups. Groups A and C exhibit substantial concentration changes over the 
course of the study but because of the comparatively high concentration preoperatively, 
the percentage changes are small. The converse is true for Groups B and D, where a much 
lower preoperative median concentration results in a large percentage increase 
postoperatively despite the actual concentration being much less than that of Group A 
and Group C. 
Another ilcoxon matched pair’s test was conducted (Table 3.5-16) to detect difference 
between days of the study. Once again the Bonferroni correction reduced the critical level 
of significance to 0.0125 (0.05/4). 
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Table 3.5-16 Results of Wilcoxon matched pairs test for percentage change of IL-6 concentrations between the 
preoperative day and consecutive days.  
Values shown as Z (significance). Significant values are indicated by *.  
IL-6 Group A Group B Group C Group D 
Day N Z (sig) N Z (sig) N Z (sig) N Z (sig) 
-1 v 1 10 2.803 (0.005*) 3 1.604 (0.109) 7 2.366 (0.018) 11 2.934 (0.003*) 
-1 v 2 9 2.666 (0.008*) 3 1.604 (0.109) 4 0.365 (0.715) 5 1.753 (0.080) 
-1 v 3 9 2.666 (0.008*) 3 1.604 (0.109) 2 1.342 (0.180) 6 2.201 (0.028) 
-1 v 4 7 2.366 (0.018) 3 1.604 (0.109) 3 1.069 (0.285) 6 1.992 (0.046) 
3.5.5 TNF-α  
TNF-α is primarily released from activated macrophages and mast cells stimulated by 
lipopolysaccharides and IL-1β. In the initial stages of the inflammatory response the TNF-
α that is released is pre-formed, constitutively expressed in macrophages and mast cells 
to allow a rapid response to stimulation (Nathan 2002). TNF-α works alongside IL-1β as 
part of the initial inflammatory response, potentiating the release of IL-6. 
3.5.5.1 DESCRIPTIVES 
This assay had a lower LOD of 0.65pg/mL and upper LOD of 2500pg/mL. Generally, TNF-α 
concentration was well above the LOD, with the lowest concentration measured being 
3.52pg/mL, which was measured on the first postoperative day from patient 2D. No 
samples were below the LOD. The highest concentration across all groups was 
20.14pg/mL, measured on day 2 from patient 3A. Concentration varied little during the 
study period and there was no obvious effect of surgery.  
3.5.5.1.1 GROUP A 
 
Figure 3.5-13 Box plot for TNF-α concentration- Group A 
Table 3.5-17 Descriptive statistics for TNF-α Group A 
TNF-α Group A 
(pg/mL) N Median (IQR) 
Day -1 10 9.353 (7.323, 11.583) 
Day 1 10 8.676 (6.606, 14.545) 
Day 2 9 7.159 (6.282, 13.6) 
Day 3 9 9.522 (7.645, 11.84) 
Day 4 7 10.411 (9.652, 14.341) 
 
There was very little change in TNF-α concentration over the course of the study in Group 
A and it did not show any expected effect of surgery (Figure 3.5-13 and Table 3.5-17). 
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TNF-α was measurable in all preoperative samples reflecting the constitutive nature of 
this cytokine, being expressed even in the absence of inflammation. Median 
concentrations fell from preoperative concentrations on Day 1 postop although the range 
increased. A further decrease in median concentration was seen on Day 2 although the 
IQR covered approximately the same range. On Day 3 there was a slight increase in 
median concentration and reduction in IQR. A further increase in median concentration 
was seen on Day 4, finishing slightly above the preoperative median. The first outlying 
value of 17.15pg/mL belongs to patient 3 on day minus one. As with IL-1β and IL-6 patient 
4 gave an outlying value on Day 3 of 18.04pg/mL reflecting his complicated recovery. 
3.5.5.1.2 GROUP B 
 
Figure 3.5-14 Box plot for TNF-α concentration- Group B 
Table 3.5-18 Descriptive statistics for TNF-α Group B 
TNF-α Group B 
(pg/mL) N Median (IQR) 
Day -1 3 7.905 (6.393, 12.254) 
Day 1 3 11.62 (9.49, 13.025) 
Day 2 3 10.466 (9.641, 12.8) 
Day 3 3 10.227 (8.879, 10.466) 
Day 4 3 8.836 (8.278,12.887) 
 
There were only minor changes in TNF-α concentration in Group B (Figure 3.5-14 and 
Table 3.5-18). All patients had measurable preoperative concentrations. Median 
concentrations followed a more expected pattern than other groups, being lowest 
preoperatively, increasing to a peak Day 1 postoperatively and gradually decreasing as 
recovery progressed. The median concentration on Day 4 remained elevated above the 
median preoperative concentration. 
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3.5.5.1.3 GROUP C 
Figure 3.5-15 Box plot for TNF-α concentration- Group C 
Table 3.5-19 Descriptive statistics for TNF-α Group C 
TNF-α Group C 
(pg/mL) N Median (IQR) 
Day -1 7 6.87 (5.424, 7.179) 
Day 1 5 7.433 (5.731, 8.587) 
Day 2 4 10.02 (7.259, 13.097) 
Day 3 2 12.381 (10.105, 13.609) 
Day 4 3 9.565 (8.988, 15.982) 
 
TNF-α was once again present in all preoperative samples in Group C (Figure 3.5-15 and 
Table 3.5-19). The median concentration increased gradually peaking on Day 3. However, 
as with the other cytokines for this group, the changing numbers of patients make 
interpretation difficult. Two outlying concentrations occurred on Day 1, of 4.20pg/mL and 
9.59pg/mL belonging to patients 2 and 3 respectively.  
3.5.5.1.4 GROUP D 
Figure 3.5-16 Box plot for TNF-α concentration- Group D 
Table 3.5-20 Descriptive statistics for TNF-α Group D 
TNF-α Group D 
(pg/mL) N Median (IQR) 
Day -1 11 5.747 (5.059, 8.901) 
Day 1 6 8.1 (5.672, 10.635) 
Day 2 5 7.75 (5.326, 8.749) 
Day 3 6 7.896 (5.828, 9.191) 
Day 4 6 7.698 (6.546, 9.05) 
 
Group D started with the lowest preoperative median concentration (Figure 3.5-16 and 
Table 3.5-20). There was a 41% increase in median concentration following surgery 
although this was not reflected in changes to the IQR, which remained similar. TNF-α 
concentrations gradually reduced as the study progressed, with days two, three and four 
having very similar median concentrations. Outliers were seen on Day 1 (patient 7, 
14.64pg/mL), Day 2 (patient 2, 3.80pg/mL), and Day 4 (patient 2, 3.72pg/mL). 
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3.5.5.2 CHANGES TO TNF-α CONCENTRATION 
3.5.5.2.1 ALL GROUPS 
Box plots of TNF-α concentrations showed much less variation than IL-6, although they 
followed a similar pattern. TNF-α concentrations increased to a peak on Day 1 before 
gradually decreasing as the study progressed. However preoperative TNF-α 
concentrations were considerably higher than IL-6. While these patterns emerge 
graphically it was necessary to confirm if these variations were real or due to chance 
using a Friedman’s test (χ2) (Table 3.5-21).  
Table 3.5-21 Results of Friedman test for concentration of TNF-α 
Abbreviations used: N-number in group; χ
2
-Friedman test statistic; df- degrees of freedom; Sig- significance. Significant 
values are indicated by *. 
TNF-α N χ2 df Sig. 
Group A 7 5.143 4 0.273 
Group B 3 2.400 4 0.663 
Group C 2 7.600 4 0.107 
Group D 5 2.560 4 0.634 
The results of the Friedman’s test showed no significant differences for any group over 
the course of the study. Because this test excludes values case-wise, Wilcoxon matched 
pairs were used to confirm these results as they include all samples for which there is a 
matching pair (Table 3.5-22). 
Table 3.5-22 Results of Wilcoxon matched pairs test for TNF-α concentrations 
Values shown as Z (significance). Significant values are indicated by *.  
TNF-α Group A Group B Group C Group D 
Day N Z (sig) N Z (sig) N Z (sig) N Z (sig) 
-1 v 1 10 0.153 (0.878) 3 1.069 (0.285) 7 1.753 (0.080) 11 0.934 (0.345) 
-1 v 2 9 0.059 (0.953) 3 0.535 (0.593) 4 1.826 (0.068) 5 0.135 (0.893) 
-1 v 3 9 0.770 (0.441) 3 0.535 (0.593) 2 1.342 (0.18) 6 1.572 (0.116) 
-1 v 4 7 1.352 (0.176) 3 1.604 (0.109) 3 1.604 (0.109) 6 1.363 (0.173) 
Although comparisons in Group C were closest to the critical significance value when 
preoperative values were compared with Days 1 and 2, they failed to surpass it. This 
confirms the results of the Friedman’s test that no significant changes in TNF-α 
concentration were shown over the course of the study for any group.  
3.5.6 IFN-γ  
IFN-γ is produced predominantly by lymphocytes in response to TNF-α induced release of 
IL-12 from macrophages (Andersson 2005). While concentrations may increase in 
response to trauma, much greater release occurs from antigen stimulated T-cells as part 
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of the adaptive immune response. IFN-γ has a main role in antiviral activity and stimulates 
chemokine production in the early phases of inflammation and suppress it in later stages 
(Nathan 2002). 
3.5.6.1 DESCRIPTIVES 
The IFN-γ assay had a lower LOD of 0.91pg/mL and an upper LOD of 2500pg/mL. Six of the 
115 samples were at or below the lower LOD, two from patient 10A (Days 1 and 3), two 
from patient 1B (Days 2 and 4) and one each from Patient 7A (Day -1) and Patient 2C (Day 
1), thus all but one patient had measureable concentrations of IFN-γ preoperatively. 
Generally there were only slight changes in IFN-γ concentration for most patients across 
the study, and those elevations that did occur appeared later than with other cytokines. 
The highest measured concentration was 93.81pg/mL from patient 4C on Day 3. 
3.5.6.1.1 GROUP A 
Figure 3.5-17 Box plot for IFN-γ concentration- Group A 
Table 3.5-23 Descriptive statistics for IFN-γ Group A 
IFN-γ Group A 
(pg/mL) N Median (IQR) 
Day -1 10 3.833 (2.513, 6.966) 
Day 1 10 4.534 (2.224, 12.509) 
Day 2 9 4.987 (3.107, 9.931) 
Day 3 9 6.047 (3.555, 8.419) 
Day 4 7 7.913 (6.103, 8.178) 
 
There were only small changes to IFN-γ concentration in Group A following surgery and 
once again most patients (90%) had measurable concentrations of this cytokine prior to 
surgery (Figure 3.5-17 and Table 3.5-23). Following surgery there was a small increase in 
median concentration but a larger increase in IQR. Patient 3A produced outlying 
concentrations on Day 2 and three with concentrations of 42.67 and 55.92pg/mL 
respectively. The median concentration rose slightly on Day 2 while IQR almost halved. 
IQR continued to shrink on Day 3 and Day 4 as concentrations became more uniform 
across the group. Median concentrations continued to increase on Day 3 and Day 4 and 
finished at more than twice the preoperative value, well above day 1 concentrations.  
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3.5.6.1.2 GROUP B 
Figure 3.5-18 Box plot for IFN-γ concentration- Group B 
Table 3.5-24 Descriptive statistics for IFN-γ Group B 
IFN-γ Group B 
(pg/mL) N Median (IQR) 
Day -1 3 3.521 (2.418, 6.966) 
Day 1 3 3.591 (1.593, 12.509) 
Day 2 3 5.103 (0, 9.931) 
Day 3 3 2.468 (.939, 8.419) 
Day 4 3 5.862 (0, 8.178) 
 
For Group B IFN-γ was found in all preoperative samples. Median concentrations followed 
an atypical course, increasing slightly on Day 1 followed by a greater increase on Day 2, a 
reduction on Day 3 and an increase on Day 4 (Figure 3.5-18 and Table 3.5-24). Day 4 had 
the highest median concentration of this group, although the IQR included 0. There was 
large variation across all postoperative days in this group with IQRs ranging from 2-3 
times the median concentration with the highest upper quartile value being recorded on 
Day 1. 
3.5.6.1.3 GROUP C 
Figure 3.5-19 Box plot for IFN-γ concentration- Group C 
Table 3.5-25 Descriptive statistics for IFN-γ Group C 
IFN-γ Group C 
(pg/mL) N Median (IQR) 
Day -1 7 3.921 (1.967, 4.554) 
Day 1 5 4.340 (1.849, 8.211) 
Day 2 4 7.172 (2.493, 14.493) 
Day 3 2 49.900 (5.987, 8.419) 
Day 4 3 8.013 (5.061, 8.178) 
 
Group C began with measurable concentrations of IFN-γ for all patients preoperatively 
and patient 4C with an outlying concentration of 7.62pg/mL (Figure 3.5-19 and Table 
3.5-25). There were increases of median concentration following surgery to a marked 
peak on Day 3, when samples were only obtained from two patients, one of whom 
(Patient 4) had the highest concentration across all day for all groups of 93.81pg/mL. 
 324 
 
Concentrations fell on Day 4 to give a median approximately twice that of Day 1 values. 
Patient 4’s values also fell on Day 4 to approximately 20% of the Day 3 value. Further 
interpretation is limited as discussed above. 
3.5.6.1.4 GROUP D 
Figure 3.5-20 Box plot for IFN-γ concentration- Group D 
Table 3.5-26 Descriptive statistics for IFN-γ Group D 
IFN-γ Group D 
(pg/mL) N Median (IQR) 
Day -1 11 5.475 (4.298, 8.008) 
Day 1 6 6.589 (2.219, 10.768) 
Day 2 5 3.704 (2.366, 6.745 
Day 3 6 4.884 (3.79, 8.295) 
Day 4 6 4.271 (2.752, 10.273) 
 
Once again all patients in Group D began with measurable concentrations of IFN-γ, 
producing a high median concentration second only to Day 1 postoperatively for this 
group (Figure 3.5-20 and Table 3.5-26). Following a more typical course, postoperative 
median concentrations peaked on Day 1 falling markedly on Day 2, increasing slightly on 
Day 3 before falling again to a value approximately 0.5pg/mL above Day 2 concentrations. 
IQR was greatest on Day 2 and Day 4.  
3.5.6.2 CHANGES TO IFN-γ CONCENTRATION 
3.5.6.2.1 ALL GROUPS 
Visually from the box plots there were no obvious trends in the changes to IFN-γ. While 
postoperative concentrations were generally higher than preoperative concentrations, 
measurable preoperative concentrations were found in all groups, reducing the likelihood 
of finding significant changes following surgery. Unlike other cytokines, increases to IFN-γ 
commonly occurred in the later stages of the study, on Day 3 and Day 4. To confirm if 
these variations were attributable to chance or a significant change a Friedman’s test (χ2) 
was used (Table 3.5-27). No significant changes in IFN-γ concentration over the course of 
the study were found using this test. As with other cytokines a post hoc analysis was 
conducted using a one tailed ilcoxon’s matched pairs test (Z) to increase the number of 
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samples included in the analysis in case this resulted in a statistically significant difference 
over one of the days. 
Table 3.5-27 Results of Friedman test for concentration of IFN-γ 
Abbreviations used: N-number in group; χ
2
-Friedman test statistic; df- degrees of freedom; Sig- significance. Significant 
values are indicated by *. 
IFN-γ N χ2 df Sig. 
Group A 7 3.657 4 0.454 
Group B 3 2.237 4 0.692 
Group C 2 8.000 4 0.092 
Group D 5 6.720 4 0.151 
One tailed tests were again used and only the pre-operative day was compared with each 
post-operative day (Table 3.5-28).  
Table 3.5-28 Results of Wilcoxon matched pairs test for IFN-γ concentrations 
Values shown as Z (significance). Significant values are indicated by *. ^=The sum of negative ranks equal the sum of 
positive ranks 
IFN-γ Group A Group B Group C Group D 
Day N Z (sig) N Z (sig) N Z (sig) N Z (sig) 
-1 v 1 10 1.172 (0.241) 3 0.535 (0.593) 7 0.405 (0.686) 11 0.105 (0.917) 
-1 v 2 9 1.125 (0.26) 3 0.535 (0.593) 4 1.826 (0.068) 5 1.753 (0.08) 
-1 v 3 9 1.007 (0.314) 3 0.535 (0.593) 2 1.342 (0.18) 6 1.363 (0.173) 
-1 v 4 7 1.521 (0.128) 3 0 (1) 3 1.604 (0.109) 6 0.943 (0.345) 
These resulted in values consistent with the Friedman test, with no statistically significant 
difference being shown between the preoperative concentrations and each postoperative 
day.  
3.5.7 SUMMARY 
IL-1β, IL-6, TNF-α and IFN-γ were measured in all patients on each day of the study and 
the results were non-parametric. Most patients had measurable concentrations of IL-1β, 
TNF-α and IFN-γ in the sample taken before surgery. Significant differences between the 
preoperative and the post-operative days of the study were seen for IL-1β and IL-6, 
although these elevations were still small. While these two cytokines were elevated TNF-
α and IFN-γ showed no relationship with surgery. The largest differences between 
preoperative and postoperative values were seen for IL-6. Patients with outlying values of 
elevated cytokines were those with complicated recoveries.   
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3.6 α GSH S-TRANSFERASE RESULTS 
The concentration of αGST was measured in daily patient samples by the ELISA methods 
described in Section 2.4. 
3.6.1 DISTRIBUTION OF GST RESULTS 
The distribution of the αGST concentrations for each group were checked for normality 
visually by preparing a histogram with normal curve superimposed, a box plot, a Q-Q and 
detrended Q-Q plot for each day. A sample is shown below from Group A on the 
preoperative day (Figure 3.5-1). In addition, formal normality tests were conducted using 
the Kolmogorov-Smirnov test (D) (Table 3.6-1). 
  
Figure 3.6-1 Graphs depicting distribution of αGST values from Group A on the preoperative day. 
(Clockwise from top left) Histogram with normal curve superimposed shows distribution skewed to the left; Box plot 
shows median bar is not centrally placed in the box and tails do not extend from the box symmetrically; Q-Q plot shows 
αGST values are not placed along the line of normality; the de-trended Q-Q plot shows an exaggerated deviation from 
the normal line. All of these graphs indicate the data to be non-parametric. 
Table 3.6-1 shows the results of the formal normality tests. A significance value of less 
than 0.05 indicates a significant variation from a normal distribution i.e. that the data are 
non-parametric. No group consistently passed normality tests. 
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Table 3.6-1 Results of Kolmogorov-Smirnov test D with (df) degrees of freedom.  
 Group A Group B Group C Group D 
 D (df) Sig. D (df)  Sig. D (df) Sig. D (df) Sig. 
Day 0 0.246 (10) 0.087 0.309 (3) 0.038 0.389 (7) 0.002 0.298 (11) 0.007 
Day 1 0.332 (10) 0.003 0.342 (3) 0.026 0.297 (5) 0.017 0.362 (6) 0.014 
Day 2 0.362 (9) 0.001 0.364 (3) 0.014 0.281 (4) 0.001 0.207 (5) 0.200 
Day 3 0.227 (9) 0.200 0.385 (3) 0.000 0.260 (2) 0.057 0.355 (6) 0.018 
Day 4 0.295 (7) 0.066 0.349 (3) 0.019 0.333 (3) 00.06 0.189 (6) 0.200 
To assess differences between days of the study, paired tests were used. While it is 
important to consider the distribution of αGST concentrations on each day of the study as 
shown above, when conducting paired analysis it is more relevant to consider the 
distribution of the residuals. The residuals are the absolute value of the difference 
between the values in the paired analysis. Their distribution also failed tests of normality 
(Table 3.5-2). Accordingly non-parametric tests were used through the analysis of αGST 
results. 
Table 3.6-2 Formal normality tests of the residuals 
 Group A Group B Group C Group D 
 D (df) Sig D (df)  Sig D (df) Sig D (df) Sig 
Day -1v1 0.277 (10) 0.028 0.439 (4) 0.001 0.387 (8) 0.001 0.353 (11) 0.000 
Day -1v2 0.516 (10) 0.000 0.439 (4) 0.000 0.325 (8) 0.013 0.353 (11) 0.000 
Day -1v3 0.515 (10) 0.000 0.439 (4) 0.001 0.455 (8) 0.000 0.351 (11) 0.000 
Day -1v4 0.428 (10) 0.000 0.449 (4) 0.001 0.391 (8) 0.001 0.352 (11) 0.000 
3.6.2 DESCRIPTIVES 
The median and interquartile ranges of all the groups are presented in Table 3.6-3 below. 
Additionally a box plot of the distribution of all αGST results is shown in Figure 3.6-2.  
Table 3.6-3 Descriptive statistics for αGST 
αGST Group A Group B Group C Group D 
 (µg/L) N Median (IQR) N Median 
(IQR) 
N Median (IQR) N Median (IQR) 
Day -1 10 3.15 
(2.03, 5.22) 
3 1.28 
(0.66, 3.57) 
7 2.01 
(0.82, 2.78) 
11 1.71 
(1.40, 2.65) 
Day 1 10 2.07 
(1.70, 2.70) 
3 0.15 
(0.09, 0.51) 
5 0.82 
(0.00, 1.95) 
6 1.21 
(1.16, 2.04) 
Day 2 9 2.53 
(1.97, 3.33) 
3 0.47 
(0.46, 0.66) 
4 5.97 
(0.93, 13.70) 
5 1.37 
(0.97, 2.25) 
Day 3 9 3.20 
(2.33, 4.24) 
3 1.39 
(1.14, 1.39) 
2 13.67 
(1.47, 25.88) 
6 3.19 
(1.22, 4.95) 
Day 4 7 3.56 
(2.76, 10.67) 
3 0.95 
(0.83, 1.93) 
3 26.42 
(14.34, 28.61) 
6 4.52 
(2.31, 5.63) 
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Figure 3.6-2 Boxplot of αGST concentrations in each group on each day 
Black dotted line indicates upper limit of reference range in healthy individuals (11.4µg/L) and red dotted line indicated 
three times this limit (34.2 µg/L), from where hepatotoxicity may be suspected. 
Figure 3.6-2 shows Group C as the only group to exceed the upper limit of the reference 
range even though they received the lower dose of paracetamol (Section 2.1). As noted in 
Section 3.1, Group C had poor retention in the study and the number of αGST values from 
this group was small.  
Group A also showed an increase in αGST concentrations, with the upper whisker 
stretching beyond the upper limit of the reference range on the final day of the study. 
Similar trends were observed in Figure 3.6-2 for both Group D, and to a lesser extent, 
Group B. However, both fall well short of the upper limit of the reference range (Figure 
3.6-2). 
It is also notable in Figure 3.6-2 that all groups start the study on day-1 with median αGST 
concentrations above zero, despite other LFTs being normal, although the median values 
for all groups were well below the upper limit of the reference range. Also of note for day 
-1 were the two outlying values from one patient in Group A and one in Group C (Figure 
3.6-2). These αGST concentrations exceeded the upper limit of the reference range, but 
were taken before the study began. These two patients had a αGST of 12.4 and 16.2 µg/L 
while having a AST concentration of 40 and 28 IU/L, which are both within the normal 
range. This could indicate an increased sensitivity of αGST, or hepatic damage yet to 
cause AST to increase. 
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3.6.3 CHANGES IN GST OVER THE STUDY PERIOD 
While trends can be observed from the box plot in Figure 3.6-2 statistical tests are 
necessary to determine if the differences were statistically significant. Initially a 
Friedman’s test (χ2) was used to assess if the distribution for each of the days were the 
same for each group. A significant result would indicate there was a difference between 
one or more of the days and all the other days of the study, which was not found to be 
present in these results, except for Group D (Table 3.5-7).  
Table 3.6-4 Results of Friedman test 
Abbreviations used: N-number in group; χ
2
-Friedman test statistic; df- degrees of freedom; Sig- significance 
 N χ2 df Sig. 
Group A 7 7.314 4 0.12 
Group B 3 5.867 4 0.209 
Group C 2 5.6 4 0.231 
Group D 5 15.520 4 0.004 
However, a repeated measures test such as Friedman’s requires a value to be present on 
all of the days of the test for the patient to be included in the analysis i.e. if one sample 
out of the five taken was missing that patient would be excluded. As a result the number 
of subjects who were included in this analysis was low (Table 3.5-7) and a poor reflection 
of the amount of data gathered.  
To further investigate differences of distribution between the days of the study a paired 
analysis was conducted using a one tailed Wilcoxon’s matched pairs test (Z). One tail was 
used because αGST was only expected to increase following surgery and IV paracetamol 
administration. To minimise the Type 1 error and the size of the Bonferroni correction, 
only the preoperative day was compared with the other days of the test. This resulted in 
four comparisons between the five tests, with the Bonferroni correction reducing the 
critical level of significance from 0.05 to 0.0125 (i.e. α/4) (Table 3.5-8). 
Table 3.6-5 Results of Wilcoxon matched pairs test 
Values shown as Z (significance). Significant values are indicated by *.  
Pair Group A n Group B n Group C n Group D n 
Day -1 vs 1 1.89 (0.059) 10 1.07 (0.285) 3 1.48 (0.138) 5 2.20 (0.028) 6 
Day -1 vs 2 1.24 (0.214) 9 1.07 (0.285) 3 0.00 (1.000) 4 2.02 (0.043) 5 
Day -1 vs 3 0.18 (0.859) 9 0.00 (1.000) 3 0.45 (0.655) 2 1.15 (0.249) 6 
Day -1 vs 4 1.18 (0.237) 7 0.53 (0.593) 3 1.07 (0.285) 3 2.20 (0.028) 6 
When the Bonferroni correction is considered there are no significant changes in αGST 
concentration over the study period.  
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Ignoring the Bonferroni correction, there are some significant differences in Group D, who 
received the lower dose of paracetamol. These differences were refelcted in the 
significant result of Friedman’s test above (Table 3.5-7), however, once the Bonferroni 
correction is considered these results serve only as an indication, and while of interest, 
cannot be interpreted as actual significant results (Table 3.5-8). Of interest here is that 
the differences do not show any consistent trend as may have been anticipated; neither 
increasing in magnitude as more paracetamol was given or reducing as recovery after 
surgery proceeded.  
Group A, who had the highest dose of paracetamol (i.e. 9g daily) with invasive surgery, 
did not show any significant changes in αGST over the course of the study, with the only 
result from this group approaching significance being from the comparison of the pre-
operative with the first postoperative day (Table 3.5-7, Table 3.5-8). There appears to be 
no relationship with αGST concentration and the total dose of paracetamol received.  
Given the major focus of this study was to examine the safety of higher doses of 
paracetamol and that αGST is such a sensitive marker of hepatotoxicity, it is worth 
examining Group A, the high paracetamol dose group, in greater detail. From examination 
of Figure 3.6-2 there are some clear trends that have not been considered in Table 3.5-8 
in an attempt to minimise the Type 1 error. To determine if this group’s elevated 
concentrations of αGST on admission may be masking some differences that arise 
following surgery, further tests were undertaken to compare the differences between the 
other days of the study. Two comparisons yielded results that required further discussion: 
Day 1 v Day 2 (Z=2.67 (p=0.008)) and Day 1 v Day 4 (Z=2.03 (p=0.043)). These differences 
are more in line with what was observed in Figure 3.6-2, however in order to find these, 
the number of tests that were conducted created a Bonferroni correction that, once 
applied, prevented these results from achieving significance. Accordingly, they are only 
indicative and must be interpreted with caution. Even where these trends were observed, 
all the αGST concentrations fell below a level of clinical significance and there was no 
evidence of hepatotoxicity occurring during the time αGST was monitored. 
3.6.3.1 αGST AND AST CONCENTRATIONS 
αGST concentration is not a standard measure of hepatocellular damage clinically. AST is 
more commonly used in the hospital setting for this purpose, in addition to being part of 
the assessment following paracetamol overdose (Amar et al. 2007). The major drawback 
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with AST is that its release from cells and appearance in the plasma is reported to be 
slower than αGST. 
To compare and validate αGST with the standard AST test, the correlation of one to the 
other was checked by pairing each patient’s αGST and AST result (Figure 3.6-3). When all 
patients were combined both αGST and AST were determined to be non-parametric with 
the Kolmogorov-Smirnov giving highly significant results for both αGST and AST. 
  
Figure 3.6-3 Correlation of αGST and AST concentrations. 
Also shown: Trend line (black) and upper limits of normal range for both αGST and AST (red lines) 
Most of the points in Figure 3.6-3 cluster around the origin, however there is some 
general trend, shown by the trend line, such that higher αGST concentrations were 
associated with higher AST concentrations. There was one notable exception where the 
highest αGST concentration was associated with a normal AST value. Additionally, not all 
elevated AST concentrations were associated with elevations of αGST, nor was the 
opposite true.  
To test the correlation a Spearman’s correlation coefficient was determined as the data 
were non-parametric. As an increase in one test was expected to result in an increase in 
the other, a one-tailed test was used. The correlation coefficient rs was 0.372 with p (one-
tailed) <0.01 indicating a significant relationship between the αGST and AST 
concentrations: as AST concentrations increased, so did αGST. The coefficient of 
determination shown in Figure 3.6-3 indicates αGST accounts for 30.4% of the variance in 
AST.  
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3.6.3.1.1 DELAYED AST ELEVATIONS 
As discussed above, one of the criticisms of AST is that its elevation after hepatic damage 
was much slower than αGST. To investigate this Figure 3.6-3 was modified to show the 
day of each test (Figure 3.6-4). 
 
Figure 3.6-4 αGST and AST concentrations showing the day of each test. 
Also shown: Trend line (black) and upper limits of normal range for both αGST and AST (red lines) 
If AST was delayed, elevations in AST would only occur in the latter stages of the study. 
Also, elevations in αGST occurring early on in the study would not be matched by 
elevations in AST, skewing those results to the left of the graph. To some degree these 
were confirmed in Figure 3.6-4 although too few patients had elevations in αGST or AST 
to make this possible visually. 
In order to confirm this, the day of the test was included into a partial correlation. It was 
seen the day of the test had a stronger relationship with AST (r= 0.344 p (one tailed) 
<0.001) than with αGST (r= 0.224 p (one tailed) 0.008), indicating increases of the day of 
the test were a better predictor of the AST results than that of αGST. Even so, both αGST 
and AST correlations coefficients were significant.  
3.6.4 INDIVIDUAL PATIENT ANALYSIS  
To confirm the αGST concentrations measured in the daily samples and to assess any 
changes that occurred within the dosing interval, three patients had αGST measured in all 
of their plasma samples taken for the pharmacokinetic analysis (as detailed in Section 
2.1). Each of the three patients were from one of the colorectal surgery groups (Groups A, 
B and D) and were chosen as they were all males with malignancy and were of broadly 
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similar age and BMI. These patients were chosen before αGST results were known and 
without reference to other liver-function tests. 
3.6.4.1 PATIENT DEMOGRAPHICS  
The demographic information of these patients is illustrated below (Table 3.6-6) followed 
by their paracetamol dose characteristics (Table 3.6-7). The patients were all male and in 
their early 50s. Their weights and BMIs were similar and all were undergoing surgery for 
colorectal cancer. 
Table 3.6-6 Individual analysis patient demographics 
Patient Age Gender Weight BMI Surgery Indication 
5A 52 M 92 26.9 Anterior resection Malignancy 
3B 54 M 87 25.4 Hemicolectomy Malignancy 
4D 52 M 89 27.5 Anterior resection Malignancy 
Table 3.6-7 Individual analysis paracetamol dose characteristics 
Patient Paracetamol Dose Interval (hour) Daily dose Total paracetamol given (g) 
5A 1.5g (16.3 mg/kg) 4 97.8 mg/kg 42.5 
3B 1g (11.5mg/kg) 6 46.0 mg/kg 20 
4D 1g (11.2mg/kg) 6 44.9 mg/kg 20 
All patients received their full quota of paracetamol. Patients 3B and 4D were very similar 
in daily dose on an mg/kg basis, with patient 5A receiving just over twice the daily mg/kg 
dose and total amount of paracetamol. While there were substantial differences between 
Group A and Groups B and D in the daily and total doses, the quantity received was not 
greatly different at 16.3mg/kg versus 11.5 and 11.2 mg/kg respectively. These doses were 
similar to the licensed paediatric dose of 10-15mg/kg with patient 5A’s 16.3mg/kg only 
just outside it (Glaxo Smith Kline 2008). 
3.6.4.2 αGST CONCENTRATIONS 
αGST concentrations were obtained in the same manner as, and measured alongside, the 
samples from the beginning of this section. The concentrations are presented below in 
Figure 3.6-5. 
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Figure 3.6-5 Patient 5A, 3B and 4D αGST concentrations over time on each day of the study 
Graphs show αGST concentrations and red reference line, which indicates upper limit of reference range (11.4µg/L). 
Circles show measured concentrations. Graphs are (clockwise from top left) 5A; 3B and 4D.  
The graph of αGST concentrations for patient 5A shows three interesting trends: 
 The concentrations at time zero for Days 2,3 and 4 are the highest, with Days 2 
and 4 exceeding the upper limit of the reference range. As time zero samples, the 
time these were taken was before the administration of paracetamol;  
 Samples after time zero decrease in αGST concentrations, even though these were 
taken after the paracetamol had been administered. αGST concentrations appear 
to reduce during the dosing interval; 
 For Group A paracetamol was administered every four hours. As such the four 
hour time sample shown in the graph was equivalent to the time zero of the next 
dose, and it would be expected that the time zero and four hour αGST 
concentrations would be similar. Curiously there was very little similarity between 
them, with the time zero sample being almost universally higher;  
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 There was no elevation as a result of the first 1.5g dose of paracetamol on day -1; 
and  
 There does not appear to have been any accumulation of αGST concentrations in 
patient 5A as the four hour time samples were approximately equivalent on all 
days of the study. However, the predose αGST concentration on the fourth day 
was the highest of all this patients concentrations.  
Graphs for Patients 3B and 4D were more comparable, as may be expected given they 
received the same paracetamol dose. The most important difference between these two 
patients was that Patient 3B underwent open surgery whereas Patient 4B’s surgery was 
laparoscopic. For patient 3B: 
 The shape of the curves for Days -1 and 1 indicated a small rise in αGST 
concentrations following administration of the paracetamol dose, which returned 
to predose concentrations by the end of the dosing interval. This effect does not 
seem to continue on subsequent days of the study where one hour αGST 
concentrations were less than or approximately equal to time zero αGST 
concentrations; and  
 There was no substantial accumulation of αGST over the study period. The one 
hour αGST concentration was less on Day 4 than Day 1. 
For patient 4D: 
 Similar patterns emerge as those of patient 3B. There was a more consistent trend 
of αGST concentrations increasing after the administration of paracetamol. Unlike 
patient 5A the paracetamol dosing interval of this patient was six hours. Therefore 
αGST concentrations would have had an additional two hours to reduce before 
the administration of the next paracetamol dose; and  
 There was no evidence of accumulation of αGST over the course of the study with 
αGST concentrations on the preoperative day amongst the highest of this patients 
values.  
3.6.5 FINDINGS AFTER STUDY PERIOD 
In addition to those data collected as part of the study protocol, further information was 
collected from several patients who remained in hospital after the study had finished. In 
these patients, results from any liver function tests that were done as part of their usual 
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care after the study were recorded. These results were not included in the above analysis 
as they were not part of the study protocol and were not accompanied by measurements 
of αGST concentrations. While this information was incomplete it nevertheless 
demonstrates clinical significance because it opposed the findings from the reportedly 
more accurate measure of hepatic damage, αGST concentrations, and had implications 
for patient safety. Figure 3.6-6 shows dramatic increases in AST concentration in many 
patients on Day 5 and following. When Days 1-4 are viewed in isolation there is no 
evidence of change to liver function tests, however, when the following days are 
considered, slight elevations that were seen on Days 3 and 4 take on new meaning. These 
changes were only seen in the high dose group, Group A. Generally these elevations 
resolved within 3-4 days after the conclusion of the study, with the exception of Patient 
9A who showed clinically significant AST elevations for a week after receiving his last 
investigational dose of paracetamol.  
 
Figure 3.6-6 AST concentrations in Group A for each patient 
Comparing those patients who showed the greatest increase in AST concentration after 
the study finished (Patients 2A, 3A, 4A and 9A), with the remainder of the group, there 
was only a very slight increase in αGST concentration seen prior to the conclusion of the 
study (Figure 3.6-7).  hile elevated above the remainder of the group, these patients’ 
αGST concentrations were still well below the upper limit of the reference range.  
Considering only Patients 2A, 3A, 4A and 9A, in whom the greatest AST elevations were 
shown, there was no consistent factor between them that explained why their AST rose. 
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Figure 3.6-7 αGST concentrations of those with large AST elevations following the conclusion of the study compared 
with the remainder of the group. 
Values shown as median (±IQR) 
These patients had a wide ranging BMI, were both male and female, had a variety of 
bowel cancer diagnoses, surgeries of both short and long durations and both drank 
alcohol and did not. There was also no distinction in their paracetamol plasma kinetics or 
urinary excretion ratio. In their urinary excretion in particular their Phase I metabolite 
output was no higher, nor their Phase II:I ratio clearly different to the remainder of their 
group. However, one clear distinction between these patients did arise; they were 
admitted to hospital for the longest period of their group, with Patients’ 2A, 3A, 4A and 
9A admitted for 20, 15, 34 and 15 days respectively, compared with the average of 8 days 
for the remainder of the group.  
3.6.6 SUMMARY 
αGST was measured in all patients on each day of the study and the results were non-
parametric. Two individuals entered into the study with αGST concentrations above 
normal but possessing normal AST concentrations. There was no significant difference 
between the preoperative and any postoperative day of the study. A correlation between 
increases in αGST and AST was demonstrated. One patient from the high dose group 
(Group A) showed substantial variation in αGST concentration over the dose period that 
was not seen in similar patients from Groups B or D, who received the normal 
paracetamol dose. There was no evidence from the analysis of αGST concentrations that 
any hepatic damage was done to any patient during the study, however, review of post-
study AST concentrations revealed that damage had occurred after the study finished. 
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3.7 CYP450 PROBE RESULTS 
A total of 518 patient plasma samples were analysed for the concentration of 9 
compounds of interest as described in Section 2.5 in 10 batches by LCMS in addition to 
approximately 100 standard samples. Access to the instrument was generously provided 
by the Department of Chemistry, UCC at limited hours over a six week period.  
The compounds eluted in the order and times shown in Table 3.7-1. Following 
chromatographic separation, samples were ionised by dual electrospray ionisation and a 
total ion chromatogram (TIC) was acquired using a quadrupole time-of-flight mass 
spectrometer. From the TIC, extracted ion chromatograms (EIC) were obtained using the 
mass/charge ratios (m/z) shown in Table 3.7-1. Compounds were quantified by the 
detector response which is proportional to parent ion abundance. Integration of detector 
response was conducted by Agilent Mass Hunter workstation Quantitative Analysis 2.00 
(Agilent Technologies, Massachusetts, USA) after the analysis had taken place. 
Table 3.7-1 Analyte, their mass/charge range of the protonate ion (M+H)
+
, elution order and elution time 
Analyte (M+H)+ range Elution Order Elution time (min) 
Paraxanthine 181.00-181.10 1 1.41 
Caffeine 195.05-195.15 2 2.14 
6-OH Chlorzoxazone 185.90-186.10 3 3.85 
Dextrorphan 258.15-258.25 4 4.10 
Phenacetin 180.05-180.15 5 6.19 
1-OH Midazolam 342.00-342.10 6 6.47 
Dextromethorphan 272.20-272.30 7 6.55 
Midazolam 326.05-326.15 8 6.78 
Chlorzoxaone 169.95-170.05 9 7.68 
3.7.1 LCMS VALIDATION 
Faults in the mass spectrometer resulted in poor chromatography from this instrument.  
 
Figure 3.7-1 Chromatogram from a prepared plasma sample containing 10mg/L of all compounds of interest.  
Red trace: UV absorbance at 280nm; Black trace: total ion chromatogram. 
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These complications are discussed in greater detail in the discussion. Figure 3.7-1 was 
obtained from a 10mg/L plasma standard, prepared as described in Section 2.5. The 
chromatogram in red displays smooth contours arising from the PDA, whereas the jagged, 
non-Gaussian peaks in black arose from the mass spectrometer. The extracted ion 
chromatograms showed more pronounced spiking (Figure 3.7-2) and this had 
ramifications for peak integration, on which quantitation depend. 
The trace arising from the PDA was good (Figure 3.7-1), affirming the sample preparation 
and chromatographic separation methods. This also indicated that the problems 
experienced with this process lay with detection, not the sample itself. 
 
Figure 3.7-2 Extracted ion chromatogram 326-326.15 (midazolam) (2.5x10^5 abundance) 
Extensive attempts were made at improving the peak shape shown in Figure 3.7-2 
including the revision of all of the MS settings optimised in Section 2.5, but these were 
unsuccessful. Reassurance was given by the researcher supervising the instrument that 
the integration software was capable of smoothing over such misshapen peaks and, given 
the time constraints, analysis should proceed. This turned out to be a flawed advice.  
3.7.1.1 SPECIFICITY/SELECTIVITY 
Specificity was examined to ensure endogenous co-eluting compounds in the patient’s 
plasma samples did not cause a matrix effect with the compounds of interest. This was 
confirmed in two ways (Polettini 2006): 
 Chromatographic separation of the compounds from the solvent front and other 
compounds was achieved (Figure 3.7-1); and 
 No interfering peaks were identified in blank human plasma samples.  
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Selectivity was confirmed by examination of EICs. EICs were extracted over a narrow m/z 
range on either side of the compound’s known m/z value (Polettini 2006). As the 
quadrupole time-of-flight mass spectrometer used was stated as able to determine m/z 
accurate to four decimal places, this, when combined with the elution time, meant the 
chances of mistaking compounds were negligible. No peaks with the same m/z were 
identified. 
3.7.1.2 INTERNAL STANDARD RECOVERY 
As detailed in the sample preparation method, the internal standard, phenacetin, was 
added before any extraction had taken place (Section 2.5). In robust sample preparation 
methods, internal standard concentrations vary little between samples, and this is a 
measure of the consistency of the extraction method. During the validation procedure, 
large variance in detector response of the internal standard phenacetin was seen. To 
examine the source of this, repeat injections were performed (Figure 3.7-3).  
 
Figure 3.7-3 Detector response for internal standard following repeated injection of plasma standard curve samples 
The results are shown of the repeated injection of a standard curve prepared in plasma, 
which contained the same concentration of internal standard in each sample. With an 
expected response around 2x106, there was considerable deviation. This triggered the 
investigation of peak shape described above. Figure 3.7-4 shows the variation in detector 
response of phenacetin across all patient sample batches by plotting the day of analysis 
against the detector response (note batches frequently ran over more than one day). 
Inconsistency in response is especially noticeable in the first few batches.  
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Figure 3.7-4 Internal standard detector response 
To quantify what can be seen in Figure 3.7-4 visually, internal standard precision values 
were determined (Table 3.7-2). 
Table 3.7-2 Internal standard precision values 
Sample batch Number of samples Precision (%RSD) 
1 37 22.50 
2 20 17.81 
3 55 20.74 
4 36 34.34 
5 35 11.90 
6 40 13.36 
7 28 12.21 
8 72 13.92 
9 73 9.68 
10 62 8.68 
 Inter-batch 29.98 
The first four of the ten batches failed standards for validation. Precision improved in 
later batches and the last six were within the 15% of the acceptable limit (Shah et al. 
1991; Bressolle et al. 1996).  
3.7.1.3 EXTRACTION EFFICIENCY 
Prior to running patient samples, nominal concentrations of analyte in diluent (water for 
LCMS) and prepared plasma samples were analysed to determine extraction efficiency. 
Three sets of samples were prepared and the first of these injected three times. There 
was a good correlation between plasma and diluent samples for most analytes until the 
5mg/L concentration after which the responses deviated (Figure 3.7-5). 
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Figure 3.7-5 Extraction efficiency of each compound 
Data shown as mean +/- standard deviation. 
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Five critical problems arose from these calibration curves which were not discovered until 
the use of the quantification software subsequent to the analysis: 
 The plasma derived curves were not linear; 
 The relationship between the diluent and plasma curves was not consistent; 
 No internal standard data could be obtained as phenacetin concentration was 
varied along with the other metabolites; and  
 The detector response was substantially less than with subsequent samples. 
These issues and the ramifications for subsequent samples meant that the analysis could 
not be accurate. Subsequent processing of the data abandoned validation standards and 
therefore results that are presented are of interest only and the applicability and 
precision of these findings is very limited. 
3.7.1.4 CALIBRATION CURVES 
Calibration curves were constructed using the ratio of the analyte’s detector response to 
that of the internal standard, phenacetin. The problems discussed above also impacted 
on these values and the intermittent changes to detection shown in Figure 3.7-3 meant 
that many of the calibration points were unusable. Accordingly calibration points were 
picked across the entire data collection to provide composite values. These were used to 
determine plasma concentration.  
Despite all of the issue discussed above, plasma concentration profiles in some patients 
for some probes were in line with those expected (Figure 3.7-6, Figure 3.7-7). 
  
Figure 3.7-6 Plasma concentration/time profile of 
chlorzoxazone on Day 1 for patient 7A.  
 
Figure 3.7-7 Plasma concentration/time profile of caffeine 
on Day-1 for patient 6D. 
The concentrations determined were converted to their molar equivalent and the 
metabolic ratio of each compound was then ascertained as shown in Table 3.7-3. 
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Table 3.7-3 Summary of CYP450 probe method 
Enzyme Drug, route and dose Sample matrix Sample time 
CYP1A2 Caffeine PO 100 mg  Plasma 1 hour post dose 
CYP2D6 Dextromethorphan PO 30mg Plasma 4 hour post dose 
CYP2E1 Chlorzoxazone PO 250 mg  Plasma 1 hour post dose 
CYP3A4 Midazolam IV 0.025mg/kg Plasma 4 hour post dose 
3.7.2 CYP 1A2 
The activity of CYP 1A2 was assessed by the molar ratio of paraxanthine to caffeine 
present in the one hour plasma sample. Despite the best efforts of the Principal 
Investigator, caffeine was above the LOD in 63/107 time zero samples, indicating caffeine 
intake in addition to that administered as part of the study, which as referred to in 
Section 2.1, patients were asked to remove from their diet as part of their involvement in 
the study. Such an example is shown in Figure 3.7-7, where the time zero sample 
contained considerable amounts of caffeine. 
3.7.2.1 GROUP A 
The molar ratio of paraxanthine to caffeine for Group A is shown in Figure 3.7-8 as 
median and quartiles. Most noticeable was the wide interquartile range, indicating a high 
variability in the data, but this is not inconsistent with the high inter-individual variation 
to be expected with this type of data. Despite this variation, a trend does emerge where 
the ratio falls from the preoperative value and slowly recovers as the study progresses. A 
reduction in the value of this ratio indicates a fall in the amount of paraxanthine relative 
to that of caffeine. Amongst many other possibilities, this could indicate a reduction in 
CYP1A2 activity postoperatively.  
 
Figure 3.7-8 Median paraxanthine:caffeine ratio for Group A patients  
Shown as median ± IQR 
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3.7.2.2 GROUP B 
Group B’s paraxanthine: caffeine ratio shows a similar pattern to that of Group A, a 
reduction from preoperative ratio and gradual return toward the end of the study (Figure 
3.7-9). The median ratio begins slightly higher than Group A at 0.87, decreased but then 
returned to a higher value by the end of the study. This pattern of change could also be 
explained by reduction in CYP1A2 activity around the time of surgery, but with a small 
group size and wide IQRs many other factors could also account for the changes.  
 
Figure 3.7-9 Median paraxanthine:caffeine ratio for Group B patients 
Shown as median ± IQR 
3.7.2.3 GROUP C 
The paraxanthine:caffeine ratio shows much less variation across the study in Group C 
than other groups, however, variation within the day still remains high (Figure 3.7-10).  
 
Figure 3.7-10 Median paraxanthine:caffeine ratio for Group C patients 
Shown as median ± IQR 
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The ratio starts lower than with previous groups (0.46) and there is very little change 
between preoperative and postoperative values until Day 2, when the ratio slightly 
increases. These changes could be explained by increases to CYP1A2 activity over the 
postoperative period. 
3.7.2.4 GROUP D 
The paraxanthine:caffeine ratio in Group D had the lowest starting value from all the 
groups. The ratio falls slightly towards the middle of the study and then increases sharply 
between Day 3 and 4. 
 
Figure 3.7-11 Median paraxanthine:caffeine ratio for Group D patients 
Shown as median ± IQR 
3.7.2.5 GROUP B+D 
The results from Group B+D have a very similar pattern to those of Group D.  
 
Figure 3.7-12 Median paraxanthine:caffeine ratio for Group B+D patients 
Shown as median ± IQR  
 347 
 
However, the starting ratio was larger than Group D, there was a greater fall towards the 
middle of the study and also the dramatic increase between Day 3 and 4. 
3.7.3 CYP 2E1 
In addition to the problems with this assay discussed above, the CYP2E1 probes 
chlorzoxazone and 6-hydroxychlorzoxazone are ideally detected in negative mode by the 
MS. Because the instrument used for this analysis was not capable of switching polarity 
within runs the detector response of these analytes was especially low.  
3.7.3.1 GROUP A 
The median 6-hydroxychlorzoxazone:chlorzoxazone ratio for Group A appeared to 
increase following surgery and then returned to preoperative values (Figure 3.7-13). One 
possible explanation for the increase in ratio seen could be a brief induction in CYP 2E1 
activity following surgery. 
 
Figure 3.7-13 Median 6-hydroxychlorzoxazone:chlorzoxazone ratio for Group A  
Shown as median ± IQR 
3.7.3.2 GROUP B 
A remarkably similar pattern in 6-hydroxychlorzoxazone:chlorzoxazone ratio to Group A 
was seen in Group B results (Figure 3.7-14). The main difference between the groups is 
Group B’s values remain around preoperative median ratio for the last three days of the 
study. Similarly, in Group A, these changes could be explained by short lived induction of 
CYP2E1 perioperatively. 
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Figure 3.7-14 Median 6-hydroxychlorzoxazone:chlorzoxazone ratio for Group B 
Shown as median ± IQR 
3.7.3.3 GROUP C 
Group C’s median 6-hydroxychlorzoxazone:chlorzoxazone ratio showed a slightly 
different course from the previous two groups. Still increasing following surgery, the 
increased ratio was maintained at a steady level for three further days postoperatively 
before returning towards preoperative values (Figure 3.7-15). The possibility of increased 
CYP2E1 activity could also explain these changes.  
 
Figure 3.7-15 Median 6-hydroxychlorzoxazone:chlorzoxazone ratio for Group C 
Shown as median ± IQR 
3.7.3.4 GROUP D 
Figure 3.7-16 shows the median 6-hydroxychlorzoxazone:chlorzoxazone ratio in Group D 
took a similar course to that seen in Groups A and B. There was a wide variation within 
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each days’ values in this group, shown by the large IQR. As above, a short lived induction 
in CYP2E1 activity could have explained these changes.  
 
 Figure 3.7-16 Median 6-hydroxychlorzoxazone:chlorzoxazone ratio for Group D 
Shown as median ± IQR 
3.7.3.5 GROUP B+D 
As a combination of two groups already shown to follow a similar pattern, the only effect 
the amalgamation of these two groups had was to reduce the size of the error bars 
(Figure 3.7-17). Otherwise, the same conclusions of increased CYP2E1 activity could be 
reached.  
 
Figure 3.7-17 Median 6-hydroxychlorzoxazone:chlorzoxazone ratio for Group B+D 
Shown as median ± IQR 
3.7.4 CYP 3A4+2D6 
Detection of midazolam was too erratic to provide usable data and 1-hyrdroxymidazolam 
was below the LOD. Dextrophan was below the LOD and the detection of 
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dextromethorphan was too inconsistent to provide enough usable data to represent 
graphically. 
3.7.5 SUMMARY 
Problems with instrumentation impaired reliability and interpretation of results. As a 
consequence assessment of CYP2D6 and CYP3A4 was not possible. Results for CYP1A2 for 
Groups A, B and D suggest an initial induction of enzyme activity immediately following 
surgery that resolves and recovery progresses. There is no discernible effect on Group C. 
Conversely assessment of CYP2E1 suggests that inhibition occurs in the immediate 
postoperative period which then returns towards preoperative activity levels as time 
passes.   
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3.8 CASE STUDIES 
The majority of the data before this point have been presented as a group. Given the high 
degree of inter-individual variation to be expected with this type of research, the course 
of a few individual patients who were involved summarise the various changes observed. 
A patient was chosen from each group and their case is presented in sections concerning: 
liver function; inflammatory cytokines; CYP450 probes; plasma paracetamol 
concentrations and finally the data from their urine analysis.  
3.8.1 PATIENT 4A 
Patient 4A was a 62 year old male who was scheduled for a low anterior resection 
following the discovery of a mid-rectal adenocarcinoma for which he had received six 
weeks of radiotherapy, completing this six weeks previously. He was a retired factory 
worker who reported consuming eight standard units of alcohol per week and until five 
years earlier was a heavy smoker, with a 20 pack year history. He was overweight with a 
BMI of 31.2kg/m2 and had a history of ischaemic heart disease and Type II diabetes. He 
was taking the following medicines prior to admission: aspirin, clopidogrel, losartan, 
lansoprazole, atorvastatin, furosemide/hydrochlorothiazide, bisoprolol, iso-sorbide 
mononitrate and metformin. He was classified by the anaesthetist as ASA 2. 
He was admitted into hospital two days prior to the scheduled procedure and was invited 
to join the study on that day. He consented the following day and the preoperative 
medication dosing and sampling took place without any deviation from Section 2.1. That 
evening he was fasted from 6pm and also received 4L of Klean Prep and a phosphate 
enema. The following day, his surgery was uneventful but took five hours, the longest of 
any patient undergoing open colectomy. He lost 2.5L of blood and received three units of 
whole blood and 3.5L of additional IV fluids. He also received 100µg fentanyl, 4mg 
ondansetron, 2g paracetamol, 140mg propofol and 60mg rocuronium intravenously, 
0.125% levobupivicaine, 100µg fentanyl and 3mg morphine lumbar epidural anaesthesia, 
in addition to inhalation of 1.5-1% sevoflurane in oxygen. Some manipulation of the liver 
was reported in the surgeon’s notes. He returned to the ICU with a lumbar epidural 
infusion of bupivicaine 0.125% and fentanyl 2µg/mL running at 15mL/hr, urinary catheter 
and central venous access. In addition to his preoperative medication he was also 
prescribed IV paracetamol 1.5g every four hours, cefuroxime 1g twice daily, 
metronidazole 500mg three times each day, 160mg of gentamicin daily, 5000 units of 
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subcutaneous heparin twice daily and a 10% glucose/10 unit insulin infusion. The 
remainder of the study protocol was undertaken without deviation from Section 2.1 and 
the patient went on to receive a total of 42.5g of paracetamol over the study period. He 
had a complicated postoperative course. On Day 2 he became pyrexial and gentamicin 
was increased to 400mg daily. As he had not resumed oral intake, and the surgeon 
wanted to continue resting the bowel, total parental nutrition (TPN) was initiated at 3pm 
on day two. He was the only study patient to receive TPN. 
Pharmacodynamic parameters obtained during the study are summarised in Table 3.8-1. 
His pain was well controlled throughout. His renal function and clotting time showed 
short-lived impairment following surgery. Transaminase concentrations remained within 
normal limits trending slightly upwards at the end of the study. Following the conclusion 
of the study his paracetamol dose was reduced to 1g every six hours. By day 7 he had not 
improved and returned to theatre where a leaking anastomosis was found which 
precipitated the formation of a stoma. He did not resume any oral nutrition for two and 
half weeks after surgery, requiring two weeks of TPN. 
Table 3.8-1 Pharmacodynamic monitoring values 
Abbreviations used: SCr- serum creatinine; AST- aspartate aminotransferase; INR- international normalised ratio; NRS- 
numerical rating scale- measure of pain experienced in last 24hrs and at time of study. 
 Day -1 Day 1 Day 2 Day 3 Day 4 
SCr (µmol/L) 94 110 87 74 69 
AST (U/L) 22 21 20 27 109 
INR 1 1.6 1.7 1.1 1 
NRS Best 0 0 0 0 0 
NRS Worst 0 3 4 3 5 
NRS Now 0 1 1.5 1 1 
3.8.1.1 LIVER FUNCTION 
Preoperative αGST concentration was high enough to indicate liver injury prior to surgery 
(Figure 3.8-1). This potential liver injury was not known at the time of the study as AST 
was not increased. The lack of sustained αGST elevation and absence of AST increase 
questioned the accuracy of this one elevated αGST. Postoperatively, there was no 
evidence of hepatotoxicity with αGST and AST remaining within normal limits until Day 4, 
when AST values spiked to just above three times the upper limit of normal. αGST 
concentrations, however, remained low, slightly above group concentrations. This 
increase in AST was minor in comparison with that seen with paracetamol toxicity, which 
registers in the thousands. As the only patient to experience an elevation outside the 
upper limit of normal this elevation is notable, but may not be clinically significant. 
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Transient LFT increases are widely reported following initiation of TPN (Gabe et al. 2010) 
and continued monitoring showed the AST elevation resolved quickly. 
 
Figure 3.8-1 Liver function tests αGST and AST on each day of the study with group median αGST (±IQR) 
3.8.1.2 CYTOKINES 
All cytokines were elevated on the postoperative day (Figure 3.8-2-Figure 3.8-5).  
 
Figure 3.8-2 Individual and group median (±IQR) IL-6 
concentration in daily samples 
 
Figure 3.8-3 Individual and group median (±IQR) IFN-γ 
concentration in daily samples 
 
Figure 3.8-4 Individual and group median (±IQR) TNF-α 
concentration in daily samples 
 
Figure 3.8-5 Individual and group median (±IQR) IL-1β 
concentration in daily samples  
IL-6 increases were especially prominent, rising to the highest level measured in any 
patient in any group. This was not surprising given that this patient had the longest 
operation of the most traumatic surgery. Despite the substantial increase in IL-6, 
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increases in the other cytokines were comparatively minor (Figure 3.8-3 and Figure 3.8-4). 
Notable was the increase in IL-1β, one of the first cytokines to be released, on the third 
and fourth day as the patient became increasingly unwell (Figure 3.8-5), however the 
magnitude of this increase was very minor. 
3.8.1.3 CYP450 PROBES 
The paraxanthine:caffeine ratio for patient 4A reduced from preoperative values. The 
ratio continued to fall in a similar pattern to the rest of the group until Day 4 when it 
showed a sharp increase (Figure 3.8-6). There is nothing in this patient’s clinical course 
that easily explains this induction on Day 4, which indicates CYP1A2 operating at above 
preoperative levels. While CYP450 activity is known to be reduced by inflammation, 
considering this patients state health on Day 4 and the indication given by IL-1β that 
inflammation was, if anything, increasing, the paraxanthine:caffeine ratio should fall, not 
peak on this day. Given the deteriorating health of this patient, subsequent samples 
would have been interesting to further examine the role of inflammation.  
Figure 3.8-7 shows the 6-hydroxychlorzoxazone:chlorzoxazone: ratio followed a similar 
course, falling from preoperative values until Day 2, indicating an induction of CYP2E1. A 
gradual increase in ratio was seen on Days 3 and 4. This coincides with the administration 
of TPN, which is known to induce CYP450 activity as seen in the last two days. While it is 
difficult to see relationships with caffeine metabolism, the inhibition of CYP2E1 by 
inflammation could explain slightly delayed inverse relationship between inflammation 
(IL-6 concentration) and the 6-hydroxychlorzoxazone:chlorzoxazone ratio. 
 
Figure 3.8-6 Individual and group median ratio (±IQR) of 
paraxanthine to caffeine in plasma  
 
Figure 3.8-7 Individual and group median ratio (±IQR) of 
6-hydroxychlorzoxazone to chlorzoxazone in plasma 
3.8.1.4 PLASMA 
Figure 3.8-10 shows the paracetamol concentrations were used to calculate 
pharmacokinetic values (Table 3.8-2). This patient’s half-life fell postoperatively. 
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Clearance, Vd and AUC values were all substantially different to the remainder of this 
patient’s group. The large reduction in clearance postoperatively, indicated metabolism 
was slowed, but this was opposed by a substantial reduction in volume of distribution. 
Because both clearance and Vd values changed by a similar magnitude, there was little 
change to the mean residence time or half-life postoperatively. However, the reduction to 
clearance may have allowed an increase in AUC postoperatively, showing some plasma 
accumulation of paracetamol, which was not seen in the remainder of the group.  
Table 3.8-2 Plasma pharmacokinetics preoperatively and postoperatively with group medians (±IQR) 
 Day -1 Day 1 
Patient 4A Group A Patient 4A Group A 
t ½ (hr) 2.22 1.75 (1.59, 2.11) 2.13 2.13 (1.80, 3.25) 
AUC (mg.hr/L.mg) 0.043 0.041 (0.032, 0.054) 0.083 0.049 (0.022, 0.057) 
Cl (L/hr) 23.07 24.56 (18.68, 31.21) 12.0475 20.60 (13.05, 26.90) 
Vd (L/kg) 0.83 0.69 (0.62, 0.83) 0.309 0.48 (0.38, 0.70) 
MRT (hr) 2.97 2.32 (2.11, 2.88) 2.13 3.10 (2.49, 4.68) 
Because Phase I processes contribute a relatively small amount to paracetamol 
metabolism overall, it is difficult to link the assessment of CYP1A2 and 2E1 to changes in 
clearance, however, both enzymes show reduced levels of activity postoperatively in this 
patient in conjunction with substantial reductions to plasma clearance. The contributions 
of the more significant pathways, glucuronidation and sulphation, do appear reduced as 
seen in the reductions to the ratio of metabolites recovered in the urine. It is possible that 
the Phase II processes are susceptible to inhibition due to inflammation, pharmacokinetic 
values were not calculated beyond the first postoperative day the relationship between 
clearance and cytokine concentration cannot be reliably determined.  
Daily plasma paracetamol concentrations at one and four hours post dose were used to 
assess for accumulation (Figure 3.8-8 and Figure 3.8-9). Both one hour and four hour 
concentrations more than doubled between preoperative and postoperative sampling. 
Following their peak on Day 1, a steady state concentration did not seem to be achieved 
and there was a continuous reduction in paracetamol concentration at both one hour and 
four hour times. The final samples had paracetamol concentrations similar to 
preoperative values and this fall indicated metabolism of paracetamol was induced.  
The increase in plasma concentrations immediately following surgery is greater than the 
remainder of his group and coincides with increases to plasma cytokine concentrations. 
Cytokines are known to reduce volume of distribution, which was also lower in this 
patient than the rest of his group. This could explain the short lived increases in plasma 
 356 
 
concentration seen. However, considering the size of the increase in IL-6, the highest of 
any patient, the plasma concentrations of this patient are too consistent with that of his 
group for any strong effect of cytokine concentrations to exist. 
 
Figure 3.8-8 Individual and group median Plasma 
concentration of paracetamol- 1hr 
 
Figure 3.8-9 Individual and group median Plasma 
concentration of paracetamol- 4hr 
Figure 3.8-10 shows a substantial increase in paracetamol glucuronide concentrations 
postoperatively. Glucuronide concentrations rose to dwarf all other metabolites and even 
surpass paracetamol itself on the final day. This reflects the considerable reserve capacity 
of glucuronidation and how its activity can expand rapidly to meet demand. 
Comparatively, paracetamol sulphate concentrations did not alter from preoperative 
values, despite the much higher concentrations of paracetamol present, indicating the 
saturation of sulphation. Furthermore, unlike paracetamol glucuronide, there is very little 
difference in paracetamol sulphate concentrations over the dose interval postoperatively, 
despite the much higher concentrations of the substrate paracetamol, indicating 
saturation of sulphonation processes. Paracetamol cysteine and mercapturate were not 
detectable preoperatively; however cysteine concentrations were greatly increased 
postoperatively and by the end of the study had risen above those of paracetamol 
sulphate. This suggests a rise in the conjugation of potentially toxic of NAPQI; however it 
is not possible to determine if NAPQI production is increased, or if, as a result of 
increased cysteine from the TPN, it is simply that GSH conjugation has increased. 
However, considering the increases in AST in this patient, it may be the former. 
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Figure 3.8-10 Concentration of paracetamol and its major metabolites in plasma 
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3.8.1.5 URINE 
The two most important graphs arising from the urine are presented in Figure 3.8-11 
Figure 3.8-12 and Figure 3.8-13. 
Marked changes were seen in all these figures that coincide with the initiation of TPN. As 
discussed in Section 1.4, the main changes to disposition of paracetamol following the 
initiation of TPN were the induction of the CYP450 system and an increase in the supply 
of sulphur containing amino acids.  
3.8.1.5.1 SULPHATE CONTRIBUTION 
This patient’s contribution of sulphate derived metabolites initially followed a similar 
track to that of his groups (Figure 3.8-11). The fall seen between Day 1 and Day 2 occurs 
even though plasma concentrations of paracetamol sulphate and cysteine seen in Figure 
3.8-10 remain steady. This could indicate as much a lack of glucuronide increase that was 
seen in other groups, as an increase in sulphate derived metabolites in this patient.  
From sample 4 on Day 2 this patient’s values diverge from his group’s, when the patient’s 
values appear to spike and then continue to slowly rise while his group’s continue to fall. 
This change coincided precisely with the initiation of TPN in this patient. As a rich source 
of inorganic sulphur and sulphur containing amino acids this would maintain the urinary 
output of sulphate derived metabolites and were indicative that the decline seen in the 
remainder of his group could be attributed to malnutrition. Other possible explanations 
for this pattern could be the patient’s condition, being of poorer health than the 
remainder of his group with evidence of returning inflammation. However this could not 
explain the marked increase in the sulphate containing metabolites in the urine seen in 
exactly the same interval as when TPN was initiated and that his values are virtually 
identical to his preoperative values, whereas the groups values declined.  
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Figure 3.8-11 Per cent of urinary metabolites excreted as sulphate derived compounds with group median (±IQR) 
3.8.1.5.2 PHASE II:I METABOLITE RATIO 
As in the previous figure, there is a clear divergence of this patient’s values from his 
groups that begin at the same time as TPN initiation (Figure 3.8-12).  
 
Figure 3.8-12 Ratio of Phase II: Phase I metabolites of paracetamol with group median (±IQR) 
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The maintained reductions in this ratio could indicate increased CYP450 activity, as has 
been shown with TPN administration (Section 1.4.5), or at least an increased conjugation 
of the CYP450 product NAPQI as discussed in Section 3.8.1.4. The lack of change in the 
ratio of these metabolites in the urine matches what is seen in the plasma 
concentrations, where the contribution of each of the metabolites remained relatively 
static, although plasma levels are not good indicators of metabolism due to difference 
rates of renal excretion. This pattern of Phase II:I ratio is unlike any other patient in his 
group, as shown by the recovery of group values towards the end of the study, and would 
suggest that the effect of TPN administration is to favour NAPQI production/recovery, not 
increase the rate of sulphonation. Further investigation reveals the cause of this altered 
Phase II:I ratio. Figure 3.8-13 shows there was no alteration to total urinary recovery of 
the dose or clear influence of TPN, maintaining total urinary recovery around 100%.  
 
Figure 3.8-13 Contribution of paracetamol metabolites to urinary recovery of dose (left axis) and percentage of total 
dose recovered (right axis) 
This shows that the change in urinary Phase II:I ratio was not due to plasma accumulation 
or alteration to urinary excretion, but was due to changes in the amount of metabolites 
produced. In fact, at 103% over the total postoperative course, this patient had the 
highest dose recovery of any in his group, where the next closest was at 98%. This was 
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achieved through an unusually high contribution of paracetamol cysteine, not through 
increases to paracetamol glucuronide as seen in all other patients of his group (Figure 3.3-
14). As a conjugate of NAPQI and indicator of CYP450 activity, this patient’s high 
paracetamol cysteine recovery, the highest of his group, may explain why he showed 
altered liver function towards the end of the study period. While TPN is known to 
increase CYP450 activity, it would also provide a source of cysteine for detoxification in 
the same manner as an antidote. However, in this patient, the increased AST 
concentrations indicate the increased cysteine was not sufficient to completely prevent 
liver injury. 
There were three other notable change in the contribution of each of the metabolites 
that coincide with the initiation of TPN: 
1. Paracetamol sulphate recovery increases; 
2. Paracetamol glucuronide recovery reduces; and 
3. The relative contribution of each metabolite remains static from the point 
onwards. 
As a source of sulphur containing amino acids (precursors for sulphonation) it is not 
surprising that paracetamol sulphate contribution increased following TPN 
administration, however the increase was to values still well below those seen 
preoperatively and its role remains minor. Assuming the abundance of cofactor supplied 
by TPN, this could be explained in two ways: SULT enzymes were saturated or Phase I 
pathways were induced and deprived Phase II pathways of substrate. It seems unlikely 
SULT enzymes were saturated because an increased capacity is exhibited earlier in the 
study by the greater recoveries of paracetamol sulphate seen. However, the possibility 
CYP450 pathways are induced to such a degree as to deprive Phase II pathways also 
seems remote. As already stated, TPN is known to cause CYP450 induction but this would 
require unreported levels of induction, in situations where inhibition is more commonly 
reported, and these are not seen in the CYP450 probe results above. Furthermore, while 
the increase to AST could be due to increased NAPQI production, given the limited extent 
of the elevation, it would seem more likely to be associated with TPN (Gabe et al. 2010). 
Additionally, the TPN administered to this patient contains 3.5g of methionine in each 
daily bag Kabi, 2011 #4630}. While well short of the maximum 300mg/kg infusion of n-
acetlycysteine given to patients in the 24 hours following overdose, this is still a 
significant amount which should reduce the risk of toxicity (Brok et al. 2006).  
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There is also something occurring in this patient at the time TPN was initiated that 
prevents the rise of glucuronidation that occurs in the other members of his group. The 
absence of this rise may explain the deviations seen in Figure 3.8-11 and Figure 3.8-12. It 
is possible that this rise in the other group members was not a factor of increased 
glucuronidation activity, but rather a reduction in the activity of the sulphur containing 
pathways. As detailed in Section 1.4.5 while malnutrition is known to increase Phase I 
metabolism, it has a more significant effect in the reduction of GSH conjugation and 
sulphonation. This would explain the apparent rise in glucuronidation, as it is not affected 
by starvation. Further evidence of this change was exhibited by the continuing rise of 
paracetamol glucuronide in the group data shown in Figure 3.3-14, indicating worsening 
exhaustion of the alternative pathways, whereas, once TPN was initiated and adequate 
nutrition supplied, this patient’s metabolic pattern abruptly stabilised. Further support for 
this hypothesis is this patients highest urinary recovery of dose, whereas the potential for 
unconjugated NAPQI remaining in the liver may explain the lower dose recovery recorded 
in the other patients.  
3.8.2 PATIENT 1B 
Patient 1B, was a 60 year old mechanical engineer. He had a BMI of 24.9kg/m2, smoked 
15-20 cigarettes a day for 35 pack years and reported drinking only on special occasions, 
having no regular alcohol consumption. He had no significant medical history or 
preoperative medications until recent complaints of biliary colic which led to the 
discovery of a high grade dysplastic polyp near his splenic flexure. He was scheduled for a 
left hemicolectomy and cholescystectomy and was graded by the anaesthetist as ASA 1. 
He was admitted the day prior to the procedure and consented for this study that 
afternoon. Preoperative study medications and sampling went ahead without deviation 
from the protocol Section 2.1. That evening he was fasted from 6pm, received four litres 
of Klean Prep and a phosphate enema the following morning. The following day his 
surgery went ahead as scheduled taking 1.75 hours. In theatre he received 0.125% 
levobupivicaine, 100µg fentanyl and 3mg morphine lumbar epidural anaesthesia, 4mg 
ondansetron, 130mg propofol, 35mg rocuronium, 2g paracetamol, parecoxib 40mg 
intravenously in addition to 1.5-1% sevoflurane in oxygen. He received 4L of IV fluid 
intraoperatively and some liver palpation was noted by the surgeon. He returned to the 
ICU with a lumbar epidural infusion of bupivicaine 0.125% and fentanyl 2µg/mL running 
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at 15mL/hr, urinary catheter and central venous access. He was also prescribed twice 
daily parecoxib 40mg, 1g paracetamol every six hours, 5000 units of subcutaneous 
heparin twice daily, pantoprazole 40mg daily, cefuroxime 1g twice daily, metronidazole 
500mg three times each day. Subsequent study procedures went ahead as in Section 2.1 
with the omission of the 15min plasma sample on the first postoperative day as no line 
was free for access. The patient received a total of 21g of paracetamol over the study 
period. His postoperative course was uncomplicated and he resumed oral intake on the 
third postoperative day with sips of water, followed by tea and toast on the fifth day. His 
epidural infusion was reduced to 12mL/hr on the first postoperative day and continued at 
this rate until midday on the fourth postoperative day when it was stopped. 
Pharmacodynamic values showed some derangement around the time of surgery, with 
increased creatinine and INR on Day 1 (Table 3.8-3). Both resolved by Day 3 without 
intervention. Pain was well controlled throughout the patient’s recovery. 
Table 3.8-3 Pharmacodynamic monitoring values 
Abbreviations used: SCr- serum creatinine; AST- aspartate aminotransferase; INR- international normalised ratio; NRS- 
numerical rating scale- measure of pain experienced in last 24hrs and at time of study. 
 Day -1 Day 1 Day 2 Day 3 Day 4 
SCr (µmol/L) 105 114 95 83 74 
AST (U/L) 24 51 39 27 21 
INR 1 1.5 1.2 1 1 
NRS Best 0 0 0 0 0 
NRS Worst 0 6 0 0 3 
NRS Now 0 4 0 0 0 
3.8.2.1 LIVER FUNCTION 
Despite the changes seen in the rest of the group, there was no alteration in this patient’s 
liver function seen with either αGST or AST (Figure 3.8-14).  
 
Figure 3.8-14 Liver function tests αGST and AST on each day of the study with group median αGST and IQR 
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Similar to patient 4A, αGST concentrations appeared to actually decrease following of 
surgery, although this patient’s preoperative αGST concentration was 10 times less than 
that of patient 4A. 
3.8.2.2 CYTOKINES 
Elevations in IL-6 were seen in this patient on the day following surgery (Figure 3.8-15) 
which was accompanied by slight increases to TNF-α (Figure 3.8-17).  
 
Figure 3.8-15 Individual and group median IL-6 
concentration in daily samples 
 
Figure 3.8-16 Individual and group median IFN-γ 
concentration in daily samples 
 
Figure 3.8-17 Individual and group median TNF-α 
concentration in daily samples 
 
Figure 3.8-18 Individual and group median IL-1β 
concentration in daily samples 
IL-6 fell on the following day but remained above that of the group until the final day of 
the study. TNF-α remained slightly elevated, but the size of the elevation was very minor. 
Elevations in IFN-γ (Figure 3.8-16) and IL-1β (Figure 3.8-18) preoperatively were slight and 
resolved postoperatively with no effect of surgery seen. 
3.8.2.3 CYP450 PROBES 
Both Figure 3.8-19 and Figure 3.8-20 show changes to the ratio of these probes for this 
patient were very close to that of the rest of his group. Ratios of caffeine:paraxanthine 
fell and then remained low for the remainder of the study, indicating induction of CYP1A2 
and subsequent production of more paraxanthine following surgery. Conversely, the ratio 
of 6-hydroxychlorzoxazone to chlorzoxazone increased initially, and then returned to 
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preoperative values. This indicates brief inhibition of CYP2E1 following surgery, which was 
quickly corrected by Day 2. 
 
Figure 3.8-19 Individual and group median ratio of 
caffeine to paraxanthine 
 
Figure 3.8-20 Individual and group median ratio of 
chlorzoxazone to 6-hydroxychlorzoxazone 
3.8.2.4 PLASMA 
Pharmacokinetic values are shown in Table 3.8-4. The half-life of paracetamol in this 
patient was slightly above that of his group preoperatively but changed very little 
following surgery to become the group’s median value. There was no substantial 
difference between the half-life of this patient and Patient 4A who received the high 
dose. The only value to show a noticeable change postoperatively was the reduced Vd, 
with all of the other values remaining relatively constant. 
Table 3.8-4 Plasma pharmacokinetics preoperatively and postoperatively with group medians (±IQR) 
 Day -1 Day 1 
Patient 4 Group  Patient 4 Group  
t ½ (hr) 2.11 1.97 (1.64, 2.11) 2.09 2.09 (1.49, 3.14) 
AUC (mg.hr/L.mg) 0.039 0.039 (0.025, 0.052) 0.040 0.040 (0.022, 0.057) 
Cl (L/hr) 25.46 25.46 (19.34, 39.82) 25.27 25.27 (17.67, 44.94) 
Vd (L/kg) 0.95 0.95 (0.61, 1.05) 0.68 0.70 (0.53, 0.93) 
MRT (hr) 2.94 2.76 (2.29, 2.94) 2.13 2.19 (1.80, 2.63) 
Figure 3.8-21 shows paracetamol concentrations changed very little following surgery and 
there was only a slight accumulation seen in the t=0 and Cmax samples postoperatively. 
Following surgery metabolite concentrations remain relatively constant with slight 
accumulation of paracetamol glucuronide, cysteine and mercapturate and reduction in 
paracetamol sulphate. 
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Figure 3.8-21 Concentration of paracetamol and its major metabolites in plasma 
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One hour and four hour concentrations of paracetamol are shown in Figure 3.8-22 and 
Figure 3.8-23. Both show a very minor accumulation until Day 2 and then a gradual return 
to preoperative levels.  
 
Figure 3.8-22 Individual and group median Plasma 
concentration of paracetamol- 1hr 
 
Figure 3.8-23 Individual and group median Plasma 
concentration of paracetamol- 4hr 
3.8.2.5 URINE 
3.8.2.5.1 SULPHATE CONTRIBUTION 
Patient 1B showed a steady reduction in sulphate derived metabolites being excreted in 
the urine until half way through Day 2 which plateaued thereafter (Figure 3.8-24). These 
values were consistently below that of the rest of his group.  
 
Figure 3.8-24 Per cent of urinary metabolites excreted as sulphate derived compounds with group median (±IQR) 
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3.8.2.5.2 PHASE II:I METABOLITE RATIO 
The ratio of metabolites in the urine from this patient was quite different from the 
expected course. Although values dipped immediately following surgery they climbed 
back to preoperative levels quickly, and finished slightly above those seen preoperatively. 
This was in stark contrast to the results of Patient 4A. In Patient 1B the contribution of 
paracetamol glucuronide increased postoperatively, exceeding the reductions in 
paracetamol sulphate recovery, and this accounts for the return of the metabolic ratio to 
beyond preoperative levels. The dip in paracetamol metabolite ratio seen on Day 1 was in 
the opposite direction to that seen in chlorzoxazone metabolism, which appears inhibited 
on this day, confounding the possibility of a role of CYP2E1. A closer relationship could be 
seen with caffeine metabolism, although this appeared most induced on Day 2, well after 
paracetamol’s metabolic ratio had recovered. A better relationship between metabolite 
ratio and cytokine concentration could be drawn with IL-6 concentrations peaking at the 
same time the metabolic ratio was at its lowest. 
 
Figure 3.8-25 Ratio of Phase II: Phase I metabolites of paracetamol with group median (±IQR) 
3.8.3 PATIENT 1C 
Patient 1C was a 41 year old female who was scheduled for a left mastectomy and axillary 
node clearance following three months of chemotherapy and radiotherapy for an invasive 
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ductal carcinoma of her left breast. Her main chemotherapy agents, docetaxel, 
doxorubicin and cyclophosphamide, were given three weekly prior to surgery. She had a 
BMI 22.3kg/m2, consumed 10-14 standard units of alcohol per week and smoked 15-20 
cigarettes a day for 20 pack years. She was taking no regular medication prior to the 
procedure and, having no medical history of note, was graded as ASA 1. She was fasted 
from midnight prior to the procedure and shortly before induction levo-bupivicaine was 
given to provide a left paravertebral block.  
Surgery and anaesthesia were uneventful. In theatre she received remifentanyl and 
propofol infusions, receiving a total of 1.9mg and 5.6mg of each respectively over the two 
hour long procedure. In addition, she received paracetamol 2g intravenously, 100mg 
diclofenac rectally and 4.5L of IV fluids. She returned to the ward with IV access into her 
external jugular vein, a peripheral line and a urinary catheter. She also had a morphine 
patient-controlled analgesia and required 32mg of this on demand over the next three 
days. Additionally, she received twice 75mg diclofenac orally and 5000 units of heparin 
subcutaneously for the remainder of the study period.  
The remainder of her recovery was uncomplicated (Table 3.8-5) and the study followed 
Section 2.1. Her urinary catheter was removed on the day after surgery and she 
continued to collect her own urine for the study. Problems on the same day drawing the 
predose sample from the external jugular line necessitated the use of the peripheral line 
which remained patent for the rest of the study. In total 21g of paracetamol was 
administered over the course of the study. 
Table 3.8-5 Pharmacodynamic monitoring values 
Abbreviations used: SCr- serum creatinine; AST- aspartate aminotransferase; INR- international normalised ratio; NRS- 
numerical rating scale- measure of pain experienced in last 24hrs and at time of study. 
 Day -1 Day 1 Day 2 Day 3 Day 4 
SCr (µmol/L) 73 80 94 90 82 
AST (U/L) 24 24 21 27 29 
INR 1.1 1.1 1 1 1 
NRS Best 0 0 0 0 0 
NRS Worst 0 1 1 3 4 
NRS Now 0 0 0 0 1 
3.8.3.1 LIVER FUNCTION 
Patient 1C’s liver function tests showed very little variation across the study duration, 
remaining below that of her group for the duration of the study (Figure 3.8-26).  
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Figure 3.8-26 Liver function tests αGST and AST on each day of the study with group median αGST and IQR 
3.8.3.2 CYTOKINES 
There were only minor elevations in cytokine concentrations following surgery that were 
either equivalent to or less than the rest of this group. IFN-γ (Figure 3.8-28) and TNF-α 
(Figure 3.8-29) concentrations showing barely any change at all over the five days of 
monitoring. IL-1β (Figure 3.8-30) and IL-6 (Figure 3.8-27) concentrations were elevated 
towards the end of the monitoring period, but these were very small.  
 
Figure 3.8-27 Individual and group median IL-6 
concentration in daily samples 
 
Figure 3.8-28 Individual and group median IFN-γ 
concentration in daily samples 
 
Figure 3.8-29 Individual and group median TNF-α 
concentration in daily samples 
 
Figure 3.8-30 IL-1β Individual and group median 
concentration in daily samples 
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3.8.3.3 CYP450 PROBES 
Figure 3.8-31 and Figure 3.8-32 were suggestive of induction of both CYP1A2 and, to a 
lesser extent, CYP2E1 in this patient, occurring maximally for both enzymes on Day 3. 
 
Figure 3.8-31 Individual and group median ratio of 
paraxanthine to caffeinein plasma  
 
Figure 3.8-32 Individual and group median ratio of 6-
hydroxychlorzoxazone to chlorzoxazone in plasma 
3.8.3.4 PLASMA 
This patient showed a marked accumulation of paracetamol glucuronide and a slight 
accumulation of paracetamol sulphate, while plasma concentration of paracetamol and 
the other metabolites remained relatively constant following surgery. Despite the 
changes seen in chlorzoxazone and caffeine metabolic ratios (Figure 3.8-31 and Figure 
3.8-32) there was not significant change in either of the CYP450 products, paracetamol 
cysteine or mercapturate (Figure 3.8-33).  
There was very little evidence of accumulation of paracetamol with preoperative and 
postoperative profiles being very similar (Figure 3.8-32). Plasma data pharmacokinetic 
parameters (Table 3.8-6) showed plasma half-life of paracetamol was longer than most of 
her groups and slightly fell postoperatively. This was accompanied by reductions to AUC. 
The two determinants of half-life, clearance and volume of distribution, both fell, but the 
fall of Vd was much larger (≈25%). These changes were reflected in reductions to MRT of 
about one third.  
Table 3.8-6 Plasma pharmacokinetics preoperatively and postoperatively with group medians (±IQR) 
 Day -1 Day 1 
Pt 1C Group median (±IQR) Pt 1C Group median (±IQR) 
t ½ (hr) 2.35 1.94 (1.60, 3.43) 2.12 1.89 (1.25, 2.27) 
AUC (mg.hr/L.mg) 0.042 0.045 (0.042, 0.079) 0.039 0.045 (0.039, 0.052) 
Cl (L/hr) 23.68 22.40 (14.00, 23.68) 25.41 22.41 (19.41, 25.41) 
Vd (L/kg) 1.29 0.88 (0.74, 1.094) 0.904 0.758 (0.612, 0.904) 
MRT (hr) 3.38 2.72 (2.233, 4.947) 2.216 2.09 (1.95, 2.22) 
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Figure 3.8-33 Concentration of paracetamol and its major metabolites in plasma 
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There was very little evidence of accumulation in either the one (Figure 3.8-34) or four 
hour concentration (Figure 3.8-35), with the one hour concentration appearing to decline 
on the third and fourth day. These show very little relation to either CYP450 enzyme 
result. 
 
Figure 3.8-34 Plasma concentration of paracetamol- 1hr 
 
Figure 3.8-35 Plasma concentration of paracetamol- 4hr 
3.8.3.5 URINE 
3.8.3.5.1 SULPHATE CONTRIBUTION 
Unlike the patients undergoing bowel surgery, there was no notable change in sulphate 
derived metabolite recovery in this patient throughout the study or in their group (Figure 
3.8-36).  
 
Figure 3.8-36 Per cent of urinary metabolites excreted as sulphate derived compounds with group median (±IQR) 
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3.8.3.5.2 PHASE II:I METABOLITE RATIO 
The metabolic ratio recovered in the urine of this patient fell from preoperative values 
and remained at this level for the duration of the study (Figure 3.8-37). This was 
consistent with the lack of change to cytokine concentration and sulphate contribution to 
recovery. 
 
Figure 3.8-37 Ratio of Phase II: Phase I metabolites of paracetamol with group median (±IQR) 
3.8.4 PATIENT 8D 
Patient 8D was a 65 year retired factory worker. He was scheduled for a laparoscopic low 
anterior resection to remove a circumferential low rectal cancer. He reported smoking 
15-20 cigarettes a day, with a 30 pack year history, and drinking 10 units of alcohol per 
week. He had a BMI of 27.7kg/m2 and with no comorbidities was graded as ASA 1. 
He was admitted and consented to this research the day prior to surgery and sampling 
and dosing proceeded as per Section 1.2 that evening. The following day his surgery 
proceeded routinely taking 4.5 hours. As part of his anaesthesia he received a total of 
375µg of fentanyl, 18mg vecuronium, 10mg morphine, 8mg dexamethasone, 8mg 
ondansetron, 2g of paracetamol and 75mg of diclofenac. He also received sevoflurane 
1.5-1% and a total of 4.5L of IV fluids perioperatively. On return to the ward he had 
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patient-controlled analgesia containing fentanyl 500µg/50mL, of which he used 48mL on 
demand until 1500hrs of Day 3 when it was removed. He also received 1g paracetamol 
every six hours and twice daily 75mg diclofenac. He was prescribed 10mg oxycodone 
(immediate release) up to every four hours after the patient-controlled analgesia was 
removed but did not require it. There was no clinically significant change in laboratory 
values and pain remained well controlled, rising slightly when the patient-controlled 
analgesia was removed (Table 3.8-7). 
Table 3.8-7 Pharmacodynamic monitoring values 
Abbreviations used: SCr- serum creatinine; AST- aspartate aminotransferase; INR- international normalised ratio; NRS- 
numerical rating scale- measure of pain experienced in last 24hrs and at time of study.. 
 Day -1 Day 1 Day 2 Day 3 Day 4 
SCr (µmol/L) 74 68 57 60 68 
AST (U/L) 9 12 32 28 42 
INR 1.0 1.1 1.0 1.0 1.0 
NRS Best 0 0 0 0 0 
NRS Worst 0 0 0 0 2 
NRS Now 0 0 0 0 1 
3.8.4.1 LIVER FUNCTION 
The concentration of αGST in Patient 8D paralleled that of the group until Day 3 when it 
rose sharply to 9.4µg/L, still within the upper limit of normal of 11.4µg/L. AST values also 
remained lower until Day 3 when it rose gradually to finish at 42U/L, slightly above the 
upper limit normal (40U/L). Neither of these tests indicated clinically meaningful changes 
to liver function during the study, and the only changes that were observed occurred on 
the last two days of the study. 
 
Figure 3.8-38 Liver function tests αGST and AST on each day of the study with group median αGST and IQR
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3.8.4.2 PLASMA 
 
Figure 3.8-39 Concentration of paracetamol and its major metabolites in plasma 
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Plasma paracetamol concentrations were similar preoperatively to postoperatively 
although there was a large increase in the Cmax concentration on Day 1. Paracetamol 
sulphate values fell postoperatively and were matched by a rise in paracetamol cysteine. 
Paracetamol cysteine concentrations in plasma remained constant despite the increased 
CYP1A2 and CYP2E1 activity suggested by the changes to caffeine and chlorzoxazone 
metabolism. Paracetamol mercapturate failed to rise above the limit of detection and 
there was no evidence of accumulation in paracetamol glucuronide (Figure 3.8-39). 
Kinetic values were altered following surgery with a reduction in half-life of over 10%. 
This reduction mainly arose from a reduction in Vd, although a slight increase in clearance 
was also seen. Almost the exact same reduction in Vd in this patient was seen in patient 
1B who received the same surgery type, however in the case of . 
Table 3.8-8 Plasma pharmacokinetics preoperatively and postoperatively with group medians (±IQR) 
 Day -1 Day 1 
Patient 8D Group  Patient 8D Group  
t ½ (hr) 2.29 2.06 (1.82, 2.40) 1.99 1.94 (1.72, 2.28) 
AUC (mg.hr/L) 0.042 0.042 (0.029, 0.054) 0.041 0.038 (0.036, 0.04) 
Cl (L/hr) 23.82 24.09 (18.54, 34.87) 24.68 26.48 (25.09, 27.55) 
Vd (L/kg) 0.93 0.87 (0.74, 1.14) 0.65 0.8 (0.58, 0.96) 
MRT (hr) 3.22 3.04 (2.55, 3.38) 2.16 2.14 (1.91, 2.30) 
There was no evidence of accumulation of paracetamol until Day 3 when both one and 
four hour concentrations increased. This was different from that of his group which 
showed no evidence of accumulation. 
 
Figure 3.8-40 Plasma concentration of paracetamol- 1hr 
 
Figure 3.8-41 Plasma concentration of paracetamol- 4hr 
3.8.4.3 CYTOKINES 
Changes to cytokine levels for Patient 8D were also largely unremarkable. There was a 
slight increase in IL-6 (Figure 3.8-42), IFN-γ (Figure 3.8-43) and TNF-α (Figure 3.8-44) but 
no change to IL-1β (Figure 3.8-45). 
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Figure 3.8-42 IL-6 Concentration in daily samples 
 
Figure 3.8-43 IFN-γ Concentration in daily samples 
 
Figure 3.8-44 TNF-α Concentration in daily samples 
 
Figure 3.8-45 IL-1β Concentration in daily samples 
3.8.4.4 CYP450 PROBES 
There was a strong increase in the ratio of paraxanthine to caffeine in the final days of the 
study (Figure 3.8-46) and the opposite was seen the chlorzoxazone ratio (Figure 3.8-47). 
The chlorzoxazone ratio opposed that of his group. 
 
Figure 3.8-46 Individual and group median ratio and IQR 
of paraxanthine to caffeinein plasma  
 
Figure 3.8-47 Individual and group median ratio and IQR 
of 6-hydroxychlorzoxazone to chlorzoxazone in plasma 
3.8.4.5 URINE 
3.8.4.5.1 SULPHATE CONTRIBUTION 
There was a slight reduction in sulphate derived metabolite contribution immediately 
postoperatively which briefly recovered. Otherwise there were only minor changes to this 
value (Figure 3.8-48). 
 379 
 
 
Figure 3.8-48 Per cent of urinary metabolites excreted as sulphate derived compounds with group median (±IQR) 
3.8.4.5.2 PHASE II:I METABOLITE RATIO 
Figure 3.8-49 shows Patient 8D’s metabolite ratio started lower than the rest of his group 
but still fell further following surgery. This was maintained for the remainder of the of the 
study period.  
 
Figure 3.8-49 Ratio of Phase II: Phase I metabolites of paracetamol with group median (±IQR) 
Similar, but to a lesser extent that Patient 4A, this ratio arose from increases to 
paracetamol cysteine contribution in the absence of increases to paracetamol 
glucuronide. Increases to paracetamol cysteine contributions did not align with either 
measured CYP450 activity or cytokine concentrations. Paracetamol glucuronide 
concentrations still remained within expected ranges.  
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4 DISCUSSION 
This study investigated the safety of high doses of IV paracetamol in postoperative 
patients. There were several factors that resulted in this research: 
 Paracetamol had re-emerged as a popular drug perioperatively and, despite it 
being toxic on overdose, doses exceeding those licensed were being advocated; 
 Paracetamol had been used safely for decades in postoperative patients when 
licensed doses were given by oral or rectal routes. However, the bioavailability of 
these routes was known to be poor in surgical patients; and 
 A new IV formulation of paracetamol became available, however the impact of its 
greater bioavailability on drug safety in surgical patients was unknown. 
These factors, the increased doses and increased bioavailability, were a cause for concern 
given the toxicity of paracetamol on overdose. However, the safety of IV paracetamol in 
postoperative patients had been assumed by health-professionals for two reasons: 
1. The active ingredient is one of the most consumed, safest drugs on the market 
when given at licensed doses (Amar et al. 2007); and  
2. This safety can be applied to the IV formulation because many aspects have been 
shown to be bioequivalent to enteral products in healthy adults (Depre et al. 
1992; Flouvat et al. 2004; Duggan et al. 2009). 
Subsequently, the product has been widely used and well tolerated by the vast majority 
of surgical patients. However, there were a growing number of reports of individuals who 
have developed toxicity after receiving licensed doses, and malnourishment seems to be 
a common theme (Vitols 2003; Kaplowitz 2004; Moling et al. 2006; Forget et al. 2009; 
Gray et al. 2011). A recent determination as to the causes of death of a hospital patient 
who died following repeated IV paracetamol doses found a “prevailing culture of 
assumed familiarity” with intravenous paracetamol “…derived from the common use of 
oral paracetamol”. This “misplaced assumed familiarity” was listed as a cause death 
(Sheriffdom of Glasgow and Strathkelvin 2011). 
Drug safety shown in healthy adults cannot always be applied to surgical patients. As 
discussed in Section 1.3 there are several differences between these two populations that 
affect drug disposition. In this specific case, IV and oral paracetamol are far from 
bioequivalent. In surgical patients the rate and extent of oral absorption of paracetamol is 
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significantly reduced (Goldhill et al. 1995; Kennedy et al. 2006; Duggan et al. 2009) and 
overcoming this with IV paracetamol is considered of therapeutic benefit and sufficient to 
justify its use (Sinatra et al. 2005; Gregoire et al. 2007; Candiotti et al. 2010; van der 
Westhuizen et al. 2011). This leads to substantial differences between the 
pharmacokinetic profiles of oral and IV paracetamol with a doubling of Cmax and plasma 
concentrations not equivalent until at least an hour after the dose (Depre et al. 1992). It 
could be possible that this delayed and reduced oral absorption conferred protection 
from paracetamol toxicity to vulnerable surgical patients, however, just as with efficacy, 
whether the link with toxicity is between Cmax or AUC is not certain. This would suggest 
that the IV formulation has hidden risks associated with its different pharmacokinetics 
and therefore safety established with oral paracetamol doses could not realistically be 
relied upon.  
These concerns and potential issues highlighted above led to the research questions of 
this clinical project: 
1. Was IV paracetamol safe in surgical patients at unlicensed doses? 
2. Did surgery change paracetamol disposition? 
3. If disposition changed, why? 
To answer these, patients scheduled for surgery volunteered to provide blood and urine 
samples and to receive up to 9.5g of paracetamol daily and daily doses of CYP450 enzyme 
probes for the day before and the four days after surgery. To analyse these samples, 
analytical tools were developed and applied to measure clinical and pharmacokinetic 
observations and address the research questions: 
1. αGST concentrations were measured in daily plasma samples to assess safety of 
paracetamol; 
2. Paracetamol pharmacokinetics and metabolite concentrations were determined 
from plasma and urine samples to assess changes to disposition; and 
3. Cytokine concentrations and CYP450 activity were measured in plasma samples to 
determine why disposition changed. 
Once these methods were established and validated analysis of samples collected from 
patients was carried out. From these, interpretation of parameters became possible, with 
conclusions finally drawn. 
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This discussion will be divided into four parts:  
1. The development and establishment of the assays; 
2. Recruitment and conduct of the study;  
3. The disposition of parenteral paracetamol and its metabolites in the various 
surgical groups and the factors affecting disposition; and finally 
4. The strengths, limitations and of future work of the research 
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4.1 DEVELOPMENT AND ESTABLISHMENT OF THE ASSAYS 
4.1.1 PARACETAMOL ANALYSIS- HPLC 
The assay used for plasma analysis was adapted from previous reports while a second 
was developed with novel conditions for urine analysis. Both assays performed well and 
both surpassed accepted validation standards.  
Challenges which presented with the development and application of the assays were of 
three categories: relating to either sample, mobile phase and run time.  
The plasma sample preparation following the method of Reith et al. (Section 2.3.3.4) was 
selected and optimised for this research as it was quick and simple, favourable qualities 
given the large numbers of samples that needed to be processed (Reith et al. 2009). 
However, by some standards, the prepared sample would have been regarded as 
relatively “dirty” (Chen et al. 2008). Small quantities of contaminant (mostly protein 
precipitate) were occasionally present in the sample. With the large number of samples 
analysed, over time, these contaminants accumulated in the guard column and increased 
back pressure. This collection at the head of the column in turn shifted retention times 
and caused problems with peak shape and integration. Replacing the guard column 
cartridge resolved these problems and as long as it was maintained, this facilitated the 
safe use of this simple and rapid sample preparation method without compromising 
accuracy. 
The mobile phase components of the first assay detailed in Section 2.2.3.1, potassium 
phosphate buffer and acetonitrile, are considered incompatible in certain conditions 
(Kromidas 2005). In this assay, precipitation of buffer crystals caused blockages of check 
values and failure of the HPLC pump. Once the source of the problem was identified, a 
warmed methanolic solution was used as a wash at the end of the run and the gradient of 
mobile phase changes between the phosphate buffer and acetonitrile were reduced. The 
final details of the mobile phase gradient and wash solution are also given in Section 
2.2.3.1. This eliminated the pump problems as well as protected the HPLC and the HPLC 
column from the corrosive effects of the phosphate buffer. 
The run time of the method adapted from Reith et al. was 25 minutes (Section 2.2.3.1). 
While reasonable in many settings, the length of this run time meant that a set of samples 
from a patient would run over several days. Additionally, the detection of paracetamol 
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mercapturate was poor in the first assay. It was therefore desirable to reduce the run 
time and improve the detection. This led to the acquisition of another column and 
redefining the chromatographic conditions from the beginning to develop an isocratic 
assay with phosphate buffer and methanol. A valuable lesson was learnt though, that it 
can take longer to do some things quickly, and even though there was the advantage of a 
shorter run time, this benefit was lost in the additional time it took to determine new 
conditions and revalidate the assay. However the additional benefit of improved 
detection of paracetamol mercapturate did justify the time spent on the development of 
the new assay. 
4.1.2 LCMS METHODS 
Changes to the disposition of drugs in surgical patients in the first instance, and elderly 
surgical patients in the second instance, is a much under researched area. Because 
CYP450 systems and Phase II systems alter quickly and extensively, it is important to be 
able to quantify those changes to identify those at risk from subsequent inefficacy and 
toxicity. This is especially relevant given that an excess or a lack of drugs in a patient who 
is haemodynamically unstable perioperatively can have effects on their postoperative 
outcome (Kennedy et al. 2000).  
In doing clinical research, the maxim of primum non nocere dictates that minimising 
discomfort and harm to the patient is the primary objective. Therefore, research 
undertaken in patients must not interfere with their recovery. Assay’s that are developed 
to support this objective are not only a great advantage to the patient but also to other 
clinical researchers who want to do this type of research. While determining the activity 
of the relevant CYP450 was necessary, methods in the literature commonly used one 
assay per drug, in a similar approach to the analysis of paracetamol described above. 
Adapting this technique for the analysis of the four CYP450 probe drugs and their 
metabolites would have necessitated prohibitively large amounts of blood to be taken 
from patients who had had major blood loss from surgery and difficulty with IV lines and 
venous access postoperatively. 
To avoid this, an assay was developed with novel conditions on HPLC using both UV and 
fluorescence detection that separated five analytical compounds which, unlike the 
paracetamol assay, were of a very heterogeneous nature with different pKa, solubility’s 
and functional groups that complicated their extraction, separation and detection. The 
 385 
 
difficulty of this assay was further increased by the need to detect the metabolite of each 
of four of these analytical compounds, which were of very similar nature to their parent. 
As the ratio of these two entities was the focus of this analysis, their clear separation and 
peak resolution needed to be obtained, but in conditions that achieved separation of the 
parent compounds, which were very different in nature. Additional complications arose 
for the glucuronidation of some of the probe metabolites that required the sample to be 
hydrolysed with enzyme incubation prior to analysis. This and each of the eight remaining 
steps in extraction were optimised as shown in Table 2.5-3.  
The development of this assay was very positive and proved very successful in terms of 
the extent and reliability of both extraction and separation methods. All compounds were 
extracted from one sample, thereby reducing the amount of blood sample required. 
Extraction was consistently around 80% for all compounds of interest and separation of 
all nine compounds was achieved in a 25 minute run. However, when the method was 
transferred to patient samples, it was limited by its inadequate detection of midazolam, 
which was anticipated given the low doses administered to patients. An LCMS assay was 
an attractive alternative as this instrument provides a much lower limit of detection. 
Similar methods were published for the simultaneous detection of CYP450 probe drugs 
using LCMS but none contained the same cocktail used here. The transfer of the HPLC to 
LCMS method was complicated by the use of a buffer and column that were not 
compatible with the LCMS instrument.  
Transfer to LCMS analysis encountered additional, unexpected challenges which led to 
the accuracy of this assay being compromised. As a result, the information on the CYP450 
analysis in the level of detail that was anticipated was not able to be retrieved, although 
from an educational point of view it was extremely useful and had provided much 
valuable data. The factors which compromised the transfer of this assay were:  
1. Changes to supervision of the LCMS; 
2. Access to the LCMS; and  
3. Problems with the instrument.  
The personnel changes for the supervision of the LCMS, which occurred at the time of 
transfer of the assay led to a loss of expertise in the operation of the equipment, making 
transfer of the assay to this instrument more of a challenge. 
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Access to a LCMS instrument was not available in the School of Pharmacy and therefore 
access to such technology was sought from another department. As a user outside of the 
parent department owning the instrument, access was only possible for a limited period 
of time for which this the researcher remains most grateful. This situation though limits 
the time available to transfer and develop the assay especially in studies where there are 
large numbers which must be processed.  
Given the use of this type of analytical equipment is central to the work of many 
disciplines, other Universities have overcome access, maintenance and supervision issues 
and prevented duplication of resources by introducing a network of Platform 
Technologies. These networks are essentially a central location in the University that 
hosts the analytical equipment for the use of the entire University and industry 
community. Such a network is present in Monash University, Australia, who saw benefits 
in creating “a one-stop first class technology shop, with access to cutting edge equipment, 
and a critical mass of leading scientists.” (Monash University 2010). Such a network is 
currently under development in UCC for researchers whose own departments do not 
possess the analytical equipment required for their analysis and will be beneficial for this 
type of research in the future. 
There were several problems with the LCMS instrument which were compounded by the 
two factors already described. Peak shape from the MS was poor and abundance was 
very low, even in standard samples prepared in mobile phase. As discussed in the Section 
3.7, at concentrations sufficient to be detected by UV, the PDA upstream from the LCMS 
produced Gaussian peaks (Figure 4.1-1), whereas the peaks from the same injection on 
the MS’s TIC were splintered and asymmetrical (Figure 4.1-2). The integration software 
was capable of smoothing over misshapen peaks, but the calibration curves constructed 
from the resultant area under the curve of these peaks were poor, with few points along 
the line of best fit and large changes in area on repeated injection of the same sample.  
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Figure 4.1-1 UV 280nm (red line), and Total Ion Chromatogram (black line) from same injection of 1ug/mL standard.  
 
Figure 4.1-2 Extracted Ion Chromatogram (EIC) 326-326.15 (2.5x10
5 
abundance) (midazolam) 
Much work was done to try to overcome these problems. The symmetry of the PDA peak 
indicated the problem was not with the sample or chromatography, and this was 
confirmed firstly by injection of other freshly prepared standards, and subsequently by 
using a new column of the same specifications. The parameters of the MS were all 
confirmed and optimised (Section 2.5.3.5) and the ion source was cleaned. During this 
time it was noticed the calibrant liquid was not being drawn into the ion source and there 
were problems with the drying of the electrospray plume which were causing 
condensation on the inside of the ESI unit. Attempts at resolving both these issues were 
made and thought to be resolved. At this stage there was only enough time left in the 
period of access to the instrument for it to run the remaining samples. A set of standards 
were run which appeared no different so the remaining samples were analysed. Further 
attempts at resolving the ESI problems revealed a piece of lint/fluff across the entrance to 
the capillary (Figure 4.1-3). Once removed, detector response did improve. It was 
concluded this was the cause of the low and irregular detector response previously 
discussed.  
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Figure 4.1-3 Electrospray Ion Source of Agilent 6520 mass spectrometer showing position of obstruction 
(Agilent Technologies Inc 2009) Used with permission. 
Throughout the use of the LCMS there were problems with the hydrogen gas sensor in 
the laboratory where the LCMS was situated. The alarm frequently detected hydrogen 
despite there being no source of hydrogen in the laboratory. Upon sensing hydrogen, the 
alarm system would shut down the supply of all the gases to the laboratory, including 
nitrogen, and without a supply of nitrogen the MS would shut down, ending the sample 
set prematurely. Aside from ending the sample set, further samples could not be analysed 
until gas had been restored and the MS recalibrated. Gas could not be restored to the 
laboratory until the system was reset, which could only be done by the system’s 
engineers, who were external to the university and unavailable over the weekend. On 
three separate occasions the system alarmed on a Friday night and as the access period 
required weekend work, this was a significant set-back. 
While delaying the analysis of further samples, the MS shutting down during the run also 
raised issues regarding the stability of the un-analysed samples sitting in the LC awaiting 
analysis. This was exacerbated by the LC not having a refrigerated sample drawer. The 
samples were loaded in the evening and the sample run overnight. On each occasion 
when the instrument shut down the samples would be removed and refrigerated 
immediately upon discovery in the morning. Extreme care was taken not to confuse 
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samples. Samples that had run successfully were re-run to examine for degradation and 
no significant change in abundance was observed.  
There was a further problem around the negative and positive detection mode of the 
instrument. The MS (an Agilent 6510 QTOF) is a powerful instrument for the 
determination of accurate mass, capable of giving molecular weights to beyond four 
decimal places at femtogram concentrations; abilities far beyond the requirements for 
this analysis, given that the masses of the analytes were known. MS can work in either 
positive or negative mode. The signal-to-noise (S/N) ratio of an analyte will be greater in 
one mode or the other and this is just a property of the analyte. The vast majority of 
compounds are best detected in positive mode and this was the case for all analytes in 
this analysis, except for two: chlorzoxazone and its 6-hydroxy metabolite. Although the 
height of the negative-mode peaks can be one-tenth those of the equivalent positive-
mode peaks, there is less noise in negative mode so signal peaks are more distinct.  
Many MS instruments can detect in both positive and negative mode simultaneously, but 
this newer technology is mostly available in nominal mass instruments, unlike the 
accurate mass Agilent 6510 being used. Upon discussing the capabilities of the MS being 
used with the manufacturer before the analysis began, they provided assurance that 
detection of both positive and negative modes was possible with this instrument too, but 
when this option was not available in the software it was revealed that this particular 
instrument was, in fact, not capable of this function. In this way the extended capabilities 
of this instrument’s accuracy was its downfall in this analysis, preventing simultaneous 
detection of positive and negative modes. Switching between negative and positive mode 
on the Agilent 6510 required the analysis to stop and the instrument to be recalibrated 
with a different calibrant solution from the one used for positive mode. This process 
cannot be automated and would have required significantly longer periods on the 
instrument and access to the instrument throughout the night. As can be seen from the 
results (Section 3.7), detection of chlorzoxazone and its 6-hydroxy metabolite in positive 
mode was still possible but in very low abundance, which is contrary to what would be 
expected given that it was administered in the highest dose of all the CYP450 probe drugs 
(Section 2.1), and a satisfactory extraction was achieved. Ideally the sample would be run 
in positive and then negative mode. This would have required frequent changing of the 
calibrant and recalibration of the instrument, which the researcher in control of the MS 
did not sanction. Additionally, because of the necessity for recalibration, the samples 
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could not have been analysed in positive and negative mode consecutively. This 
effectively would have doubled the sample load on the instrument and run times would 
have gone beyond the allocated access time for this project. It also would have resulted in 
the samples sitting in the sample drawer at room temperature for twice as long, as they 
waited to be re-run in negative mode. Further, the volume of the sample following 
extraction was not always sufficient to allow for two injections and the volume of the 
plasma sample was not always sufficient for duplicate samples. When these factors were 
considered in addition to the time constraints, the only option was to run the samples in 
positive mode in expectation that the anticipated high concentrations of chlorzoxazone 
and its 6-hydroxy metabolite in the samples would be sufficient to overcome the 
problems with their detection in positive mode. 
The final product of the extraction process was filtered before injection in the LCMS. The 
researcher supervising the LCMS did not believe a guard column would be sufficient to 
protect the MS from any contaminant remaining in the sample, even though such 
methods are reported (Kharasch et al. 2004) and there were no changes to backpressure 
on the HPLC used for method development. This meant that the samples could not be 
filtered “on-line” with a guard column and that a separate filtering step was necessary. 
There were some limitations to the type of filtration that could be used. Namely, the 
product of the final evaporation was reconstituted in 50% methanol, which was not 
compatible with a number of filters typically used for clean-up of samples before LCMS 
injection. Further, there was a limited budget and over 600 samples to filter.  
When choosing the product, the technical assistance of two suppliers both referred onto 
a manufacturer, Millipore (Massachusetts, USA). Millipore recommended a 96 well plate 
format filter that was subsequently purchased. The additional apparatus for the 
operation of the filter, a vacuum manifold and a vacuum pump, were to be lent by 
Millipore, this loan did not materialise due to the vacuum pump been irreparably 
damaged by the previous user imediately prior to its use in this work. No other vacuum 
pump was available from within the department for the period of time it was required. A 
water vacuum was used in its place which produced a vacuum just at the lowest end of 
the usable range specified by the manufacturer. Given the low vacuum, filtration was 
slow and recoveries were very poor, with 100µL of sample yielding approximately 10-
20μL of filtrate, with a small amount of the sample remaining unfiltered but the majority 
lost to evaporation. This introduced variation arising from the evaporation of the sample, 
 391 
 
in addition to a volume that would not pass through the filter at the vacuum used. 
Attempts to improve the yield included pre-wetting the filter with the methanolic 
solution used to reconstitute the sample following evaporation, occluding unused wells 
with adhesive plate films and centrifuging the filtration system in place of using a vacuum, 
none of which caused significant improvements to the yield. As there was no budget for 
an alternative filtration product this process was deemed adequate as, with careful 
handling, there was sufficient volume filtered for a single injection into the LCMS and the 
internal standard incorporated at the beginning of the extraction could be used to 
account for any changes due to evaporation of the sample during filtration.  
Despite these problems, the extraction procedure was very successful in terms of 
recovery and developing the method provided much useful experience and knowledge. 
As discussed above, the problems mainly arose with this method in the detection of the 
compounds subsequent to their successful extraction from plasma. With additional time 
on the LCMS this method could be validated, however insufficient patient plasma would 
prevent its application to this project. 
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4.2 RECRUITMENT AND CONDUCT OF THE STUDY 
4.2.1 SETTING 
For the first two groups of patients, the setting of Hospital 1 was as close to ideal as 
possible for this type of research. Groups A and B patients returned from theatre with a 
triple lumen central line and urinary catheter to an ICU with one-to-one nursing. Blood 
and urine samples were obtained on time with comparative ease. In a small hospital, it 
was possible to establish personal relationships with the various staff and they were 
generally supportive of the research and would offer help when it was not widely outside 
their usual practices i.e. emptying urinary catheter bags into collection vessel as opposed 
to into the sluice. Other than this relatively small amount of help, these groups required 
no other assistance for conducting the study in the postoperative phase at all.  
The major drawback of Hospital 1 was that recruitment into the study was slow. Fewer 
than one colectomy was performed a week and many of these patients were unfit for 
inclusion. It was difficult finding patients sick enough to require major surgery, but well 
enough to be involved in the research. Of those eligible, the consent rate of 70% of 
eligible patients was good, considering the research was demanding for the patient. 
Similarly high rates have been reported elsewhere in Irish populations (Desmond et al. 
2011), which are higher than found in other populations (Myles et al. 1999; Dorantes et 
al. 2000). Ideal situations for consenting patients for this type of study have been 
determined by patient surveys as: 
1. At preadmission testing; 
2. With enough time for patients to consult with their own surgeon, who endorses 
the research; 
3. In private, when the patient is in street clothes  
4. With assurances the investigator would also consent if eligible (Mingus et al. 
1996).  
The evening prior to surgery, after being recently diagnosed with potentially life 
threatening cancer, is a difficult time for anybody without the addition of being asked to 
consent to a clinical trial. The difficulties in consenting for clinical research at this time 
have been previously reported and are in part due to the shorter hospital stays that are 
demanded by economic pressures (Mingus et al. 1996). Consequently, the four aspects 
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listed above were often unobtainable. Frequently, preadmission testing did not occur as 
the cases were urgent, so consenting was done at the time of admission. This prevented 
patients having enough time to consult with their own physician and also meant the 
patient was on the ward and often in a hospital gown. Despite these issues, there was an 
overwhelming spirit of good will, altruism and willingness to participate in Groups A and 
B. The most significant hurdle to recruitment was not the chance of being administered 
large doses of paracetamol or frequent blood tests, but the necessity to abstain from 
caffeinated drinks. Here a lack of cultural understanding on the researcher’s part came 
into play because it became clear that asking Irish adults to abstain from tea for a week 
was extremely difficult given that tea is such an integral part of everyday life in this 
culture. Despite this, in the first two groups of patients, three made totally unsolicited 
offers to write letters in support of the study to any potential study patient, commending 
participation in the study to them. 
There was no apparent difference between consenters and non-consenters in this study, 
although other work has shown that the most important influences on consent rate 
include: age of the patient (those >60 years being more likely to consent), trust in the 
investigator and trust in the institution/hospital (Patel et al. 2004). Prospective study 
participants who were less trusting of or assured by study personnel or who “felt like a 
guinea pig” were shown by Patel et al. to be less likely to participate.  
Conducting the study became more difficult in the third and fourth groups (Groups C and 
D). Group C, the mastectomy patients, were frequently post chemo/radiotherapy. 
Patients consented to an external jugular line being inserted in theatre as a central line 
could not be justified. However, even these lines would frequently occlude. This lead to a 
number of missed samples. The external jugular lines proved less effective than 
peripheral lines and were very positional for obtaining blood samples. Most had occluded 
by the second day, if not before. Additionally, urinary catheters were removed promptly 
after surgery and many patients had trouble collecting their own urine postoperatively. It 
was also not possible to ensure the bladder had been emptied every four hours, which 
could be assumed while catheterised. Another problem was that, when the IV catheter 
that was in place occluded, the maintenance of IV access beyond the first postoperative 
day was difficult to justify to the surgeon as it was only for the purposes of this research. 
No IV antibiotics were prescribed to these patients and IV fluids did not continue beyond 
the first postoperative day. With the frequent occlusion of lines and trouble reinserting 
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them, few patients had complete data sets. As a result of these sampling problems, this 
group was abandoned. 
Reconfiguration of surgical services in Hospital 1 necessitated moving to a second site 
(Hospital 2) where Group D was collected. At Hospital 2, the Investigator was there as a 
researcher external to the hospital, compared with Hospital 1, where the Investigator was 
a member of staff with clinical duties.  
4.2.1.1 ADDITIONAL CHALLENGES EXPERIENCED AT HOSPITAL 2 
Clinical research, whilst highly rewarding, presents many obstacles which have to be 
overcome. It became clear on transferring to the second hospital that a large part of 
those obstacles is actually building relationships with those who are involved on a day to 
day basis with the patients. This is especially difficult, for instance, when there is shift 
work involved and frequent changes of personnel that occur in large institutions.  
Irregular contact with ward staff meant that they may not be as familiar with the study 
protocol as would be desired. While the Investigator was primarily responsible for the 
conduct of the study, the assistance of many individuals was required to varying degrees 
for the smooth running of the study. At Hospital 1, the necessary relationships had been 
built up over time because the Investigator was a member of staff. At Hospital 2 the key 
relationships that needed to be re-established were with: 
 Ward management; 
 Nursing staff; 
 Ancillary staff/healthcare assistants; 
 Admissions co-ordinators; 
 Medical records; 
 Surgical teams; and 
 Anaesthetists. 
In most cases “assistance” meant not disturbing the conduct of the study and adhering to 
study protocols, which for the staff part, would be considered standard care. Education 
was conducted with all ward staff, but due to the size of Hospital 2, there were frequent 
changes to nursing staff and it was not possible to ensure all staff coming in contact with 
study patients had received training.  
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Additionally, staff may not have fully realised the ramifications of their actions to the 
validity of the study, i.e. disposing of a urine collection or inaccurate recording of time of 
paracetamol dose administration. In Hospital 1, as it was much smaller, it was possible to 
explain the reasons for a request in the study protocol to all members of staff. In Hospital 
2, study patients were admitted to one of three surgical wards, greater than tripling the 
number of staff involved and on occasion they were outliers on medical wards. 
Following their surgery, study patients in Hospital 2 returned to a six bed ward. Here they 
were cared for by one nurse and one healthcare assistant, who also had responsibility for 
another room of equal size. In comparison, Hospital 1 returned bowel resection patients 
to an ICU with one to one nursing. With the additional demands on staff in Hospital 2, the 
timing of paracetamol administration outside of those given by the Investigator was less 
certain. There were no paracetamol doses that were recorded as being administered 
outside of their correct time and this was assumed for the purposes of these results. 
However, conduct incidentally noted on the ward in relation to the administration of 
other drugs indicated that this may not have always been the case.  
There is no evidence to confirm, but it was presumed by the Investigator, that having 
capacity as a member of staff with other clinical duties improved adherence to the 
protocol by other staff because the Investigator would have had: more incidental 
presence on the ward; been better known to staff; and had the support of a department 
of other pharmacy staff who could have assisted and alerted the Investigator to issues 
involving the study. Additionally, the Investigator being familiar to the other staff and part 
of the normal preoperative routine (in the Investigator’s capacity as a pain team member) 
may have improved the consent rate in Hospital 1, which was much lower in Hospital 2. 
These presumptions are supported by the findings of Patel et al. discussed above that 
relate a patients likelihood to consent to their trust in study personnel and the host 
institution (Patel et al. 2004).  
Anaesthetists at Hospital 2 used different anaesthetics from those used in Hospital 1 for 
the same surgery and they generally refused to put in central lines. Only two study 
patients in Hospital 2 had central lines and both were removed before the conclusion of 
the study. In addition, the Surgeon at Hospital 2 used different surgical techniques, with 
the majority being laparoscopic bowel resections. He also encouraged early re-feeding 
and the use of high protein drinks after surgery, which reduced the time of fasting 
experienced by patients in this group.  
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4.2.2 PATIENTS 
Diagnoses were comparable within groups and between groups A, B and D, with the 
exception that Group D had some non-malignant indications for surgery. Procedures were 
also similar between Groups A and B, whereas the majority of the procedures for Group D 
were laparoscopic. This technique led to Group D having considerably longer duration of 
surgery.  
There were a few patients who were withdrawn from the study, mostly as a result of loss 
of IV access for blood sampling. Only one patient was withdrawn as the result of a drug 
administered during the study, but upon review by the anaesthetist it was thought 
unlikely to be associated with the study. 
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4.3 CHANGES TO DISPOSITION  
As shown in Table 3.4.1 there were alterations to half-life. Median increases were 0.6 and 
0.2 hours in Group A and B respectively, while smaller reductions in Group C and D of 0.1 
hours were seen in both groups. Half-life is the drug disposition term with the greatest 
clinical utility because of its tangible nature, however, on its own it describes very little 
about a drugs disposition. Equation 3.4-2 shows that it is a composite term comprising of 
both the Vd and clearance of a drug. Clearance itself arises from both a drugs metabolism 
(in paracetamol’s case this is entirely hepatic) and elimination. These three factors: Vd, 
metabolism and elimination, provide the structure for the discussion of the changes to 
paracetamol’s disposition in surgical patients. Absorption is not considered as 
paracetamol was administered parenterally. 
4.3.1 DISTRIBUTION 
Volume of distribution (Vd) was calculated using a non-compartmental method that is 
commonly used (Rowland et al. 1995; Allegaert et al. 2004; Liukas et al. 2011). As 
discussed in Section 1.4.4.2.2, the Vd of IV paracetamol is listed as approximately 0.9 L/kg 
(Flouvat et al. 2004). As shown in Section 3.4.4, preoperative volumes of distribution are 
largely in agreement with this figure aside from Group A, whose preoperative value was 
slightly lower at 0.77L/kg. At slightly more than 20% different from the reported 
population values, the difference in paracetamol distribution is substantial however, as a 
drug with intermediate distribution, the reduction is not clinically meaningful. Indeed, 
there are several other studies reviewed with similar and even lower volumes of 
distribution in man (Prescott 1996). Given the wide IQR shown in Table 3.4-75, Group A’s 
reduced preoperative Vd is most likely due to the wide intra-individual variation seen in 
this value compounded by the use of medians, not means in the analysis. The mean Vd 
was closer to the listed value, but given the small group size, the use of parametric tests 
was not statistically warranted. There are two other factors that make Group A stand out 
from the remaining groups that could explain this slightly smaller distribution 
preoperatively: their higher age and prevalence of obesity as shown in Table 3.1.1. Age 
related changes to blood flow and extracellular fluid volumes have been shown to reduce 
drug Vd as discussed in Section 1.4.3 (Schwartz 2007; Liukas et al. 2011), however with a 
median age of 64 years, only 5 years greater than the closest other group, this 
explanation would seem unlikely. Secondly, with five out of the 10 in the group being 
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classified as obese, the finding of reduced weight corrected volumes may be applicable 
given that there are only four other obese in the entire study (Prescott 1980; Abernethy 
et al. 1982b; Depre et al. 1992; Ward et al. 1999). Furthermore, there was possibly some 
impact from the bowel preparations those patients received which may in turn have led 
to dehydration, but the impact of this on plasma volume has been reported to be 
negligible and if this was a factor it would also be seen in Group B who underwent the 
same treatment (Zafar et al. 1987; Kim et al. 2001; Kim et al. 2006). 
When preoperative and postoperative Vds are compared there are stark changes. There 
were reductions to Vd observed in all groups which were statistically significant in Group 
A. The universality of these changes and their direction was surprising. Generally, 
increased volumes of distribution are reported in surgical patients, in response to 
increases to capillary leakiness and reductions in plasma proteins due to the stress 
response. However there are few studies in adults that report this for paracetamol and 
none reuse the same patient before and after surgery as has been done here 
(Schuitmaker et al. 1999; Viscusi et al. 2008; Fouad et al. 2009). Generally gentamicin is 
used for this purpose. As discussed in Section 1.3.3.3 gentamicin is poorly protein bound 
and highly lipophilic, making it ideal for the determination of extracellular fluid volume. In 
surgical patients, amongst vast inter-individual variation, gentamicin’s distribution is 
generally greater than given for healthy adults (Zaske et al. 1980; Mann et al. 1987; 
Beckhouse et al. 1988; Dasta et al. 1988; Reed et al. 1989; van Dalen et al. 1990; 
Schuitmaker et al. 1999; Viscusi et al. 2008; Fouad et al. 2009). Additionally, the timing 
when distribution is estimated in these papers varies considerably, sampling intra- or 
immediately post-operatively, or not stating the time of sampling in relation to the 
patient’s surgery at all. This has been reported to have a significant impact on the Vd due 
to changes in haemodynamics and the stress response that wax and wane as recovery 
progresses (Dasta et al. 1988). Furthermore, while generally surgical patients, many of the 
participant in these studies are critically ill and septic, much worse than the generally 
expected course. The effect of infection alone on Vd is much greater than routine surgical 
trauma and therefore the applicability here may be limited (Zaske et al. 1980; Mann et al. 
1987; Beckhouse et al. 1988; Dasta et al. 1988; Reed et al. 1989; van Dalen et al. 1990) 
Reductions in distribution when compared with the general population have also been 
reported in major surgical patients (Wurthwein et al. 2005) and medium and intensive 
care unit patients (de Maat et al. 2010). The latter group had paracetamol Vds of 
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approximately 0.66L/kg, similar to what was shown postoperatively in this study (Table 
3.4.4). While not assessing it directly, a study using IV paracetamol also indicated 
reductions to Vd through increases to Cmax following repeated doses postoperatively 
(Holmer Pettersson et al. 2006). 
As discussed in Section 1.3.3, there are three factors that can affect the Vd:  
1. Blood flow; 
2. Drug Binding; and 
3. Extracellular fluid. 
It is possible that blood flow may have been reduced in these patients, impairing 
distribution. Reductions to blood flow could arise from three causes: stress induced 
vasoconstriction; blood loss during surgery and lack of activity and bedrest.  
Extensive vasoconstriction seems the most likely explanation for this reduction to Vd and 
could arise from the increase in circulating catecholamines from the stress response 
(Udelsman et al. 1994). There are two conflicting facts on the role of catecholamines in 
these patients: cytokine concentrations were low, but oliguria was present. Cytokines 
stimulate the release of catecholamines and result in vasoconstriction, therefore without 
cytokines, stimulation of vasoconstriction would be low; however, the presence of 
oliguria in the majority of patients is a strong indicator of catecholamine release and the 
activity of the stress response. The low concentrations of cytokines reported in this study 
in Section 3.5 are questionable, as, given the nature of surgery and complicated 
postoperative courses of some patients, they were expected to be much higher. The 
limitations of this assay are discussed further below.  
Consistent with the involvement of the stress response in causing the changes to 
distribution is the finding that those patients with open major surgery (Groups A and B) 
did have smaller volumes of distribution than the other patients postoperatively. This 
may have arisen from a greater degree of activation of the stress response and 
vasoconstriction, although this was not shown in cytokine concentrations, but was 
supported in changes to urine output. Section 3.3.3 shows diuresis began from Sample 
2.2 in both Groups A and B where oliguria was barely seen at all in Group C and only until 
Sample 1.3 in Group D. When these changes to Vd and urine output are considered 
together it may give some indication of the extent of stress response experienced by each 
group. hile it is to be expected that Group C’s stress response would be the least (due 
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to the intermediate nature of their surgery), the finding that Group D’s is less than Group 
A or B’s is interesting. ith similar indications for surgery, the difference between open 
and laparoscopic surgical techniques may explain this.  
The laparoscopic procedures performed on the majority of Group D, while considerably 
longer with attending increases to administered anaesthetics, seem to have evoked less 
stress response than the much shorter laparotomy procedures. In short, it appears that 
the extent of surgical trauma is more important than time in theatre in predicting the 
extent of the stress response for a group of patients with the same indication for surgery. 
These findings are widely reported elsewhere (Glaser et al. 1995; Kehlet 1999; 
Desborough 2000; Jess et al. 2000; Le Blanc-Louvry et al. 2000; Gupta et al. 2001; 
Giannoudis et al. 2006; Vlug et al. 2009; Madbouly et al. 2010b). However, because 
cytokine levels in this study were so low in all groups, they could not be used to confirm 
this. 
The role of blood loss seems less important. Samples used for the estimation of Vd 
postoperatively were taken on the evening of the day after surgery. Blood loss arising 
from surgical trauma is unlikely to have been a factor as late as when these samples were 
taken, in all but two cases, fluid balance had been restored and patients were 
haemodynamically stable. Therefore, given intraoperative blood loss alone would have 
been replaced and paracetamol is not extensively protein bound, reductions to Vd seem 
unlikely to be explained by this factor alone. However, with pitting oedema observed in 
many patients loss of fluid from the plasma into the ECF may explain the reduced Vd. As 
discussed in Section 1.3.3.3 the volume of ECF is increased postoperatively. Fluid 
sequestered from ECF in plasma during “third spacing” is not available for drug 
distribution, however this is more associated with infection and sepsis and the effect is 
mainly on highly hydrophilic drugs 
There may have been a minor role played by inactivity. All patients would have remained 
almost permanently supine until the time Vd was determined. Inactivity, with subsequent 
reduction in blood flow to adipose and other inactive tissues may reduce drug 
distribution to these tissues and result in a reduction to Vd being measured (Ylitalo 1991). 
Without published of similar design it is difficult to compare and validate results. 
The paper by Schuitmaker exemplifies some previous barriers to this type of work. Based 
only on oral dosing, their calculations of Vd required complicated modelling techniques, 
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and secondly, unreliable postoperative absorption and bioavailability may introduce 
significant inaccuracies (Hopkins et al. 1990; Kennedy et al. 2006). Both of these factors 
could be overcome with the use of IV formulations. 
Consequences for the patient arising from a reduced Vd include faster elimination, and 
potentially better distribution into the CNS (considered as paracetamol’s site of action) 
(Gibb et al. 2008). The latter could result in greater efficacy, whereas the former could 
result in toxicity and is discussed under metabolism below. Considering this potential for 
toxicity, those with LFT or αGST increases did not show Vds different from the remainder 
of the group.  
Further plasma samples were taken later in the study at one (C1) and four (C4) hours. 
Unexpectedly, paracetamol concentrations in the one hour samples followed an inverse 
parabolic pattern across the study period (Figure 3.4-8). C1 concentrations of 
paracetamol increased from preoperative values until Day 2 and then, rather than 
maintain a steady concentration as would typically be expected following multiple 
infusions, they fell to equate to preoperative values by Day 4. Because pharmacokinetic 
sampling was not carried out on these days a definitive explanation for these changes 
cannot be determined, however, a C1 concentration is influenced by both the Vd and 
clearance. In addition to those points discussed above, Vd related changes later in the 
postoperative period that could explain this phenomenon could include: 
 Falling Vd secondary to continuing stress response until Day 2 followed by 
reductions in the stress response and subsequent vasodilation; 
o Development of diuresis around this time in most patients supports this, 
although diuresis had begun well before plasma sampling on Day 2 in most 
patients. 
 Further expansion to plasma volume arising from; 
o The consistently positive fluid balances and oedema especially prominent 
in Group A and B; 
o Reductions to plasma proteins through starvation and the stress response 
(although paracetamol is not considered heavily bound to plasma 
proteins). 
Reduction to clearance could also explain these changes. The contribution of clearance to 
the change in these values is now discussed. 
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4.3.2 METABOLISM/CLEARANCE 
As paracetamol is not renally metabolised, nor excreted renally to any great extent, the 
rate of clearance is dependent on hepatic metabolism. There were several changes to 
paracetamol’s plasma concentration and urinary recovery that indicated paracetamol 
metabolism had changed following surgery. The first, paracetamol’s plasma 
concentration, provides information about the rate of metabolism, the second, urinary 
recovery, provides indications on how metabolism is occurring and by which pathways. 
The changes to C1 concentrations described in the previous section on Vd (increase until 
Day 2 and then fall to approximately preoperative concentrations) show variation in 
elimination across the study and can provide some information about changes to 
clearance. These changes to C1 were most prominent in Group A, with statistically 
significant reductions from Days 1 and 2 to Day 4, although a similar pattern was 
noticeable in Group B and to a lesser extent Group D (Table 3.4.6). Problems with plasma 
sampling in Group C make their results difficult to compare. The postoperative oliguria 
developed into polyuria in most patients prior to midday on Day 2. Sampling for this day 
took place later that night from 10pm. Therefore continuing stress response-induced 
reductions to Vd on this day seem unlikely as a cause for the peak concentration 
occurring on this day indicating other factors at play. This continuing increase in 
paracetamol concentration until Day 2 is anomalous and is explored further. 
It seems most likely that in Groups A, B and D patients there was an initial inhibition of 
paracetamol metabolism on the first two days following surgery. Metabolic capacity was 
then recovered and may have progressed to the point of induction. Inhibition of 
metabolism would lead to accumulation of paracetamol from the previous dose and this 
could explain the increases to C1 apparent in the first two postoperative days. The 
reduced urinary dose recovery of paracetamol on Days 1 and 2 in Groups A and B support 
this hypothesis of accumulation in the plasma (Tables 3.3-17 and 3.3-20). Mechanisms of 
both Phase I and II drug metabolism are known to be inhibited by surgery, anaesthesia or 
the stress response and these have been shown to return as recovery progresses 
(Pessayre et al. 1978; Nimmo et al. 1981; Frye et al. 2002; Renton 2005; Aitken et al. 
2006; Morgan et al. 2008). Processes behind these changes are reviewed in Section 1.3.4, 
however the lack of studies using repeated measures means the sequence of the 
inhibition followed by induction cannot be compared. While the effect of the stress 
response on cytokine concentration and urine output had resolved by Day 2 in most cases 
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in this study, a prolonged effect on drug metabolising enzymes has been shown 
elsewhere (Nimmo et al. 1981). The literature would also support that alterations to 
clearance in Group D would be less considering the less invasive procedure and reduced 
stress response arising from laparoscopic surgery (Glaser et al. 1995). Following the 
sequential increases in C1 concentations on Days 1 and 2, the subsequent reduction in 
concentration is most likely a result of the stress response resolving. However this does 
not explain the continued reduction in C1 concentations on Days 3 and 4 to approximate 
preoperative values that arose from a single dose. This could be a factor of induction of 
metabolism through repeated exposure to the paracetamol, which has been shown 
elsewhere (Gregoire et al. 2007; Kim et al. 2007), or through exposure to other drugs or 
hormones arising from surgery (Kairaluoma et al. 1979; Ray et al. 1985). Enzyme 
induction was also shown to occur four to eight days following surgery by approximately 
30-50%, returning to normal by four weeks (Nimmo et al. 1981), findings which align well 
with the reduced C1 values shown here. Without full kinetic profiles on Days 2-4, 
increased clearance cannot definitively be proven in this study, however other factors 
that could explain this pattern of C1 concentrations can be eliminated:  
 Dose - this did not change. An individual’s dose was consistent throughout the 
study;  
 Accumulation due to steady state - this was already achieved. In stable 
environments, steady state is assumed after five half-lives (Dhillon et al. 2006). 
Half-lives shown in Table 3.4-1 estimate steady-state would have been achieved 
half way through Day 1, assuming disposition factors remained constant. The fact 
that C1 concentrations still rose on Day 2 invalidates this assumption; and 
 Changes to Vd – these have been discussed above. 
While indicative, C1 concentrations are difficult to interpret in isolation. As previously 
mentioned, they are influenced by both distribution and clearance. Full kinetic profiles of 
paracetamol were taken on Day -1 and Day 1 and provide accurate clearance values. 
Reported clearance values in healthy males range from 22-27L/hr (Prescott 1996) and the 
values reported here are in general agreement with this. Some patients do show changes 
after surgery (Table 3.4-3). Figure 3.4-5 displayed a downward trend in Group A, while 
values in the other groups stayed remarkably constant. The lack of numbers and small 
changes in the others groups makes their interpretation and inference to the causes of 
the changes in Group A difficult. These reductions to clearance are in the face of 
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reductions to volume of distribution, which, if anything, should improve the efficiency of 
metabolic processes by increasing the concentration of paracetamol in the plasma 
available for metabolism. If one was to assume the reduction to Group A’s clearance was 
a short-lived inhibitory effect of surgery, it is supported by the reductions in urinary 
recovery of paracetamol on Day 1 seen in this group described above. Group A’s urinary 
dose recoveries on Day 1 were the lowest of any postoperative day. Consistent with this 
reduction in clearance only occurring in Group A is that none of the other groups had 
their lowest urinary recoveries on Day 1. Additionally, all patients would have been 
catheterised at this time, reducing the possibility of incomplete urine collections 
explaining these findings. However, a major confounder of this explanation is that if this 
reduced clearance seen in Group A was due to inhibition of metabolism, then a similar 
trend would be expected in Group B as they underwent the same surgery, but this was 
not seen. This suggests a degree of dose limitation in the clearance of paracetamol. This 
has been shown with single-high doses (Prescott et al. 1973; Prescott 1980; Mutlib et al. 
2006), but has not been reported with doses similar to those that were used here 
(Gelotte et al. 2007).  
Generally clearance of paracetamol is not altered following surgery (Lewis et al. 1991; 
Schuitmaker et al. 1999; Wurthwein et al. 2005). Slightly increased clearances were seen 
in another study (Ray et al. 1985) but this had methodological flaws, most importantly the 
use of an oral dose of paracetamol for the calculation of clearance. A more recent study 
using IV formulations in surgical patients has reported reductions similar to those seen 
here (Fouad et al. 2009).  
One patient who was an outlier in Group A with an increased value was Patient 1A, who 
went on to have a very complicated postoperative course. The processes of induction of 
metabolism are very slow in comparison to inhibition (Park 1996), taking up to 48 hours 
(Barry et al. 1990). Thus most factors in this patient would lead to the expectation of a 
reduction in clearance, as seen in the rest of the group, not the increase seen. The 
increase of Patient 1A is difficult to explain and is most likely due to error, especially when 
it is considered that his opposing change to Vd resulted in a half-life consistent with the 
remainder of his group. This would indicate a problem with the administration of the 
paracetamol dose as both the calculation of clearance and Vd account for dose, whereas 
k and the equation for half-life do not. The only other factor seen in his clinical scenario 
on Day 1 which could account for such a divergent clearance figure is his IL-6 
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concentration, which at 349pg/mL was one of the highest measured. Stress is known to 
cause vasoconstriction, which can increase hepatic blood flow and therefore drug 
clearance, however this can be discounted as the patient’s distribution volume increased 
and even if it had not, paracetamol has a low hepatic extraction ratio so changes to 
hepatic blood flow would not have a major impact on clearance (Lewis et al. 1991). 
Additionally, IL-6, as by far the most potent down-regulator of CYP450, is known to inhibit 
metabolism, not induce it (Gurley et al. 1997; Siewert et al. 2000; Morgan et al. 2008). 
Despite this there was evidence of induced CYP2E1 activity in this patient with his ratio 
for 6-hydroxychlorzoxazone:chlorzoxazone as 2.5:1, whereas the group median was 0.9:1 
(Section 3.5.3). However it is possible poor absorption of this orally administered 
chlorzoxazone influenced this analysis by reducing the amount of parent drug in the ratio. 
As an outlier, if this patient was removed from the analysis, the consistency of the other 
values in the group did result in a statistically significant reduction in postoperative 
clearance in Group A.  
In summary there are some changes in paracetamol disposition that could be attributed 
to high doses and surgery, however reflection on the half-life values (Table 3.4-3) shows 
that these changes do not lead to accumulation and are unlikely to be clinically important 
on their own. Further unexpected findings to support this were from the one and four 
hour plasma concentrations that had been normalised for dose (Figures 3.4-8 and 3.4-9). 
There were no visual differences occurring between dose groups which had suggested 
that paracetamol had not accumulated in the high dose group beyond that of the normal 
dose groups. This would indicate that the metabolic processes that eliminate paracetamol 
were not overwhelmed at this higher dose. 
So the question arises over how drug elimination of paracetamol was maintained 
following surgery, and to what extent the milieu of reported changes to drug metabolism 
influence how paracetamol was eliminated. This question is most applicable to the high 
dose group, with more frequent doses of larger amounts, and if this was influenced by 
surgery.  
There were several changes in the pattern of metabolite excretion in the urine that were 
of interest. The high dose group (Group A) showed several clear changes to the excretion 
pattern in the postoperative period. The most significant change was the increased 
contribution of paracetamol glucuronide to the excretion, which increased by more than 
20% over the course of the study (Figure 3.3-14). This was matched with an increasingly 
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large reduction in paracetamol sulphate, which finished with less than half its 
preoperative contribution. There was also a bulging of Phase I metabolite contribution on 
Days 1 and 2, consistent with the possible increase in CYP2E1 activity as evidenced by 
increases to the ratio of metabolite:parent ratio of the probe drug chlorzoxazone (Section 
3.7.3). This was consistent with the literature where identical patterns of change to 
metabolite excretion have been reported following increased doses (in healthy adults) 
(Clements et al. 1984; Gelotte et al. 2007), repeated doses (Hendrix-Treacy et al. 1986; 
Allegaert et al. 2005) and repeated increased doses (Gelotte et al. 2007). All scenarios 
exhibit similar increases to the contribution of paracetamol glucuronide, as is the case 
here in this study (Hendrix-Treacy et al. 1986; Allegaert et al. 2005). Repeated doses of 
paracetamol have been suggested to have an inductive effect on UGT enzymes (Allegaert 
et al. 2005) and this has been reflected in increases to amounts of paracetamol 
glucuronide recovered in the urine. While in vitro methods exist for quantification of UGT 
activity, existing in vivo methods depend on morphine administration (de Wildt et al. 
1999). Morphine could have been used as a marker drug, but hospital policy did not allow 
fentanyl patient-controlled analgesia that would have been needed to replace morphine 
patient-controlled analgesia to facilitate this analysis .  
The reduction in paracetamol sulphate and Phase I excretion in Group A on Days 3 and 4 
of the study are of interest. Sulphate-derived metabolites (paracetamol sulphate, cysteine 
and mercapturate) share a common precursor, GSH. GSH is itself derived mostly from 
dietary protein. Because GSH detoxifies NAPQI, it is integral to the safety of paracetamol. 
Reductions to excretion of sulphate derived metabolites indicated a potential drop in GSH 
levels which may have led to a drop in NAPQI detoxification. Sulphation is known to 
saturate (Hendrix-Treacy et al. 1986; Martin et al. 1991), however, its decreased 
contribution later in the study is more difficult to explain. Group A were fasted until at 
least Day 3 postoperatively. The question of the nutritional impact on these patients on 
inorganic sulphate reserves arises given inorganic sulphate’s necessity for the production 
of GSH and precursors for sulphation. When viewed as a whole for this group, the 
contribution of sulphate-containing metabolites reduced at the same time as overall dose 
recovery (Figures 3.3-19 and 3.3-9 respectively). Group A’s median sulphate-containing 
metabolite contribution on the final day was almost half that of their Day 1 postoperative 
value. If this indicates exhaustion of inorganic sulphate stores, there is a possibility that 
the unaccounted for paracetamol seen in the reductions to dose recovery remains in the 
body as unconjugated NAPQI. This would explain the appearance of raised liver function 
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tests in some Group A patients after the study was concluded. Even if adequate 
concentrations of inorganic sulphur remained in the blood, reductions to sulphonation 
could also arise from insufficient sulfotransferase activity to maintain intracellular 
concentrations after several days of repeated paracetamol administration (Hendrix-
Treacy et al. 1986; Hindmarsh et al. 1991).  
Results for Group B in Table 3.3-32 show a similar, but much less marked pattern with 
statistically significant increases to paracetamol glucuronide excretion and reductions to 
paracetamol sulphate excretion. In Group C similar changes were seen in comparison with 
preoperative values although relative contributions postoperatively were more consistent 
(Table 3.34). There was a large degree of similarity between Group A and D in their 
metabolite pattern in the early postoperative period with statistically significant 
reductions to paracetamol sulphate recovery and increases to glucuronide and Phase I 
products, however this was not to the same extent as Group A.  
At the outset of this research, it was believed that changes previously seen to the Phase 
II:I metabolic ratio were a product of CYP450 induction postoperatively, but there are 
problems with this assumption: 
Using the contribution of paracetamol cysteine and mercapturate to urinary recovery of 
paracetamol as an approximation of Phase I metabolism assumes that all of their 
precursor, NAPQI, produced by this pathway is rapidly conjugated and excreted. The 
culmination of published work and results of this study would now suggest this not to be 
the case and that the role of nutrition is more significant. Conjugation of NAPQI relies on 
the presence of sufficient quantities of GSH, which as detailed in the discussion of the 
urine results, is depleted in fasting postoperative patients and at higher doses (Slattery et 
al. 1987).  
The assumption also relies on the change of ratio being due solely to changes in the 
contribution Phase I metabolites, while Phase II metabolites remain static. As most clearly 
shown in the contribution of each metabolite to overall recovery for Group A (Figure 3.3-
14), the reduction to paracetamol sulphate and increase to paracetamol glucuronide 
recovery in the urine would suggest this is not the case. To the contrary, both Phase II 
metabolites are dynamic, as previously reported (Hendrix-Treacy et al. 1986), and the 
metabolic ratio is a combination of both Phase I and II changes. 
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From a pure mathematical standpoint, because Phase I products contribute a much 
smaller value to this ratio, a small change in their contribution can cause a 
disproportionately large change in the ratio. Additionally, as much smaller values, they 
are more sensitive to analytical errors arising from the instrumentation. 
Finally, and perhaps most importantly, the rapid changes seen in Group A’s metabolic 
ratios postoperatively, cannot be explained by CYP450 enzyme induction. CYP450 enzyme 
induction is a slow process, requiring the up-regulation of transcription and synthesis in 
the cells that are involved in enzyme production (Takahashi et al. 1993) and several 
aspects of the stress response would oppose these processes (Renton 2005; Morgan et al. 
2008). Generally inhibition of CYP450 enzymes is reported postoperatively (Monshouwer 
et al. 1996; Morgan 1997; Haas et al. 2003). Results from the analysis of the individual 
CYP450 enzymes are difficult to interpret because of methodological problems with the 
assay (discussed above) and unfortunately the two drug probes which were assessable 
had additional confounders. Both were administered orally to patients known to have 
poor oral absorption. This could explain the variation in chlorzoxazone ratio. In the case of 
caffeine, additional intake, outside of that administered in the study, could explain the 
variation seen in its metabolic ratio and despite the best efforts of the Investigator, the 
possibility of this additional intake could not be excluded. 
Similar but less pronounced changes were seen in Group B. Especially prominent in this 
group was the contribution of paracetamol-cysteine that did not diminish as it did in 
Group A (Figure 3.3-15). This observation could further suggest exhaustion of GSH in 
Group A by the high dose, as, in that group, both paracetamol-cysteine and paracetamol-
sulphate reduced, whereas in Group B paracetamol-cysteine increased towards the end 
of surgery. This is supported by the evidence of enzyme induction in this group shown in 
Section 3.7, which would cause an increase in the production of NAPQI and therefore its 
metabolite, paracetamol cysteine, when sufficient stores of GSH are present. The lack of 
change in metabolite ratio in Group C (Figure 3.3-28) also supports this hypothesis of the 
role of nutrition, more than stress, as these patients were able to eat the day after 
surgery, but experienced a similar stress response to the surgical patients in Group A and 
B (Section 3.5). There is further support for role of nutrition from Group D findings, where 
reductions to sulphate derived metabolites were reversed early on Day 3 and trended 
back towards preoperative levels. This group were able to eat as soon as they could 
tolerate it, which was generally the evening of Day 2. 
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Although this metabolic ratio, comparing Phase II with Phase I products, has not been 
used previously, applying it to other published results leads to similar findings as those 
described here. The paper by Pickering et al. is one of the only other papers to publish 
urinary metabolite concentrations in surgical patients over several days. When the ratio is 
calculated, their data follow a similar form, beginning from the day after surgery with a 
ratio of 5.2 which reduces to 2.7, 2.6 and 2 on each subsequent postoperative day 
(Pickering et al. 2011). This compares favourably with the ratios shown here for Groups C 
and D especially, in addition to the Group A Patient 4A who received TPN.  
Prior to the review of the results, cytokines were thought to play an important role in 
determining CYP450 activity (Section 1.3.1). Inflammation caused by infection or 
underlying inflammatory conditions is known to down regulate most drug metabolising 
enzymes and transporters, both in acute scenarios, such as following surgery, or chronic 
conditions such as extra-hepatic cancer, inflammatory bowel disease or congestive heart 
failure (Frye et al. 2002; Carcillo et al. 2003; Haas et al. 2003; Aitken et al. 2006; Morgan 
et al. 2008). This reduction in Phase I activity can lead to a decrease in drug clearance, 
increasing plasma drug concentrations and potentially may cause drug toxicity or 
increases in the incidence of adverse effects (Schmith et al. 2008). While mostly 
associated with untoward events, this inhibition can also be protective against toxicity of 
compounds that are activated by Phase I metabolism (Renton 2000; Morgan 2001; 
Renton 2001; Renton 2004) such as NAPQI formation. Results of this study (Section 3.5) 
show cytokine concentrations fell rapidly postoperatively and for the remainder of the 
study were often close to the lower limit of detection. The cytokine most affected by 
surgery was IL-6, which showed substantial increases in Day 1 in some patients. However, 
as a whole, group values showed only minor changes with very large inter-individual 
variation. As is consistent with the nature of IL-6, its concentration fell rapidly on the 
following postoperative days. Therefore, it was difficult to draw any relationship with 
paracetamol concentrations as there was no consistent elevation in this cytokine across a 
group. Another group used the erythromycin breath test as a measure of CYP3A4 in major 
surgical patients up to 72 hours after surgery and compared this with their IL-6, IL-1β and 
TNF-α blood concentrations (Haas et al. 2003). CYP3A4 activity progressively declined 
from preoperative values to the 72 hour sample and the depth of this decline was 
significantly and negatively correlated with peak IL-6 concentrations only, not subsequent 
concentrations. In almost all cases the peak IL-6 concentration occurred within the first 24 
hours of surgery at sampling times not included in this Thesis’ analysis. Similar to this 
 410 
 
work by Hass et al., Section 3.5 showed the other cytokines measured exhibited even less 
of an effect from surgery (compared with IL-6) and their elevation was even more 
inconsistent and minor, but this may be related to sampling times used in this present 
study. 
Previous work that examined cytokine concentration postoperatively began sampling at 
the time surgical wounds were closed (Leung et al. 2000; Haas et al. 2003; Catena et al. 
2009). Therefore, the daily interval used in this study may not have been appropriate for 
the determination of the peak cytokine elevation in the study patients. These sample 
times were not used in this study for a culmination of reasons, including that the effect of 
surgery was thought to cause longer elevation in cytokine levels and determining 
paracetamol pharmacokinetics was the primary importance, while the assessment of 
other factors, such as cytokine concentration, were less so. Paracetamol concentrations 
arising from intraoperative samples would have been meaningless as they would have 
been between steady state and single dose conditions, therefore calculation of 
pharmacokinetic values could not be accurately performed.  
Other potential confounders to these cytokine results include the use of NSAIDs in some 
patients which are known to depress cytokine elevations (Chambrier et al. 1996) and thus 
the full extent of cytokine concentrations increases may not have been visible. 
There is only one other group that has examined the regular administration of 
supratherapeutic doses of paracetamol similar to those in Group A. Gelotte et al. found 
that although sulphonation of capacity was exceeded, rapidly increased formation of the 
glucuronide conjugate prevented an increase in NAPQI synthesis (Gelotte et al. 2007). 
This is at odds with this study where statistically significant increases in Phase I 
metabolites were seen in Group A towards the end of the study (Figure 3.3-14), findings 
similar to those of Slattery et al. (Slattery et al. 1987). The conflict between the findings 
here and those of Gelotte et al. may have arisen because of the difference in subjects and 
the trial conditions most obviously that their study was conducted in healthy adults in a 
clinical trials centre where patients were regularly fed and given oral doses of 
paracetamol. This study highlights the difference between a usually homogeneous, 
healthy study group used to establish pharmacokinetic parameters and the usual clinical 
setting of immense individuality and variation which can fluctuate on an hourly basis, 
depending on the severity of illness or metabolic assault. 
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With hepatotoxic doses, paracetamol metabolism is impaired and the half-life prolonged. 
(Prescott 1980). Increased half-lives were shown here when they were measured on the 
first postoperative day, but these were well within ranges contained in the product 
literature. However, plasma paracetamol concentrations can also provide information on 
toxicity. One of the first studies to advocate the use of unlicensed doses of IV 
paracetamol as a loading dose prior to surgery lists a 150mg/L four hour plasma 
concentration as the threshold for hepatotoxicity to occur, 200mg/L as a risk of some 
damage and 300mg/L as a concentration at which liver damage will always occur 
(Gregoire et al. 2007). Gregoire et al. cite Prescott and Rumack as their sources (Prescott 
1996; Rumack 2002). In this present study the maximum four hour concentration was 
recorded in Patient 8A on day 2 and at 32.9mg/L, was well short of the 150mg/L threshold 
for toxicity suggested above. Those patients who went on to developed AST elevations 
above the upper limit of normal (Patients 2A, 3A, 4A and 9A) all had four hour 
paracetamol concentrations consistently below this. While empiric, this may suggest that 
four hour concentrations are not a good predictor of hepatic injury. While thoughts then 
shift to examining prevalence of the Phase I products in the urine, these are only excreted 
once they are made safe by GSH. NAPQI causing toxicity is not excreted. With this in mind 
another measure of hepatotoxicity, αGST, was measured. αGST concentrations are touted 
as a better predictor of hepatotoxicity than standard laboratory tests (Beckett et al. 1985; 
Rees et al. 1995; Clarke et al. 1997; Kumle et al. 2003; Chouker et al. 2005). These 
concentrations provided one of the biggest surprise of the study. Even in the group of 
patients receiving an excess of twice the licensed daily dose (Group A), no clinically 
significant increase in αGST concentrations were seen after four days of this dose. In 
many cases αGST appeared to decrease following surgery, which was completely opposed 
to what was expected. αGST is marketed as an early marker of hepatic damage, however, 
the results of this study question this assertion. While no patient showed AST elevation 
during the study, several did go on to have elevations once the study had finished. The 
fact that αGST concentrations did not show these elevations prior to the AST rise was very 
disappointing. Examining αGST alone would suggest the high doses of paracetamol are 
completely safe over a four day period and it is only AST concentrations that question this 
assertion. Similar work administering up to 8g daily to patients also failed to report liver 
function tests beyond the three days the study dose was administered, despite them 
being obtained (Temple et al. 2007).  
 412 
 
There is some explanation for the safety of the high dose given to Group A offered in the 
literature. Experimental animals have shown changes to the location paracetamol is 
metabolised in the liver following repeated, high, dosing, which has led to a reduction in 
bioactivation and production of NAPQI (Shayiq et al. 1999). If the percentage of a dose 
metabolised to NAPQI fell, then the safe dose could theoretically increase. It is not until 
GSH stores are depleted by 90% that hepatotoxicity can ensue (James et al. 2003; Hinson 
et al. 2010). In addition, there are several studies in man that have shown the capacity for 
glucuronidation exceeds that utilised by currently licensed doses of paracetamol. Clearly 
the key determinant of safety is the state of an individual’s CYP2E1 activity and the 
opposition provided by their GSH reserves. Both factors are linked to nutrition. This 
finding is not new, but the example shown by Patient 4A suggests that care must be taken 
with how nutrition is managed in postoperative patients. In his case, the supplementation 
of sulphur-containing amino acids by administration of TPN may have been outweighed 
by the induction in CYP450 enzymes this protein rich solution caused in an undercurrent 
of induction to his CYP450 enzymes following surgery. It may also be relevant in his case 
that once paracetamol toxicity has developed, GSH synthesis and conjugation is 
depressed, so that paracetamol toxicity forms something like a positive feedback 
mechanism (Lauterburg et al. 1982). This may explain why he went on to develop 
elevated ASTs in the face of receiving methionine in the TPN (Fresenius Kabi 2011), what 
is equivalent to the low dose of the antidote to paracetamol toxicity. However, the 
paracetamol-cause of the increased AST could be questioned as LFT elevations are very 
commonly seen with TPN initiation of administration alone (Gabe et al. 2010)  
4.3.3 ELIMINATION 
Both previous sections on disposition refer to one of the most obvious impacts of the 
stress response to an external observer: a reduction in urine output following surgery. 
The reduction in urine volume following surgery is a well-known phenomenon in 
response to injury-induced increases of arginine vasopressin and aldosterone 
concentrations in the circulation (Section 1.3). For this research, a reduction in urine 
output was not of interest in itself, but was of concern because of its effect on the 
excretion of paracetamol, which is unreliable when urine volumes are low (Kietzmann et 
al. 1990). This had major ramifications for what was of interest to this research; the 
change in metabolism. This was because traditional metabolic ratios used to determine 
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changes to metabolism contain both metabolite and parent concentration, and therefore, 
because of the unreliability of paracetamol excretion, these could not be used. 
Accordingly, another ratio was derived that was urine flow independent, but still provided 
information about changes to metabolism. This ratio compared the concentration of 
Phase II with Phase I metabolite in urine as the urinary excretion of all of the metabolites 
of paracetamol are urine flow rate independent (Prescott et al. 1973).  
While data showing a change in metabolism following surgery were presented in the 
Section 3.3 of the results, it was necessary to rule out other factors that could have had 
an undue influence and invalidate these finding. Firstly, recovery of the paracetamol dose 
in the urine needed to be high and consistent as this confirmed the fact that urine 
remained the main route of excretion of paracetamol following surgery. In this study, 
catheterised patients in the steady state period had good recoveries, generally around 
90-95% of the administered dose. These values are concordant with those reported 
elsewhere (Miners et al. 1992; van der Marel et al. 2003). This confirmed the validity of 
the assay and that the effect of the reduction in urine flow rate was not substantial 
enough to make a difference to overall recovery. However, urinary recovery of 
paracetamol from the single preoperative dose was 40-60% slightly below the 65% that 
has been reported in other studies (Kietzmann et al. 1990). This may have been due to 
incomplete urine collections, both in terms of the volume collected and duration. Ideally 
all urine produced within the four hourly interval collection period would have been 
collected in the relevant collection. While this was requested of patients, enforcing 
patients to empty their bladder every four hours throughout the night would have seen 
recruitment drop even further. Therefore, complete evacuation of the bladder could not 
be confirmed by the Investigator and there were several four hourly samples pre-
operatively that contained no urine. In addition, incomplete urine collections could have 
arisen from patients being unable (or unwilling) to collect the entire volume of their 
urine, loss of urine through transferring between the collection and storage vessels or the 
use of an absorbent collection vessels (such as cardboard bedpan). In terms of duration of 
urine collection, it may have been more appropriate to collect urine right up until the 
time of surgery. However, asking patients to collect their own urine at this time would 
produce almost insurmountable issues given the necessity for pre-operative sedation and 
procedures such as X-ray and ultrasound immediately prior to surgery. 
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The factors discussed above may also apply to Group C patients who were only briefly 
catheterised and mostly collected their own urine. This group had the lowest measured 
urine volumes, although they did not receive as much IV fluid as the other groups. Group 
C had large variability in dose recovery over the course of the study, even though the net 
collection was around 95% of the overall administered dose. As drug input was constant, 
this could be explained by accumulation of the metabolites in the urine in the bladder and 
the difficulties arising from obtaining complete urine collections from patients, especially 
females (which constituted the entirety of this group). 
Other differences between groups that were noticed included that the recoveries were 
lowest in the high dose group (Group A), especially towards the end of the study period. 
This may suggest a rise in extra-renal excretion, plasma accumulation or excretion as 
metabolites not monitored. Increases to extra-renal excretion cannot be ruled out but 
these have been shown to be only a minor contributor in previous work (Hjelle et al. 
1984; Jayasinghe et al. 1986; Gregus et al. 1988). However, biliary excretion has also been 
shown to be dose dependant (Siegers et al. 1984) so the importance of this route is still a 
possibility. Plasma accumulation of paracetamol in this group seems to be an unlikely 
cause of the change in recovery as, while increased paracetamol concentrations were 
seen until Day 2, they reduced on Days 3 and 4 to pre-operative concentrations. 
Increased metabolism may have led to accumulation of metabolites in plasma, but these 
are readily excreted so this would seem to be an unlikely cause. The metabolites not 
monitored as part of this study are generally considered to make an insignificant 
contribution to the overall metabolite excretion (Prescott 1996). As shown in Section 1.2 
there are many other metabolites of paracetamol not monitored in this study but given 
the presence of the phenol moiety in their structure, if they were a significant contributor 
large peaks would be expected on the HPLC traces at 242nm (Silverstein et al. 1991). 
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4.4 STRENGTHS, LIMITATIONS, AND FUTURE WORK 
4.4.1 STRENGHTS 
This is the first study to examine the effects of surgery on paracetamol pharmacokinetics 
in the same patient. One of the major strengths of this study is that paired or repeated 
measures methods were used to detect statistical significance to allow each patient to act 
as their own control. Previous work of this nature has compared paracetamol’s 
pharmacokinetic values obtained from postoperative patient’s and then sought to 
compare these to published values obtained from normal, healthy individuals. There are 
some flaws in this method for determining an effect of surgery as it assumes surgical 
patients’ have normal drug disposition prior to their surgery. However, as referred to in 
Section 1.3, very few people have “normal” values for drug disposition as these are 
themselves, in fact, an average. For example, very few people would have a Vd of exactly 
0.90L/kg and this is borne out of the fact that paracetamol’s half-life is given as a range of 
2-3 hours. By not using the same patient, research ignores all the genetic and 
environmental variation that those patients have even prior to surgery and can grossly 
underestimate the effect size as a consequence. 
The high dose used in this study was novel, especially considering the population to which 
it was administered, however, the fact that it was administered without any evidence of 
hepatic damage is a significant strength. The dose was chosen because 1g every four 
hours was well established (Schug et al. 1998) and had been shown to “be unlikely to 
have useful clinical impact” (Schuitmaker et al. 1999) as a result of failing to reach 10mg/L 
concentrations which were considered to be therapeutic. The next logical step was to 
either 2g six hourly (8g in total) or to the dose used here, 1.5g four hourly. Considering 
the toxicity to be linked to a maximum concentration, rather than exposure, the latter 
was chosen. There is a lack of pharmacokinetic studies in the adult surgical populations 
and the use of an IV formulation adds significant strength as it facilitates the accurate 
calculation of paracetamol pharmacokinetics. 
A further strong point is drawn from the multitude of tests applied to the patient. 
Simultaneous measurement of plasma and urine concentrations of paracetamol, CYP450 
activity, cytokine concentrations and αGST concentrations allows their integration to 
produce explanations to phenomena that are only otherwise observed. It can also direct 
future research more precisely when observations do not line up. 
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4.4.2 LIMITATIONS 
The most significant short fall of this study was that it failed to reach its recruitment 
goals. As a consequence, this study was probably not large enough to detect differences 
in disposition in the groups that received normal doses that arose due to surgery. 
However, the effect size of surgery when combined with the larger dose was large 
enough to result in detection of significant results, even though the recruitment into this 
group was less than desired. Without powering the study for comparisons between 
groups, differences due to dose and surgery type can only be discussed 
phenomenologically, without the strength of statistical rigour. In addition to these 
comparisons, larger groups may allow the detection or exclusion of the role of other 
potential influences on disposition, such as smoking, obesity and others discussed in 
Section 1.4. This study is too small to detect these. 
While changes to disposition values, such as clearance, were not detected in the normal 
dose groups (which was potentially due to under-powering), the possibility cannot be 
ignored that this was because there weren’t any changes to detect. The metabolic 
capacity of paracetamol is vast, with several overlapping mechanisms competing for 
whatever paracetamol is around. What this study has contributed is information of the 
changes in metabolism that arise underneath a constant clearance value. Changes were 
virtually instantaneous, when sulphonation decreased, glucuronidation’s increase was 
immediate, without a noticeable reduction to total excretion. Even in Group B, with only 
four participants, statistically significant alterations to the contribution of paracetamol 
sulphate and glucuronide were seen (Table 3.3-32). 
Further limitations arise from the number of plasma samples that were missing due to 
problems with obtaining blood. These were discussed above under conduct of the study. 
Urine data could also be flawed by incomplete bladder emptying and partial urine 
collections. While catheterised, these influences are minimised, however once urinary 
catheters were removed, these issues re-emerged. Longer urine collections 
preoperatively may have led to a more complete recovery of paracetamol and given a 
better indication of metabolism. Although close to reported values, this reduction in 
recovery may have altered excretion patterns as the proportion of metabolites in the 
urine changes with time following a single dose. A metabolite ratio of this type is 
considered to be highly variable and show large interindividual variation. While factors 
such as gender, sample time and dose recovery could not be excluded as confounding the 
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metabolic ratios used in this research, their contribution was analysed and found to be 
minor. However a larger analysis that could control for these variables in a multiple 
regression would be more appropriate. Given the change in metabolite ratio was seen in 
Group D, a group that showed very little change in plasma kinetics or concentrations of 
paracetamol metabolites, the question arises whether the change in urinary ratio was a 
result of repeated dosing rather than a change in metabolism. However, as no previous 
published work has used the metabolite ratio used here or reported metabolite 
concentrations on repeated days, it is impossible to validate this possibility. Another 
limitation is due to the comparison of single-dose with steady-state paracetamol kinetics. 
An ideal comparison would have been to have patients at steady state paracetamol 
concentrations prior to surgery. The only flaw in this type of analysis would be that it 
could not account for changes in paracetamol metabolism due to repeated dosing. 
The most significant limitation of α-GST measurement was the cessation of monitoring at 
the conclusion of the sampling period. This was done as a number of patients were 
discharged shortly after the conclusion of the study and due additionally to the cost of 
the assay, which necessitated limiting the number of samples analysed. Additionally, 
there was a spuriously high preoperative concentration of αGST seen in many patients. 
This diluted the significance of any postoperative elevations seen and also could suggest 
the under-reporting of alcohol consumption. However, all those with high αGST 
concentrations preoperatively had AST concentrations within the normal range. 
The primary limitation of the cytokine analysis, as discussed above, was the comparatively 
late sampling time. This almost certainly missed peak cytokine concentrations and as 
such, their effect on paracetamol kinetics could not be determined. Additionally, the 
number of cytokines that were monitored were superfluous as, although of interest, IL-6 
has been shown to have the most significant correlation with drug metabolism (Abdel-
Razzak et al. 1993; Muntane-Relat et al. 1995; Frye et al. 2002; Morgan et al. 2008). It was 
on the advice of a company representative that all four pro-inflammatory cytokines were 
measured, however, retrospectively, this advice may have been self-serving. 
There may have also been problems with absorption of the CYP450 probes caffeine and 
chlorzoxazone that were administered orally. Future work of this kind in major surgical 
patients should rely solely on the use of probes that can be administered via IV. This is 
due to the well-known problems with oral absorption in surgical patients. Unfortunately 
at the date of this study no IV formulation of chlorzoxazone was commercially available, 
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so alternative probes for CYP2E1 would need to be identified. Additionally, caffeine 
should be avoided as a probe for CYP1A2 due to the difficulties in preventing incidental 
intake, discussed above. 
Finally, there were some factors that could reduce the generalisability of the data to 
other groups: 
 There was an under-representation of females in Groups A and D. Similarly, there 
were no male patients in the intermediate surgery Group C; 
 The majority of bowel surgery patients underwent anterior resection, followed by 
colectomies. This may limit the applicability to the general population as it 
deviates slightly with the colorectal cancer statistics for the Irish population, 
discussed in Section 1.6, from which more colectomies would be expected. This 
may reflect the expertise of the hospital where these patients were treated and 
the comparative ease of diagnosis of rectal cancers. An additional source of 
deviation in the data may arise from the National Cancer Registry recording the 
number of diagnoses, not the number of patients with each diagnoses coming 
forward for surgery, which was recorded in this Thesis.  
 Generally the age of patients was younger than expected from the data given by 
the National Cancer Registry of Ireland for colorectal cancer patients (National 
Cancer Registry Ireland 2010) and this may also affect the generalisability. This 
may be due to the problems recruiting older patients due to their comorbidities 
and a large number of older colorectal cancer patients who were assessed for 
inclusion into the study were not fit. Additionally, it was observed during the study 
that older patients were more difficult to cannulate, would often occlude their 
cannula and were more sensitive to the effects of midazolam.  
 All surgery was elective. Applicability of data to emergency surgery could not be 
assumed as factors relating to fasting and the stress response could be different. 
However, this would exclude relatively few as the vast majority of these 
procedures are planned; 
 Most indications for surgery were for malignancy, which could reduce to the 
applicability of data to other diagnoses for surgery; 
 Most patients were either overweight or obese. This is known to influence CYP450 
enzyme activity;  
 419 
 
 Most patients did not smoke or had given up smoking in the last 5 years. As 
enzyme activity reportedly normalises within one week of smoking cessation 
(Faber et al. 2005) this limits the applicability of these data to surgical patients 
who do smoke as their induced level of enzyme activity is maintained, even after 
36 hours of smoking withdrawal (Eldon et al. 1987); and 
 Alcohol consumption reported was less than reported in other European 
populations and may have been the subject of recall bias (Tonnesen et al. 1999). 
Alcohol consumption is a known inducer of CYP2E1 and if significant quantities of 
alcohol were normally consumed by the patient and then abruptly withdrawn 
upon admission to hospital, this could have had a significant effect on 
paracetamol’s metabolism. If consumption was under-reported then these 
patients could not be identified.  
4.4.3 FUTURE WORK 
Future work could include: 
 Conducting a much larger study in patients undergoing various types of surgery 
who received licensed daily doses, collecting only their urine. A less invasive study 
such as this would potentially increase patient recruitment. This would finally 
conclude the relationship between surgery and changes to paracetamol’s 
metabolic ratio; 
 Comparing changes of Vd with blood losses and fluid administration. This could 
determine the effect of IV fluid administration on paracetamol distribution, and if 
colloidal fluids have an influence; 
 Calculation/presentation of values that represent the change within individuals, 
not within the group. A “per cent change” value could be determined, but this can 
over-represent small changes seen in individuals with initially low values; 
 Combining urine and plasma data to calculate and model formation clearance and 
apparent oral clearance and predict steady state concentrations from the 
preoperative single dose with the use of pharmacokinetic software; 
 Determination of a correlation between CYP450 activity and the recovery of 
paracetamol-cysteine and mercapturate. This would hold significant value and 
could determine the true effect of enzyme induction on paracetamol’s metabolic 
ratio; 
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 Administering morphine to patients to assess UGT activity in conjunction with IV 
paracetamol. Fentanyl patient-controlled analgesia/non morphine based analgesia 
would be necessary to facilitate this; 
 The measurement of inorganic sulphate in the urine in surgical patients receiving 
paracetamol to determine if it matches the reduction of sulphate-containing 
metabolites in the urine; 
 Conducting a larger study in non-surgical patients that compares the effects of 
repeated IV and oral dosing on paracetamol metabolism; 
 Monitoring liver function in a similar study beyond that of the time where the 
investigational doses were stopped. Examining post study AST concentrations 
suggest that at least an additional three sampling days would be necessary;  
 Obtaining plasma samples closer to the time of surgery to measure peak cytokine 
concentration appears to be the most significant factor. For reasons of economy, 
it would seem efficient to examine changes to IL-6 concentration alone and not 
those of the other cytokines assessed as part of this study;  
 Conducting the study in patients with central lines or obtaining an intravenous 
cannula designed for bloodletting. Postoperative patients are renowned for their 
poor venous access and failure of venous access was a perennial issue in this 
study. In addition, many of the study patients had recently received IV 
chemotherapy which can, through frequent use, reduce the number of veins 
suitable for cannulation. This will always be a barrier to this type of research and 
choosing a group of patients who frequently return to the ward with central lines 
is probably the easiest way around this problem; 
 Consider the use of other CYP450 probes. Aside from the problems with the assay, 
detailed above, there were additional problems with probes chosen for this 
analysis. Midazolam was a problem from a clinical perspective; its potency as a 
hypnosedative is its main advantage in clinical use, however, for the purposes of 
this study it was a substantial drawback. Whereas some studies were able to 
administer up to 10mg of midazolam, administering this dose to postoperative 
patients who were receiving narcotics could have led to severe respiratory 
depression and hypotension. Consequently a compromise dose was chosen, but 
this lead to the necessity of LCMS detection. Ideally a probe that could be given in 
higher doses and detected by UV would be used in this research. Secondly, using 
caffeine as a probe was a significant problem for patients. As discussed above, 
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requesting patients to abstain from tea and coffee was the source of many 
refusals to participate. The likelihood of patients taking caffeinated drinks during 
the study cannot be ignored and this raises questions about the validity of the 
findings. As already suggested, another probe for CYP1A2 should be considered; 
and finally 
 More Pharmacists conducting clinical research. 
The concept of a Clinical Pharmacist leading and conducting research of this nature is 
unusual in Ireland, if not the world, but it makes a lot of sense. Pharmacists have many 
advantages in the understanding of pharmacokinetics, why samples must be taken on 
time and what the best strategy is if they are missed. Clinical Pharmacists are also well 
used to the hospital ward environment, dealing with hospital patients and working with 
and around teams of other health professionals. Although Pharmacists do not have “built 
in” technical skills such as phlebotomy, cannulation or observation recording, these can 
be and were taught to the Investigator in this study. Aside from the barrier of being 
unable to prescribe drugs, Pharmacists can be just as able to conduct clinical research as 
any other health professional and thankfully Hospital 1 were largely of the opinion of “not 
why?, but why not?” and provided all the extra training that was necessary alongside 
newly recruited nurses.  
Despite this, there was initially a high level of suspicion from other staff, especially 
surgeons, which took some time to overcome. As mentioned previously, surgeons were 
aware of the study, were content to have their patients involved, but only as long as it did 
not cause them any interference. The relationship between the study and both surgeons 
was more one of non-maleficence than beneficence. Other staff members were also 
suspicious initially, but after a few patients staff members affected were generally 
interested in the research and by the end of the study most were happy to assist where 
they were able to.  
While there are few barriers to Pharmacists carrying out this type of research, it is 
immensely beneficial for Pharmacists to be involved in it. Although Pharmacists talk a lot 
about drugs, it is rare for Pharmacists to administer them to a patient. It was a 
revelationary experience to administer a drug, such as midazolam, and see the effect on 
the patient straight away as well as the varying sensitivities to this drug both between 
individuals and within individuals over the postoperative course. This variability captured 
the essence of this research.  
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5 CONCLUSIONS 
A clinical pharmacokinetic study was undertaken in surgical patients in two hospitals. The 
study examined changes to the disposition of IV paracetamol and the safety of licensed 
and a higher, unlicensed dose.  
The safety of both licensed and unlicensed doses was assessed during the study. Results 
indicated that there was no evidence that IV doses of up to 9.5g of paracetamol a day 
caused any clinically relevant liver damage during the study period. However, monitoring 
beyond the conclusion of the study showed substantial elevations in AST concentrations 
in some individuals, questioning the assumption of safety. No clear determining factor 
arose that could identify those individuals that showed AST elevation, other than that 
they had prolonged hospital stays (over 20 days). Given this evidence of safety, the next 
step would be to establish if this increased dose improved surgical analgesia. 
There were also several changes to paracetamol disposition. In terms of kinetics, the most 
commonly seen were reductions to paracetamol’s Vd postoperatively. Vd changes were 
frequently offset by smaller increases to clearance and resulted in small reductions to 
half-life postoperatively. Curiously, paracetamol concentrations did not achieve a steady 
state, but instead concentrations peaked on the second day and then reduced to nearly 
preoperative values.  
Changes to urinary excretion were also seen. In the high dose group there was a 
substantial increase in the role of paracetamol glucuronide in the recovery of the dose for 
most patients. However, along with the other groups, the ratio of Phase II to Phase I 
metabolites reduced sharply following surgery. The absence of literature reporting 
paracetamol using this ratio makes interpretation of these changes difficult as it is 
impossible to determine if the they have arisen from a “push” of increasing Phase I 
products, or a “pull” of retracting Phase II products. Regardless, these changes return 
towards preoperative values within the study period in most cases and therefore do not 
align well with the changes to liver function. 
While large enough to show significant differences within tests, this study is too small to 
be able to draw conclusion about safety or the effect of co-variates between groups of 
patients. However patient recruitment in this population is difficult. As described above, a 
study that would examine only paracetamol’s urinary metabolic ratio in a larger group of 
surgical patients undergoing surgery of multiple severities could be a useful next step. 
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Such a study may benefit from better recruitment rates and confirm the relationship 
between surgery, the stress response and paracetamol’s metabolic ratio. 
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APPENDIX 4 CONSENT FORM- ST JOHN’S HOSPITAL  
 
CONSENT BY SUBJECT FOR PARTICIPATION IN RESEARCH 
 
Patient Name: ___________________ 
 
Title of Protocol: Paracetamol metabolism in general surgical patients 
 
Doctor Directing Research: Dr. Brendan Conroy    Phone: (061)462222 
 
 You are being asked to participate in a research study.  The staff at St John’s Hospital study the 
nature of disease and attempt to develop improved methods of diagnosis and treatment.  In order to decide 
whether or not you want to be a part of this research study, you should understand enough about its risks and 
benefits to make an informed judgement.  This process is known as informed consent.  This consent form 
gives detailed information about the research study, which will be discussed with you.  Once you understand 
the study, you will be asked to sign this form if you wish to participate. 
 
NATURE AND DURATION OF PROCEDURE(S):  
Paracetamol (Panadol

/Calpol

) is a medication that most people will have taken or have 
been given at sometime in their lives.  It is generally considered to be a safe drug when 
used at its recommended dose.  It is commonly used for minor ailments such as headaches, 
however it is also extremely useful for patients who have had surgery. Studies have shown 
that when it is used with stronger painkillers such as morphine, patients need less of these 
stronger drugs and hence have fewer side effects.  
Because there is the general feeling that paracetamol is such a safe drug, some doctors are 
now using higher doses in patients who have had surgery. Currently there is little published 
research that this practice is safe and this is what we want to investigate. We expect the 
findings of this study to be very important for surgical care. 
The aims of this study are  
1 To see if paracetamol at higher than normal doses achieves better pain control in 
surgical patients. 
2 To see if surgery changes the way the body metabolises paracetamol by sampling the 
blood and urine  
3 To monitor patients liver function from the blood samples that are taken to determine 
if the higher doses of paracetamol have any effect on the liver. 
 
If you choose to enrol in this study you may receive up to two and a half times the normal 
daily dose of paracetamol on the day before surgery and for up to 4 days after. We will 
also be using very low doses of four other medications to look at your liver’s ability to 
metabolise medicines. For the purposes of the study and to ensure your safety up to 26-
teaspoon size samples of blood will be collected over these 5 days as well as saliva and all 
your urine. This is to monitor for the breakdown products of paracetamol, if any of the 
harmful effects of paracetamol occur and to look at your genetics that relate to your liver’s 
ability to metabolise medicines. We will also be asking you questions about your pain to 
see if you think your pain has improved 
 
POTENTIAL RISKS AND BENEFITS: 
This study may be using higher than normal doses of paracetamol. The current dose 
recommendations represent a dose that is known to be safe over long periods. The risks of 
adverse effects from paracetamol are thought to increase over time as the breakdown 
products build up. Because of this, higher doses over short periods are thought to be safe. 
However by using these higher doses there may be an increased risk of problems 
associated with paracetamol toxicity. You will receive regular monitoring for the duration 
of the study and in the unexpected event that toxicity does occur you will not participate 
 486 
 
 
  
toxicity. An antidote for paracetamol toxicity is readily available and in the event of physical 
injury caused by taking part in the research project, compensation shall be available. We will 
let you know any significant new information that we find out during the course of the study 
that may relate to your willingness to continue.  
We will be asking to take some blood samples. Some potential risks with taking blood 
include a bruise at the site of vein puncture; inflammation of the vein and possible infection 
but care will be taken to avoid complications. The blood sample will be used for the sole 
purpose of this study and the information we receive will not be presented in a form that will 
identify you. 
 
By participating in this study you may receive higher doses of paracetamol, which has been 
shown in trials to reduce the need for more potent painkillers such as morphine. This may 
improve pain management. By using less of these more potent painkillers you are less likely 
to experience their adverse effects. Medications like morphine, in their usual doses, can often 
cause nausea, vomiting, constipation and hallucinations.  
The information that we will record during this study will help show us whether these higher 
paracetamol doses are safe so that the benefits you experience can be passed on to the general 
population 
 
POSSIBLE ALTERNATIVES: 
Participation in this study is voluntary. Choosing not to participate in this study will not alter 
the treatment you receive. You can also choose withdraw from this study at any time without 
effecting your treatment.  
 
AGREEMENT TO CONSENT 
 The research project and the treatment procedures associated with it have been fully 
explained to me.  All experimental procedures have been identified and no guarantee has 
been given about the possible results.  I have had the opportunity to ask questions concerning 
any and all aspects of the project and any procedures involved.  I am aware that participation 
is voluntary and that I may withdraw my consent at any time.  I am aware that my decision 
not to participate or to withdraw will not restrict my access to health care services normally 
available to me.  Confidentiality of records concerning my involvement in this project will be 
maintained in an appropriate manner.  When required by law, government agencies and 
sponsors of the research may review the records of this research. 
 I understand that the investigators have such insurance as is required by law in the 
event of injury resulting from this research. 
 I, the undersigned, hereby consent to participate as a subject in the above described 
project conducted at St John’s Hospital.  I have received a copy of this consent form for my 
records.  I understand that if I have any questions concerning this research, I can contact the 
doctor and fellow investigators listed above.  If I have further queries concerning my rights in 
connection with the research, I can contact the Clinical Research Ethics Committee of the 
Cork Teaching Hospitals, Lancaster Hall, 6 Little Hanover Street, Cork. 
 
 After reading the entire consent form, if you have no further questions about giving 
consent, please sign where indicated. 
 
 
 
___________________      ___________________ 
Doctor/Co-investigator      Signature of Subject 
Dr. Brendan Conroy / Philip Murphy (Clinical Research Pharmacist)     
     
Witness:                                      Date:                             Time:   
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APPENDIX 5 CONSENT FORM- MERCY UNIVERSITY HOSPITAL 
 
 
 
CONSENT BY SUBJECT FOR PARTICIPATION IN RESEARCH 
 
Patient Name:   ________ 
 
Title of Protocol: Paracetamol metabolism in general surgical patients 
 
Doctor Directing Research: Dr. Donal Harney    Phone: (021)4271971 
 
You are being asked to participate in a research study. The staff at Mercy University Hospital studies the nature of 
disease and attempt to improve methods of diagnosis and treatment.  In order to decide whether or not you want to be 
a part of this research study, you should understand enough about its risks and benefits to make an informed 
judgement.  This consent form gives detailed information about the research study, which will be discussed with you.  
Once you understand the study, you will be asked to sign this form if you wish to participate. 
 
NATURE AND DURATION OF PROCEDURE(S):  
Paracetamol (Panadol/Calpol) is a medication that most people will have taken or have been 
given at some time in their lives.  It is generally considered to be a safe drug when used at its 
recommended dose.  It is commonly used for minor ailments such as headaches; however it is also 
extremely useful for patients who have had surgery. Studies have shown that when it is used with 
stronger painkillers such as morphine, patients need less of these stronger drugs and hence have 
fewer side effects.  
Because there is the general feeling that paracetamol is such a safe drug, some doctors are now 
using higher doses in patients who have had surgery. Currently there is little published information 
about the way the body handles medicines around the time of surgery and this may affect the 
safety of medicines, such as paracetamol. This is what we want to find out. We expect the findings 
of this study to be very important for surgical care. 
The aims of this study are  
1 To see if surgery changes the way the body metabolises paracetamol by sampling the blood 
and urine  
2 To monitor patients liver function from the blood samples that are taken to determine if the 
higher doses of paracetamol have any effect on the liver. 
If you choose to enrol in this study you will receive the standard, normal dose of paracetamol (1g 
every six hours). We will also be using very low doses of four other medications to look at your 
liver’s ability to metabolise medicines. One of these medicines is caffeine so to be as accurate as 
possible we ask you not to drink tea, coffee or other caffeinated beverage while you are in the 
study. Herbal teas are provided.  
We will also ask for some blood samples. Up to 24-teaspoon size samples of blood will be collected 
over the entire length of the study as well as all your urine. This is to monitor for the breakdown 
products of paracetamol, to ensure the paracetamol isn’t unsafe and to look at your genetics that 
relate to your liver’s ability to metabolise medicines. We will also be asking you questions about 
your pain to see if you think if it is controlled. 
 
POTENTIAL RISKS AND BENEFITS: 
You will receive the standard normal dose of paracetamol. This dose is known to be safe over long 
periods in health adults and is routinely used in surgical patients.  
As with any medicine there is a small risk from the harmful effects of paracetamol, although these 
are extremely rare. You will receive regular monitoring for the duration of the study and in the 
unexpected event that toxicity does occur you will not receive any further paracetamol. An antidote 
for paracetamol is readily available. We will let you know any significant new information that we 
find out during the course of the study that may relate to your willingness to continue.  
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CONSENT BY SUBJECT FOR PARTICIPATION IN RESEARCH 
 
We will be asking to take some blood samples. Some potential risks with taking blood include a 
bruise at the site of blood sampling, inflammation of the vein and possible infection but care will be 
taken to avoid complications. The blood sample will be used for the sole purpose of this study and 
the information we receive will not be presented in a form that will identify you. 
 
By participating in this study you will receive regular doses of paracetamol, which has been shown 
in trials to reduce the need for more potent painkillers such as morphine. This may improve pain 
management. By using less of these more potent painkillers you are less likely to experience their 
adverse effects. Medications like morphine, in their usual doses, can often cause nausea, vomiting, 
constipation and hallucinations.  
 
The information from this study will help show us whether paracetamol is safe so that any benefits 
you experience in pain relief can be passed on to others. By being involved in the study you will be 
contributing to what we expect to be important research for surgical care. 
 
POSSIBLE ALTERNATIVES: 
Participation in this study is voluntary. Choosing not to participate in this study will not alter the 
treatment you receive. You can also choose to withdraw at any time without effecting your 
treatment.  
 
AGREEMENT TO CONSENT 
The research project has been fully explained to me.  All experimental procedures have been 
identified and no guarantee has been given about the results.  I have had the opportunity to ask 
questions about the project and the procedures involved.  I am aware that participation is voluntary 
and that I may withdraw my consent at any time.  I am aware that my decision not to participate or 
to withdraw will not restrict my access to health care services normally available to me.  
Confidentiality of records concerning my involvement in this project will be maintained in an 
appropriate manner. I understand that the investigators have such insurance as is required by law 
in the event of injury resulting from this research. 
 
I, the undersigned, hereby consent to participate as a subject in the above described project. I have 
received a copy of this consent form for my records.  I understand that if I have any questions 
concerning this research, I can contact the investigators listed above. If I have further queries 
concerning my rights in connection with the research, I can contact the Clinical Research Ethics 
Committee of the Cork Teaching Hospitals, Lancaster Hall, 6 Little Hanover Street, Cork.  
 
After reading the entire consent form, if you have no further questions about giving consent, please 
sign where indicated. 
 
 
 
___________________      ___________________ 
Signature of Subject       Doctor/Co-investigator  
 
          
Witness:                                     Date:                             Time:   
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APPENDIX 6 DRUG ADMINISTRATION AND SAMPLE COLLECTION FORM 
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APPENDIX 9 BASELINE MEDICAL INFORMATION SHEET 
 
  
 493 
 
APPENDIX 10 MIDAZOLAM IMPORTATION LICENSE 
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APPENDIX 11 MIDAZOLAM POSSESSION LICENSE 
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APPENDIX 12 MIDAZOLAM SUPPLY AGREEMENT 
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APPENDIX 13 ADDITIONAL PLASMA CONCENTRATION GRAPHS 
Paracetamol Cysteine 
Median plasma paracetamol cysteine concentrations are presented as median +/- 
quartiles preoperatively (red line) and day 1 postoperatively (blue line).  
 
There was very little change in concentration over the dose intervals. Group A 
paracetamol cysteine concentrations were noticeably higher following surgery, and in 
Group D some elevation was seen towards the end of the sampling period on the 
postoperative day. 
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Paracetamol Mercapturate 
Median plasma paracetamol mercapturate concentrations are also presented as median 
+/- quartiles preoperatively (red line) and day 1 postoperatively (blue line).  
 
Paracetamol mercapturate was only found in very low concentrations in the plasma. 
There appears to be no effect of dose or surgery. 
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APPENDIX 14 REVIEW OF β-GLUCURONIDASE METHODS 
 
Ref Drug Sample 
Volume 
Amount β-glu Vehicle pH Temp Time IS Clean Up 
(Chen et al. 
2002) 
CZX 0.5mL 
plasma 
1000 1mL 0.2M 
NaAc  
4.75 37 4 Phenacetin 50uL 
20umol/L 
5ml EE 
(Chen et al. 
2003) 
CZX 0.5mL 
plasma 
1000 1mL NaAc  4.75 37  Phenacetin 50uL 
20umol/L 
5mL DEE 
(Chen et al. 
2003) 
MDZ 1mL 
plasma 
200 NaAc  4.75    DEE 
(Daali et al. 
2008) 
DX 0.25mL 
urine 
2000 1mL vs. 
85uL 10N HCl 
0.1M 
NaAc 
5 37 O/N 5uL Levallorphan 2.3 
nmol/mL 
↑pH 90uL KOH 10N 
and 500uL NA2CO3 
1M. 5mL Hex:EA 
(50:50) for 15 min. 
Spin. Add 0.5mL OPA 
50mM to organic 
(Desiraju et al. 
1983) 
CZX 0.5mL 
urine 
? NaAc 4.6 37 O/N N-butyl-p-aminophenol ↑pH 7.4, 1mL KP, 
5mL EA X2. Dry. 50uL 
MeOH 
(Dreisbach et 
al. 1995) 
CZX 0.5mL 
plasma 
1200    O/N 6 fluorochlorzoxazone DEE 
(Frye et al. 
1997) 
4’OH 
mephenytoin 
0.5mL 
urine 
 500uL 
NaAc 1M 
5 37 3 100uL 0.05mg/mL 
phensuximide 
5mL DEE. Dry 500uL 
40% MeOH. Inj 
100uL 
(Frye et al. 
1996) 
CZX 0.5mL 
plasma 
1000/0.5mL 
0.2% NaCl 
1mL NaAc 
0.2M 
4.75 37 3 Incubation completed 
in 2hours with 1000u 
3mL DEE. Dry. 200uL 
MP inject 50 
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Ref Drug Sample 
Volume 
Amount β-glu Vehicle pH Temp Time IS Clean Up 
(Girre et al. 
1994) 
CZX 0.5mL 
plasma/ 
urine (dil 
1:100) 
2000 (20uL)   37 O/N  4mL 0.6N PCA, 2 X 
4mL EA 
(Gurley et al. 
2005) 
Cocktail 250uL 
serum 
500/250uL 0.2M 
NaAc 
5 37 2.5   
(Haufroid et al. 
2005) 
CZX 500uL 
plasma 
20uL 500uL 2M 
NaAc 
4.5 37 O/N  500uL removed. 1mL 
1.2M PCA. Spin. 1mL 
extracted with 2mL 
EA. Dry 1.5mL. 500uL 
MP inj 20uL 
(Kashuba et al. 
1998b) 
DEX 3mL urine 100MU   37 18  ↑pH 12 SPE 
(Liangpunsakul 
et al. 2005) 
CZX 0.5mL 
urine 
2000   37 1   
(Lutz et al. 
2004) 
DEX 250uL 
urine+ 
250uL 
MeOH 
     5uL Levallorphan 2.3 
nmol/mL 
 
(Lutz et al. 
2008) 
DEX 500uL 
urine 
      Column switchin 
(Manyike et al. 
2000) 
PA 500uL 
urine 
40uL 500uL 
NaAc 
0.125M 
5 37 O/N  Filter 
(Mishin et al. 
1998) 
CZX 500uL 
plasma  
200/0.1mL 
0.2%NaCl 
1mL NaAc 
0.2mM 
4.75    5mL DEE. Dry 3.5mL. 
Wet with 250uL 40% 
ACN. Sonicate 
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Ref Drug Sample 
Volume 
Amount β-glu Vehicle pH Temp Time IS Clean Up 
(O'Shea et al. 
1994) 
CZX 2mL 
plasma+ 
0.5mL 
H2O 
200 1mL 1:1 
1M NaAc: 
1M glacial 
acetic acid 
5 20 O/N  SPE 
(Park et al. 
1984) 
DEX 2mL urine 0.2mL 50mM 
NaAc pH 
3.5 
5-
5.5 
37 18  ↑pH 12 1M NaOH. 
6mL Hex mix 40min. 
Freeze off aqueous. 
Back extract with 
0.2mL 0.1M HCl mix 
30min. Repeat for 
aqueous layer 
(Petsalo et al. 
2008) 
Cocktail 125uL 
urine 
750U in 125uL 
0.9% NaCl 
250uL 
0.1M 
NaAc 
5 37 6 phenacetin 480uL spiked with 
20uL of IS in ACN 
(Sarich et al. 
1997) 
ME 200uL 
urine 
10uL 1mL Ac 
200mM 
5 37  O/N  2 X 3mL 2:1 EA:DEE. 
Dry. 0.5mL 20% ACN 
inj 5uL 
(Scott et al. 
1999) 
Cocktail 0.5mL 1000/0.5mL 
0.2% NaCl 
1mL 0.2M 
NaAc 
4.75 37 3  SPE 
(Stiff et al. 
1993) 
CZX 0.5mL 
plasma 
1000/0.5mL 
0.2% NaCl 
1mL NaAc 
0.2M 
4.75 37 3  SPE 
(Streetman et 
al. 1999) 
DEX 3mL urine 100mU   37 18  ↑pH 12, SPE 
(Varela et al. 
2008) 
CZX  2000   37 1   
(Wang et al. 
2003) 
CZX 0.5mL 
urine 
2000 0.2mL 
NaAc 
0.2M 
5 37 1 Phenacetin +10uL sodium 
azide0.6M 
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Ref Drug Sample 
Volume 
Amount β-glu Vehicle pH Temp Time IS Clean Up 
(Zhang et al. 
2008) 
Cocktail 0.5mL 
urine 
1250 250uL in 
20mM 
ammonium 
formate pH 
4.75 
.25mL 
20mM 
AcA 
4.75 37 12   
(Zhu et al. 
2001) 
CZX 0.5mL 
plasma 
?   37 3 10uL 1mM Phenacetin 5mL DEE 
Abbreviations used: AcA- Acetic Acid; CA-Caffeine; CZX-Chlorzoxazone; DM-Dextromethorphan; EA-Ethyl acetate; EE-Ethyl ether; DEE-Diethyl ether; 
KP-Phosphate buffer; MDZ-Midazolam; MeOH-Methanol; ME-Mephenytoin; MP-Mobile Phase; NaAc-Sodium Acetate; O/N-Overnight; OPA-
Orthophosphoric Acid; PA-Paracetamol; PCA-Perchloric acid. 
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